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Abstract 
This thesis describes some novel aspects of the s-BuLi mediated lithiation/trapping of 
N-Boc heterocycles, including a systematic investigation into the lithiation/trapping of 
N-Boc piperazines. 
Chapter 2 details an in situ ReactIR
™
 investigation into the time required for both the 
lithiation and trapping events of some commonly used N-Boc heterocycles. The 
remarkable difference in the time taken for trapping with some electrophiles is of 
particular note. 
 
The information garnered in this investigation was used to direct the racemic and 
asymmetric lithiation of N-Boc piperazines, as described in Chapters 3 and 4. A series 
of complications were encountered and overcome. The methodology culminated in the 
synthesis of enantiopure mono- and disubstituted N-Boc piperazines B and C through 
asymmetric lithiation/trapping of piperazine A. 
 
In Chapter 5, an investigation into the synthesis of the (–)-sparteine surrogate (–)-D is 
reported. Two strategies are described: the synthesis and classic resolution of D and the 
synthesis of enantiopure (–)-D from commercially available precursors. 
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Chapter One: Introduction 
Organolithium reagents are of utmost importance to the modern synthetic chemist and 
since their discovery by William Schlenk in 1917,
1
 they have become ubiquitous in 
organic synthesis. Modern organolithium chemistry was pioneered by Ziegler who, in 
1930, showed that organolithium reagents could be formed from the reaction of lithium 
metal and alkyl or aryl halides; thus n-BuLi was born.
2
 Further revolutionary work on 
the structure and reactivity of organolithiums was conducted by Ziegler, Wittig and in 
particular, Gilman.
3
 Gilman showed that THF could be used to enhance the reactivity of 
n-BuLi and additionally, determined the temperatures and times for which many 
organolithiums are stable. This allowed the development of many of the common 
synthetic transformations used by organic chemists today, several of which have been 
used in the work presented in this thesis.
3
 
Due to the significant covalent character of organolithiums, many alkyl and aryl lithium 
reagents are highly soluble in hydrocarbon solvents and are available commercially as 
solutions; these are often the starting point for the formation of organolithium reagents. 
A single carbon substituent does not provide sufficient stabilisation for the electron 
deficient lithium atom. Therefore, simple organolithium reagents in hydrocarbon 
solvents are founds as aggregates, often as hexamers, tetramers or dimers with the 
aggregation state governed by steric hindrance. For example, n-BuLi exists as a 
hexamer with the octahedral arrangement of the lithium atoms bridged by n-butyl 
ligands, whereas the more bulky t-BuLi exists as a tetramer.
4
 
Coordinating ligands or solvents (such as Et2O and THF) provide a source of electron 
density for the electron deficient lithium atoms. These ligands allow the formation of 
lower aggregates and hence greater reactivity, as originally observed by Gilman.
3
 The 
modulation of the reactivity of organolithiums using ligands has become a cornerstone 
of synthetic organic chemistry, with ethereal solvents being used in almost all 
organolithium reactions. Importantly, the use of stoichiometric quantities of amine-
containing ligands greatly enhances the reactivity of organolithiums.
4
 Three commonly 
used amine ligands are shown in Figure 1.1. 
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Figure 1.1 
Many bioactive natural products and drug molecules exist as single stereoisomers due to 
the ability of natural systems to discriminate between the enantiomers of a compound. 
This proclivity of the natural world is both a blessing and a burden for the synthetic 
chemist, requiring the continued development of novel methods for the synthesis of 
complex enantioenriched organic compounds. This fundamental work allows us, as a 
community, to generate complex biologically active molecules with a view to 
improving the health and well-being of humanity. 
Organolithium-based methodology has played a significant role in the advancement of 
the types molecules that can be predictably synthesised. A whole host of biologically 
active molecules have been synthesised using functionalised organolithium reagents.
5
 A 
few of the many examples include the beetle pheromone (–)-japonilure,6 (–)-kainic acid7 
and the alkaloid (+)-pseudoheliotridane
8
 (Figure 1.2). 
 
Figure 1.2 
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1.1 Directed Deprotonation by Organolithium Reagents: The Complex 
Induced Proximity Effect 
Directed deprotonation to generate dipole-stabilised carbanions α to heteroatoms is an 
important area of organolithium chemistry and has been widely investigated over the 
past few decades. This synthetic strategy has been used extensively for the 
incorporation of electrophilic partners, generating a new stereocentre. Typically, a 
directing group is appended to a heteroatom, for example nitrogen, which then allows 
lithiation α to the heteroatom substituent. The Lewis basic directing group of 1 
facilitates coordination of an organolithium species resulting in the reversible formation 
of complex 2 prior to the lithiation event (Scheme 1.1). This effect was termed the 
“complex induced proximity effect” (CIPE) by Beak and Meyers in 1986.9 Subsequent 
deprotonation α to the heteroatom results in generation of an organolithium species 3, 
which can be stabilised by an adjacent positive charge on the heteroatom as in 4, this is 
known as a dipole-stabilised carbanion.
10
 Electrophilic trapping then releases the α-
functionalised substrate 5. 
 
Scheme 1.1 Mechanism of directed deprotonation 
Complex 2 is referred to as the pre-lithiation complex
11
 and its formation results in an 
increased reactivity of the substrate towards deprotonation by holding the alkyllithium 
reagent in close proximity to the acidic proton. Several reviews of the use of directed 
deprotonation and the complex induced proximity effect have been published by 
Beak.
12-14
 Strong experimental evidence for the existence of the CIPE in systems such 
as that depicted in Scheme 1.1 has been presented.
14
 
The complex induced proximity effect can control the regioselectivity of the lithiation 
of suitably configured substrates, for example benzyl carprolactam 6. The 
thermodynamically favoured reaction would be removal of the methylene proton to 
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generate amide enolate 7. In fact, kinetic deprotonation at the benzyl position occurs, 
directed by the CIPE, to give 8 (Scheme 1.2).
9
 
 
Scheme 1.2 
Although the CIPE model explains both the ability to effect α-deprotonation of 
relatively unreactive substrates and the prevalence for the formation of kinetic products, 
there was debate over the existence of a discrete pre-lithiation species. An alternative 
proposed by Beak was termed the “kinetically enhanced metalation” model where the 
directing group kinetically accelerates the proton transfer to the base by binding in the 
transition state for the deprotonation.
15
 In other words, deprotonation is a single step 
process accelerated by the directing group, rather than a two step process as required by 
the CIPE. To distinguish between the two possibilities Beak performed an elegant set of 
deprotonation experiments using a urea substrate and assessed the kinetic isotope effects 
(Scheme 1.3). Lithiation of mono-deuterated urea 9-d1 with s-BuLi/TMEDA at –78 °C 
resulted in a >20:1 preference for removal of the proton over the deuterium. This was 
expected due to the kinetic isotope effect. Lithiation of a 50:50 mixture of undeuterated 
9 and bis-deuterated 9-d2 resulted in a 5:1 mixture of lithiated products. This implies 
that deprotonation of urea 9 proceeds, at least in part, via a two step process. The first 
step was thought to be a slow, rate determining formation of a pre-lithiation complex 
followed by rapid removal of the benzylic proton in the second step. If lithiation was to 
proceed via a one-step kinetically enhanced metalation process then a >20:1 kinetic 
isotope effect would be observed. The same kinetic isotope ratio would also have been 
detected if deprotonation was the rate determining step within the two step sequence. 
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Scheme 1.3 Kinetic isotope effect in the lithiation of 9 
Additional evidence for the existence of the pre-lithiation complex and CIPE arises 
from studies into the kinetics of the asymmetric deprotonation of nitrogen heterocycles 
(see Scheme 1.11). Furthermore, direct observation of such complexes with in situ 
ReactIR
™
 spectroscopy has been performed and will be discussed in detail in Chapter 2. 
Beak, Seebach and Meyers pioneered the development of CIPE lithiation techniques for 
lithiation adjacent to nitrogen, introducing a range of directing groups including 
amides,
10,16-22
 nitrosamines
23,24
 and formamidines
25-28
 amongst others.
12
 More recent 
examples from the groups of Metallinos
29,30
 and Hodgson
31-33
 include the use of ureas 
and thioamides as directing groups respectively. The requirements for a synthetically 
useful directing group are an ability to coordinate to the organolithium species (Lewis 
basicity), low reactivity towards nucleophilic attack and facile methods for 
incorporation into, and removal from, the substrate. A breakthrough came in 1989 when 
Beak introduced the use of a Boc group as a directing group for the α-lithiation of N-
Boc heterocycles.
34
 Deprotonation of N-Boc piperidine 10 was accomplished using s-
BuLi and TMEDA in Et2O at –78 °C for 3.5 h to give lithiated intermediate 11 (Scheme 
1.4). Subsequent trapping with electrophiles gave α-substituted piperidines in 53-100% 
yield. Electrophiles used included Me3SiCl, Bu3SnCl, dimethyl sulfate, diphenyl 
disulfide and benzaldehyde.  
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Scheme 1.4 
In the pioneering investigation a range of N-Boc heterocycles were investigated, 
including N-Boc pyrrolidine 12. Lithiation of 12 followed by trapping with Me3SiCl 
resulted in α-silyl pyrrolidine 13 in 81% yield (Scheme 1.5). 
 
Scheme 1.5 
The use of the Boc group to direct the lithiation of nitrogen heterocycles was quickly 
adopted by the synthetic community. As well as being effective in facilitating α-
lithiation, the Boc group is highly resistant to nucleophilic attack. The Boc group is 
simple to introduce, usually with di-tert-butyl dicarbonate, and simple to remove under 
a range of conditions, usually with TFA or HCl.
35
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1.2 Lithiation/Trapping of N-Boc Heterocycles 
Over the past 25 years, directed lithiation, and in particular, asymmetric directed 
lithiation has developed into a powerful method for the generation of α-substituted N-
Boc heterocycles and a review of this work has recently been published.
36
 Generally, 
enantioselective lithiation has been performed using a strong organolithium base, such 
as s-BuLi, in the presence of a chiral ligand. Historically, (–)-sparteine, a naturally 
occurring lupin alkaloid, has been the most important chiral ligand for asymmetric 
deprotonation chemistry (Figure 1.3).
4
 It was first used by Nozaki and Noyori for the 
synthesis of cyclic allenes and in the asymmetric addition of organolithium or Grignard 
reagents to unsymmetrical ketones. However, these transformations proceeded with 
poor levels of enantioselectivity.
37-39
 (–)-Sparteine is extracted from scotch broom and 
has, until recently, been cheap and commercially available. Its enantiomer, (+)-
sparteine, although being a natural product was, until recently, unavailable from 
commercial suppliers (Figure 1.3). 
 
Figure 1.3 
The use of (–)-sparteine in asymmetric deprotonation chemistry was first reported by 
Hoppe in 1989 for the lithiation of prochiral alkenyl carbamates. Lithiation, followed by 
selective crystallisation of one diastereomer of the lithiated intermediate, subsequent 
transmetalation to titanium and treatment with aldehydes led to homo-aldol products 
with good levels of enantioselectivity.
40
 
More importantly, Hoppe published a pioneering report on the first enantioselective 
lithiation/trapping reaction in 1990.
41
 Treatment of O-alkyl carbamate 14 with s-BuLi/ 
(–)-sparteine at –78 °C in Et2O for 5 h effected asymmetric deprotonation via the CIPE 
to give lithiated intermediate (S)-15. Trapping with CO2 or Me3SnCl proceeded with 
good yields and levels of enantioselectivity, giving both (R)-16 and (S)-17 in >98:2 er 
and in 75% and 76% yields respectively (Scheme 1.6). 
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Scheme 1.6 
The absolute stereochemistry was ascertained by comparison of the optical rotation of 
(R)-16 with a sample synthesised from (R)-lactic acid. Hoppe postulated that the 
organolithium intermediate (S)-15 was configurationally stable and that trapping 
occurred with retention of configuration.  
 
1.2.1 Asymmetric Lithiation/Trapping of N-Boc Pyrrolidine  
In 1991, a seminal report by Beak and Kerrick applied Hoppe’s enantioselective 
deprotonation methodology to N-Boc pyrrolidine 12.
42
 Asymmetric deprotonation of 12 
was accomplished using s-BuLi/(–)-sparteine at –78 °C in Et2O for 4-6 h. Subsequent 
trapping with electrophiles gave α-substituted pyrrolidines in good yield (55-76%) and 
excellent levels of enantioselectivity (94:6-98:2 er). In one example, the use of Me3SiCl 
as the electrophile gave α-silyl pyrrolidine (S)-13 in 76% yield and 98:2 er (Scheme 
1.7). The absolute configuration of the products was confirmed by comparison with 
products derived from (S)-proline. 
 
Scheme 1.7 
Asymmetry in chiral ligand mediated lithiation/trapping reactions requires 
diastereomeric interactions within the sequence, which is provided by the chiral diamine 
coordinating to the organolithium reagent. Two mechanisms for the observed 
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stereoselectivity in the lithiation/trapping of 18 were feasible (Scheme 1.8). First 
(Pathway A), it was proposed that the enantiodetermining step was an asymmetric 
deprotonation, where the organolithium/diamine complex acted as a strong chiral base 
resulting in a diastereoenriched, configurationally stable organolithium complex (R)-19. 
This then reacted stereospecifically with an electrophile to give the enantioenriched α-
substituted product (R)-20. Alternatively (Pathway B), a post-deprotonation asymmetric 
substitution could occur. Deprotonation with the strong base would give racemic 
lithiated species 19. Enantioenriched products (R)-20 could be obtained from 19 under 
the influence of the chiral ligand by different pathways depending upon the rate of 
epimerisation of 19 relative to the rate of electrophile trapping. 
 
Scheme 1.8 Postulated mechanisms for enantioenrichment in lithiation/trapping 
reactions   
To probe the mechanism by which enantioenrichment was induced, Beak performed a 
series of elegant experiments.
13
 First, (–)-sparteine and Me3SiCl were added to a sample 
of racemic 2-lithio-N-Boc pyrrolidine 22, generated either by deprotonation of N-Boc 
pyrrolidine 12 or Sn/Li exchange of stannane 21 using s-BuLi (Scheme 1.9). The α-
substituted pyrrolidine 13 isolated was essentially racemic and thus ruled out a post-
deprotonation enantiodetermining step. 
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Scheme 1.9  
Next, enantioenriched stannane (S)-21 (98:2 er) was treated with s-BuLi to induce Sn/Li 
exchange, giving lithiated intermediate (R)-22. Trapping with Me3SiCl then gave (S)-13 
with 96:4 er (Scheme 1.10). This shows conclusively that 2-lithio pyrrolidine (R)-22 
was configurationally stable at –78 °C for at least the time required for electrophilic 
trapping to occur and that asymmetric deprotonation was the enantiodetermining step 
(see Scheme 1.8, Pathway A). 
  
Scheme 1.10 
An investigation into the kinetics of the deprotonation of N-Boc pyrrolidine 12 with      
i-PrLi/(–)-sparteine complex 23 was performed by Beak with a view to elucidating the 
mechanism of deprotonation (Scheme 1.11).
11
 It was found that the reaction was zero-
order with respect to organolithium/diamine complex 23. This observation rules out a 
single step deprotonation event from N-Boc pyrrolidine 12. A mechanism that can 
account for the observed non-dependence of organolithium concentration on reaction 
rate is the rapid formation of a pre-lithiation complex 24 followed by rate-determining 
deprotonation to give lithiated intermediate (S)-25. Beak proposed complex 24 as the 
pre-lithiation complex, amongst several possible complexes, due to the close proximity 
of the chiral diamine to the reaction centre. 
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Scheme 1.11 Mechanism of CIPE asymmetric deprotonation 
Computational studies into the deprotonation of 12 using an i-PrLi/(–)-sparteine 
complex were reported by Wiberg and Bailey.
43
 It was shown that the pro-S proton was 
removed favourably due to a steric phenomenon. The transition state for removal of the 
pro-R proton was 3.2 kcal mol
-1
 higher in energy than the corresponding pro-S 
transition state due to the former being more sterically congested.  
Although enantioselective deprotonation of N-Boc pyrrolidine 12 using s-BuLi/(–)-
sparteine is highly successful giving rise to a range of enantioenriched products, the 
system suffers from one major intrinsic limitation. The natural alkaloid (–)-sparteine 
was, until recently, only available in bulk as one enantiomer. This considerable 
drawback precludes the synthesis of the opposite enantiomeric series of products. The 
total synthesis of (+)-sparteine and a synthesis of (–)-sparteine that would be applicable 
to the synthesis its enantiomer has been achieved by Aubé and O’Brien respectively.44,45 
However, these syntheses are not practical for the synthesis of (+)-sparteine on a multi-
gram scale. Initial attempts to find other ligands that would induce comparable levels of 
enantioselectivity were moderately successful.
46,47
  
In 2002, the O’Brien group published the first practical (+)-sparteine surrogate (+)-26.48 
It was designed to mimic (+)-sparteine, but it lacked the D ring as well as one of the 
stereogenic centres (Figure 1.4).
49
 Structural comparisons of (+)-sparteine and diamine 
(+)-26 complexed to lithium, as well as the calculated transition state for the 
deprotonation reaction suggested that the D ring was not essential for 
enantioinduction.
50
 Synthesis of (+)-sparteine surrogate (+)-26 was accomplished in 
three steps from (–)-cytisine (see Scheme 5.1 for details).51 
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Figure 1.4 Design of the (+)-sparteine surrogate (+)-26 
It was shown that (+)-sparteine surrogate (+)-26 was comparable to (–)-sparteine for the 
lithiation/trapping of N-Boc pyrroline 12 in terms of yield and enantioselectivity. 
Lithiation of 12 with s-BuLi/(+)-26 at –78 °C in Et2O for 5 h and subsequent trapping 
with Me3SiCl gave α-silyl pyrrolidine (R)-13 in 84% yield and 95:5 er (Scheme 1.12). 
 
Scheme 1.12 
O’Brien and co-workers later reported the use of the Alexakis diamine52 (R,R)-27 as a 
ligand for the enantioselective s-BuLi mediated lithiation/trapping of N-Boc pyrrolidine 
12 (Scheme 1.13). Synthesis of α-silyl pyrrolidine (S)-13 was accomplished in 72% 
yield and 95:5 er after lithiation of N-Boc pyrrolidine 12 using s-BuLi/(R,R)-27 at –78 
°C in Et2O for 3 h before trapping with Me3SiCl. The yield and enantioselectivity were 
comparable with those obtained in the same reaction with (–)-sparteine and (+)-
sparteine surrogate (+)-26. Importantly, the synthesis of the Alexakis diamine 27 begins 
with resolution of cyclohexane-1,2-diamine with tartaric acid allowing both 
enantiomers to be synthesised. 
 
Scheme 1.13 
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Understandably, the suitability of a diamine for asymmetric lithiation chemistry has 
been assessed by evaluation of the level of enantioselectivity of products obtained. 
Although this method is useful for identifying excellent ligands in terms of 
enantioinduction, it gives no information about the reactivity of a particular                   
s-BuLi/diamine complex. Thus, O’Brien and co-workers performed competition 
experiments to determine a relative reactivity series for some commonly used chiral and 
achiral diamines.
53
 Lithiation of N-Boc pyrrolidine 12 in the presence of 2.6 eq. of s-
BuLi, 1.3 eq. of (–)-sparteine and 1.3 eq. of (+)-sparteine surrogate (+)-26, followed by 
trapping with Me3SiCl led to a surprising result (Scheme 1.14). Silyl pyrrolidine (R)-13 
was isolated in 64% yield with a 90:10 er, i.e. the same sense of enantioinduction as 
seen with (+)-sparteine surrogate (+)-26. This showed that s-BuLi/(+)-26 was much 
more reactive than s-BuLi/(–)-sparteine for the lithiation of N-Boc pyrrolidine 12. A 
range of such competition experiments was performed with diamines and (–)-sparteine 
and the relative reactivity series of a selection of diamines is shown in Figure 1.5. 
 
Scheme 1.14 
 
Figure 1.5 Reactivity series of a selection of diamines 
In contrast to asymmetric lithiations in Et2O, it has been observed that lithiation of 
substrates using s-BuLi/(–)-sparteine in THF proceed with negligible levels of 
enantioselectivity.
54,55
 This has been attributed to the THF complexing preferentially to 
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the organolithium.
56
 As part of a detailed study, O’Brien and co-workers have shown 
that this was not the case when using s-BuLi/(+)-sparteine surrogate (+)-26 in THF. 
This observation was guided by investigating the solution structure of i-PrLi/chiral 
diamine complexes in Et2O-d10 and THF-d8 at –78 °C using 
6
Li and 
13
C NMR 
spectroscopy experiments.
57
 Beak showed, through analogous NMR spectroscopic 
experiments, that a complex of i-PrLi (an achiral model for s-BuLi) and (–)-sparteine in 
Et2O existed as heterodimer 23 (Figure 1.6).
58
 O’Brien found that a complex of i-PrLi 
and (+)-sparteine surrogate (+)-26 in Et2O existed as a homodimer 29. The sterically 
less hindered (+)-26 presumably allowed homodimer formation. When analogous 
experiments were conducted in THF-d8, it was found that (–)-sparteine did not displace 
THF from the organolithium complex until 3.0 eq. of (–)-sparteine (relative to i-PrLi) 
were added. In contrast, addition of 1.0 eq. of (+)-26 resulted in the formation of a 
monomeric complex 30 of i-PrLi and (+)-26.  
 
Figure 1.6 Solution structures of i-PrLi and (–)-sparteine or (+)-26 
Whereas (–)-sparteine does not form chiral organolithium complexes in THF, the (+)-
sparteine surrogate (+)-26 does. This result has far reaching consequences for 
organolithium chemistry; asymmetric lithiation adjacent to heteroatoms in THF is 
possible with the (+)-sparteine surrogate (+)-26 but not with (–)-sparteine. For example, 
lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-sparteine in THF at –78 °C for 5 h, 
followed by trapping with benzaldehyde gave (R,R)-31 in 50% yield and (R,S)-32 in 
14% yield and both diastereomers had enantiomeric ratios of 51:49 er (Scheme 1.15). 
This was indicative of lithiation proceeding via a s-BuLi/THF complex, as indicated by 
the NMR spectroscopic experiments. Conversely, a comparable reaction with (+)-26 
resulted in (S,S)-31 being isolated in 45% yield and (S,R)-32 in 20% yield, both with 
high levels of enantioselectivity (95:5 er). 
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Scheme 1.15 s-BuLi/chiral diamine mediated lithiation/trapping of 12 in THF 
The observation that (–)-sparteine does not form complexes with s-BuLi in THF, but 
lithiation/trapping still occurs to give racemic products, was turned into an advantage by 
O’Brien; racemic lithiation/trapping could be performed without a the use of a diamine. 
Building upon this observation, an operationally simple, fast, diamine-free racemic 
lithiation/trapping of N-Boc heterocycles in THF at –30 °C was developed.59 Racemic 
α-substituted N-Boc pyrrolidines were obtained through lithiation of N-Boc pyrrolidine 
12 with s-BuLi in THF at –30 °C for 5 min followed by trapping. A wide range of 
electrophiles were tolerated, giving racemic α-substituted pyrrolidines 13, 31-35 in 67-
84% yield (Scheme 1.16). This chemistry was also applied to the synthesis of α-
functionalised N-Boc imidazolidine and N-Boc piperazine products.  
  
Scheme 1.16 Racemic Lithiation/Trapping of 12 in THF 
With the success of the ‘high temperature’ racemic lithiation of N-Boc heterocycles, 
Gelardi and O’Brien set about an investigation of the asymmetric high temperature 
lithiation of N-Boc pyrrolidine 12 in order to develop a more efficient, sustainable 
procedure.
60
 Raising the temperature above –78 °C was envisaged to require substantial 
reaction optimisation. The following salient points were identified: (i) lithiation at 
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higher temperatures would take a shorter time to reach completion; (ii) the chemical 
stability of the lithiated N-Boc heterocycles may be compromised at higher 
temperatures; (iii) the enantioselectivity (i.e., the kinetic selectivity due to the 
interaction of the s-BuLi/diamine complex with the N-Boc heterocycle) would be a 
function of temperature; and, (iv) the configurational stability of the lithiated 
intermediate would be compromised at high temperatures.
61
  
Significant experimentation led to the development of optimised conditions. Lithiation 
of N-Boc pyrrolidine 12 with s-BuLi and either (–)-sparteine or (+)-sparteine surrogate 
(+)-26 in Et2O at –30 °C for 2 min was followed by trapping. Employment of (–)-
sparteine and trapping with benzaldehyde gave (R,R)-31 in 58% yield and 90:10 er and 
(R,S)-32 in 34% yield and 89:11 er (Scheme 1.17). Access to antipodes (S,S)-31 and 
(S,R)-32 in 67% yield (90:10 er) and 27% (90:10 er) respectively was accomplished 
using (+)-sparteine surrogate (+)-26. A small reduction in enantiomeric ratio occurs in 
comparison with reactions at –78 °C (see Scheme 1.13). This was probably due to a 
reduction in the kinetic selectivity of the deprotonation.  
 
 
Scheme 1.17 ‘High temperature’ asymmetric lithiation/trapping of 12 
The electrophile scope was investigated with s-BuLi/(+)-sparteine surrogate (+)-26 
using the optimised conditions. A further five α-substituted N-Boc pyrrolidines 33, 36-
39 were synthesised in 55-73% yield and 84:16-92:8 er (Scheme 1.18). 
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Scheme 1.18 Asymmetric Lithiation/Trapping of 12 with s-BuLi/(+)-26 
2-Allyl pyrrolidine (S)-38 was accessed through a Li/Cu transmetallation before 
trapping, whereas 2-phenyl pyrrolidine (S)-39 was available through a Li/Zn 
transmetalation then Negishi coupling (see Section 1.3 for discussion of these 
methodologies). This high temperature asymmetric lithiation methodology was also 
applied to N-Boc piperidine 10 and N-Boc piperazine systems with slightly modified 
reaction conditions. 
The requirement for stoichiometric amounts of the chiral diamines is a drawback of the 
asymmetric lithiation methodology. Initial attempts at using a substoichiometric amount 
of (–)-sparteine resulted in products being isolated in poor yield and er due to lack of 
catalytic turnover, as the diamine does not easily dissociate from the lithiated 
intermediate.
62
 
To provide a solution to this problem, the O’Brien group developed a catalytic 
asymmetric lithiation protocol using a ligand exchange approach.
63
 This process allows 
a chiral diamine to be recycled by exchange with a stoichiometric amount of a second 
ligand. Scheme 1.19 details the proposed catalytic cycle for the catalytic lithiation of N-
Boc pyrrolidine 12 with s-BuLi, (–)-sparteine and achiral bispidine 28. N-Boc 
pyrrolidine 12 underwent lithiation with a complex of s-BuLi/(–)-sparteine 40 (present 
in a substoichiometric quantity, 0.2 eq.) to give lithiated complex 25. Then, ligand 
exchange occurred between the s-BuLi/achiral bispidine complex 41 and the N-Boc 
pyrrolidine/(–)-sparteine complex 25. This regenerated the reactive s-BuLi/(–)-sparteine 
complex 40 and allowed catalytic turnover. Finally electrophilic trapping of 25 or 42 
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with, for example Me3SiCl, then formed the desired α-substituted N-Boc pyrrolidine 
(S)-13. 
 
Scheme 1.19 Mechanism of the catalytic asymmetric lithiation of 12 
There are three requirements that must be met for this approach to succeed. First, ligand 
exchange must be able to occur. Secondly, organolithium species 25 and 42 must be 
configurationally stable and finally, deprotonation by the s-BuLi/(–)-sparteine complex 
40 must be significantly faster than by the achiral s-BuLi/bispidine complex 41. 
When lithiation of N-Boc pyrrolidine 12 was performed with s-BuLi, 0.2 eq. of (–)-
sparteine and 1.2 eq. of bispidine 28, followed by trapping with Me3SiCl, α-silyl 
pyrrolidine (S)-13 was isolated in 76% yield and 90:10 er (Scheme 1.20). An analogous 
catalytic lithiation in the presence 0.2 eq. of (+)-sparteine surrogate (+)-26 and 1.2 eq. 
of 28 gave (R)-13 in 66% yield and 94:6 er. 
 
Scheme 1.20 
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Only a small decrease in enantiomeric ratio was seen, compared to the stoichiometric 
method (see Scheme 1.13). This was due to the significantly lower reactivity of the      
s-BuLi/bispidine 28 complex 41 relative to the s-BuLi/(–)-sparteine complex 40. The 
use of (+)-26 resulted in a better enantiomeric ratio than with (–)-sparteine due to the 
increased reactivity of the s-BuLi/(+)-26 system. 
One major drawback of this system was that the achiral bispidine 28 was not 
commercially available and had to be synthesised. However, its synthesis was 
accomplished in two steps with a good yield.
64,65
 Further work led to the development 
of other stoichiometric diamines suitable for the two-ligand catalysis methodology, 
although they also required synthesis.
53,66
 Another problem encountered was that the 
stoichiometric diamines could not be separated from the chiral diamines (–)-sparteine or 
(+)-26, precluding the recovery and re-use of the valuable chiral ligands.  
To overcome this limitation, O’Brien and co-workers developed the use of 
commercially available lithiated dimethylaminoethanol (LiDMAE) 43 as a 
stoichiometric ligand.
67
 Importantly, this ligand could be separated from (–)-sparteine 
through a simple acid/base work-up protocol. Lithiation of N-Boc pyrrolidine 12 using 
s-BuLi with a substoichiometric amount of (–)-sparteine and stoichiometric LiDMAE 
43, followed by trapping with benzaldehyde, gave substituted pyrrolidines (R,R)-31 in 
64% yield and 90:10 er and (R,S)-32 in 25% yield and 89:11 er (Scheme 1.21).  
 
Scheme 1.21 
To showcase the synthetic utility of the two-ligand catalysis methodology, the synthesis 
of (+)-L-733,060, a neuronkinin-1 receptor antagonist, was accomplished starting from 
(R,R)-31 (Scheme 1.22). Boc removal with TFA followed by allylation gave allyl 
pyrrolidine (R,R)-44 in 58% yield. Next, ring expansion to hydroxyl piperidine (S,S)-46 
was accomplished in 83% yield by treatment of (R,R)-44 with TFAA and Et3N. Ring 
expansion occurred via formation and opening of intermediate aziridinium ion 45 and 
was followed by base-mediated ester hydrolysis. The final two steps proceeded without 
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issue. Firstly O-alkylation of (S,S)-46 was accomplished with NaH and benzyl bromide 
47 giving benzyl ether (S,S)-48 in 98% yield. N-Deallylation was performed using Pd(0) 
and N,N′-dimethylbarbituric acid to give (+)-L-733,060 in 99% yield. 
 
Scheme 1.22 Synthesis of (+)-L-733,060 from (R,R)-31 
The enantioselectivity of asymmetric deprotonation reactions is generally excellent 
(90:10-95:5 er). However, synthesis of enantiopure substituted N-Boc heterocycles is 
not usually possible using asymmetric deprotonation chemistry. An ingenious method to 
circumvent this issue has been developed by Rayner and O’Brien.68 It was envisaged 
that asymmetric lithiation followed by trapping with an enantiomerically pure sulfinate 
would lead to the generation of enantiomerically pure α-sulfoxide N-Boc heterocycles. 
Subsequent sulfoxide/Mg exchange would generate configurationally stable 
heterocyclic Grignard reagents, which could undergo electrophilic trapping.  
As a demonstration of this strategy, lithiation of 4-chloro-N-Boc piperidine 49 (first 
reported by Beak with (–)-sparteine69) with s-BuLi and the Alexakis diamine (R,R)-27 
in Et2O at –78 °C followed by trapping with enantiomerically pure Andersen’s sulfinate 
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(SS)-52 gave sulfoxides (R,R,SS)-53 in 51% yield and 99:1 er and (S,S,SS)-54 in 25% 
yield and 87:13 er (Scheme 1.23). Mechanistically, piperidine 49 underwent α-lithiation 
to give 50, which cyclised to give cyclopropane (S,R)-51, which then underwent a 
second lithiation. 
 
Scheme 1.23 Synthesis of enantiopure sulfoxide (R,R,SS)-53  
Sulfoxide/Mg exchange was accomplished rapidly at room temperature by treatment of 
(R,R,SS)-53 with i-PrMgCl to give enantiopure Grignard reagent (R,R)-55 (Scheme 
1.24). Electrophilic trapping delivered 56-58 in 64-89% yield and in 99:1 er. 
Importantly, the Grignard reagent 55 was configurationally stable at room temperature 
for the duration of the reaction. 
 
.  
Scheme 1.24 Sulfoxide/Mg exchange/trapping approach to enantiopure N-Boc 
heterocycles  
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Additionally, Mg/Zn transmetallation and subsequent Negishi coupling delivered 2-aryl 
heterocycles 59-62 in 68-74% yield, with 99:1 er (Scheme 1.25). 
 
 
Scheme 1.25 Sulfoxide/Mg exchange/trapping approach to enantiopure 2-aryl N-Boc 
heterocycles 
The beauty of this sulfoxide methodology is that it allows the synthesis of a range of 
enantiopure substituted N-Boc heterocycles from a bench stable common intermediate, 
(R,R,SS)-53. Unfortunately, trapping of N-Boc pyrrolidine 12 with Anderson’s sulfinate 
(SS)-52 was unsuccessful. This may be due to the instability of the N-Boc pyrrolidine 
sulfoxide.
70
 
 
1.2.2 Dynamic Kinetic Resolution of N-Boc Pyrrolidine  
An alternative method to generate enantioenriched α-substituted N-Boc heterocycles 
through lithiation/trapping is dynamic kinetic resolution. If the intermediate 
organolithium species is configurationally unstable in the presence of a chiral ligand, at 
a particular temperature, then the degree of enantioselectivity can be controlled by the 
relative rates of electrophilic trapping of the diastereomeric lithiated intermediate/ligand 
complexes. A general reaction mechanism is shown in Scheme 1.26.
4,13
 First, 
deprotonation of substrate 18 with an organolithium reagent (RLi) and a chiral ligand 
(L
*
) results in a mixture of diastereomeric organolithium complexes, (R)-19 and (S)-19. 
These two diastereomeric intermediates can undergo relatively rapid interconversion 
through configurational instability at the rate kinv. These species react at different rates 
(kR or kS) with an electrophile resulting in products (R)-20 and (S)-20. For this process 
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to be successful, the rate of interconversion of diastereomeric complexes (kinv) must be 
faster than the rate of electrophilic trapping (kR and kS). The degree of enantioselectivity 
is governed by the energy difference between the energies of the trapping transition 
states.
13
 
 
Scheme 1.26 Mechanism of dynamic kinetic resolution 
In 2005, Coldham and co-workers published a dynamic kinetic resolution of 2-lithio-N-
Boc pyrrolidine.
71
 Treatment of stannane 21 with n-BuLi gave 2-lithio-N-Boc 
pyrrolidine. Addition of lithiated ligand 63 generated diastereomeric lithiated 
intermediates and subsequent warming to –20 °C facilitated interconversion of these 
intermediates. Trapping with Me3SiCl gave α-silyl pyrrolidine (S)-13 in 54% yield and 
96:4 er (Scheme 1.27).  
 
Scheme 1.27 
A dynamic kinetic resolution via deprotonation of N-Boc pyrrolidine 12 with s-BuLi 
was also demonstrated. Silyl pyrrolidine (S)-13 was isolated in 54% yield and 95:5 er 
(Scheme 1.28). 
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Scheme 1.28 
Critically, a large excess of n-BuLi (>10 eq.) and slow addition of the electrophile were 
required for high levels of enantioselectivity. Additionally, the DKR process was highly 
electrophile dependent. High enantiomeric ratios were only obtained with Me3SiCl. 
 
1.2.3 Asymmetric Lithiation/Trapping of N-Boc Piperidine 
With the great degree of success seen with the asymmetric lithiation of N-Boc 
pyrrolidine 12, it is perhaps surprising that asymmetric lithiation of N-Boc piperidine 10 
was much more problematic. Although racemic lithiation with s-BuLi/TMEDA 
proceeds smoothly
34
 the asymmetric variant originally met with failure. Beak 
investigated the s-BuLi/(–)-sparteine mediated lithiation/trapping of N-Boc piperidine 
10.
72
 Lithiation in Et2O at –78 °C for 16 h, followed by trapping with Me3SiCl 
generated (S)-64 in only 8% yield and 87:13 er (Scheme 1.29). The major product was a 
mixture of isomeric enamines 65 obtained in 43% yield. The very slow rate of lithiation 
of N-Boc piperidine 10 using s-BuLi/(–)-sparteine allowed nucleophilic attack of s-
BuLi on the Boc group to become competitive. Nevertheless, the absolute sense of 
chiral induction was confirmed by X-ray crystallography of a derivative of (S)-64. The 
s-BuLi/(–)-sparteine complex 40 favours removal of the pro-S proton of both N-Boc 
piperidine 10 and N-Boc pyrrolidine 12. 
  
Chapter One: Introduction 
 
25 
 
 
Scheme 1.29 
Computational studies performed on N-Boc piperidine 10 suggested that the α-proton is 
much less acidic than the corresponding α-proton of N-Boc pyrrolidine 12. The 
activation energy for removal of a proton from N-Boc piperidine 10 is 2-3 kcal mol
-1
 
higher than with the five-membered analogue, thus explaining the relatively slow rate of 
lithiation of the former.  
In an attempt to develop a high yielding asymmetric lithiation/trapping of N-Boc 
piperidine 10, Coldham and O’Brien explored 14 different diamines.73 The investigation 
generated modest results with the use of Alexakis diamine (R,R)-27 being slightly more 
successful than (–)-sparteine. Lithiation of 10 for 6 h at –78 °C before trapping gave 
(S)-64 in 13% yield and 90:10 er (Scheme 1.30). 
 
Scheme 1.30 
It was shown that 4-substitited piperidines undergo asymmetric lithiation more readily 
than N-Boc piperidine 10. For example, lithiation of 4-phenyl piperidine 66 with          
s-BuLi/(R,R)-27 followed by trapping with Me3SiCl gave (S,S)-67 as a single 
diastereomer
74
 in 40% yield and 87:13 er (Scheme 1.31). For explanation of the 
diastereoselectivity, see Scheme 1.42. Additionally, lithiation of acetal 68 and trapping 
with Me3SiCl gave (S)-69 in 53% yield and 53:47 er.  
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Scheme 1.31 
The increased yields of (S,S)-67 and (S)-69 showed that lithiation of these 4-subsitiuted 
piperidines was easier than N-Boc piperidine 10 under the same reaction conditions. In 
fact, Beak had previously shown through competition experiments that lithiation of 4-
phenyl N-Boc piperidine 66 was easier than the lithiation of N-Boc piperidine 10 using 
s-BuLi/TMEDA.
75
 
Work within the O’Brien group showed that lithiation with s-BuLi/(+)-sparteine 
surrogate (+)-26 was more rapid than with s-BuLi/(–)-sparteine (see Scheme 1.14).53 
Thus, it was hypothesised that (+)-26 would be more successful in the lithiation of N-
Boc piperidine 10. This was the case, lithiation for 6 h at –78 °C followed by addition of 
a selection of electrophiles gave α-substituted piperidines (R)-64, 70-72 in 73-92% yield 
and 86:14-88:12 er (Scheme 1.32). Trapping with Me3SiCl resulted in (R)-64 being 
obtained in a much improved 73% yield and 86:14 er. 
 
Scheme 1.32 Asymmetric lithiation/trapping of 10 with s-BuLi/(+)-26 
Other electrophiles were investigated by O’Brien and co-workers, but they gave lower 
enantiomeric ratios of products (Scheme 1.33). Lithiation of N-Boc piperidine 10 
followed by trapping with bulky silyl reagent PhMe2SiCl gave (R)-73 in 85% yield and 
73:27 er. Trapping with methylating agents, such as methyl iodide and dimethyl sulfate, 
gave 2-methyl piperidine (R)-74 in 45% yield in both cases, and 64:36 er and 60:40 er 
respectively. It was suggested that in these cases, trapping at –78 °C did not occur 
readily due to the steric bulk of the diamine. On warming the reaction from –78 °C 
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towards room temperature, the higher temperatures allowed trapping to occur. It was 
suggested that as the reactions warmed up, the lithiated intermediates became 
configurationally unstable, leading to the observed reduction in enantioselectivity.
61
 
 
Scheme 1.33 Asymmetric lithiation/trapping of 10 with s-BuLi/(+)-26  
Interestingly, an electrophile competition experiment proved that PhMe2SiCl trapped 
out the lithiated intermediate slowly, even at –40 °C. Lithiation of 10 using s-BuLi/(+)-
26 was performed at –78 °C for 6 h, then the temperature was raised to –40 °C and 
PhMe2SiCl was added. After 2 h at –40 °C, a fast trapping electrophile, methyl 
chloroformate, was added. Silyl piperidine (R)-73 was isolated in 5% yield and 80:20 er 
and ester (S)-72 was isolated in 67% yield and 85:15 er (Scheme 1.34). This 
conclusively proved that PhMe2SiCl trapped lithiated N-Boc piperidine slowly even at –
40 °C in the presence of the (+)-sparteine surrogate (+)-26. The reduction in 
enantiomeric ratio of the two products can be attributed to partial configurational 
instability of the lithiated intermediate at –40 °C. 
 
Scheme 1.34 Electrophile competition experiment in the lithiation/trapping of 10    
Earlier work by Coldham and O’Brien also showed slower trapping of lithiated N-Boc 
piperidine 10 by PhMe2SiCl than with Me3SiCl by examination of enantiomeric ratios 
of the corresponding products.
73
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1.2.4 Dynamic Kinetic and Thermodynamic Resolution of N-Boc Piperidine  
Coldham applied a dynamic kinetic resolution (DKR) approach to the synthesis of 
substituted N-Boc piperidines.
76
 Treatment of stannane 70 with n-BuLi and ligand ent-
63 in Et2O at –10 °C effected Sn/Li exchange generating diastereomeric lithiated 
intermediates that readily interconverted. After an hour at –10 °C, Me3SiCl was added 
slowly over 4.5 h. Silyl piperidine (S)-64 was isolated in 62% yield and 93:7 er (Scheme 
1.35). 
 
Scheme 1.35 
A dynamic kinetic resolution via deprotonation of N-Boc piperidine 10 with s-BuLi was 
also demonstrated (Scheme 1.36). Racemic lithiation was accomplished using s-
BuLi/TMEDA in THF at –78 °C for 3.5 h. Subsequent warming to –20 °C before 
addition of n-BuLi and ent-63 and then Me3SiCl gave silyl piperidine (S)-64 in 60% 
yield and 95:5 er. 
 
Scheme 1.36 
The electrophile scope of this reaction was poor. Quenching the diastereomeric 
intermediates with dimethyl sulfate, DMF, Bu3SnCl or allyl bromide resulted in 
products with little or no enantioselectivity. This was attributed to more reactive 
electrophiles being unable to discriminate efficiently between the diastereomeric 
organolithium complexes.  
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As well as asymmetric deprotonation and DKR, a third mechanism by which 
enantioenriched substituted N-Boc heterocycles can be accessed is dynamic 
thermodynamic resolution (DTR).
77
 If the intermediate organolithium species is 
configurationally unstable in the presence of a chiral ligand, but the diastereomeric 
organolithium complexes do not interconvert on the timescale of the electrophilic 
trapping then the ratio of enantiomeric final products is dependent upon the ratio of the 
diastereomeric organolithiums. A general reaction mechanism is shown in Scheme 
1.37.
4,13
 First, deprotonation of substrate 18 with an organolithium (RLi) and a chiral 
ligand (L*) results in a mixture of diastereomeric organolithium complexes, (R)-19 and 
(S)-19. These two diastereomeric organolithiums can undergo interconversion through 
configurational instability at the rate, kinv, at a given temperature, to give a 
thermodynamic ratio of (R)-19 and (S)-19. These two diastereomeric complexes react 
with electrophiles (kR and kS), resulting in products (R)-20 and (S)-20. Because kR and 
kS are greater than the rate of interconversion of (R)-19 and (S)-19 (kinv), the 
thermodynamic ratio of diastereomeric organolithiums is effectively frozen. The 
enantioselectivity of a DTR process will directly reflect the thermodynamic ratio of 
diastereomeric organolithium species (R)-19 and (S)-19, which is governed by the 
energy difference between the two lithiated intermediates. In practice, the 
thermodynamic diastereomeric ratio of (R)-19 and (S)-19 is often formed at an elevated 
temperature (>–78 °C) and then the mixture is cooled to –78 °C to prevent further 
interconversion before an electrophile is added. 
 
Scheme 1.37 Mechanism of dynamic thermodynamic resolution 
An initial attempt at a DTR process applied to N-Boc piperidine 10 using ent-63 as a 
ligand resulted in a poor degree of enantioselectivity.
76
 However, a screen of 24 ligands 
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by Coldham and co-workers led to the development of a modestly successful method.
78
 
Lithiation of N-Boc piperidine 10 was performed at –78 °C with s-BuLi/TMEDA in 
Et2O. Then, the lithiated ligand 75 was added and the reaction warmed to –40 °C before 
ageing for 1.5 h to establish the thermodynamic ratio of diastereomeric organolithium 
complexes. Next, the reaction was cooled to –78 °C to prevent further interconversion 
of organolithiums, prior to addition of the electrophile. In this way, α-substituted 
piperidines (S)-64, (S)-70, (R)-76-77 were isolated in 47-65% yield and 77:23-80:20 er 
(Scheme 1.38). Allyl piperidine (R)-77 was formed through a Li/Zn/Cu transmetallation 
prior to electrophilic trapping. 
 
 
Scheme 1.38 Dynamic thermodynamic resolution of 10  
In 2010 Beng and Gawley reported a highly successful catalytic DTR approach for the 
formation of substituted N-Boc piperidines.
79
 Lithiation of 10 using s-BuLi/TMEDA 
was performed before addition of a substoichiometric amount (0.1 eq.) of lithiated 
ligand 78 and warming to –45 °C for 3 h. Following cooling to –78 °C, electrophile 
trapping gave a range of product in excellent yield and er. In one example, trapping with 
phenyl isocyanate gave (R)-79 in 68% yield and >99:1 er (Scheme 1.39). 
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Scheme 1.39 
For this procedure to be effective the asymmetric ligand-complexed lithiated 
intermediates must be configurationally labile at the reaction temperature and the 
TMEDA-complexed lithiated intermediates must be configurationally stable. 
Investigations showed that this was the case at temperatures below –27 °C. A full 
mechanistic study into the catalytic dynamic resolution of N-Boc piperidine 10 was 
reported.
80
  
 
1.2.5 Synthesis of Disubstituted N-Boc Piperidines 
In order to increase the complexity of substituted piperidine products, Beak investigated 
the regioselective and diastereoselective lithiation of racemic monosubstituted N-Boc 
piperidines.
74,75
 The regioselectivity and diastereoselectivity observed can be 
rationalised by the mechanism shown in Scheme 1.40.  
The substituent of N-Boc piperidine 80 adopts an axial orientation to avoid the 
unfavourable A
1,3
-type strain between the Boc group and the substituent.
81
 Lithiation of 
monosubstituted N-Boc piperidine 80 gives rise to the equatorially lithiated species 81. 
Equatorial lithiation is favoured because of the complex induced proximity effect and 
the fact that it avoids the repulsive interactions between the carbanionic lone pair in a p-
orbital and the amide π bond.13 Trapping with retention occurs to give equatorially 
substituted piperidine trans-82. Regioselectivity in the deprotonation event is due to 
lithiation occurring at the least sterically hindered position. 
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Scheme 1.40 Rationale for trans selectivity in the lithiation/trapping of 80 
Lithiation of 2-methyl-N-Boc piperidine 74 with s-BuLi/TMEDA followed by trapping 
gave disubstituted piperidines as single regioisomers and diastereomers.
75
 A set of 
representative examples, trans-74-d1, trans-83 and trans-84 are shown in Scheme 1.41. 
 
Scheme 1.41 Synthesis of 2,6-trans-disubstitited piperidines from 74  
This methodology has been recently applied to the synthesis of 2,6-dialkyl piperidine 
natural products by Beak,
82
 Beng and Gawley
83
 and Ferringa.
84
  
The synthesis of 2,4-disubsbtitiuted piperidines has been investigated by Beak.
74
 For 
example, lithiation of 4-phenyl N-Boc piperidine 66 with s-BuLi/TMEDA followed by 
trapping with methyl iodide gave cis-2,4-disubsitiuted piperazine cis-86 in 83% yield as 
a single diastereomer (Scheme 1.42). The diastereoselectivity can be rationalised 
through the phenyl ring of 66 adopting an equatorial orientation and the reaction 
proceeding through equatorial lithiation to lithiated species 85.  
 
Scheme 1.42 Synthesis of 2,4-cis-disubstitited piperidine cis-86 
Lithiation/trapping of 3-substituted piperidine 87 with s-BuLi/TMEDA and dimethyl 
sulfate resulted in the formation of trans-2,5-dimethyl piperidine trans-89 in 34% as a 
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single diastereomer (Scheme 1.43).
75
 The methyl substituent of 87 adopted an equatorial 
orientation and equatorial lithiation resulted in the formation of lithiated species 88. 
  
Scheme 1.43 Synthesis of 2,5-trans-disubstitited piperidine trans-89  
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1.3 Expanding the Electrophile Scope via Transmetallation. 
The asymmetric lithiation/trapping methodology of N-Boc heterocycles described thus 
far has been essentially limited to trapping with electrophiles that contain a carbonyl 
functionality or can undergo SN2 reactions. Addition of, for example, allyl halides 
generally resulted in low yields of 2-allyl cyclic amines.
85
 The enantiomeric ratios can 
also be lower than expected due to competing single electron transfer processes.
86
 To 
address these limitations, Dieter developed the transmetallation of racemic lithiated 
species derived from N-Boc pyrrolidine 12 and N-Boc piperidine 10 with CuCN.2LiCl 
and subsequent trapping with a wide range of electrophiles such as vinyl halides, allyl 
halides, propargyl bromides and Michael acceptors.
87-92
 Dieter also showed that 
lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-sparteine followed by 
transmetallation with 0.5 eq. of CuCN.2LiCl resulted in formation of dialkyl cuprate 90. 
Subsequent trapping with allyl bromide gave 2-allyl N-Boc pyrrolidine (R)-38 in 100% 
yield and 89:11 er (Scheme 1.44).
93
 There was only a slight loss of enantioenrichment 
from the lithiated intermediate, which is typically generated with ~95:5 er. 
 
Scheme 1.44 Asymmetric lithiation/transmetallation/trapping of 12 
Transmetalation of enantioenriched lithiated species using CuCN.2LiCl followed by 
trapping with allyl bromide has been widely accepted by the synthetic community. It 
has been used with N-Boc pyrrolidine based systems,
60,68,94
 and with N-Boc piperidines 
through DTR
78,85
 or asymmetric deprotonation.
95
 The general transmetallation to copper 
strategy has also been used in the synthesis of a range of naturally occurring alkaloids 
by Dieter,
96
 O’Brien,94 Coldham85 and Gawley83.  
In 2006, Campos published a pioneering report on the enantioselective α-arylation of N-
Boc pyrrolidine 12.
97
 Lithiation of 12 was followed by transmetallation to form 
configurationally stable alkyl zinc species 91 (Scheme 1.45). Palladium catalysed 
Negishi coupling using palladium(II) acetate and t-Bu3PHBF4 gave a range of 2-aryl 
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pyrrolidines in good yield and excellent enantioselectivity (96:4 er). As a typical 
example, 2-phenyl pyrrolidine (R)-39 was obtained in 82% yield and 96:4 er.  
 
Scheme 1.45 Asymmetric lithiation/Negishi coupling of 12 
Campos and co-workers applied the lithiation-arylation protocol to the synthesis of 
glucokinase activator (R)-93 on a large scale via synthesis of (R)-92 (Scheme 1.46).
98
 In 
a testament to both the asymmetric lithiation and Negishi methodology, (R)-92 was 
isolated in 64% yield with 96:4 er on a 6.0 mol scale. In total, 2.13 kg of (R)-92 was 
synthesised over two batches via this approach. 
 
Scheme 1.46 
The diamine-free high temperature lithiation methodology developed by O’Brien (see 
Scheme 1.16) has been applied to the α-arylation of N-Boc pyrrolidine 12 and N-Boc 
imidazolidine.
59
 Additionally, in 2011, O’Brien and Campos published a comprehensive 
study into the enantioselective lithiation/arylation of N-Boc pyrrolidine 12.
99
 The use of 
alternative diamines, namely the (+)-sparteine surrogate (+)-26 and the Alexakis 
diamine (R,R)-27, was investigated, as was the aryl halide scope and a two-ligand 
catalytic system. Vinyl halides were also successfully coupled. The application of the 
developed methodology to the synthesis of several natural products and drug molecules 
was undertaken: (S)-nicotine, (S)-SIB-1508Y, (R)-crispine A and (R)-maackiamine were 
all synthesised in a short number of synthetic steps (Figure 1.7) 
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Figure 1.7 
The lithiation/arylation methodology has been successfully applied to other 
heterocycles. Coldham reported the racemic lithiation/Negishi coupling of N-Boc 
piperidine 10
100
 and the O’Brien group reported an isolated asymmetric example.95 The 
asymmetric lithiation of the relatively unreactive N-Boc piperidine 10 with s-BuLi and 
the (+)-sparteine surrogate (+)-26 preceded transmetallation and Negishi coupling with 
4-bromoveratrole, to give aryl piperidine (S)-94 in a modest 33% yield and 82:18 er 
(Scheme 1.47). 
 
Scheme 1.47 
Coldham attempted to use a DTR lithiation approach to form 2-aryl piperidines.
101
 
However, it was found that zinc to palladium transmetallation did not occur, possibly 
due to coordination of the bulky DTR ligands to the zinc. To circumvent this problem, 
Sn/Li exchange of enantioenriched stannane (S)-70 (itself synthesised via a DTR 
protocol) and then Negishi coupling give 2-aryl piperidines with modest levels of 
enantioselectivity, (R)-95 and (R)-96 were obtained in 71% and 56% yields respectively 
and in 82:18 er (Scheme 1.48). Subsequently, Gawley reported a catalytic dynamic 
resolution method for the α-arylation and vinylation of N-Boc piperidine 10 in 2010.102  
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Scheme 1.48 DTR lithiation/Negishi coupling of (S)-70 
Knochel and co-workers applied the racemic lithiation/arylation methodology to the 
synthesis of di- and trisubstituted piperidines.
103
 Lithiation of 4-substitiuted piperidines 
followed by Negishi coupling gave rise to cis-2,4-disubstitiuted piperidines in good 
diastereomeric ratios and the rationale for the cis-diastereoselectivity is shown in 
Scheme 1.42. Lithiation/arylation of 4-substituted piperidines 66, 97 and 98 using 4-
iodobenzotrifluoride, Pd(dba)2 and either SPhos or RuPhos gave 2-aryl piperidines cis-
99, cis-100 and cis-101 in 64% yield (97:3 dr), 81% yield (95:5 dr) and 81% yield (95:5 
dr) respectively (Scheme 1.49). 
Scheme 1.49 Racemic lithiation/Negishi coupling of racemic N-Boc piperidines 
Interestingly, lithiation of 2-methyl N-Boc piperidine 74 followed by transmetallation 
and Negishi coupling gave trans-2,5-substituted N-Boc piperidine trans-102 in 90% 
yield and 93:7 dr. None of the expected trans-2,6-substituted N-Boc piperidine trans-
103 was observed (Scheme 1.50). Knochel proposed that formation of trans-102 can be 
accounted for by β-hydride elimination of the palladium intermediate. The resulting 
“PhPdL2H” complex can then undergo syn-addition to the tetrahydropyridinyl ring, 
placing the palladium in the least sterically hindered 3-position. Reductive elimination 
then gave the 2,5-substitited product trans-102. The high level of diastereoselectivity 
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was accounted for by the “PhPdL2H” complex remaining coordinated to the bottom face 
of the ring after β-hydride elimination. 
 
Scheme 1.50 Unexpected synthesis of trans-2,5-substituted N-Boc piperidine trans-102 
Baudoin capitalised on Knochel’s observation and recently developed a β-selective 
arylation of N-Boc piperidines through a regioselective ligand controlled 
lithiation/arylation procedure.
104
 Lithiation of N-Boc piperidine 10 under standard 
racemic conditions (s-BuLi/TMEDA in Et2O at –78 °C) was followed by 
transmetalation and arylation using 4-bromobenzotrifluoride, Pd2(dba)3 and Buchwald 
ligands to give a mixture of α- and β-arylated piperidines 105 and 106 (Scheme 1.51). 
When using similar conditions to those employed by Knochel, namely using SPhos as a 
ligand, 105 and 106 were isolated in a combined 78% yield in a 94:6 ratio. Interestingly, 
use of pyrrole derived phosphine ligand 104 gave a 91:9 mixture of 106 and 105, with 
the former being isolated in 59% yield after flash column chromatography. 
 
Scheme 1.51 Ligand controlled regioselective lithiation/arylation of 10 
The use of phosphine ligand 104 resulted in good regioselectivity for the β-arylated 
products for a wide range of aryl iodides. Computational studies showed that reductive 
elimination to form the C-Ar bond was the rate-determining step, with the transition 
state for the formation of β-arylated product 106 being 1.4 kcal mol-1 lower in energy 
than the corresponding transition state for formation of α-arylated product 105 (when 
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104 was used as a ligand). Application of the same reaction conditions to analogous 5, 7 
and 8- membered rings resulted in the preferential formation of α-arylated products.  
Recently, Fu and co-workers have reported an enantioselective nickel catalysed alkyl-
alkyl cross coupling between N-Boc pyrrolidine 12 and secondary alkyl halides.
105
 
Racemic lithiation of N-Boc pyrrolidine 12 with s-BuLi/TMEDA followed by 
transmetalation using ZnCl2 was performed. Coupling in the presence of a nickel 
catalyst and chiral diamine (R,R)-107 was successful with a range of secondary alkyl 
iodides and bromides to give 2-alkyl pyrrolidines in excellent yield and er. In one 
example, coupling with cyclohexyl iodide gave (S)-108 in 80% yield and 97:3 er 
(Scheme 1.52). Experiments using an enantioenriched organozinc species showed 
ligand controlled stereoselectivity regardless of the original enantioenrichment. The 
origin of enantioselectivity is not known, but kinetic resolution has been ruled out. 
 
Scheme 1.52 
In a ground-breaking recent publication, Feringa disclosed the direct palladium-
catalysed cross coupling of alkyl and aryl bromides with alkyl and aryl lithium reagents 
at room temperature.
106
 A wide range of examples was given, but the coupling of 
secondary alkyl lithiums and aryl bromides was probably of most interest. In one 
example, coupling between i-PrLi and 4-bromoanisole 109 using Pd(t-Bu3P)2 in toluene 
at room temperature gave 110 in 78% yield (Scheme 1.53). It is possible that this 
methodology could be applied to the racemic synthesis of 2-aryl N-Boc heterocycles.  
 
Scheme 1.53  
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1.4 Project Outline 
The research described within this thesis covers a number of issues relating to the 
lithiation/trapping of N-Boc heterocycles.  
Since Beak’s original report of the Boc directed lithiation of nitrogen heterocycles, 
considerable advances have been made. However, the time taken for the lithiation and 
trapping events has never been systematically studied. Building on previous work 
within the O’Brien group, the use of in situ ReactIR™ spectroscopy to build-up a full 
picture of the time taken for lithiation and trapping events will be detailed. This should 
lead to an improved understanding of the processes involved and aid reaction 
optimisation. Monitoring changes in the carbamate νC=O allows progress of the reaction 
to be observed, from 111 through the pre-lithiation complex 112, lithiated intermediate 
113 and finally the α-substituted N-Boc heterocycle 114 (represented in generic form in 
Scheme 1.54). This investigation is presented in Chapter 2. 
 
Scheme 1.54  
The lithiation of N-Boc pyrrolidine 12 and N-Boc piperidine 10 has been extensively 
studied by Beak, O’Brien and others. However, very little work has been performed on 
N-Boc piperazine systems, even though piperazines are very common within medicinal 
compounds.
107
 Although a few reports of racemic lithiation/trapping exist, there has 
only been one isolated example of the asymmetric lithiation/trapping of N-Boc 
piperazines.
108
 A general, asymmetric lithiation/trapping of N-Boc piperazines 115 will 
be detailed, with a full exploration of the scope and limitations of the methodology 
(Scheme 1.55).  
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Scheme 1.55 
In situ ReactIR
™
 spectroscopy will be used to determine the time taken for the lithiation 
and trapping events. Additionally, transmetallation to zinc and subsequent Negishi 
coupling to give α-aryl piperazines will be explored. Both the racemic and asymmetric 
lithiation/trapping investigations will be reported (Chapters 3 and 4). 
The major problem faced by the modern asymmetric lithiation chemist is the lack of a 
reliable supply of (–)-sparteine. Although the (+)-sparteine surrogate (+)-26 is in many 
ways superior to (–)-sparteine for asymmetric deprotonation chemistry, the antipode    
(–)-26 is not readily available. Chapter 5 will detail investigations into the synthesis of a 
direct (–)-sparteine replacement, the (–)-sparteine surrogate (–)-26. Firstly, an attempt at 
the classical resolution of racemic surrogate 26 will be explored. Secondly, a synthesis 
of enantiopure (–)-26 from commercially available precursors, building on work 
previously reported within the O’Brien group, will be described (Scheme 1.56). 
 
Scheme 1.56
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Chapter Two: In situ IR Monitoring of the 
Lithiation/Trapping of N-Boc Heterocycles 
The lithiation of N-Boc heterocycles using s-BuLi and diamines has traditionally been 
performed at –78 °C for between three and six hours before addition of the electrophile. 
However, there is little evidence to suggest that these lengthy reaction times are 
required apart from with the most unreactive substrates. It was envisaged that a 
comprehensive in situ ReactIR
™
 spectroscopic investigation involving monitoring of the 
lithiation of N-Boc heterocycles with a range of diamines would provide definitive 
lithiation times for each N-Boc heterocycle. This would be of much use in the 
optimisation of lithiation methodology as well as providing a handy guide for the 
application of this methodology to new substrates. 
This chapter details an investigation into the in situ ReactIR
™
 monitoring of the 
lithiation times of commonly used N-Boc heterocycles to build up a relative reactivity 
series. Heterocycles that have been regularly investigated by the synthetic community 
have been used in conjunction with diamines, such as TMEDA, (–)-sparteine and the 
(+)-sparteine surrogate (+)-26.  
The use of in situ ReactIR
™
 spectroscopy has been recently adopted by several groups 
for the monitoring of lithiation reactions. However, very few examples of the use of this 
technique for the monitoring of the electrophilic trapping step have been performed. 
The second part of this chapter will look at the time taken for electrophile trapping 
using N-Boc pyrrolidine 12, 4-phenyl N-Boc piperidine 66 and N-Boc-N′-benzyl 
piperazine 117 as representative substrates (Figure 2.1). The effect of the substrates, the 
nature of electrophiles and of the diamines will be presented.  
 
Figure 2.1 N-Boc heterocycles used for the in situ ReactIR
™
 spectroscopic study of 
trapping times  
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2.1 Previous Use of the in situ IR Monitoring of Lithiation Reactions 
Directed lithiation adjacent to heteroatoms has previously been studied using in situ IR 
spectroscopy. Beak and Smith reported the first use of such a technique in 1983 when 
they observed the existence of a pre-lithiation complex directly, using stopped flow in 
situ IR and observing shifts in the carbonyl region of the spectrum.
18
 Addition of s-BuLi 
to hindered amide 118 (νC=O 1650 cm
-1
) in cyclohexane at 25 °C led to the rapid 
formation of pre-lithiation complex 119 (νC=O 1625 cm
-1
). Lithiation then occurred to 
give lithiated species 120 (νC=O 1588 cm
-1
) (Scheme 2.1). The use of a non-coordinating 
solvent ensured lithiation proceeded through s-BuLi tetramers. An investigation into the 
kinetics of the lithiation of 118 with s-BuLi/TMEDA showed a rate enhancement. This 
was speculatively attributed not to be due to de-aggregation of the s-BuLi tetramers, but 
to the fact that TMEDA activates the coordinating organolithium agregate.
20
 
 
Scheme 2.1 
In 1984, An investigation into the enolisation of ketones with n-BuLi and s-BuLi in 
cyclohexane was reported by Smith.
109
 Using stopped-flow in situ IR it was shown that 
the organolithium reagents reacted as aggregates, reversibly forming a pre-lithiation 
complex 122 from ketone 121, before lithiation to give the enolate 123 (Scheme 2.2).  
 
Scheme 2.2 
Smith went on to investigate the nucleophilic addition of s-BuLi to esters and pre-
lithiation complexes were similarly observed.
110
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Collum probed the mechanism of enolisation of esters using LDA in ethereal 
solvents.
111
 In Et2O, addition of LDA to ester 124 (νC=O 1727 cm
-1
) resulted in the 
formation of pre-lithiation complex 125 (νC=O 1703 cm
-1
) before formation of lithium 
enolate 126 (νC=C 1646-1664 cm
-1
) (Scheme 2.3). Interestingly, the pre-lithiation 
complex was not observed for enolisation in THF. Kinetic studies indicated that 
enolisation was effected by the LDA/THF monomer after pre-equilibration from the 
dimer. Further studies into the role of solvents and additives and the resulting LDA 
aggregation states were conducted.
112
  
 
Scheme 2.3 
Collum and co-workers also reported the monitoring of the α-lithiation of imine 127 by 
in situ ReactIR
™
 spectroscopy.
113
 Deprotonation of imine 127 with n-BuLi in pentane 
with a range of diamines to give 128 was followed by monitoring the disappearance of 
the band for the starting material (νC=N 1661 cm
-1
) (Scheme 2.4). ReactIR
™
 spectroscopy 
was also used to determine the relative rates of α-deprotonation and 1,2-addition to a 
different imine through kinetic studies. 
 
Scheme 2.4 
In 2001, Beak reported the first use of in situ ReactIR
™
 spectroscopy to monitor a Boc-
directed α-lithiation process.114 Addition of n-BuLi to a mixture of allylamine derivative 
129 (νC=O 1695 cm
-1
) and (–)-sparteine led to consumption of 129 and rapid formation of 
pre-lithiation complex 130 (νC=O 1675 cm
-1
) before slow formation of lithiated 
intermediate 131 (νC=O 1640 cm
-1
) (Scheme 2.5). Investigation into the kinetics of 
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deprotonation showed that the reaction rate exhibited a zero-order dependence on the 
concentration of n-BuLi/(–)-sparteine. This gave credence to the assumption that the 
signal at νC=O 1675 cm
-1 
was indeed due to pre-lithiation complex 130. 
 
Scheme 2.5 
More recently, O’Brien and Campos used in situ ReactIR™ spectroscopy to determine 
the time taken for the lithiation of N-Boc piperidine 10 using s-BuLi and TMEDA, (–)-
sparteine or (+)-sparteine surrogate (+)-26 at –70 °C.95 Addition of s-BuLi to 10 (νC=O 
1695 cm
-1
) in MTBE led to the formation of pre-lithiation complex 132 (νC=O 1675 cm
-
1
). Then, addition of TMEDA resulted in deprotonation and lithiated intermediate 11 
(νC=O 1644 cm
-1
) was observed (Scheme 2.6). Lithiation was found to be complete 
within 1 hour at –70 °C. This was the first direct observation of a pre-lithiation complex 
for an N-Boc heterocycle. 
 
Scheme 2.6 
Lithiation in the presence of (–)-sparteine was considerably slower. Lithiated 
intermediate 11 was found to be only a minor component (~10%) after 6 hours. 
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Conversely, lithiation of N-Boc piperidine 10 using s-BuLi/(+)-sparteine surrogate (+)-
26 led to rapid formation of lithiated species 11, with lithiation reaching completion 
within 3 hours. The reactivity series of the s-BuLi/diamine complexes observed in this 
study corroborated the reactivity series determined by competition experiments in the 
lithiation of N-Boc pyrroline 12 (see Scheme 1.14).
53
 
In situ ReactIR
™
 spectroscopy is a powerful tool for detecting reactive intermediates 
and for elucidating reaction times and kinetics. Additionally, it can be used to probe the 
subtleties of reaction mechanisms. In 2012, O’Brien and Coldham reported the benzylic 
lithiation of 2-phenyl N-Boc pyrrolidine 39, with the methodology development assisted 
by the use of in situ ReactIR
™ 
spectroscopy.
115
 Lithiation of 2-phenyl N-Boc pyrrolidine 
39 (νC=O 1701 cm
-1
) with n-BuLi in THF at –78 °C was monitored by in situ ReactIR™ 
spectroscopy. It was found that fast initial lithiation to give lithiated species 133 (νC=O 
1643 cm
-1
) occurred within 2 min (Scheme 2.7). However, the reaction only reached 
partial completion. This was attributed to the fact that N-Boc rotamers 39a and 39b do 
not readily interconvert at –78 °C. Only 39a can undergo benzylic lithiation due to the 
alignment of the Boc group. α-Lithiation of 39b does not occur as n-BuLi is not basic 
enough to cause the transformation. 
 
Scheme 2.7 Partial lithiation of 2-phenyl N-Boc pyrrolidine 39 
ReactIR
™
 spectroscopy was used to find a temperature at which N-Boc rotamers 39a 
and 39b could interconvert without significant loss of enantioenrichment, due to 
configurational instability of the intermediate organolithium.
61
 The optimised conditions 
of –50 °C for 5 min before electrophile addition led to a range of products in good yield 
and er. In one example, 2-phenyl N-Boc pyrrolidine (R)-39 (97:3 er) was converted into 
ester (R)-134 in 78% yield and 94:6 er (Scheme 2.8). 
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Scheme 2.8 
Interestingly, ReactIR
™
 spectroscopy showed that the rotamers of the six-membered 
analogue, 2-phenyl N-Boc piperidine 95 interconverted rapidly at –78 °C. A pre-
lithiation complex was not observed in these cases, possibly due to the use of THF as a 
solvent, as observed by Collum in the enolisation of esters with LDA.
112
 
In situ ReactIR
™
 spectroscopy has not only been used to monitor the lithiation of N-Boc 
heterocycles. O’Brien and Campos showed that it was possible to monitor the entirety 
of a lithiation/transmetallation/Negishi coupling sequence with N-Boc pyrrolidine 12.
99
 
Lithiation of 12 (νC=O 1697 cm
-1
) using s-BuLi/(–)-sparteine proceeded via a pre-
lithiation complex (not shown) to give 2-lithio-N-Boc pyrrolidine (S)-25 (νC=O 1644 cm
-
1
) within 1 h (Scheme 2.9). Subsequent addition of ZnCl2 caused no change in the IR 
spectrum at –70 °C. However, transmetallation was observed upon warming to 20 °C to 
give an organozinc species (S)-91 (νC=O 1653 cm
-1
). Finally, Negishi coupling was 
observed upon addition of bromobenzene, palladium(II) acetate  and t-Bu3PHBF4 to 
give (R)-39 (νC=O 1702 cm
-1
). 
 
Scheme 2.9 
With the pioneering work by Beak, Smith, Collum, Campos and O’Brien, the use of in 
situ ReactIR
™
 spectroscopy for monitoring lithiation reactions has become more 
commonplace. Recently Coldham applied the use of in situ ReactIR
™
 monitoring to the 
lithiation of N-Boc tetrahydroisoquinoline 135.
116
 It was shown that only partial 
lithiation occurred at –78 °C due to the fact that the N-Boc rotamers of 135 did not 
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interconvert at low temperature. However, with n-BuLi in THF at –50 °C, complete 
benzylic lithiation of N-Boc tetrahydroisoquinoline 135 (νC=O 1696 cm
-1
) occurred to 
give lithiated species 136 (νC=O 1635 cm
-1
) (Scheme 2.10) 
 
Scheme 2.10 
Clayden and co-workers have used the technique for monitoring the organolithium 
mediated intramolecular arylation and vinylation of ureas.
117-119
 In one study, treatment 
of vinyl urea (S)-137 (νC=O 1664 cm
-1
) with s-BuLi in Et2O at –78 °C led to the 
formation of pre-lithiation complex 138 (νC=O 1646 cm
-1
) and then lithiated species 139 
(νC=O 1608 cm
-1
). Upon warming the reaction to –15 °C, rearrangement to 141 (νC=N 
1575 cm
-1
) occurred through intermediate 140. Finally, quenching the reaction with 
MeOH resulted in the formation of rearranged product (R)-142 (νC=O 1665 cm
-1
) 
(Scheme 2.11).
118
 
 
Scheme 2.11 Organolithium mediated rearrangement of (S)-137 
Researchers at Pfizer have used in situ ReactIR
™
 spectroscopy to assess the stability of 
intermediates in an Ireland-Claisen rearrangement.
120
 Treatment of N-Boc ester 143 
(νC=O 1752, 1714 cm
-1
) with >2.0 eq. of LDA at –65 °C resulted in the formation of 
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conjugated enolate 144 (νC=N and νC=C 1620 cm
-1
). Subsequent warming to 0 °C caused 
rearrangement to acid 145 (Scheme 2.12). 
 
Scheme 2.12 
To date, as far we are aware, only one example detailing the ReactIR
™
 spectroscopic 
monitoring of the trapping of an organolithium species has been reported. In 2008, 
Yamamoto published an investigation into the trapping and rearrangement of a lithium 
enolate.
121
 Phenyl ester 146 (νC=O 1763 cm
-1
) was subjected to LDA in THF at   –78 °C 
and the rapid formation of lithium enolate 147 (νC=C 1702 cm
-1
) was observed. 
Subsequent addition of nitrosobenzene resulted in fast trapping and formation of 
oxazetidin-4-one 149 (νC=O 1846 cm
-1
) via 148, within 1 min. Upon warming to –20 °C, 
149 underwent fragmentation resulting in the formation of imine isomers 150 (νC=N 
1695, 1679 cm
-1
) (Scheme 2.13). The observation of oxazetidin-4-one 149 by in situ 
ReactIR
™
 spectroscopy was used as proof of the reaction mechanism. 
 
Scheme 2.13 
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In situ IR monitoring of lithiation reactions has allowed real time visualisation of 
reaction progress and the ability to investigate the effect of solvents, temperature and 
additives. ReactIR
™
 spectroscopic monitoring of lithiation reactions has been used for 
the direct observation of pre-lithiation complexes and other reaction intermediates, 
hence allowing elucidation of reaction mechanisms. Additionally, the technique has 
been used recently to study the rotation of Boc rotamers of N-Boc heterocycles at low 
temperature. However, the incredibly powerful technique has not previously been 
applied to the systematic study of the lithiation/trapping of N-Boc heterocycles. 
Whilst ReactIR
™
 spectroscopic monitoring of lithiation reactions is a powerful 
technique, there are significant limitations. The absolute concentration of a species in a 
reaction is impossible to determine from the absorbance alone. Calibration curves can 
be obtained for some species, although this is not possible for transitory, unstable 
organolithium intermediates. Additionally, due to the corrosive nature of s-BuLi, the 
reactions need to be run at low concentration to avoid damaging the ReactIR
™
 probe. 
Therefore, in order to generate a reliable signal to noise ratio, measurements cannot be 
recorded more frequently than every minute. This prevents drawing accurate 
comparisons about relatively fast lithiation reactions. Also, the temperature dependence 
of the IR spectrum makes it difficult to vary the reaction temperature within an 
experiment.  
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2.2 In situ ReactIR
™
 Spectroscopic Monitoring of N-Boc Heterocycle 
Lithiations 
Building upon previous work within the O’Brien group, both published95,99 and 
unpublished,
122
 the development of a definitive guide for the time required for complete 
lithiation of a range of N-Boc heterocycles with a range of diamines was undertaken. 
The substrates chosen for study are shown in Figure 2.2. Heterocycles that have 
previously been widely studied for asymmetric lithiation/trapping methodologies such 
as N-Boc pyrolidine 12 and N-Boc piperidine 10 were included, together with substrates 
at the main focus of this thesis, N-Boc piperazines 117, 151 and 152. The effect of ring 
size was of interest and therefore N-Boc azepine 153 and N-Boc imidazolidine 154 were 
chosen as substrates. The effect of heteroatoms and substituents in the 4-position of 
piperidines was of interest and therefore N-Boc morpholine 155 and substituted N-Boc 
piperidines 49, 66, 68, 97, 98 and 156 were also chosen for study.  
 
 
Figure 2.2 N-Boc heterocycles used for the in situ ReactIR
™
 spectroscopic study of 
lithiation times 
The diamines employed were TMEDA, (–)-sparteine and the (+)-sparteine surrogate 
(+)-26. In general, reactions were performed by pre-mixing a solution of N-Boc 
heterocycle and diamine at –78 °C in Et2O before addition of s-BuLi. An IR spectrum 
was recorded every minute and the time taken for the lithiation to reach completion was 
determined based on the decrease in νC=O for the starting material and the corresponding 
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increase in νC=O for the lithiated species. No attempt to trap the lithiated intermediates 
was undertaken, except in the case of N-Boc morpholine 155.  
Since Beak’s pioneering report of the asymmetric lithiation/trapping of N-Boc 
pyrrolidine 12,
42
 it has been the heterocycle of choice for the development of many new 
asymmetric deprotonation methodologies.
36
 Therefore, initial in situ ReactIR
™
 
spectroscopic studies focused on verifying the results obtained within the O’Brien group 
with N-Boc pyrrolidine 12.
122
  
ReactIR
™
 monitoring of the addition of s-BuLi to 12 at –78 °C in Et2O in the presence 
of TMEDA was performed (Scheme 2.14). The data are presented in two forms. Firstly, 
the 3D plot shows the progress of the reaction over time and the appearance and 
disappearance of signals within the carbonyl region can clearly be seen. Secondly, the 
2D plot shows the change in absorbance at specific wavelengths over time, with N-Boc 
pyrrolidine 12 shown in blue, the pre-lithiation complex 157 in green and the lithiated 
species 25 in red. In this case, addition of s-BuLi to 12 caused the partial disappearance 
of the signal at νC=O 1702 cm
-1
 and a new signal being observed at νC=O 1679 cm
-1
. Due 
to the overwhelming literature precedent and the signal’s transitory nature, this was 
assigned to the pre-lithiation complex 157. A second new signal was observed at νC=O 
1650 cm
-1
 and assigned to the lithiated intermediate 25. The data shows that complete 
lithiation occurs within 5 min at –78 °C. This agrees with previous work in the O’Brien 
group.
122
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Scheme 2.14 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi/TMEDA. The position of the arrow shows the time when the indicated reagent 
was added to the reaction mixture 
The fact that the lithiation was complete within 5 min shows that the 3.5 h lithiation 
time originally used by Beak was unnecessary.
34
 The structures of 157 and 25 shown 
(and those presented throughout this chapter) are possibly oversimplified, as aggregated 
species may have formed. Nonetheless, work by Beak proposed similar structures of a 
pre-lithiation complex and lithiated intermediate with i-PrLi/(–)-sparteine (see Scheme 
1.11).
11
 
An analogous reaction was performed in the presence of (–)-sparteine (Scheme 2.15). 
Addition of s-BuLi to a mixture of 12 (νC=O 1702 cm
-1
) and (–)-sparteine resulted in 
formation of the pre-lithiation complex 157 (νC=O 1680 cm
-1
). Due to the lithiation with 
s-BuLi/(–)-sparteine being slower than with s-BuLi/TMEDA more of the pre-lithiation 
complex 157 was initially observed. Complete consumption of both starting material 12 
and pre-lithiation complex 157 to give 2-litio-N-Boc pyrrolidine 25 (νC=O 1643 cm
-1
) 
occurred within 1 h. Clearly, the lithiation event does not require the long lithiation 
times (4–6 h) originally reported.42,62 
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Scheme 2.15 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi/(–)-sparteine.  
Lithiation of N-Boc pyrrolidine 12 with s-BuLi and (+)-sparteine surrogate (+)-26 
proceeded rapidly via pre-lithiation complex 157 (νC=O 1680 cm
-1
) to give lithiated N-
Boc pyrrolidine 25 (νC=O 1647 cm
-1
) in under 2 min (Scheme 2.16). The 5 h lithiation 
time reported by O’Brien and co-workers was unnecessary.48  
 
 
Scheme 2.16 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi/(+)-sparteine surrogate (+)-26 
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As can been seen from these two results, lithiation of N-Boc pyrrolidine 12 with s-
BuLi/(+)-26 was an order of magnitude faster than with s-BuLi/(–)-sparteine, 
corroborating observations made using competition experiments by O’Brien and co-
workers (see Scheme 1.14).
53
 This trend has also been reported using in situ ReactIR
™
 
spectroscopy studies on N-Boc piperidine 10.
95
 
In 2010, O’Brien and co-workers reported the diamine-free lithiation of N-Boc 
pyrrolidine 12 using s-BuLi in THF at a range of temperatures. When the lithiation was 
performed for 1 h at –78 °C, followed by electrophile trapping, yields of up to 89% of 
α-substituted pyrrolidines were reported.59 This indicated that complete lithiation was 
occurring within 1 h. To confirm this observation, ReactIR
™
 monitoring of this 
lithiation of N-Boc pyrrolidine 12 in THF was performed (Scheme 2.17). Interestingly, 
addition of s-BuLi to 12 (νC=O 1697 cm
-1
) in THF did not result in an observable peak 
for the pre-lithiation complex. The only new species to be identified was lithiated 
species 158 (νC=O 1649 cm
-1
). Lithiation was sluggish, taking 90 min to reach 
completion. However, the yield of α-substituted pyrrolidines obtained by O’Brien after 
a lithiation time of 1 h (89%) indicates that the reaction was nearly complete after this 
time. The solution structure of organolithium 158 is unknown. It is possibly a 
monomeric species coordinated by two molecules of THF. However, other aggregation 
states are possible. 
 
 
Scheme 2.17 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi in THF 
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An experiment to determine the background rate of the lithiation of 12 in Et2O in the 
absence of a diamine was also conducted (Scheme 2.18). A previous report had shown 
that lithiation for 1 h with s-BuLi in Et2O at –78 °C followed by trapping resulted in 
only an 8% yield of an α-substituted pyrrolidine.59 Addition of s-BuLi to 12 (νC=O 1701 
cm
-1
) in Et2O at –78 °C resulted in almost complete formation of pre-lithiation complex 
159 (νC=O 1680 cm
-1
). As expected, lithiation to give 22 (νC=O 1642 cm
-1
) was slow, with 
only a small amount of lithiated species being observed within 90 min. The structure of 
the pre-lithiation complex 159 is unknown. Due to the poor de-aggregating effect of the 
relatively non-coordinating Et2O solvent, lithiation may be effected by an aggregate.  
 
 
Scheme 2.18 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi in Et2O 
With the investigations into the optimum lithiation times for N-Boc pyrrolidine 12 with 
a range of ligands confirming previous results and observations, attention was turned to 
N-Boc piperazines. Lithiation of N-Boc-N′-benzyl piperazine 117 was performed under 
standard conditions (Et2O, –78 °C), using the three chosen diamines and under diamine-
free conditions in THF. The results of this investigation are presented in Scheme 2.19. 
As expected, lithiation of N-Boc-N′-benzyl piperazine 117 (νC=O 1696-1702 cm
-1
) 
proceeded via a pre-lithiation complex 160 (νC=O 1663-1681 cm
-1
) in all cases except 
under diamine-free conditions (Scheme 2.19d) to give lithiated species 161 (νC=O 1642-
1646 cm
-1
) or 162 (νC=O 1645 cm
-1
). It is worth noting that when (+)-26 was used, pre-
lithiation complex 160 was observed at a lower frequency (νC=O 1663 cm
-1
) than when 
TMEDA or (–)-sparteine were employed (νC=O 1680-1681 cm
-1
). 
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Scheme 2.19. Lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi and ligands, (a) 
TMEDA, (b) (–)-sparteine, (c) (+)-26, (d) THF  
Unsurprisingly, the reactivity order of the ligands is the same as seen with N-Boc 
pyrrolidine 12 and N-Boc piperidine 10. Use of s-BuLi and (+)-sparteine surrogate (+)-
26 results in the fastest lithiation, with N-Boc-N′-benzyl piperazine 117 being 
completely converted into lithiated species 161 within 2 min (Scheme 2.19c). With 
TMEDA, lithiation to 161 was complete within 5 min (Scheme 2.19a) and with (–)-
sparteine lithiation was complete within 1 h (Scheme 2.19b). The use of diamine-free 
conditions in THF resulted in lithiation to 162 being almost complete within 1 h, with 
the pre-lithiation complex not being observed (Scheme 2.19d). The times required for 
lithiation are similar to those seen for N-Boc pyrrolidine 12. 
(b) (a) 
(c) (d) 
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The effect of the protecting group on N-Boc piperazine was assessed by ReactIR
™
 
monitoring of N-Boc-N′-t-butyl piperazine 152 (νC=O 1694-1701 cm
-1
) (Scheme 2.20). 
As now expected, lithiation with s-BuLi/diamines proceeded via a pre-lithiation 
complex 163 (νC=O 1664-1681 cm
-1
) to lithiated piperazine 164 (νC=O 1644-1646 cm
-1
).  
 
         
      -       
Scheme 2.20 Lithiation of N-Boc-N′-t-butyl piperazine 152 with s-BuLi and ligands, (a) 
TMEDA, (b) (–)-sparteine, (c) (+)-26, (d) THF  
Although the reactivity order of the ligands remained the same, the t-butyl group 
resulted in much slower lithiation than seen with N-Boc-N′-benzyl piperazine 117. For 
example, lithiation of N-Boc-N′-t-butyl piperazine 152 with s-BuLi/(+)-sparteine 
surrogate (+)-26 took 5 min to reach completion (Scheme 2.20c) whereas with N-Boc-
N′-benzyl piperazine 117, lithiation was complete with 2 min (see Scheme 2.19c). 
Similarly, lithiation of N-Boc-N′-t-butyl piperazine 152 with s-BuLi and (–)-sparteine 
took more than 5 h (Scheme 2.20b) but was complete with 1 h with the N-benzyl 
(a) (b) 
(c) (d) 
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analogue 117 (see Scheme 2.19b). This difference in lithiation times is remarkable 
considering the distance of the nitrogen protecting group from the actual site of α-
lithiation.  
ReactIR
™
 monitoring studies with s-BuLi and diamines were performed with the full 
range of N-Boc heterocycles depicted in Figure 2.2. The results are summarised in 
Table 2.1 with in situ ReactIR
™
 traces detailed in the experimental section (see Chapter 
6.3). A full series of experiments with each N-Boc heterocycle and each diamine was 
not performed. However, sufficient experimentation was completed to provide a 
reactivity series for all 14 substrates. Table 2.1 details the time taken, in minutes, for 
complete lithiation of a particular N-Boc heterocycle using 1.3 eq. of s-BuLi and 
diamine at –78 °C (unless otherwise stated). Different diamines provided different 
relative time scales, with s-BuLi/(+)-sparteine surrogate (+)-26 or TMEDA resulting in 
relatively fast lithiations and s-BuLi/(–)-sparteine resulting in slow lithiations. The 
different reactivities of these lithiation systems allowed a relative order for very reactive 
and very unreactive N-Boc heterocycles to be established. Table 2.1 is ordered with the 
N-Boc heterocycles most reactive towards lithiation first and the most reticent last. 
Substrates were prepared using literature procedures
59
 or were available from elsewhere 
within the group.
70,122,123 
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TMEDA   1
a
 2
 a
 5 5 8 
(–)-Sparteine 1a 2 10 a 30 a 60 60 90 
(+)-26     2 2 2 
 
 
       
TMEDA  13  40 60 45
b
, 25
c
 50
b
, 35
c
 120
c
 
(–)-Sparteine  > 300      
(+)-26 4 5 30 20    
a
 2.6 eq. of s-BuLi and diamine were used. 
b
 Reaction performed at –60 °C. c Reaction 
performed at –50 °C. 
Table 2.1 Reactivity series of commonly used N-Boc heterocycles 
N-Boc morpholine 155 was found to undergo lithiation extremely rapidly, reaching 
completion within one minute when employing the slowest lithiation system, namely, s-
BuLi and (–)-sparteine. Lithiation was performed using 2.6 eq. of s-BuLi and (–)-
sparteine followed by trapping with benzophenone (Scheme 2.21). The trapping step 
was not monitored by ReactIR
™
 spectroscopy. Rapid deprotonation resulted in the 
formation of lithiated species (S)-166 (presumed stereochemistry), which was not 
stable.
122
 Under the reaction conditions ring-opening of 2-lithio-N-Boc morpholine (S)-
166 occurred to give alkoxide 167. A subsequent vinylic lithiation gave 168.
75
 Trapping 
with benzophenone and subsequent cyclisation resulted in oxazolidinone 169 being 
isolated in 40% yield. Due to the rapid vinylic lithiation of 167, 2.6 eq. of s-BuLi were 
required to ensure complete formation of 168. A similar ring-opening has been observed 
by Lautens for a related bicyclic system.
124
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Scheme 2.21 Mechanism of the formation of 169 
In order to determine the time required for the lithiation of 4-chloro N-Boc piperidine 
49 and 4-OTrisyl N-Boc piperidine 156, 2.6 eq. of s-BuLi/diamine were required. After 
the first rate determining lithiation of 49 to give 50, intramolecular cyclisation occurred 
to give a azabicyclo[3.1.0]hexane 51. A second rapid lithiation of the acidic cyclopropyl 
proton then occurred to give 170 (Scheme 2.22).
69
  
 
Scheme 2.22 Mechanism of lithiation of 49 
Lithiation of N-Boc imidazolidine 154 was the second fastest lithiation monitored. 
Reaction with s-BuLi and (–)-sparteine resulted in a rapid (2 min) but partial lithiation 
to 171 at –78 °C (Scheme 2.23). Coldham has previously noted (by 1H NMR 
spectroscopy) that the barrier to rotation of N-Boc rotamers 154a and 154b at –78 °C 
was >100 h, explaining the partial lithiation observed.
125
 Only N-Boc rotamer 154a 
underwent lithiation to 171; Coldham has shown that lithiation of rotamer 154b does 
not occur, possibly due to steric hindrance from the N-i-Pr group. 
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Scheme 2.23 Partial lithiation of N-Boc imidazolidine 154 
The effect of ring size on the lithiation times can be clearly seen. As previously 
observed using ReactIR
™
 spectroscopy, the lithiation of N-Boc pyrrolidine 12 was 
significantly faster than the lithiation of N-Boc piperidine 10.
95,99
 This study shows 
lithiation of the former using s-BuLi/TMEDA was complete within 5 min at –78 °C (see 
Scheme 2.14), whereas with N-Boc piperidine 10, complete lithiation required 50 min at 
–60 °C and 35 min at –50 °C. The seven-membered analogue N-Boc azepine 153 took 
even longer to lithiate, requiring 120 min at –50 °C to reach completion. Previous 
attempts at the lithiation/trapping of N-Boc azepine 153 with s-BuLi/TMEDA at –78 °C 
for 3-3.5 h resulted in poor yields of isolated products, which can now be accounted for 
by slow lithiation.
34,101
 
As previously noted, the time required for complete lithiation of N-Boc-N′-benzyl 
piperazine 117 was considerably shorter than for lithiation of N-Boc-N′-t-butyl 
piperazine 152. This was assumed to be due to steric factors even though the sterically 
demanding group is far removed from the site of lithiation. N-Boc-N′-methyl piperazine 
151 has a similar steric footprint and reactivity to N-Boc-N′-benzyl piperazine 117, 
adding support to this proposition. 
Interestingly, the lithiation of N-Boc-N′-benzyl piperazine 117 takes a considerably 
shorter time than the lithiation of N-Boc piperidine 10. Considering both systems are 
six-membered, the geometry of the heterocycle/s-BuLi/diamine complex would be 
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expected to be similar. It is possible that for N-Boc piperazines, back donation from the 
α-proton C-H σ bonding orbital into the anti-periplanar, low energy antibonding σ* C-N 
orbital makes the α-proton more acidic than that in N-Boc piperidine 10 (Figure 2.3). 
However, it is possible that this is an oversimplification and that the energy of the 
transition state structures governs lithiation rates.
43,72
 
 
Figure 2.3 Frontier molecular orbital explanation for the increased acidity of 117 
The above argument cannot explain the increase in reactivity of N-Boc imidazolidine 
154 in comparison with N-Boc pyrrolidine 12 as the former cannot adopt the necessary 
anti-periplanar geometry. Alternatively, the rate acceleration seen with N-Boc 
morpholine 155, N-Boc piperazine 117 and N-Boc imidazolidine 154 could be due to 
the acidifying effect of a β-heteroatom through simple electron withdrawal. 
The effect of the substituents on N-Boc piperidine is illuminating. Electron withdrawing 
substituents in the 4-position (OTrisyl and chloro) result in the time required for 
lithiation to be significantly reduced. Substituted piperidines 49 and 156 undergo 
complete lithiation with s-BuLi/TMEDA within 1 min and 2 min respectively, whereas 
the parent N-Boc piperidine 10 takes 50 min at –60 °C. It has been postulated that the 
difference in reactivity between 4-chloro-N-Boc piperidine 49 and N-Boc piperidine 10 
is due to overlap of the C-H σ bonding orbital and the σ* antibonding orbital of the C-Cl 
bond (Figure 2.4).
70
 This effectively makes the reactive α-proton more acidic, resulting 
in increased reactivity. 
 
Figure 2.4 Frontier molecular orbital explanation for the increased acidity of 49 
4-Methyl N-Boc piperidine 97 has similar lithiation times to N-Boc piperidine 10, with 
the methyl substituent having little effect on reactivity: 45 min and 50 min respectively 
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with s-BuLi/TMEDA at –60 °C. 4-Phenyl and 4-OTIPS piperidines 66 and 98 undergo 
lithiation slightly faster than N-Boc piperidine 10. The relative lithiation times of 4-
phenyl N-Boc piperidine 60 and 4-OTIPS N-Boc piperidine 98 are interesting. The use 
of s-BuLi/TMEDA results in 4-OTIPS N-Boc piperidine 98 undergoing complete 
lithiation in 40 min, whereas 4-phenyl N-Boc piperidine 66 takes 60 min for lithiation to 
reach completion, indicating that silyl-protected piperidine 98 is lithiated more readily. 
Conversely phenyl piperidine 66 underwent complete lithiation faster than silyl-
protected piperidine 98 when using s-BuLi/(+)-sparteine surrogate (+)-26 (20 min and 
30 min respectively). It is possible that this switch in relative rates is due to sterics. The 
bulky OTIPS group of 98 may clash with the relatively more bulky ligand (+)-26, thus 
slowing the reaction. 
Lithiation of acetal-protected piperidine 68 was rapid using s-BuLi and (+)-sparteine 
surrogate (+)-26 (4 min). However, only partial lithiation occurred. It is not known why 
this is the case but the same outcome was noted in an earlier study in the group.
122
 It is 
noteworthy that asymmetric lithiation/trapping of acetal protected piperidine 68 has 
been performed using Alexakis’ diamine, giving a 53% yield after trapping with 
Me3SiCl (see Scheme 1.31).
73
  
In situ ReactIR
™
 spectroscopy is an incredibly powerful tool for studying the time taken 
for the lithiation of N-Boc heterocycles. This study has detailed the wide reactivity of N-
Boc heterocycles towards deprotonation and highlighted patterns in the effect of 
substrate structure and diamine on lithiation times. Building upon earlier studies, this 
work has provided definitive lithiation times for a range of commonly used substrates 
and should act as a guide for further methodology development. Previous methods for 
determining the optimum lithiation times relied upon several lithiation/trapping 
reactions and analysis of the yields and enantioselectivities of these reactions, or 
alternatively, the use of competition experiments. The use of ReactIR
™
 spectroscopy to 
directly observed lithiation times not only simplifies the determination of lithiation 
times, but also does away with the reliance on the sometimes troublesome electrophilic 
trapping step. 
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2.3 In situ ReactIR
™
 Spectroscopic Monitoring of 2-Lithio-N-Boc 
Heterocycle Trapping 
2.3.1 Subtleties of Electrophilic Trapping of 2-Lithio-N-Boc Heterocycles 
It is tempting to assume that electrophilic trapping is a straightforward process with the 
electrophiles reacting rapidly with the highly reactive lithiated N-Boc heterocycles. 
There are several reports that hint that this may not be the case. Specifically, it is well 
known that alkyl lithium reagents can react slowly with chlorosilanes.
126-130
 
As shown in Schemes 1.33 and 1.34 the trapping of lithiated N-Boc piperidine 10 with 
certain electrophiles (PhMe2SiCl, methyl iodide and dimethyl sulfate) resulted in 
products with lower levels of enantioenrichment than expected.
95
 This was attributed to 
slow electrophile trapping at low temperature (–78 °C). As the reaction warmed up 
towards room temperature the enantioenriched lithiated intermediate became 
configurationally unstable.
61,131
 Subsequent trapping led to the observed low 
enantioselectivity. A second example is shown in Scheme 1.36. Coldham’s DTR of N-
Boc piperidines was only successful when Me3SiCl was used as an electrophile. This 
was due to the fact that Me3SiCl was relatively unreactive towards the lithiated N-Boc 
piperidine 10, which allowed discrimination between the diastereomeric organolithium 
complexes.
76
  
Slow trapping of lithiated N-Boc heterocycles is not just limited to N-Boc piperidine 10. 
The trapping of lithiated N-Boc pyrrolidine 12 by Me3SiCl may or may not be slow, but 
trapping clearly occurred at a temperature at which the lithiated intermediate was 
configurationally stable, as evidenced by the high er of the α-silyl pyrolidine product 
(see Scheme 1.7). This was not the case when trapping with sterically hindered silyl 
electrophiles. Products with poor levels of enantioselectivity were isolated, presumably 
due to the poor reactivity of the silanes towards the organolithium intermediates at low 
temperatures.
132-134
 For example, lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-
sparteine followed by trapping with Ph3SiCl gave silyl pyrrolidine (S)-172 in 52:48 er 
(66% yield) (Scheme 2.24).
132
 Trapping with the less hindered PhMe2SiCl led to 
products with excellent levels of enantioenrichment and (S)-173 was obtained in 93% 
yield and 97:3 er. Although trapping lithiated N-Boc pyrrolidine 12 with PhMe2SiCl 
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proceeded without complication, slow trapping was suspected with the analogous 
lithiated N-Boc piperidine 10.
95
  
 
Scheme 2.24 
The empirical evidence detailed suggests that the trapping rates of electrophiles with 
different N-Boc heterocycles may be markedly different. Unfortunately, drawing firm 
conclusions from isolated yields and enantioselectivities is difficult and provides scant 
information on the actual rates of electrophile trapping. It was envisaged that ReactIR
™
 
spectroscopy could provide more useful information on the time required for trapping 
with different electrophiles and N-Boc heterocycles. Additionally, the effect of different 
diamines, solvents and temperatures on the time taken for trapping could be directly 
quantified.  
 
 2.3.2 In situ ReactIR
™
 Spectroscopic Monitoring of Electrophilic Trapping 
The ReactIR
™
 spectroscopic investigation of the rate of electrophile trapping was 
focused on three N-Boc heterocycles: N-Boc pyrrolidine 12, N-Boc 4-phenyl piperidine 
66 and N-Boc-N′-benzyl piperazine 117 (see Figure 2.1). The substituted piperidine 66 
was chosen over N-Boc piperidine 10 as lithiation times at –78 °C for the latter were too 
long to be practical (see Table 2.1). 
A comparison of the time required for complete trapping with the three lithiated 
substrates using Me3SiCl as an electrophile was performed. The chlorosilane was 
chosen as an electrophile due to the fact that it is known to trap organolithiums slowly 
in some cases. This could allow any difference due to the nature of the N-Boc 
heterocycles to become evident. Reactions were generally performed at –78 °C to allow 
useful comparisons with previously reported reactions. Racemic lithiation using s-
BuLi/TMEDA in Et2O was chosen due to the short lithiation time. 
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To start with, s-BuLi was added to a stirred solution of N-Boc pyrrolidine 12 (νC=O 1702 
cm
-1
) and TMEDA in Et2O at –78 °C (Scheme 2.25). Complete lithiation occurred 
within 5 min to give lithiated N-Boc pyrrolidine 25 (νC=O 1650 cm
-1
). Then, Me3SiCl 
was added to the reaction. Formation of α-silyl N-Boc pyrrolidine 13 (νC=O 1695 cm
-1
) 
was observed (light blue line), and was complete within 15 min, as can be seen from the 
3D and 2D graphs. The reaction was then quenched with aqueous ammonium chloride 
at –78 °C. Following work-up and purification, 13 was isolated in 81% yield from this 
specific experiment. The pre-lithiation complex has not been included on the 2D graph 
for the sake of clarity. Although it appears that the 2D plot shows starting material 12 
reforming upon addition of the electrophile, the increase in absorbance at νC=O 1702 cm
-
1
 is due to the broadness of the peak for the product, α-silyl N-Boc pyrrolidine 13 (νC=O 
1695 cm
-1
).  
 
 
Scheme 2.25 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 12 
with s-BuLi/TMEDA and Me3SiCl. The position of the arrows show the time when the 
indicated reagents was added to the reaction mixture 
This result is identical to that reported by Beak, α-silyl N-Boc pyrrolidine 13 was 
obtained in 81% yield when lithiation of N-Boc pyrrolidine 12 was accomplished with 
s-BuLi/TMEDA followed by addition of Me3SiCl and subsequent warming to room 
temperature.
34
  
When lithiation of N-Boc 4-phenyl piperidine 66 (νC=O 1699 cm
-1
) was performed using 
s-BuLi/TMEDA to give lithiated species 174 (νC=O 1646 cm
-1
), followed by trapping 
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with Me3SiCl, 2-silyl piperidine cis-67 (νC=O 1691 cm
-1
) formed slowly at –78 °C 
(Scheme 2.26). The rate of trapping was much slower than with N-Boc pyrrolidine 12, 
as clearly shown by the 2D graph in Scheme 2.25. Trapping was incomplete after 2 h at 
–78 °C. At this point, the reaction was quenched with aqueous ammonium chloride and 
cis-α-silyl N-Boc-piperidine cis-67 was isolated in 39% yield with 49% recovered 
starting material 66. When Beak performed the same reaction, but allowed the reaction 
to warm to room temperature before quenching, cis-67 was obtained in 99% yield.
34
 
Silyl piperidine cis-67 was obtained as a single diastereomer due to an equatorial 
orientation of the phenyl ring, preferential equatorial lithiation and trapping with 
retention (see Scheme 1.42).
74
 
 
 
Scheme 2.26 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 66 
with s-BuLi/TMEDA and Me3SiCl 
When an analogous reaction using N-Boc-N′-benzyl piperazine 117 (νC=O 1698 cm
-1
) 
was performed, the rate of trapping was considerably slower than with N-Boc 4-phenyl 
piperidine 66. Very little trapping by Me3SiCl to give 175 (νC=O 1695 cm
-1
) was 
observed by ReactIR
™
 spectroscopy. The reaction was quenched after 1 h at –78 °C and 
α-silyl-N-Boc piperazine 175 was isolated in only 6% yield with 87% recovered starting 
material 117 (Scheme 2.27). When the same reaction was warmed to room temperature 
prior to quenching α-silyl-N-Boc piperazine 175 was obtained in a 68% yield (see 
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Scheme 3.4).
135
 ReactIR
™
 spectroscopy clearly shows that the low yield of products cis-
67 and 175 was due to inefficient trapping and not the lithiation step.  
 
Scheme 2.27 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 117 
with s-BuLi/TMEDA and Me3SiCl 
These three experiments show that there is a dramatic difference in the time taken for 
trapping with Me3SiCl for the three N-Boc heterocycles 12, 66 and 117. Historically, 
the standard operating procedure for lithiation/trapping reactions involved warming the 
reactions to room temperature slowly (over many hours) after addition of the 
electrophile. This procedure has unwittingly allowed the isolation of products in 
excellent yields in the cases of 4-phenyl piperidine 66 and N-Boc-N′-benzyl piperazine 
117 as trapping only proceeds quickly upon warming. In addition, for some substrates, 
trapping is complete relatively quickly at –78 °C and so long trapping times are not 
required. 
Work within the O’Brien group hinted at the slow trapping of lithiated N-Boc piperidine 
10 with methyl iodide and dimethyl sulfate.
95
 Therefore, in situ ReactIR
™
 monitoring of 
trapping using these electrophiles was investigated. Trapping rates with dimethyl sulfate 
and isolated product yields along with the 2D ReactIR
™
 traces are shown in Scheme 
2.28. It can be seen that trapping of the lithiated intermediate of N-Boc pyrrolidine 12 
was fast, with complete trapping occurring within 3 min to give 33, which was isolated 
in 66% yield. Trapping of lithiated N-Boc 4-phenyl piperidine 66 was much slower, 
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when the reaction was quenched after 2 h at –78 °C only a 52% yield of cis-86 was 
obtained (due to incomplete trapping). Trapping of lithiated N-Boc-N′-benzyl piperazine 
117 was even slower, with only a 4% yield of 176 obtained when quenching after 1 h at 
–78 °C.  
             
              
           
Scheme 2.28 In situ ReactIR
™
 spectroscopic monitoring of lithiation/trapping with s-
BuLi/TMEDA and dimethyl sulfate 
Lithiation of N-Boc heterocycles 12, 66 and 117 followed by trapping with methyl 
iodide showed the same order of trapping rates as with dimethyl sulfate (Scheme 2.29). 
Trapping of the lithiated intermediate from N-Boc pyrrolidine 12 was fast, with 
complete trapping occurring within 3 min at –78 °C to give 33 in 33% yield. This low 
yield is puzzling but, it is worth noting that a racemic lithiation of N-Boc pyrrolidine 12 
and trapping with methyl iodide has not been previously reported. Trapping of lithiated 
N-Boc 4-phenyl piperidine 66 was much slower, taking 30 min at –78 °C to reach 
completion, giving cis-86 in 70% yield. Trapping of lithiated N-Boc-N′-benzyl 
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piperazine 117 was much slower, being almost complete after 2 h at –78 °C, and led to 
the desired substituted N-Boc piperazine 176 in 75% yield. 
         
         
        
Scheme 2.29 In situ ReactIR
™
 spectroscopic monitoring of lithiation/trapping with s-
BuLi/TMEDA and methyl iodide 
The trend that lithiated N-Boc pyrrolidine 12 traps faster than lithiated N-Boc 4-phenyl 
piperidine 66, which in turn traps faster than lithiated N-Boc-N′-benzyl piperazine 117 
holds true for all three electrophiles. The differences in the rates at which the lithiated 
substrates are trapped are considerable. It is postulated that the trapping of lithiated N-
Boc-N′-benzyl piperazine 117 is slower than the trapping of lithiated N-Boc 4-phenyl 
piperidine 66 due to the fact that the α-carbanion of N-Boc-N′-benzyl piperazine 117 is 
more stable due to back donation into the low energy σ* of the anti-periplanar C-N 
bond. This is the same rationale as given for the rapid lithiation of 117 (see Figure 2.3). 
The ReactIR
™
 monitoring of the methylation of lithiated N-Boc heterocycles shows 
conclusively that methyl iodide traps faster than dimethyl sulfate. It was expected that 
the opposite would be the case, with the harder dimethyl sulfate reacting faster with the 
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hard organolithium. Although direct observation of the trapping of lithiated N-Boc 
piperidine 10 has not been performed in this investigation, O’Brien’s previous work on 
the lithiation of N-Boc piperidine 10 and subsequent trapping with methylating agents is 
consistent with the observation that methyl iodide traps faster than dimethyl sulfate at –
78 °C. A slightly higher enantiomeric ratio of 2-methyl N-Boc piperidine (R)-74 was 
obtained when using methyl iodide (64:36 er) compared to dimethyl sulfate (60:40 er) 
(see Scheme 1.33). The fact that methyl iodide reacts faster ensures that trapping 
probably occurred at a lower temperature. Therefore, less epimerisation of the newly 
created stereocentre through configurational instability was observed. This work has 
shown that Me3SiCl traps lithiated N-Boc heterocycles slower than both methyl iodide 
and dimethyl sulfate. This observation is contradicted by the fact that silyl piperidine 
(R)-64 was obtained in an excellent 86:14 er when trapping lithiated N-Boc piperidine 
10 with the relatively unreactive Me3SiCl (see Scheme 1.32). A lower enantioselectivity 
of (R)-64 would be expected due to the presumed slow trapping with Me3SiCl. 
The effect of different ligands on the trapping times was investigated next. To start 
with, lithiation of N-Boc-N′-benzyl piperazine 117 under diamine-free conditions (s-
BuLi/THF at –78 °C) followed by trapping with methyl iodide was performed. 
Complete trapping within 1 h at –78 °C occurred and 176 was isolated in 75% yield 
(Scheme 2.30). In contrast, when TMEDA in Et2O was used, complete trapping took 2 
h (see Scheme 2.29). It is possible that the reduction in steric bulk surrounding the 
lithium centre of the organolithium intermediate allowed faster trapping. 
            
Scheme 2.30 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 117 
with s-BuLi in THF and methyl iodide 
To investigate whether increasing the steric bulk of the diamine would have an effect on 
trapping rates, the lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-sparteine in Et2O 
at –78 °C followed by trapping with Me3SiCl was investigated. It can be seen from the 
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2D ReactIR
™
 spectrum in Scheme 2.31 that the trapping of lithiated N-Boc pyrrolidine 
12 with Me3SiCl in the presence of (–)-sparteine was very slow. When the reaction was 
quenched with aqueous ammonium chloride after 90 min at –78 °C, silyl N-Boc 
pyrrolidine (S)-13 was isolated in 12% yield and 98:2 er (determined by CSP-GC), 
along with 84% recovered starting material 12.  
           
Scheme 2.31 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 12 
with s-BuLi/(–)-sparteine and Me3SiCl at –78 °C 
For comparison, the analogous reaction with s-BuLi/TMEDA resulted in complete 
trapping within 15 min at –78 °C (see Scheme 2.25). These two results show that, for 
relatively unreactive electrophiles, the diamine has a considerable effect on the rates of 
not only lithiation, but also of the electrophilic trapping step.  
Beak and others have previously reported excellent results for the lithiation/trapping of 
N-Boc pyrrolidine 12 with s-BuLi, bulky chiral diamines and Me3SiCl. When 
employing s-BuLi/(–)-sparteine, silyl N-Boc pyrrolidine (S)-13 was isolated in 76% 
yield and 98:2 er (see Scheme 1.7).
42
 This indicates that although trapping with Me3SiCl 
is slow at –78 °C, trapping occurs as the reaction warms slowly to room temperature. 
Importantly, trapping occurs at a temperature below the point at which 2-lithio-N-Boc 
pyrrolidine 25 becomes configurationally unstable.  
Recent work within the O’Brien group has shown that lithiated N-Boc pyrrolidine 12 is 
configurationally stable at –40 °C in the presence of (–)-sparteine for at least 1 h.60 
Therefore, lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-sparteine at –78 °C was 
performed and the reaction was then allowed to warm to –40 °C. Once the ReactIR™ 
spectrum had stabilised, Me3SiCl was added (Scheme 2.32). Complete trapping was 
observed within 10 min at –40 °C and silyl N-Boc pyrrolidine (S)-13 was isolated in 
73% yield and 98:2 er. 
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Scheme 2.32 In situ ReactIR
™
 spectroscopic monitoring of the lithiation of 12 with s-
BuLi/(–)-sparteine at –78 °C and trapping with Me3SiCl at –40 °C 
The lithiation/trapping of N-Boc pyrrolidine 12 utilising Me3SiCl as the electrophile has 
historically been the test reaction for ligand screens and new methodology development. 
This ReactIR
™
 spectroscopic investigation has shown that the electrophile trapping in 
this case is not as straightforward as previously assumed. It is possible that this subtlety 
has had a detrimental effect on previous methodology development with potentially 
useful diamines being discarded due to inefficient trapping by Me3SiCl at low 
temperatures. One example may be the large ligand screen performed by Coldham and 
O’Brien for the asymmetric lithiation of N-Boc piperidine 10.73  
Although there was reason to suspect trapping with Me3SiCl, methyl iodide and 
dimethyl sulfate would be relatively sluggish, there was no empirical evidence to 
suggest that this would be the case with other commonly used electrophiles. With this in 
mind, a broader electrophile range was investigated to determine the effects of N-Boc 
heterocycle structure and diamine structure on the time required for trapping. First, 
cyclobutanone was employed as the electrophile; it was predicted to trap quickly and 
would not generate diastereomeric products. Lithiation of the three chosen N-Boc 
heterocycles was accomplished using s-BuLi/TMEDA in Et2O at –78 °C. As expected, 
trapping of lithiated N-Boc pyrrolidine 12 with cyclobutanone was fast, with complete 
trapping occurring in less than 1 min, giving 177 in 74% yield with 12% recovered N-
Boc pyrrolidine 12 (Scheme 2.33). Trapping of lithiated N-Boc 4-phenyl piperidine 66 
and N-Boc-N′-benzyl piperazine 117 were also complete within 1 min giving cis-178 
and 179 in 56% and 59% yield respectively. Starting materials 66 and 117 were 
recovered from these reactions in 31% and 29% respectively. 
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Scheme 2.33 In situ ReactIR
™
 spectroscopic monitoring of lithiation/trapping with s-
BuLi/TMEDA and cyclobutanone 
The moderate yields (56-74%) and recovery of significant quantities of starting 
materials (12-31%) of these three reactions can be attributed to enolisation of 
cyclobutanone by the lithiated N-Boc heterocycle, thus destroying the lithiated 
intermediate and regenerating starting material. This was confirmed by the observation 
of an aldol product of cyclobutanone 180 by 
1
H NMR spectroscopy. By-product 180 
was isolated in 24% yield in the case of N-Boc 4-phenyl piperidine 66 (Scheme 2.34). 
 
Scheme 2.34 
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The trapping times of other electrophiles with lithiated N-Boc pyrrolidine 12 and N-
Boc-N′-benzyl piperazine 117 in the presence of TMEDA were also studied. Trapping 
of the lithiated intermediate derived from N-Boc pyrrolidine 12 was performed with 
Bu3SnCl, benzophenone and benzaldehyde and the results are summarised in Scheme 
2.35. In all cases, complete trapping took less than 1 min at –78 °C to give products 21, 
31, 32 and 36 in good to excellent yields (full ReactIR
™
 traces are presented in Chapter 
6.3). 
        
 
Scheme 2.35 
Similarly, trapping of the lithiated intermediate of N-Boc-N′-benzyl piperazine 117 (the 
slowest to trap with Me3SiCl) was performed with Bu3SnCl, benzophenone and 
benzaldehyde. Complete trapping in less than 1 min at –78 °C was observed giving 
products 181-185 in moderate to good yields (Scheme 2.36). When trapping with 
benzophenone, a small amount of oxazolidinone 183 was formed through cyclisation by 
attack of the intermediate lithium alkoxide onto the carbamate carbonyl. 
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Scheme 2.36 
The relative stereochemistry of syn-184 was assigned unambiguously by X-ray 
crystallography. As expected, the piperazine adopts a chair conformation with the α-
substituent in the axial position to reduce A
1,3
-type strain between the substituent and 
the Boc group. The X-ray crystal structure of syn-184 (with 50% thermal ellipsoids) is 
shown in Figure 2.5. 
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Figure 2.5 X-Ray Structure of syn-184 with thermal ellipsoids shown at 50% 
Since the trapping with cyclobutanone, Bu3SnCl, benzophenone or benzaldehyde was 
fast even with N-Boc-N′-benzyl piperazine 117, it was interesting to discover whether 
the use of a bulky diamine would slow down the rate of trapping with these ‘fast’ 
electrophiles. To this end, lithiation of N-Boc pyrrolidine 12 with s-BuLi/(–)-sparteine 
in Et2O at –78 °C was performed and trapping with benzophenone and benzaldehyde 
was performed. In both cases, trapping was complete within 1 min at –78 °C (Scheme 
2.37). With benzophenone, alcohol (R)-36 was isolated in 74% and 96:4 er. The use of 
benzaldehyde gave diastereomeric alcohols (R,R)-31 in 66% and 97:3 er and (R,S)-32 in 
21% and 92:8 er.  
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Scheme 2.37 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 12 
with s-BuLi/(–)-sparteine and ‘fast’ electrophiles 
Lithiation of N-Boc-N′-benzyl piperazine 117 using s-BuLi/(–)-sparteine in Et2O at –78 
°C followed by trapping with benzophenone was performed to determine whether the 
combination of a bulky diamine and N-Boc-N′-benzyl piperazine 117 would result in 
slower trapping. However, trapping with benzophenone occurred within 1 min at –78 
°C to give alcohol (R)-182 in 38% yield and oxazolidinone (R)-183 in 14% yield in 
81:19 er (Scheme 2.38). Unfortunately, a CSP-HPLC method to determine the er of (R)-
182 could not be found. The overall yield was modest due the formation of alkene by-
product 186, which was observed in a 20:80 ratio by 
1
H NMR spectroscopy (relative to 
the combined amount of (R)-182 and (R)-183) but unfortunately could not be isolated. 
The formation of this by-product will be discussed in detail in Chapter 4. 
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Scheme 2.38 In situ ReactIR
™
 spectroscopic monitoring of the lithiation/trapping of 117 
with s-BuLi/(–)-sparteine and benzophenone 
These experiments show that the use of a bulky diamine does not slow the trapping step 
with ‘fast’ electrophiles, at least not beyond the resolution of the ReactIR™ equipment 
(1 min), even when using N-Boc-N′-benzyl piperazine 117. 
Work detailed within this section has shown that trapping of lithiated N-Boc 
heterocycles is not necessarily a straight forward process. Building upon empirical 
evidence from previous reports, this investigation has shown that Me3SiCl, methyl 
iodide and dimethyl sulfate react much more slowly with lithiated N-Boc heterocycles 
than the other electrophiles examined. Figure 2.6 details the reactivity series of the 
electrophiles investigated to date. 
 
Figure 2.6 
Remarkable differences in the rate of trapping of different lithiated N-Boc heterocycles 
with ‘slow’ electrophiles have been uncovered. Trapping of lithiated N-Boc pyrrolidine 
12 was relatively fast, allowing the synthesis of highly enantioenriched α-substituted 
pyrrolidines. Conversely, trapping of lithiated N-Boc-N′-benzyl piperazine 117 was 
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extremely slow which, as will be detailed in Chapter 4, has consequences for the 
asymmetric lithiation of N-Boc piperazines.   
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2.4 Conclusions and Future Work 
In situ ReactIR
™
 spectroscopy has been used to monitor the time taken for the complete 
lithiation of a range of commonly used N-Boc heterocycles by observing the changes in 
the carbonyl stretch (νC=O) of the Boc group. Without resorting to a full study of the 
reaction kinetics, a reactivity series of lithiation substrates has been prepared with the 
three most widely used diamines: TMEDA, (–)-sparteine and the (+)-sparteine surrogate 
(+)-26. This study has confirmed that lithiation reactions of N-Boc heterocycles using s-
BuLi in the presence of TMEDA or (+)-26 are relatively rapid compared with those 
facilitated by s-BuLi/(–)-sparteine. In most cases the historically lengthy reaction times 
are unnecessary. Figure 2.7 shows the N-Boc heterocycles in order of reactivity towards 
deprotonation. 
 
 
Figure 2.7 Order of reactivity of N-Boc heterocycles towards deprotonation 
Additionally, this chapter reports the first study of the trapping times of lithiated N-Boc 
heterocycles with different electrophiles. It has been shown that electrophiles can be 
classed as either ‘fast’ or ‘slow’ trapping. When employing ‘slow’ electrophiles 
(Me3SiCl, methyl iodide and dimethyl sulfate), trapping of lithiated N-Boc-N′-benzyl 
piperazine 117 is considerably slower than trapping of lithiated N-Boc 4-phenyl 
piperidine 66, which in turn is considerably slower than the trapping of lithiated N-Boc 
pyrrolidine 12. There is no obvious reason for the large differences between the three 
heterocycles. The time taken for complete trapping is increased as the steric bulk around 
the lithiated centre increases. This investigation has shown that this effect can explain 
some of the lower enantiomeric ratios observed when using N-Boc piperidine 10 and 
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‘slow’ trapping electrophiles. For ‘fast’ electrophiles, trapping occurs within one minute 
regardless of substrate or diamine. This fact shows that the long trapping times (1-16 h) 
are not necessary except with ‘slow electrophiles’.  
It would be interesting to assess the effect of the (+)-sparteine surrogate (+)-26 on rates 
of trapping with ‘slow’ electrophiles in comparison with (–)-sparteine to assess whether 
the sterically less bulky ligand results in faster trapping. 
The use of in situ ReactIR
™
 spectroscopy to study the times required for complete 
lithiation and electrophile trapping could be used to make a specific target molecule in 
the shortest time possible. For example, lithiation of N-Boc pyrrolidine 12 with s-BuLi 
and the (+)-sparteine surrogate (+)-26 at –78 °C, followed by trapping with 
benzaldehyde could conceivably be complete within 5 min (Scheme 2.39). 
 
Scheme 2.39 
Chapters 3 and 4 will show how the data generated through ReactIR
™
 spectroscopy was 
used to optimise the lithiation/trapping of N-Boc piperazines. 
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Chapter Three: Racemic Lithiation/Trapping of N-Boc 
Piperazines 
Nitrogen heterocycles hold a privileged position within pharmaceutical compounds. The 
‘top 200 brand-name drugs by sales in 2012’ shows that 36 contain piperazine, 
pyrrolidine or piperidine part structures.
107
 A 2003 study showed that piperazines are 
one of the most common fragments found in orally-active drugs, with more than 70 
drugs containing the group.
136
 In fact, a recent study has shown that the piperazine 
moiety is the fourth most common ring in drugs approved by the FDA between 1983 
and 2012, with 51 of 1175 drugs containing the group.
137
 Additionally, many 
commercially available screening molecules and bioactive compounds contain a 
piperazine. One analysis suggests that 5.4% of the ZINC database and 7.7% of the 
ChEMBL database contain piperazines.
138
 However, very few drugs contain piperazines 
which are substituted at carbon. Examples include Indinavir, a protease inhibitor for 
treatment of HIV,
139
 and Vestipitant,
140
 a neurokinin-1 antagonist under development 
for the treatment of nausea and anxiety (Figure 3.1).  
 
Figure 3.1 
Although there are a multitude of excellent methods for the synthesis of piperazines 
substituted at carbon, the lithiation/trapping of N-Boc piperazines is relatively under 
developed. 
This chapter details studies into the racemic lithiation/trapping of N-Boc piperazines, 
examining the scope and limitations of substrates and electrophiles. First, the synthesis 
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and lithiation of a range of commonly used and novel N-Boc piperazines is discussed. 
Second, an investigation into the racemic lithiation/Negishi coupling of N-Boc 
piperazines is described.   
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3.1 Overview of Synthesis of Substituted Piperazines 
3.1.1 Overview of Racemic Lithiation/Trapping of N-Boc Piperazines 
The first attempt at the α-lithiation/trapping of N-Boc piperazines was carried out by 
Wermuth et al in 1997.
141
 N-Boc-N′-phenyl piperazine 187 was deprotonated using      
s-BuLi/TMEDA in THF at –78 °C. When methyl iodide was used as the electrophile, 
rather than isolating the expected α-substituted piperazine, ring fragmentation and N-
methylation occurred to give vinyl carbamate 188 in 45% yield (Scheme 3.1). 
Alternatively, quenching the lithiation after 2 h with aqueous ammonium chloride 
resulted in isolation of secondary amine 189 in 65% yield.  
 
Scheme 3.1 
The proposed mechanism of ring fragmentation is shown in Scheme 3.2 and is 
analogous to that shown in Scheme 2.21 for the fragmentation of N-Boc morpholine 
155. Equatorial deprotonation of N-Boc-N′-phenyl piperazine 187 affords lithiated 
intermediate 190. This can undergo β-elimination, enabled by the antiperiplanar 
arrangement of the Li-C and C-N bonds, to give lithium amide 191. The phenyl ring 
provides charge stabilisation and facilitates ring fragmentation. Upon addition of the 
electrophile, trapping occurs on nitrogen to give vinyl carbamate 192.  
 
Scheme 3.2 Mechanism of ring fragmentation of N-Boc-N′-phenyl Piperazine 187 
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When the lithiated intermediate was warmed to –20 °C for 1 h, imidazolidinone 193 
was isolated in 50% yield (Scheme 3.3). Imidazolidinone 193 was formed through ring 
fragmentation and subsequent nucleophilic attack of the lithium amide onto the 
carbonyl of the Boc group. 
 
Scheme 3.3 
The first α-substituted N-Boc piperazine synthesised through directed lithiation was 
reported by van Maarseveen and co-workers in 2005.
135
 Both N-Boc-N′-benzyl 
piperazine 117 and N-Boc-N′-methyl piperazine 151 were subjected to s-BuLi/TMEDA 
in Et2O, first at 78 °C and then at 10 °C for 1 h. Subsequent trapping with Me3SiCl or 
Bu3SnCl gave α-substituted benzyl piperazines 175 and 181 in 68% and 71% yield 
respectively (Scheme 3.4). Alternatively, α-substituted methyl piperazines 194 and 195 
were isolated in 5% and 82% yield respectively. No explanation for the low yield 
obtained when using N-Boc-N′-methyl piperazine 194 and Me3SiCl was provided. 
However, this reaction will be discussed in more detail later in this Chapter (see Scheme 
3.34).  
  
Scheme 3.4 Racemic lithiation/trapping of 117 and 151 
The lithium/copper transmetallation strategy developed by Dieter
93
 was employed to 
expand the electrophile scope to include alkyl halides (Scheme 3.5). N-Boc-N′-benzyl 
piperazine 117 was deprotonated with s-BuLi/TMEDA and transmetallation was 
achieved through the addition of a CuCN.2LiCl solution. Trapping with allyl bromide 
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or n-butyl bromide gave 196 and 197 in good yields of 89% and 85% respectively. Use 
of benzyl bromide as electrophile gave 198 in a lower yield (54%). Additionally, the 
lithium/copper transmetalation methodology also worked well with N-Boc-N′-methyl 
piperazine 151 and alkyl halide electrophiles. 
 
Scheme 3.5 Racemic lithiation/transmetallation/trapping of N-Boc-N′-benzyl Piperazine 
117 
Using a protocol developed by Beak for the synthesis of disubstituted piperidines,
74,75
 
van Maarseveen also investigated the synthesis of 2,6-diallylated piperazine through 
deprotonation of 2-allyl-N-Boc piperazine 199. Lithiation at the least hindered 6-
position using s-BuLi/TMEDA followed by transmetalation to the organocuprate and 
trapping with allyl bromide gave cis-200 in 83% yield (Scheme 3.6). 
 
Scheme 3.6 
The cis-relative stereochemistry of 2,6-allyl piperazine cis-200 was tentatively assigned 
by analysis of coupling constants in the 
1
H NMR spectrum. This stereochemical 
assignment is surprising. It is expected that the allyl group of 199 would adopt an axial 
orientation in order to reduce A
1,3
-type strain. In analogy to piperidines,
74
 equatorial 
deprotonation and retentive trapping would lead to a 2,6-trans configuration (see 
Scheme 1.40). The stereochemical assignment is probably incorrect as evidenced by 
experiments detailed in Chapter 4 (see Scheme 4.37).  
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Building on the chemistry developed by van Maarseveen and co-workers, Martin 
reported the synthesis of cis-2,6-disubstituted N-Boc piperazines whilst investigating 
the synthesis of analogues of ()-alstonerine.142 2-Allyl N-Boc piperazine 196 was 
synthesised in 84% yield according to van Maarseveen’s procedure.135 A second α-
lithiation was carried out, followed by trapping with DMF to give a mixture of aldehyde 
epimers. Exposure to silica gel and Et3N caused equilibration of the epimeric aldehydes 
(via enolisation) to provide cis-disubstituted piperazine cis-201 in 81% yield (Scheme 
3.7). This equilibration process is well established with N-Boc piperidines.
143
 
 
Scheme 3.7 
In 2006, Takeda Pharmaceuticals reported the use of three N-Boc piperazine substrates 
117, 202 and 203 in racemic lithiation/trapping methodology.
144
 As an example, N-Boc-
N′-benzyl piperazine 117 was deprotonated using s-BuLi/TMEDA in THF at –78 °C for 
2 h. The reaction was warmed to –30 °C and immediately cooled to –78 °C again before 
addition of benzophenone. Oxazolidinone 183 was isolated in 64% yield (Scheme 3.8). 
Reinscheid also reported the synthesis of 183 using the same method in 2008.
145
 
 
Scheme 3.8 Racemic lithiation/trapping of 117, 202 and 203 
The use of 4-methylbenzyl protected N-Boc piperazine 202 as a substrate was also 
described by Takeda. Lithiation under the same conditions and trapping with 
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benzophenone gave oxazolidinone 204 in 82% on a 0.3 mol scale (Scheme 3.8). 
Additionally, the first use of N-Boc-N′-trityl piperazine 203 as a substrate was also 
reported. Racemic lithiation was accomplished using s-BuLi/TMEDA at –78 °C for 2 h, 
followed by warming to –50 °C. Subsequent cooling and trapping with dicyclohexyl 
ketone then gave oxazolidinone 205 in 74% yield (Scheme 3.8). The use of long 
lithiation times at –78 °C and warming before trapping, as used by van Maarseveen and 
Takeda, have been shown to be unnecessary by the ReactIR
™
 spectroscopic 
investigation reported in Chapter 2.  
A second example of the use of N-Boc-N′-trityl piperazine 203 as a substrate was 
reported by Bikam Pharmaceuticals.
146
 Racemic lithiation of N-Boc-N′-trityl piperazine 
203 was performed using s-BuLi/TMEDA, but the reaction was left for only 10 min 
before the addition of the electrophile (DMF). Aldehyde 206 was obtained in an 
excellent 96% yield (Scheme 3.9). Elaboration to an alkyne from aldehyde 206 was 
achieved using the Ohira-Bestmann reagent in 40% yield. Selective removal of the trityl 
group under weakly acidic conditions (1% w/v Cl3CCOOH/CH2Cl2, 0 °C) gave 
secondary amine 207 in 29% yield and in 12% overall yield from 206.  
 
Scheme 3.9 
The diamine-free lithiation methodology developed in the O’Brien group for the 
lithiation of N-Boc pyrrolidine 12 (see Scheme 1.16) was also applied to the lithiation of 
N-Boc-N′-benzyl piperazine 117.59 Lithiation with s-BuLi using THF as a coordinating 
solvent was carried out at –30 °C for 5 min before trapping (Scheme 3.10). A range of 
electrophiles were used, giving 2-substititued piperazines 175, 183, 208 and 209 in 71-
83% yield.  
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Scheme 3.10 Racemic lithiation/trapping of N-Boc-N′-benzyl Piperazine 117 at –30 °C 
in THF 
In 2010, Coldham showed that N-Boc-N′-tert-butyl piperazine 152 was also amenable to 
racemic deprotonation/trapping in preparation for development of a dynamic 
thermodynamic resolution method to asymmetric α-substituted piperazines.147 N-Boc-
N′-tert-butyl piperazine 152 was lithiated using s-BuLi/TMEDA in Et2O at –78 °C for 5 
h. A range of electrophiles were used, giving α-substituted piperazines 210-214 in 65-
77% yield (Scheme 3.11). 
 
 
Scheme 3.11 Racemic lithiation/trapping of N-Boc-N′-t-butyl Piperazine 152 
 
3.1.2 Alternative Methods for the Synthesis of Substituted Piperazines 
The most commonly used method to access enantiopure α-substituted piperazines 
involves the manipulation of protected amino acids, generally available from the chiral 
pool. This method has been utilised for the synthesis of mono- and 2,5-disubstitiuted 
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piperazines.
148,149,150
 A representative procedure is shown in Scheme 3.12.
151
 The 
methyl ester of D-alanine (S)-215 was acylated with chloroacetyl chloride to give amide 
(S)-216. Exposure to benzylamine formed an intermediate di-keto piperazine, and after 
reduction with LiAlH4, enantiopure α-methyl piperazine (S)-217 was isolated in 60% 
yield over 3 steps.  
 
Scheme 3.12 
Classical resolution has been a widely used strategy for the synthesis of enantioenriched 
substituted piperazines. In one example, the enantiopure piperazine moiety of the 
protease inhibitor Indinavir (see Figure 3.1) was synthesised on a process scale by 
Merck, starting from pyrazine 218.
152
 A Ritter reaction using t-butyl acetate and H2SO4 
generated amide 219 in 90% yield. Hydrogenation of the pyrazine ring using Pd(OH)2/C 
and subsequent classical resolution of the resulting piperazine using pyroglutamic acid 
(S)-220 (which was recycled) gave (S)-221 in 45% yield (Scheme 3.13). 
 
Scheme 3.13 
Alternatively, the enantioenriched piperazine group of Indinavir can be synthesised 
through asymmetric hydrogenation of tetrahydropyrazine 222 with a rhodium/(R)-
BINAP catalyst system. Piperazine (S)-223 was isolated in 100% yield with 98.5:1.5 er 
(Scheme 3.14).
153
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Scheme 3.14 
A one-pot procedure for the synthesis of enantioenriched 2-aryl N-Boc piperazine N′-
oxides from pyrazine N-oxides has been reported by Almqvist.
154
 Pyrazine N-oxide 224 
was treated with phenyl magnesium bromide in the presence of ()-sparteine. Reduction 
in the same pot with NaBH4 followed by Boc protection gave piperazine N-oxide ()-
225 in 21% yield and 91:9 er, with unknown absolute stereochemistry (Scheme 3.15). 
 
Scheme 3.15 
Transition metal catalysis has recently been used by several groups for the synthesis of 
piperazines. In 2007, Wolfe reported the synthesis of cis-2,6-disubstituted piperazines 
through a palladium-catalysed carboamination reaction of an acyclic amino-alkene 
precursor and aryl bromides.
155
 In one example, when enantiopure (S)-226 (derived 
from valine) was subjected to 1 mol% Pd2(dba)3 and 8 mol% tri-2-furyl phosphine in 
the presence of 4-bromoanisole 109, (S,R)-227 was isolated in 62% yield and >95:5 dr 
as a single enantiomer (Scheme 3.16).  
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Scheme 3.16 
In 2008, a synthesis of trans-2,6-disubstitiuted piperazines through palladium catalysed 
hydroamination was reported.
156
 In one example, racemic acyclic precursor 228 was 
subjected to 5 mol% palladium catalyst 229 and 10 mol% AgBF4 resulting in the 
formation of trans-2,6-disubstitiuted piperazine trans-230 in 93% yield and >95:5 dr 
(Scheme 3.17). 
 
Scheme 3.17 
Recently, Nelson and co-workers have developed a gold catalysed synthesis of 
substituted piperazines.
138
 When racemic alkyne 231 was subjected to 5 mol% 
Au(PPh3)Cl and 5 mol% AgSbF6 in dioxane at 100 °C, alkene 232 was isolated in 90% 
yield. Subsequent reduction with triethylsilane and TFA gave 2,6-disubstituted 
piperazine trans-233 in 68% yield and 88:12 dr (Scheme 3.18).  
 
Scheme 3.18 
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Bode has reported the use of his SnAP (tin amine protocol) reagents for the synthesis of 
piperazines.
157
 Imines were formed in situ from amine 234 and aldehydes in the 
presence of 4 Å MS, before addition of copper(II) triflate (Scheme 3.19). A range of 
piperazines were isolated in good yields. Examples included aryl piperazines 235 and 
236, alkyl piperazine 237 and ester 238 (74-82% yields). Additionally, a range of 2,5- 
and 2,6-disubstituted piperazines were synthesised using this methodology. 
Mechanistically, it was proposed that the reaction proceeds via a copper(II) promoted 
stabilised carbon centred radical that can undergo endo cyclisation with the intermediate 
imine.
158
 
 
 
Scheme 3.19 Racemic synthesis of piperazines using SnAP reagent 234 
In summary, there are a plethora of excellent methods for the racemic synthesis of α-
substituted piperazines. Additionally, several highly diastereoselective methods for the 
formation of 2,5- and 2,6-disubstiituted piperazines have been recently developed. 
However, the enantioselective syntheses generally rely on the use of chiral pool starting 
materials or classical resolution of racemic piperazines rather than asymmetric 
synthesis.  
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3.2 Racemic Lithiation/Trapping of N-Boc Piperazines 
One main goal of the research disclosed within this thesis was the development of a 
general asymmetric lithiation/trapping protocol of N-Boc piperazines. In order to 
generate robust asymmetric methodology, the racemic lithiation/trapping of N-Boc 
piperazines was first investigated. The lithiation/trapping of a range of N-Boc 
piperazines has been accomplished by other groups since the first report by van 
Maarseveen.
135
 However, lithiation times are often lengthy and warming steps have 
been incorporated into the methodology. This report details attempts to develop a more 
general, racemic lithiation/trapping procedure. 
Several differentially protected N-Boc piperazines were used in this investigation 
(Figure 3.2). Several substrates that had been used in previous work, namely N-benzyl, 
N-methyl, N-t-butyl and N-trityl protected piperazines 117, 151, 152 and 203 were 
synthesised, along with three novel substrates 239-241.  
 
Figure 3.2 Protected N-Boc piperazines used for racemic lithiation/trapping studies 
N-Boc-N′-benzyl piperazine 117 was the most attractive substrate to work with. It is 
commercially available, simple to make on a multigram scale,
59
 orthogonally protected 
with many simple means of deprotection
35
 and contains a UV chromophore that 
facilitates the development of simple CSP-HPLC methods. Work within the O’Brien 
group has shown that the racemic deprotonation of N-Boc-N′-benzyl piperazine 117 can 
be performed using a diamine-free protocol (s-BuLi, THF, –78 °C, 1 h).59 Investigations 
began using this methodology and trapping with a range of electrophiles gave α-
substituted N-Boc piperazines 175, 176, 181, 183, 208 and 242-244 in 44-90% yield 
(Scheme 3.20). This method was consistently higher yielding than the ‘high 
temperature’ diamine-free protocol (–30 °C, 5 min, THF).  
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Scheme 3.20 Racemic lithiation/trapping of N-Boc-N′-benzyl Piperazine 117 
As presented in Chapter 2, in situ ReactIR
™
 spectroscopy has shown that lithiation of N-
Boc-N′-benzyl piperazine 117 reached completion within 1 h using the diamine-free 
procedure (see Scheme 2.19d). However, under diamine-free conditions, the lithiation 
of sterically more demanding N-Boc-N′-t-butyl piperazine 152 was incomplete after 2 h 
(see Scheme 2.20d). In contrast, lithiation using s-BuLi/TMEDA in Et2O at –78 °C was 
complete within 15 min (see Scheme 2.20a). Subsequent trapping with either methyl 
chloroformate or benzophenone gave ester 245 or oxazolidinone 246 in 45% and 57% 
yield respectively (Scheme 3.21). 
 
Scheme 3.21 Racemic lithiation/trapping of N-Boc-N′-t-butyl Piperazine 152 
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As previously discussed, the N-trityl group has been used successfully as a protecting 
group for piperazines undergoing lithiation/trapping reactions (see Schemes 3.8 and 
3.9). This investigation began by examining the electrophile scope of the racemic 
lithiation of N-Boc-N′-trityl piperazine 203. Due to concerns that a high degree of steric 
hindrance may render lithiation with s-BuLi/THF impractically slow, the s-
BuLi/TMEDA system was employed (1 h at –78 °C in Et2O). Trapping with methyl 
chloroformate gave the desired 247 in 35% yield along with disubstituted N-Boc 
piperazine 248 in 29% yield (Scheme 3.22). Diester 248 formed from deprotonation of 
the more acidic α-proton of 247, either by residual s-BuLi or the intermediate lithiated 
piperazine, followed by a second trapping with methyl chloroformate.  
 
Scheme 3.22 
The use of benzophenone as an electrophile resulted in the formation of oxazolidinone 
249 in 50% yield and alcohol 250 in 11% yield (Scheme 3.23). It is possible that if the 
reaction was left for sufficient time at room temperature before quenching, complete 
cyclisation to give oxazolidinone 249 as a single product would result. 
 
Scheme 3.23 
Lithiation of N-Boc-N′-trityl piperazine 203 and trapping with Bu3SnCl or 
cyclohexanone resulted in stannane 251 and oxazolidinone 252 in 86% and 37% yield 
respectively (Scheme 3.24). The poor yield of 252 can potentially be attributed to 
enolisation of cyclohexanone by the lithiated piperazine intermediate. Cyclohexanone 
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routinely gives the lowest yields of all the electrophiles used for the racemic 
lithiation/trapping of N-Boc piperazines. 
 
Scheme 3.24 Racemic lithiation/trapping of N-Boc-N′-trityl Piperazine 203 
Other novel bulky protecting groups were investigated as substrates for the racemic 
lithiation/trapping methodology. The 9-phenylfluoren-9-yl (PhFl) protecting group is an 
infrequently used bulky protecting group for amines, and has comparable steric bulk to 
the trityl group.
35,159
 It is more stable to removal under acidic conditions but it can be 
easily removed using hydrogenolysis.
160
 Synthesis of the desired substrate, N-Boc-N′-
PhFl piperazine 240, started with mono-protection of piperazine 253 using 9-bromo-9-
phenylfluorene (PhFlBr), with Pb(NO3)2 as a bromide scavenger, to give 254 in 83% 
yield (Scheme 3.25). 9-Bromo-9-phenylfluorene is commercially available or can be 
easily prepared from 9-fluoreneone on a multi-gram scale.
161
 Boc protection of the 
remaining secondary amine gave N-Boc-N′-PhFl piperazine 240 in 92% yield (Scheme 
3.25). 
 
Scheme 3.25 
Racemic lithiation of N-Boc-N′-PhFl piperazine 240 under standard conditions (s-
BuLi/TMEDA, Et2O, –78 °C, 1 h) was investigated. Following trapping with methyl 
chloroformate, α-substituted piperazine 255 and diester 256 were isolated in 36% and 
17% yield respectively, along with recovered starting material 240 (43%) (Table 3.1, 
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entry 1). The overall poor yield was attributed to the low solubility of 240 in Et2O. To 
improve the yield, solvents that are better at dissolving highly hydrophobic compounds 
were investigated. In fact, MTBE
57,95
 and toluene
54
 have both previously been used in 
asymmetric lithiation reactions. N-Boc-N′-PhFl piperazine 240 was soluble in MTBE 
when heated, and stayed in solution even when cooled to –78 °C. Using MTBE as a 
solvent, α-substituted piperazine 255 was isolated in 58% yield with 23% recovered 
starting material 240 (entry 2). N-Boc-N′-PhFl piperazine 240 was fully soluble in 
toluene with ester 255 being obtained in 77% yield along with 240 (20%) (entry 3). 
Interestingly, none of the diester 256 was observed with either MTBE or toluene as 
solvent. 
 
Entry Solvent Yield 255 (%)
a
 Yield 256 (%)
a
 Yield 240 (%)
a
 
1 Et2O 36 17 43 
2 MTBE 58 - 23 
3 Toluene 77 - 20 
a
 Yield after flash column chromatography. 
Table 3.1 Effect of solvent on the racemic lithiation/trapping of N-Boc-N′-PhFl 
piperazine 240 
During an investigation into the asymmetric lithiation/trapping methodology of N-Boc 
piperazines (see Chapter 4) it became clear that bulky protecting groups were essential 
to the success of the methodology. To this end, the use of N-Boc-N′-cumyl piperazine 
241 as a substrate was considered (Figure 3.3). 
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Figure 3.3 
Originally, the cumyl group found utility as a protecting group for amides. It was 
introduced as such by Snieckus as a directing group for the ortho-metalation of 
amides.
162
 The cumyl group was simultaneously discovered by Clayden and used in the 
α-lithiation of N-cumyl protected benzamides and subsequent de-aromatising anionic 
cyclisations.
163,164
 Coldham has previously reported the use of a cumyl protecting group 
for the lithiation/trapping of the corresponding N-Boc imidazolidine, although no 
attempt at removing the protecting group was detailed.
165
 
′The first challenge was to synthesise the desired N-Boc-N′-cumyl piperazine 241. This 
was achieved by a route analogous to that employed by McDermott in the synthesis of 
N-Boc-N′-t-butyl piperazine 152.108 The HCl salt of N-Boc piperazine 257 was formed 
and reacted with NaCN in the presence of acetone to give amino nitrile 258 in 81% 
yield.
166
 A Bruylants reaction with phenyl magnesium chloride displaced the nitrile 
(presumably via formation of the iminium ion) and gave the desired N-Boc-N′-cumyl 
piperazine 241 in 77% yield (Scheme 3.26).  
 
Scheme 3.26 
In order for N-Boc-N′-cumyl piperazine 241 to be a viable substrate for the 
lithiation/trapping methodology, the cumyl group had to be easily removable to allow 
further derivatisation of the α-substituted N-Boc piperazines. It was envisaged that 
deprotection could be achieved by hydrogenolysis. This proved to be the case, 
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deprotection of 241 to give N-Boc piperazine 257 occurred readily using H2 (1 atm.) 
and catalytic Pd/C for 48 h (Scheme 3.27). Alternatively, rapid deprotection can be 
achieved using transfer hydrogenolysis using Pearlman’s catalyst and ammonium 
formate in EtOH at reflux for 2 h (see Scheme 4.22).  
 
Scheme 3.27 
Having tackled the synthesis and deprotection of N-Boc-N′-cumyl piperazine 241, the 
racemic lithiation/trapping methodology was investigated. Racemic lithiation under 
standard conditions (s-BuLi/TMEDA, Et2O, –78 °C, 1 h) followed by trapping with a 
range of electrophiles gave 259-264 in 27-98% yield (Scheme 3.28). Amide 264 (from 
the reaction with t-butyl isocyanate) was isolated in a poor 27% yield. In this reaction a 
considerable amount of cyclised product 265 was observed by the 
1
H NMR spectrum of 
the crude mixture. Unfortunately, cyclised product 265 could not be isolated cleanly by 
flash column chromatography. 
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Scheme 3.28 Racemic lithiation/trapping of N-Boc-N′-cumyl Piperazine 241 
Lithiation of N-Boc-N′-cumyl piperazine 241 followed by trapping with benzophenone 
gave a mixture of uncyclised alcohol 266 (23%) and oxazolidinone 267 (74%) (Scheme 
3.29). When trapping with paraformaldehyde a mixture of uncyclised 268 and cyclised 
269 were obtained. They were isolated in 57% and 26% yields respectively. 
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Scheme 3.29 Racemic lithiation/trapping of N-Boc-N′-trityl Piperazine 241 
Transmetalation from lithium to copper followed by trapping with allyl bromide, using 
the protocol developed by Dieter,
93
 and applied to N-Boc piperazines by van 
Marrseveen,
135
 was highly successful giving α-allyl piperazine 270 in 80% yield 
(Scheme 3.30). 
 
Scheme 3.30 
Although racemic lithiation/trapping of 117, 152, 203, 240 and 241 proceeded smoothly 
to give α-substituted piperazines, other substrates proved more problematic. In fact, a 
range of unexpected products were encountered when trapping certain substrates with 
particular electrophiles. For example, lithiation of N-Boc-N′-methyl piperazine 151 
using the diamine-free protocol followed by trapping with methyl chloroformate gave 
rise to fragmentation by-products 271 and 272 in 33% and 11% yield respectively 
(Scheme 3.31). None of the desired α-substituted piperazine was observed by 1H NMR 
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spectroscopy. Both by-products 271 and 272 were formed through ring fragmentation 
followed by N-acylation. Product 272 could arise from vinylic α-lithiation/trapping of 
vinyl carbamate 271, as previously observed with N-Boc morpholine 155 (see Scheme 
2.21). 
 
Scheme 3.31 
Lithiation/trapping of N-methyl-N′-Boc piperazine 151 with phenyl isocyanate gave a 
35% yield of the desired α-substituted piperazine 273 along with by-products 274 (24%) 
and 275 (29%). It can be envisaged that urea 275 was formed from the anion of 274 
reacting with phenyl isocyanate (Scheme 3.32). 
 
Scheme 3.32 
In contrast, under the same lithiation conditions ring fragmentation did not occur with 
N-methyl-N′-Boc piperazine 151 when trapping with benzophenone. Here 
oxazolidinone 276 was isolated in 83% yield along with tertiary alcohol 277 in 12% 
yield (Scheme 3.33). 
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Scheme 3.33 
A previous report by van Maarseveen disclosed the racemic lithiation of 151 using       
s-BuLi/TMEDA followed by trapping with Me3SiCl. Only 5% of the desired 2-silyl 
piperazine 194 was isolated (see Scheme 3.4).
135
 Repeating this work, employing the 
published conditions, led to the formation of ring fragmentation by-products 278 and 
279 in 37% and 32% yield respectively (Scheme 3.34). The desired product 194 was not 
observed by analysis of the 
1
H NMR spectrum of the crude product. Vinyl carbamate 
278 is thought to arise through fragmentation followed by cleavage of the weak N-Si 
bond upon aqueous work-up. Vinylic lithiation of the intermediate silyl vinyl carbamate 
followed by trapping with a second equivalent of Me3SiCl gave rise to silane 279, after 
N-desilylation upon aqueous work-up. 
 
Scheme 3.34 
The ring-opening side-reaction also arose in the lithiation/trapping of N-Boc-N′-allyl 
piperazine 239. For example, trapping with methyl chloroformate resulted in the desired 
piperazine ester 280 being formed in 25% yield together with ring-opened product 281 
in 16% yield (Scheme 3.35). Ring-fragmentation was a side-reaction when N-Boc-N′-
allyl piperazine 239 was lithiated under diamine-free conditions and trapped with 
phenyl isocyanate. The desired piperazine 282 and ring-opened by-product 283 were 
obtained in 41% and 14% yields respectively (Scheme 3.35). 
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Scheme 3.35 
As the side-reaction occurred with some electrophiles and not with others, an 
investigation into the mechanism by which ring fragmentation occurred was undertaken. 
Wermuth and co-workers previously showed that ring fragmentation of N-Boc-N′-
phenyl piperazine 187 occurred in the absence of electrophiles.
141
 It was postulated that 
fragmentation of N-Boc-N′-methyl piperazine 151 was occurring in an analogous 
fashion, prior to electrophilic trapping. This process could have been driven by slow 
trapping of lithiated intermediates at low temperatures, a process known to be slow with 
piperazines and certain electrophiles (see Chapter 2). To evaluate whether ring 
fragmentation was occurring at elevated temperatures, lithiation of N-Boc-N′-methyl 
piperazine 151 was performed using s-BuLi in THF at –78 °C for 1 h to give lithiated 
intermediate 284. Then, the temperature was raised to 0 °C for 1 h before quenching 
with aqueous ammonium chloride. Only starting material was returned, with 151 being 
isolated in 88% yield (Scheme 3.36). No ring fragmentation by-products were observed 
by 
1
H NMR spectroscopy of the crude product.  
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Scheme 3.36 
This experiment shows that, unlike the fragmentation seen with N-Boc-N′-phenyl 
piperazine 187 and N-Boc morpholine 155, the electrophile has a role to play in ring 
fragmentation of some N-Boc piperazines. The mechanism shown in Scheme 3.37 is 
proposed to explain the experimental observations. The lithiated intermediate 285 could 
react through either the organolithium component or through the nitrogen lone pair. The 
former would be expected. However, the latter explains the observed reaction products. 
The nitrogen lone pair of the lithiated intermediate 285 could attack the electrophile 
resulting in a quaternary ammonium species 286. This in turn could easily undergo 
elimination to give the vinyl carbamate 287 (Scheme 3.37). The size of the protecting 
group and the size of the ligands around the lithium centre have an effect on reaction 
outcome.  
 
Scheme 3.37 Mechanism of ring fragmentation of N-Boc piperazines 
The attack of an electrophile by a nitrogen lone pair in the presence of a much more 
nucleophilic organolithium was unanticipated. However, there is literature precedent for 
the attack of a nitrogen lone pair on chloroformates in the presence of lithium enolates. 
Majewski and co-workers reported the ring-opening of tropinone 288 when 
investigating functionalisation via enantioselective deprotonation with chiral LDA-type 
bases (Scheme 3.38).
167,168
 Generation of the lithium enolate 289 followed by trapping 
with trichloromethyl chloroformate resulted not in the formation of the desired β-keto 
ester but solely in carbamate (R)-290 (92% yield, 98:2 er). The nitrogen lone pair 
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attacked the chloroformate and then ring fragmentation occurred. In contrast, the use of 
benzaldehyde or methyl cyanoformate (Mander’s reagent) gave the desired α-
substituted ketones with no ring-fragmented products.
169
 
 
Scheme 3.38 
Clayden and co-workers have reported a stereoselective de-aromatising cyclization 
reaction to generate spiro-lactams (Scheme 3.39).
170
 Enolate formation from (S)-291 
with LHMDS was followed by N-acylation with methyl chloroformate to give 
pyridinium ion (S)-292, rather than enolate acylation. Subsequent de-aromatising 
cyclisation gave lactam (R,S)-293 in 99% yield and 94:6 dr.  
 Scheme 3.39 
The results presented within this section show clearly that both the N-Boc piperazine 
structure and the electrophile have an effect on the reaction outcome. Fragmentation did 
not occur during the racemic lithiation/trapping using N-benzyl, N-t-butyl, N-PhFl or N-
cumyl piperazines 117, 152, 240 and 241 with any electrophile. However, with N-
methyl and N-allyl piperazines 151 and 239 fragmentation occurs with methyl 
chloroformate, Me3SiCl or phenyl isocyanate, although not with benzophenone. These 
results indicate that the smaller protecting groups of 151 and 239 allow the lone pair of 
lithiated intermediate 285 to attack some electrophiles, whereas the bulkier protecting 
groups prevent this pathway. Fragmentation does not occur with benzophenone, 
possibly due to the hindered nature of the electrophilic carbonyl.   
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3.3 Investigation of the Synthesis of 2-Aryl N-Boc Piperazines 
One of the most interesting and synthetically useful modifications to the 
lithiation/trapping of N-Boc heterocycles is the Negishi chemistry developed by 
Campos.
97-99
 Application of the lithiation/Negishi methodology to N-Boc-N′-benzyl 
piperazine 151 was performed by O’Brien and Barker, reputedly giving 2-phenyl 
piperazine 294 in a moderate 55% yield (Scheme 3.40).
59
 This is the first and only 
example of such a Negishi coupling using N-Boc piperazines to date.  
 
Scheme 3.40 
Enantiopure α-aryl piperazines are occasionally found in nature. For example, several 
members of the dragmacidin family of natural products contain a 2,5-diaryl piperazine 
moiety. Dragmacidin (Figure 3.4) was isolated from Dragmacidin sp., a Caribbean 
underwater sponge and exhibits potent in vitro cytotoxicity with IC50 <10 μg/mL against 
A-549, HCT-8 and MDAMB human cancer cell lines.
171
 
 
Figure 3.4 
With the goal of synthesising compounds such as dragmacidin in mind, the α-arylation 
of N-Boc-N′-benzyl piperazine 117 was investigated. A repeat of the lithiation/arylation 
reported by Barker and O’Brien was performed, albeit with slightly modified 
conditions. Lithiation of N-Boc-N′-benzyl piperazine 117 was performed using s-BuLi 
in THF at –78 °C and the cross-coupling performed at room temperature rather than at 
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reflux. However, rather than isolating solely 294, an inseparable 67:33 mixture of 
regioisomers 295 and 294 was obtained in a combined 42% yield (Scheme 3.41). The 
presence of 3-phenyl piperazine 295 was confirmed through an independent synthesis of 
295.
154,172
  
 
Scheme 3.41 
Analysis of the 
1H NMR spectra published by O’Brien indicated that 294 and 295 were 
obtained as an approximately 50:50 ratio when the cross-coupling step was performed 
at reflux. In the original analysis of the 
1
H NMR spectrum, the regioisomers 294 and 
295 were thought to be a 50:50 mixture of N-Boc rotamers of 294. Interestingly, a small 
amount of β-arylated N-Boc pyrrolidine was recovered by Campos during the synthesis 
of glucokinase activator (R)-93 on a large scale (see Scheme 1.46).
98
 
A mechanistic explanation, analogous to that proposed by Knochel for the formation of 
2,5-disubsitituted piperidines (see Scheme 1.50),
103
 can be provided for the formation of 
β-substituted piperazine 295. β-Hydride elimination of the palladium intermediate 296 
could be occurring to give 297. The resulting “PdPhL2H” complex could undergo syn-
addition to alkene 297, placing the palladium preferentially in the sterically less 
hindered 3-position of 298. Reductive elimination could then proceed to give the β-
substituted product 295 (Scheme 3.42).  
 
Scheme 3.42 Mechanism for formation of β-substituted piperazine 295 
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This argument suggests that steric considerations would determine the resulting ratio of 
regioisomeric products. In 2013, Baudoin reported the ligand controlled β-selective 
arylation of N-Boc piperidine 10 (see Scheme 1.51).
104
 The explanation for β-selectivity 
was that the energy of the transition state for the rate determining C-Ar bond forming 
reductive elimination was lower for formation of the β-isomer compared to the α-
substituted product. Regardless of the cause of regioselectivity, it was envisaged that an 
exploration of different catalyst and ligand systems would be illuminating. The results 
of such a study are presented in Table 3.2.  
 
 
Entry 
Catalyst / Ligand (5 
mol%) 
Temperature 
Yield (%)
a
  
295 + 294 
295:294
b
 
1 Pd(dba)2, RuPhos  rt 63 60:40 
2 Pd(dba)2, DavePhos
c
 rt - - 
3 Pd(dba)2, JohnPhos
d
 rt - - 
4 Pd(dba)2, SPhos
d
 rt - - 
5 Pd(dba)2, QPhos
d
 rt - - 
6 PEPPSI-i-Pr rt 38 95:5 
7 PEPPSI-i-Pr reflux 37 90:10 
a
 Yield after flash column chromatography. 
b
 Ratio determined by 
1
H NMR 
spectroscopy. 
c
 46% yield of vinyl carbamate 299 and 49% recovered 117. 
d
 Only vinyl 
carbamate 299 and starting material 117 observed by analysis of the 
1
H NMR spectrum; 
reaction not purified. 
Table 3.2 Lithiation/arylation of N-Boc-N′-benzyl piperazine 117 
Chapter Three: Racemic Lithiation/Trapping of N-Boc Piperazines 
 
113 
 
The catalyst and ligand system employed by Knochel (5 mol% Pd(dba)2 and 5 mol% 
RuPhos)
103
 was investigated first and a 60:40 mixture of 295 and 294 was isolated in 
63% yield (Table 3.2, entry 1). A small range of other monodentate phosphine ligands 
were investigated. However, no arylation products were observed (entries 2-5). In all 
four cases, ring fragmentation by-products were observed in the 
1
H NMR spectra of the 
crude products. In the reaction employing DavePhos as a ligand, vinyl carbamate 299 
was isolated in 46% yield with 49% recovered 117 (entry 2). It is possible that in these 
cases Zn/Pd transmetalation was slow and the intermediate organozinc species 
fragmented. The N-heterocyclic carbene based PEPPSI-i-Pr catalyst system was also 
investigated.
173,174
 Almost complete regiocontrol was attained; a 95:5 mixture of          
3-phenyl N-Boc piperazine 295 and 2-phenyl N-Boc piperazine 294 was isolated in 38% 
yield when the Negishi reaction was performed at room temperature (Table 3.2 entry 6). 
In an attempt to improve the yield of arylated products using PEPPSI-i-Pr as catalyst the 
cross coupling step was heated at reflux (entry 7). However, there was no improvement 
in the yield of 295 and 294 (37%) and the regioselectivity dropped marginally (90:10). 
Interestingly, lithiation/arylation of N-Boc-N′-cumyl piperazine 241 using PEPPSI-i-Pr 
resulted in the formation of α-substituted piperazine 300 in 12% yield without any of 
the β-arylated adduct being formed (Scheme 3.43). This reversal of regioselectivity is 
possibly due to steric considerations, although it could also be due to significantly more 
complex reasons. Unfortunately, the yield was low; ring fragmented by-product 301 
was isolated in 30% yield with 53% recovered starting material. It is possible that the 
yield was low due to incomplete lithiation of 241 within 2 h in THF at –78 °C. 
However, the presence of a significant quantity of vinyl carbamate 301 indicates that the 
cross-coupling step was also problematic. 
 
Scheme 3.43 
Chapter Three: Racemic Lithiation/Trapping of N-Boc Piperazines 
 
114 
 
Although this initial result using N-Boc-N′-cumyl piperazine 241 was promising, the 
low yield and formation of by-product 301 was problematic. An alternative strategy to 
achieve regioselectivity was employed. Preventing the intermediate palladium complex 
from undergoing β-hydride elimination could possibly allow the formation of 2-phenyl 
N-Boc piperazine 294 as a single regioisomer. As it is known that the use of bidentate 
phosphine ligands can prevent β-hydride elimination from an alkyl-metal moiety,175,176 a 
small screen of bidentate ligands for the lithiation/Negishi coupling reaction was 
performed. Reactions were carried out using 5 mol% of Pd(dba)2 and 6 mol% of ligand, 
or with 5 mol% Pd(dppf)Cl2 (Scheme 3.44). Disappointingly, neither 294 nor 295 were 
observed in any reaction. It is worth noting that in the Campos’ original 
lithiation/arylation report with N-Boc pyrrolidine 12, the use of Pd(dppf)Cl2 gave no 
product.
97
 
 
 
Scheme 3.44 Attempted lithiation/arylation of 117 using bidentate phosphine ligands  
The lack of any reaction when using bidentate ligands, possibly due to poor 
transmetallation of the organozinc species, led to the attempted use of boronate coupling 
partners. In 2007, Whiting reported the use of asymmetric lithiation/trapping chemistry 
to synthesise the boronic acid and pinacol ester of N-Boc pyrolidine 12.
177
 Lithiation 
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under standard conditions (s-BuLi/(–)-sparteine, –78 °C, Et2O) followed by trapping 
with tri-isopropyl borate gave boronic acid (S)-302 in 72% yield and 95:5 er (Scheme 
3.45). Trapping with isopropoxy pinacol borate gave boronic ester (S)-303 in 88% yield 
with an unspecified enantiomeric ratio. 
 
Scheme 3.45 
It was envisaged that both boronic acids and esters would be poor coupling partners for 
a sp
2
-sp
3
 Suzuki-Miyaura coupling reaction. Therefore, the synthesis of an α-9-BBN 
derivative of N-Boc piperazine, a much better coupling partner for sp
2
-sp
3
 Suzuki-
Miyaura reactions, was undertaken.
178,179
 In 1998, Marshall reported the total synthesis 
of (+)-discodermolide and a key step in the synthesis was a one-pot lithiation followed 
by borylation with B-methoxy-9-BBN then Suzuki-Miyaura coupling catalysed by 
Pd(dppf)Cl2.
180
 This methodology was used in an attempt to synthesise 2-phenyl N-Boc 
piperazine 294. It was envisaged that the use of a bidentate ligand would prevent β-
hydride elimination from the organopalladium species and that transmetalation would 
prove facile.  
Diamine-free lithiation of N-Boc-N′-benzyl piperazine 117 was followed by trapping 
with B-methoxy-9-BBN to give boronate complex 304. Suzuki coupling with 
iodobenzene catalysed by Pd(dppf)Cl2 was then attempted. Unfortunately, formation of 
2-phenyl N-Boc piperazine 294 was not observed, with the intermediate trialkyl borane 
being the only product identified (Scheme 3.46). 
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Scheme 3.46 
The lack of success when using this approach could be due to the fact that secondary 
alkyl groups migrate much more slowly than primary alkyl groups.
179
 It may be possible 
to optimise the coupling step with a more sustained effort.
181
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3.4 Conclusions and Future Work 
The racemic lithiation/trapping of a range of protected N-Boc piperazines has been 
accomplished. A small range of electrophiles was used, to provide access to a variety of 
α-substituted piperazines. Separation of the enantiomers of many of these compounds 
was achieved using CSP-HPLC, with a view to the development of an asymmetric 
lithiation/trapping of N-Boc piperazines. When using N-Boc-N′-methyl piperazine 151 
and trapping with certain electrophiles, for example methyl chloroformate, 
fragmentation product 271 was observed. However, when using larger protecting 
groups such as N-benzyl, N-t-butyl, N-PhFl or N-cumyl, ring fragmentation was not 
observed and α-substituted N-Boc piperazines 208, 245, 255 and 259 were isolated 
(Scheme 3.47). 
 
Scheme 3.47 
A preliminary investigation into the lithiation/arylation of N-Boc piperazines has been 
performed. The methodology was complicated by a proclivity for formation of a 
mixture of α- and β-arylated piperazine regioisomers when using N-Boc-N′-benzyl 
piperazine 117. A wide screen of ligands was undertaken and almost complete 
selectivity (95:5) for the formation of β-phenyl piperazine 295 was achieved using the 
N-heterocyclic carbene ligated palladium catalyst PEPPSI-i-Pr. However, the mixture of 
295 and 294 was obtained in only 38% yield (Scheme 3.48). Additionally, use of N-
Boc-N′-cumyl piperazine 241 under the same lithiation/arylation conditions resulted in a 
reversal in regioselectivity with selective formation of the α-phenyl piperazine 300 in 
12% yield.  
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Scheme 3.48 
It is possible that with future work these reactions may be optimised to give high 
yielding, selective methods for the synthesis of either α- or β-arylated piperazines. 
Further investigations into the catalyst system, reaction conditions and nature of the aryl 
halide could be fruitful. Specifically, the use of Badoin’s phosphine ligands may 
facilitate the selective formation of β-arylated piperazines. Additionally, it may be 
possible to optimise the lithiation/arylation of N-Boc-N′-cumyl piperazine 241 to give 
solely α-arylated piperazines in good yield. To this end, the lithiation could be improved 
by employing s-BuLi/TMEDA in Et2O and the arylation may be improved by using an 
alternative PEPPSI derivative, solvent or by altering the electronics of the aryl halide. 
To expand the electrophile scope further, future work could investigate the application 
of Fu’s enantioselective ligand controlled nickel catalysed lithiation/Negishi coupling to 
N-Boc piperazines.
105
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Chapter Four: Asymmetric Lithiation/Trapping of N-Boc 
Piperazines 
N-Boc pyrolidine 12 and N-Boc piperidine 10 have been extensively studied as 
substrates for the s-BuLi/diamine mediated asymmetric lithiation/trapping 
methodologies. However, the equally important N-Boc piperazine systems have been 
comparatively neglected. At the start of this project, there was only one example of the 
asymmetric lithiation/trapping of N-Boc piperazines using s-BuLi and a chiral diamine. 
This chapter details a thorough investigation of the asymmetric lithiation/trapping of N-
Boc piperazines. The role of the piperazine protecting group on the reaction outcome is 
explored in detail, with a range of side-reactions being encountered, investigated and 
overcome. The use of a chiral auxiliary protecting group for the asymmetric 
lithiation/trapping of N-Boc piperazines, facilitating the synthesis of enantiopure α-
substituted piperazines is detailed. A formal synthesis of the anti-retroviral Indinavir 
and the synthesis of disubstituted piperazines are disclosed.  
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4.1 Previous Asymmetric Lithiation/Trapping of N-Boc Piperazines 
To date, there has been only one reported example of s-BuLi/chiral diamine-induced 
asymmetric deprotonation of N-Boc piperazines. McDermott’s group at AstraZeneca 
used N-Boc-N′-t-butyl piperazine 152 as a substrate.108 Lithiation using s-BuLi/()-
sparteine under standard conditions (Et2O, 78 °C, 5 h) was followed by trapping with 
CO2 to give carboxylic acid (R)-214, which was not purified. The crude carboxylic acid 
underwent amidation with benzyl piperazine in the presence of HATU to give amide 
(R)-305 in 48% yield and 89:11 er (Scheme 4.1). Only one example of this supposedly 
unoptimised asymmetric deprotonation was reported. As shown by the ReactIR
™
 study 
using N-Boc-N′-t-butyl piperazine 152 in Chapter 2, the lithiation of 152 with s-BuLi/ 
(–)-sparteine was incomplete after 5 h, possibly accounting for the moderate yield of 
(R)-305 (see Scheme 2.20b) 
 
Scheme 4.1 
It was suspected that the absolute stereochemical configuration of (R)-214 was the same 
as the products obtained from the s-BuLi/(–)-sparteine mediated lithiation/trapping of 
N-Boc pyrrolidine 12 and N-Boc piperidine 10. This was confirmed by X-ray 
crystallography of a derivative (R,R)-307, which was prepared by debenzylation of (R)-
305 followed by amidation with (R)-N-tosyl proline (R)-306 (Scheme 4.2). 
 
Scheme 4.2 
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Workers at AstraZeneca showed that the asymmetric lithiation could be performed on a 
multi-gram scale. Lithiation of N-Boc-N′-t-butyl piperazine 152 was performed on a 10 
g scale giving (R)-305 in slightly lower er (83:17).
182
  
An interesting concept for the synthesis of enantioenriched α-substituted N-Boc 
piperazines was briefly explored by Guerrini and co-workers for the synthesis of the 
biologically active enantiomer of SHA-68, a neuropeptide S receptor (NPSR) 
antagonist.
183
 Enantiopure α-methylbenzyl-substituted N-Boc piperazine (S)-308 was 
deprotonated using s-BuLi/TMEDA in THF and trapped with benzophenone. A 60:40 
mixture of separable diastereomeric oxazolidinones (S,S)-309 and (R,S)-310 was formed 
and after isolation, (S,S)-309 and (R,S)-310 were attained in 45% and 40% yield 
respectively (Scheme 4.3). The (S)-α-methylbenzyl group acts as a chiral auxiliary, 
inducing a slight preference for removal of the pro-(S) proton. The poor 
diastereoselectivity is understandable considering the large distance between the chiral 
auxiliary and the site of deprotonation. Nevertheless, this use of a chiral auxiliary 
facilitated the isolation of enantiomerically pure α-substituted piperazines. The major 
disadvantage of this approach is that the synthesis of the starting N-Boc piperazine (S)-
308 took five steps and proceeded in only 20% yield. 
 
Scheme 4.3 
The relative stereochemistry of the minor diastereomer (R,S)-310 was determined by X-
ray crystallography. The target, neuropeptide S receptor antagonist SHA-68, was 
synthesised from (R,S)-310 in two steps. The chiral auxiliary was removed using Fmoc-
Cl to give enantiomerically pure (R)-311 in 69% yield. Fmoc deprotection using DBU 
and subsequent in situ urea formation gave SHA-68 in 76% yield (Scheme 4.4). 
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Scheme 4.4 
In related work, Coldham has described a dynamic thermodynamic resolution (DTR) 
process for the synthesis of enantioenriched α-substituted N-Boc piperazines.147 
Deprotonation was performed using s-BuLi/TMEDA, initially at –78 °C then at –10 °C 
for 1 h. Then, the reaction was cooled to –78 °C before lithiated ligand 312 was added 
and the reaction warmed to –30 °C and aged for 1 h to establish the thermodynamic 
ratio of diastereomeric organolithium complexes. The reaction was cooled to –78 °C to 
prevent further interconversion of organolithiums, prior to addition of the electrophile. 
When using N-Boc-N′-t-butyl piperazine 152 as a substrate, α-substituted piperazines 
210-214 were isolated in 30-75% yield and 60:40-80:20 er (Scheme 4.5). 
 
 
Scheme 4.5 Dynamic thermodynamic resolution of N-Boc-N′-t-butyl piperazine 152 
Other piperazines were used as substrates for the DTR methodology. When using N-
Boc-N′-benzyl piperazine 117, silane (R)-175 was isolated in 48% yield and 80:20 er 
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(Scheme 4.6). N-Methyl piperazines (R)-195 and (S)-313 were obtained in 34% yield 
(65:35 er) and 35% yield (77:23 er) when using and N-Boc-N′-methyl piperazine 151. It 
is possible that the low yields of (S)-195 and (R)-313 might be due to ring fragmentation 
side-reactions occurring, but no information on this was reported. 
 
 
Scheme 4.6 Dynamic thermodynamic resolution of 117 and 151  
The reported studies into the asymmetric lithiation/trapping of N-Boc piperazines were 
promising. However, a systematic study of the substrate and electrophile scope was not 
performed. Additionally, products were generally isolated in moderate yields and 
enantioselectivities.   
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4.2 Asymmetric Lithiation/Trapping of N-Boc Piperazines 
4.2.1 Asymmetric Lithiation/Trapping of N-Boc-N′-Benzyl Piperazines 
As described in Chapter 3, the racemic lithiation/trapping of N-Boc-N′-benzyl 
piperazine 117 was highly fruitful; trapping with a wide range of electrophiles gave α-
substituted products in 44-90% yields (see Scheme 3.20) and the enantiomers of most of 
these products were separated using CSP-HPLC. With the success of the racemic 
lithiation/trapping with N-Boc-N′-benzyl piperazine 117, the study into the asymmetric 
variant began with this substrate. 
The ReactIR
™
 spectroscopic studies reported in Chapter 2 were used to determine the 
optimum lithiation times. Complete lithiation of N-Boc-N′-benzyl piperazine 117 was 
achieved using s-BuLi/(–)-sparteine in Et2O at –78 °C for 1 h. Subsequent trapping with 
benzophenone gave oxazolidinone (R)-183 in 54% yield and 81:19 er (Scheme 4.7). The 
configuration of (R)-183 was assigned by analogy with McDermott’s work108 and the er 
was determined by CSP-HPLC. Use of the (+)-sparteine surrogate (+)-26 resulted in 
oxazolidinone (S)-183 being isolated in a disappointing 36% yield and 75:25 er.  
 
Scheme 4.7 
In an attempt to develop the methodology into a general procedure for the synthesis of a 
wide range of enantioenriched α-substituted N-Boc piperazines, the electrophile scope 
was examined. Asymmetric lithiation of N-Boc-N′-benzyl piperazine 117 with s-
BuLi/(–)-sparteine followed by trapping with methyl chloroformate gave the desired 
substituted N-Boc piperazine (R)-208 in 71% yield and 88:12 er. However, ring 
fragmented by-product, vinyl carbamate 314, was also isolated, in 12% yield (Scheme 
4.8). 
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Scheme 4.8 
A similar outcome was found when the (+)-sparteine surrogate (+)-26 was used. The 
desired substituted N-Boc piperazine (S)-208 was obtained in an excellent 88% yield 
and 85:15 er, along with vinyl carbamate 314 in 8% yield (Scheme 4.9).  
 
Scheme 4.9 
As outlined in Chapter 3, it is proposed that ring fragmentation occurs via the nitrogen 
lone pair of lithiated piperazine 285 reacting with the electrophile preferentially (see 
Scheme 3.37). Although ring fragmentation was observed with N-Boc-N′-methyl 
piperazine 151 and N-Boc-N′-allyl piperazine 239 when using diamine-free conditions 
(see Chapter 3.2), there was no evidence for the formation of vinyl carbamate 314 when 
using N-Boc-N′-benzyl piperazine 117 (see Scheme 3.20). Clearly, the use of a chiral 
diamine has an effect on the reaction outcome.  
Ring fragmentation side-reactions did not only occur when using methyl chloroformate 
as the electrophile. Lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(–)-
sparteine and trapping with Me3SiOTf gave none of the desired α-silyl N-Boc 
piperazine 175. Fragmentation product 299 was the only product, isolated in 51% yield 
(Scheme 4.10).  
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Scheme 4.10 
In a further example, lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(+)-
sparteine surrogate (+)-26 and trapping with Bu3SnCl resulted in only 17% of the 
desired stannane (R)-181 in 77:23 er (Scheme 4.11). Ring fragmentation product 299 
was the major product, as confirmed by the 
1
H NMR spectrum of the crude mixture, 
although it could not be isolated cleanly from the reaction mixture. 
 
Scheme 4.11 
Ring fragmentation was a serious hurdle to the development of a general method for the 
asymmetric lithiation/trapping of N-Boc piperazines. Furthermore, it was not the only 
major obstacle encountered in the early stages of this project. Previous work within the 
group had shown that asymmetric lithiation of N-Boc-N′-benzyl piperazine 117 using  s-
BuLi/(–)-sparteine and trapping with Me3SiCl gave α-silyl piperazine 175 in 38% yield 
and only 52:48 er (Table 4.1, entry 1).
184
 During this investigation, the use of alternative 
diamines gave similar results. Using s-BuLi/(+)-sparteine surrogate (+)-26, α-silyl 
piperazine 175 was obtained in 53% yield and 50:50 er (entry 2). With the Alexakis 
diamine (S,S)-27, α-substituted N-Boc piperazine 175 was obtained in a poor 9% yield 
and 52:48 er (entry 3).  
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Entry Diamine Time (h) Yield 175 (%)
a
 er 175 (S:R)
b
 
1 (–)-sparteine 5 38 52:48c 
2 (+)-26 1 53 50:50 
3 (S,S)-27 1 9 48:52 
a 
Yield after flash column chromatography. 
b
 Er determined by CSP-HPLC. 
c
 See 
reference 184. 
Table 4.1 Attempted asymmetric lithiation/trapping of 117 with Me3SiCl 
The poor levels of enantioselectivity can be explained by the rate of trapping of the 
intermediate organolithium with Me3SiCl. The use of in situ ReactIR
™
 spectroscopy has 
shown that trapping of lithiated N-Boc-N′-benzyl piperazine 117 with some 
electrophiles, particularly with Me3SiCl, is exceptionally slow at –78 °C (see Scheme 
2.27). As the reaction is warmed to room temperature the lithiated intermediate becomes 
configurationally unstable.
61
 Importantly, epimerisation occurs before trapping, 
resulting in essentially racemic 175 being isolated. No ring fragmentation by-products 
were observed when using Me3SiCl, unlike when using the more reactive Me3SiOTf 
(see Scheme 4.10). It is noteworthy that lithiated N-Boc-N′-benzyl piperazine 117 reacts 
less rapidly with ‘slow’ electrophiles than lithiated N-Boc pyrrolidine 12 or 4-phenyl N-
Boc piperidine 66. This is an intrinsic limitation of the lithiation/trapping of N-Boc 
piperazines. 
Further investigation of the use of slow trapping electrophiles in the asymmetric 
lithiation/trapping of N-Boc-N′-benzyl piperazine 117 was undertaken. Lithiation was 
performed using s-BuLi and chiral diamines and trapping was accomplished through the 
addition of either methyl iodide or dimethyl sulfate. The results of this investigation are 
presented in Table 4.2.  
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Entry E
+
 Diamine 
Yield (%)
a
, er 
(S:R)
b
 176 
Yield 315 (%)
a
 
1 Me2SO4 TMEDA 65 - 
2 MeI (S,S)-27 45 (55:45 er) - 
3 Me2SO4 (S,S)-27 - 51 
4 MeI (–)-sparteine 33 (61:39 er) 13 
5 Me2SO4 (–)-sparteine 11 (58:42 er) 43 
6 Me2SO4 (+)-26 - 50 
a
 Yield after flash column chromatography. 
b
 Er determined by CSP-HPLC. 
Table 4.2 Effect of electrophile and diamine on the α-methylation of N-Boc-N′-benzyl 
piperazine 117 
It was shown in Chapter 3 that racemic lithiation of N-Boc-N′-benzyl piperazine 117 
with s-BuLi/THF and trapping with methyl iodide or dimethyl sulfate gave 176 in 74% 
and 69% yields respectively; no ring-fragmented product 315 was seen (see Scheme 
3.20). As a control, the effect of TMEDA on the reaction outcome was performed. 
Racemic lithiation using s-BuLi/TMEDA in Et2O at –78 °C and trapping with dimethyl 
sulfate gave 176 in 65% yield with no ring-fragmented product 315 (Table 4.2, entry 1).  
The asymmetric lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(S,S)-27 
followed by trapping with methyl iodide gave (S)-176 in 45% yield and 55:45 er (entry 
2). The expected enantiomer, (R)-176, was determined to be the minor component by 
comparison of the measured optical rotation ([α]D +4.8 (c 1.0 in EtOH)) with that 
reported in the literature ([α]D +56 (c 0.44 in EtOH for a sample of >99:1 er)).
150
 This 
unexpected sense of enantioinduction could be due to a dynamic thermodynamic 
resolution process occurring as the reaction warmed up.  
Surprisingly, when asymmetric lithiation was performed under identical conditions (s-
BuLi/(S,S)-27, Et2O) and dimethyl sulfate was used as the electrophile, no α-methyl N-
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Boc piperazine 176 was observed (by analysis of the 
1
H NMR spectrum of the crude 
product) and ring-fragmented product 315 was isolated in 51% yield (entry 3). These 
result shows that both the diamine and the electrophile have an effect on the reaction 
outcome. Next, the effect of alternative chiral diamines was investigated. Lithiation of 
117 with s-BuLi/(–)-sparteine and trapping with methyl iodide gave a mixture of 
products (entry 4). α-Methyl N-Boc piperazine 176 was isolated in 33% yield (61:19 er) 
and ring-fragmented product 315 was isolated in 13% yield. This result highlights the 
effect of the diamine on the product distribution. In comparison, when (S,S)-27 was 
used, only by-product 315 was observed (entry 3). The low er (61:39 er) of (S)-176 
implies that, as expected, slow trapping was occurring and that the reaction was 
warming to a temperature at which the lithiated intermediate was configurationally 
unstable before any significant amount of trapping took place. When (–)-sparteine was 
used with dimethyl sulfate, the substituted N-Boc piperazine (S)-176 was isolated in 
11% yield (58:42 er) and by-product 315 was obtained in 43% yield (entry 5). Whereas 
the use of methyl iodide favoured formation of α-methyl piperazine (S)-176, the use of 
dimethyl sulfate favoured the formation of fragmentation product 315 (entries 4 and 5). 
Finally, when lithiation was performed using s-BuLi/(+)-sparteine surrogate (+)-26 and 
trapped with dimethyl sulfate, only vinyl carbamate 315 was isolated, in 50% yield 
(entry 6).  
To explain the dramatic effects of altering both the diamine and electrophile, the 
mechanism of fragmentation must be considered. The extent to which fragmentation 
occurred can be rationalised by a competition between two pathways (Scheme 4.12). In 
pathway A, trapping of the lithiated intermediate 285 by the electrophile gives the 
desired α-substituted piperazines 116. Pathway B involves the nitrogen lone pair 
attacking the electrophile, giving quaternary ammonium species 286 which undergoes 
β-elimination to give vinyl carbamate 287. The ReactIR™ spectroscopic studies 
presented in Chapter 2 show that for N-Boc pyrrolidine 12 the presence of a bulky 
diamine retarded electrophilic trapping with slow electrophiles (see Scheme 2.31). This 
is highly likely to be the case with N-Boc-N′-benzyl piperazine 117 as well. It is 
proposed that this decrease in the rate of electrophilic trapping in the presence of bulky 
chiral diamines allows the reaction to proceed (either partially or fully) through pathway 
B.  
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Scheme 4.12 Competing electrophile trapping pathways  
In situ ReactIR
™
 studies showed that trapping of the organolithium with methyl iodide 
is faster than trapping with dimethyl sulfate (when using TMEDA as a ligand). This 
observation and the mechanism in Scheme 4.12 can explain the different reaction 
outcomes with the two electrophiles. For example, when utilising s-BuLi/(S,S)-27 to 
effect lithiation, trapping with methyl iodide favoured formation of α-methyl piperazine 
176, whereas with dimethyl sulfate, the formation of fragmentation product 315 was 
favoured (Table 4.2, entries 2 and 3). As trapping with methyl iodide is faster, the 
reaction can proceed along pathway A. With dimethyl sulfate trapping of the 
organolithium is slower, resulting in predomination of pathway B. The same effect can 
be seen with (–)-sparteine (entries 4 and 5).  
The product ratio of α-substituted piperazines 116 to vinyl carbamates 287 is dependent 
upon the relative rates of pathways A and B. The structure of the N-Boc piperazines and 
diamines, and the reactivity of the electrophiles all exert an influence on these rates, as 
highlighted by the results disclosed in this section and by the in situ ReactIR
™
 studies 
presented in Chapter 2.  
Not only does the use of a bulky chiral diamine exacerbate the problems of slow 
trapping and the fragmentation side-reaction, a further complication was observed when 
trapping with benzophenone. Racemic lithiation/trapping of N-Boc-N′-benzyl piperazine 
117 using diamine-free conditions and benzophenone resulted in the desired 
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oxazolidinone 183 being isolated in 90% yield (see Scheme 3.20). However, for 
lithiation with s-BuLi in the presence of bulky chiral diamines the reaction was more 
complex. Trapping with benzophenone gave alkene containing by-product 186 formed 
along with the desired product 183 (Table 4.3). Unfortunately, the isolation of pure 
alkene 186 from the crude reaction mixtures was not successful. However, 
unambiguous structural assignment was accomplished by mass spectrometry and 
1
H 
NMR spectroscopy, and by analogy to known compounds.
185
 Table 4.3 shows the effect 
of the diamine on the ratio of desired oxazolidinone 183 and alkene 186 (determined by 
analysis of 
1
H NMR spectra of the crude mixtures) and the er of oxazolidinone 183. 
Small, but significant, amounts of alkene 186 were formed (relative to the desired 
product) when (S,S)-27 (entry 1) or (–)-sparteine (entry 2) were used, and the desired 
oxazolidinone 183 were isolated in 60% and 54% respectively. However, when (+)-
sparteine surrogate (+)-26 was used, alkene 186 was the major product of the reaction, 
with (S)-183 isolated in only 35% yield (entry 3).  
 
Entry Diamine Yield 183 (%)
a
 er 183 (R:S)
b 
 183:186
c
  
1 (S,S)-27 60 14:86 87:13 
2 (–)-sparteine 54 81:19 78:22 
3 (+)-26 35 25:75 41:59 
a
 Yield after flash column chromatography. 
b
 Er determined by CSP-HPLC. 
c
 Ratio 
determined by 
1
H NMR spectroscopy of the crude product. 
Table 4.3 Effect of the diamine on lithiation/trapping of N-Boc-N′-benzyl piperazine 
117 with benzophenone 
It is hypothesised that alkene 186 was formed through a radical process. The presence 
of benzophenone ketyl radical in the reaction mixture was evident from the persistent 
deep green colour observed when the benzophenone was added to the lithiated 
piperazine. Single electron transfer (SET) from the organolithium 161 to the 
benzophenone resulted in piperazine radical 317 and benzophenone ketyl radical 316 
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(Scheme 4.13), as described by Gawley for pyrrolidine and piperidine based systems 
with benzophenone or alkyl halides.
86,186-188
 Disproportionation of the piperazine radical 
317 gave alkene 186 and starting material 117. 
 
Scheme 4.13 Mechanism of formation of alkene 186 via radical 317   
The reduction in er of oxazolidinone 183 (relative to results with methyl chloroformate 
under comparable conditions, see Scheme 4.8) can be attributed to some SET-mediated 
trapping. Radical trapping of the planar N-Boc piperazine radical 317 and 
benzophenone ketyl 316 would give the desired product, but without control over the 
newly formed stereocentre. This mechanism presumably resulted in a lower er of 
oxazolidinone 183; SET trapping is well precedented with benzophenone.
186,189
 In the 
lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(S,S)-27, oxazolidinone (S)-
183 was formed in 60% yield and a respectable 86:14 er (Table 4.3 entry 1), indicating a 
low level of radical trapping. However, lithiation with the (+)-sparteine surrogate (+)-26 
generated (S)-183 in 35% yield and a poorer 75:25 er (entry 3). This suggests that 
radical trapping was more prevalent in this case. Notably, these side-reactions did not 
occur in the racemic, diamine-free lithiation. It was hypothesised that the use of a bulky 
diamine reduced the rate of anionic trapping with benzophenone thus allowing SET 
side-reactions to become competitive processes. Investigation by in situ ReactIR
™
 
spectroscopy could not confirm or contradict this hypothesis. Complete trapping was 
shown to occur within 1 min at –78 °C, regardless of the route of trapping (see Scheme 
2.38). However, the relative time scales of anionic trapping and SET trapping in the 
presence or absence of bulky diamines could not be determined due to the resolution of 
the ReactIR
™
 equipment. The reason for variable levels of SET side-reaction in the 
presence of different ligands is unknown. 
Fragmentation of the piperazine ring and slow trapping by certain electrophiles were the 
two most significant problems encountered with N-Boc-N′-benzyl piperazine 117. These 
problems, along with the SET side-reactions encountered with benzophenone, conferred 
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a poor electrophile scope on the lithiation/trapping of N-Boc-N′-benzyl piperazine 117. 
In the presence of chiral diamines, all electrophiles tested resulted in at least partial 
fragmentation, near-racemic products or single electron transfer side-products.  
 
4.2.2 Diamine Displacement Strategy 
Racemic lithiation of N-Boc-N′-benzyl piperazine 117 and trapping with either methyl 
iodide or dimethyl sulfate proceeded without issue to give 2-methyl piperazine 176 (see 
Scheme 3.20 and Table 4.2, entry 1). However, ring-fragmentation was generally 
observed when the analogous asymmetric reaction was performed (see Table 4.2, 
entries 3-6). This was due to slower electrophile trapping in the presence of a bulky 
diamine, as observed with N-Boc pyrrolidine 12 through in situ ReactIR
™
 monitoring 
(see Scheme 2.31). To circumvent the ring-fragmentation problem it was envisaged that 
reducing the steric bulk around the newly formed stereogenic centre would allow faster 
rates of trapping with ‘slow’ electrophiles. Two approaches were conceivable, Sn/Li 
exchange and a diamine displacement strategy. Previously, a Sn/Li exchange process 
was successfully used by O’Brien and co-workers to improve the yield and er of α-
substituted N-Boc piperidines with slow trapping electrophiles.
95
 Unfortunately, for N-
Boc-N′-benzyl piperazine 117 this strategy was unfeasible as the requisite 
enantioenriched stannane could not be synthesised in a useful yield due to ring-
fragmentation side reactions (see Scheme 4.11). 
A diamine displacement method was therefore investigated with a view to reducing the 
steric bulk around the organolithium centre. It was hypothesised that asymmetric 
deprotonation of N-Boc-N′-benzyl piperazine 117 could be performed with s-BuLi and a 
chiral diamine to generate an enantioenriched organolithium intermediate. Then, 
displacement of the bulky chiral diamine from the organolithium intermediate could 
possibly be achieved with either a coordinating solvent, such as THF, or a smaller 
diamine such as TMEDA. This would reduce the steric bulk around the enantioenriched 
organolithium, allowing faster trapping with problematic electrophiles. ReactIR
™
 
spectroscopic monitoring had shown that the trapping of lithiated N-Boc-N′-benzyl 
piperazine 117 with methyl iodide, in the presence of THF or TMEDA proceeded 
sufficiently quickly at –78 °C. 
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Diamine displacement of enantioenriched organolithium species is precedented from the 
catalytic two-ligand approach developed by O’Brien (see Scheme 1.19).63 A further 
example was reported by Metallinos whist investigating the asymmetric 
lithiation/trapping of urea 318.
29
 Lithiation with s-BuLi/(–)-sparteine followed by 
trapping with methyl iodide gave (S)-319 in 25% yield and 80:20 er (Scheme 4.14). 
However, when the lithiated intermediate was transferred to a solution of methyl iodide 
in THF at –78 °C, (S)-319 was isolated in 25% yield and 84:16 er. This slight 
improvement in enantioinduction was attributed to the THF displacing (–)-sparteine 
from the organolithium. 
 
Scheme 4.14 
When lithiation of N-Boc-N′-benzyl piperazine 117 was performed using s-BuLi/(–)-
sparteine followed by trapping with methyl iodide, 2-methyl N-Boc piperazine (S)-176 
was isolated in 33% yield (61:39 er) along with ring-fragmented product 315 in 13% 
yield (see Table 4.2, entry 4). This was the most promising result obtained for the 
asymmetric lithiation/trapping of N-Boc-N′-benzyl piperazine 117 with methylating 
agents, and so the diamine displacement strategy was applied to this system. Once 
lithiation of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(–)-sparteine was complete (1 
h at –78 °C in Et2O), TMEDA (5 eq.) was added and the reaction was stirred for 30 min 
before addition of methyl iodide. The desired product, 2-methyl N-Boc piperazine (S)-
176 was isolated in 43% yield and 87:13 er (Scheme 4.15). Ring-fragmented by-product 
315 was not observed (by analysis of the 
1
H NMR spectrum of the crude product). 
Although the yield of (S)-176 was moderate, the enantiomeric ratio was greatly 
improved using the diamine displacement strategy. In fact, the enantiomeric ratio of (S)-
176 (87:13 er) probably reflects the ratio of organolithium intermediates. It is known 
that lithiation/trapping of N-Boc-N′-benzyl piperazine 117 with s-BuLi/(–)-sparteine and 
the ‘fast’ electrophile, methyl chloroformate, gave ester (R)-208 in 88:12 er (see 
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Scheme 4.8). Clearly, diamine exchange was occurring, reducing the steric hindrance 
around the organolithium centre and facilitating faster trapping with methyl iodide. This 
also indicated that the lithiated piperazine coordinated to TMEDA is configurationally 
stable at –78 °C for the duration of the reaction. 
 
Scheme 4.15 
With the success of the diamine displacement strategy using s-BuLi/(–)-sparteine, the 
analogous reaction with s-BuLi/(+)-sparteine surrogate (+)-26 was investigated. 
Previous results showed that lithiation of N-Boc-N′-benzyl piperazine 117 under these 
conditions and trapping with dimethyl sulfate resulted in formation of only ring-
fragmented by-product 315 in 50% yield (see Table 4.2, entry 6). The use of the 
diamine displacement protocol gave no improvement. By-product 315 was the sole 
product and was isolated in 50% yield (Scheme 4.16). Clearly, TMEDA was unable to 
displace (+)-26 from the lithiated intermediate.  
 
Scheme 4.16 
Although this lack of improvement when using (+)-26 was disappointing, the result was 
not a surprise. It is known through NMR spectroscopy studies that the (+)-sparteine 
surrogate (+)-26 binds more tightly to organolithiums than (–)-sparteine.57  
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4.2.3 Investigation of the Asymmetric Lithiation/Trapping N-Boc Piperazines with 
Sterically Hindered Protecting Groups  
By far the most serious problem encountered in the asymmetric lithiation/trapping of N-
Boc-N′-benzyl piperazine 117 was ring fragmentation, which occurred with the vast 
majority of electrophiles investigated. It was envisaged that replacing the benzyl 
protecting group with a more sterically hindered group would prevent the lone pair from 
attacking susceptible electrophiles and thus prevent the unwanted ring fragmentation 
by-products, as was noticed first in the racemic lithiation/trapping reactions.  
Asymmetric lithiation/trapping of N-Boc-N′-t-butyl piperazine 152 was investigated as 
this was the substrate used in McDermott’s study.108 Lithiation of 152 using s-BuLi/(–)-
sparteine in Et2O at –78 °C for 6 h (optimised lithiation time determined by ReactIR
™
 
spectroscopy, see Scheme 2.20b), followed by trapping with methyl chloroformate gave 
ester (R)-245 in 72% and 89:11 er (Scheme 4.17). Importantly, no ring fragmented by-
products were observed in the 
1
H NMR spectrum of the crude product. The opposite 
enantiomer (S)-245 was synthesised in 90% yield and 89:11 er by deprotonation of 12 
with s-BuLi/(+)-sparteine surrogate (+)-26 for only 10 min at –78 °C, followed by 
trapping with methyl chloroformate. 
 
Scheme 4.17 
Next, an investigation into the use of benzophenone as an electrophile was conducted to 
assess the degree of SET side-reactions compared with the desired anionic electrophile 
trapping. Lithiation of N-Boc-N′-t-butyl piperazine 152 with s-BuLi and a chiral 
diamine was performed followed by trapping with benzophenone. When (S,S)-27 was 
used, oxazolidinone (R)-246 was isolated in 36% yield and 85:15 er (Table 4.4, entry 1). 
Although the yield was relatively low, alkene 320 was not observed in the 
1
H NMR 
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spectrum of the crude product. The use of (–)-sparteine resulted in the isolation of (R)-
246 in 74% yield and a respectable 90:10 er with alkene by-product not being observed 
(entry 2). When using the (+)-sparteine surrogate (+)-26, a small amount of alkene by-
product 320 was observed (entry 3). Nevertheless, the desired oxazolidinone (S)-246 
was isolated in 76% yield and 86:14 er. Compared with the reaction using N-Boc-N′-
benzyl piperazine 117 as a substrate (see Table 4.3), the SET side-reactions appear to be 
much less of a problem with N-Boc-N′-t-butyl piperazine 152 with higher enantiomeric 
ratios and lower amounts of alkene by-products being observed. It is unknown why this 
might be the case. As with N-Boc-N′-benzyl piperazine 117, the use of (+)-sparteine 
surrogate (+)-26 resulted in a greater degree of SET side-reactions.  
 
Entry Diamine Time 
Yield 246 
(%)
a
 
er 246 
(R:S)
b
 
246:320
c
 
1 (S,S)-27 1 h 36 15:85 100:0 
2 (–)-sparteine 6 h 74 90:10 100:0 
3 (+)-26 1 h 76 14:86 85:15 
a
 Yield after flash column chromatography. 
b
 Er determined by CSP-HPLC. 
c
 Ratio 
determined by 
1
H NMR spectroscopy of the crude product. 
Table 4.4 Effect of the diamine on lithiation/trapping of N-Boc-N′-t-butyl piperazine 
152 with benzophenone 
The use of the bulky t-butyl protecting group prevented ring fragmentation side-
reactions and decreased the degree of SET side-reactions. However, the use of N-Boc-
N′-t-butyl piperazine 152 had some drawbacks. The major limitation was that the t-butyl 
group cannot easily be removed once it has fulfilled its role as a protecting group.
147
 
This limits the synthetic utility of the methodology. A minor, but nonetheless frustrating 
limitation was that the substrate does not contain a UV chromophore. This makes CSP-
HPLC method development more complex in cases where the electrophile itself does 
not introduce a chromophore into the product. To by-pass these problems, substrates 
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with large, sterically hindered and UV chromophore containing, but easily removable, 
protecting groups were investigated. 
Previous work within the O’Brien group briefly explored the use of N-Boc-N′-trityl 
piperazine 203 as a substrate for asymmetric lithiation/trapping reactions.
184
 
Asymmetric lithiation using s-BuLi/(–)-sparteine for 5 h at –78 °C in Et2O followed by 
trapping with methyl chloroformate gave (R)-247 in 74% yield and 80:20 er (Scheme 
4.18). 
 
Scheme 4.18 
To explore the scope of the lithiation/trapping of N-Boc-N′-trityl piperazine 203 
lithiation was accomplished using s-BuLi/(+)-sparteine surrogate (+)-26 before trapping 
with a small range of electrophiles. The desired enantioenriched α-substituted N-Boc 
piperazines (S)-247, (S)-249 and (R)-251 were obtained in good yield (74-81%) 
(Scheme 4.19). Importantly, ring fragmentation by-products were not observed in the 
1
H NMR spectra of the crude reaction mixtures. Methyl ester (S)-247 was isolated in a 
good 81% yield and 81:19 er when trapping with methyl chloroformate. This result is 
comparable with that obtained using (–)-sparteine (74% yield and 80:20 er). Unlike with 
racemic s-BuLi/TMEDA mediated lithiation/trapping (see Scheme 2.22) none of the 
disubstituted N-Boc piperazine 248 was formed during the reaction. Oxazolidinone (S)-
249 was isolated in 80% yield in a lower 73:27 er and stannane (R)-251 was obtained in 
74% yield and 82:18 er. The lower er seen benzophenone is probably due to a small 
amount of racemic SET trapping.  
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Scheme 4.19 Asymmetric lithiation/trapping of 203 with s-BuLi/(+)-26 
Although the yields obtained were promising, the enantiomeric ratios were 
disappointing when compared to those with either N-Boc-N′-benzyl piperazine 117 (see 
Scheme 4.8) or N-Boc-N′-t-butyl piperazine 152 (see Scheme 4.17). For this reason, 
further investigation into the use of N-Boc-N′-trityl piperazine 203 was abandoned.  
In an attempt to improve the enantioselectivity, the lithiation/trapping of phenyl 
fluorenyl protected piperazine 240 was studied using s-BuLi and the (+)-sparteine 
surrogate (+)-26 at –78 °C (Table 4.5). When using Et2O as solvent, ester (S)-255 was 
isolated in an acceptable 68% yield and 86:14 er (Table 4.5, entry 1). It was envisaged 
that changing the solvent to either MTBE or toluene would improve the yield due to 
better solubility of the starting material 240, as seen with the racemic variant (see Table 
3.1). However, this was not the case: when using MTBE, (S)-255 was isolated in a 
reduced 59% yield and 85:15 er (entry 2); with toluene, the yield of (S)-255 was a 
disappointing 40% (81:19 er) (entry 3). 
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Entry Solvent Yield (S)-255 (%)
a
 er (S)-255
b
 
1 Et2O 68 86:14 
2 MTBE 59 85:15 
3 Toluene 40 81:19 
a
 Yield after flash column chromatography. 
b
 Er determined by CSP-HPLC. 
Table 4.5 Effect of solvent on the asymmetric lithiation of 240 with s-BuLi/(+)-26 
Although the yield and er of (S)-255 attained when using Et2O as a solvent were 
acceptable, the low solubility of the substrate was a problem and no further 
investigation into the lithiation of N-Boc-N′-PhFl piperazine 240 was undertaken. 
The racemic lithiation/trapping of N-Boc-N′-cumyl piperazine 241 gave high yields of 
α-substituted N-Boc piperazines with a range of electrophiles (see Chapter 3.2). 
Therefore, the asymmetric lithiation/trapping methodology was investigated. The length 
of time required for complete lithiation of N-Boc-N′-cumyl piperazine 241 using s-BuLi 
and chiral diamines had not been established by ReactIR
™
 spectroscopy. Therefore, by 
analogy with N-Boc-N′-t-butyl piperazine 152, deprotonation with s-BuLi/(–)-sparteine 
was performed for 6 h before addition of the electrophiles. Trapping with methyl 
chloroformate gave (R)-259 in 71% yield and 90:10 er (Scheme 4.20). The yield and er 
is comparable to that obtained with N-Boc-N′-benzyl piperazine 117 (see Scheme 4.8) 
and N-Boc-N′-t-butyl piperazine 152 (see Scheme 4.17). Crucially, no ring fragmented 
by-products were observed with 241. The use of Bu3SnCl resulted in (S)-263 being 
isolated in 61% yield and 89:11 er. In order to determine the enantiomeric ratio of 
stannane (S)-263, Sn/Li exchange using n-BuLi at –78 °C in THF followed by trapping 
with methyl chloroformate to give ester (R)-259 was performed. When using 
benzophenone, (R)-267 was obtained in 53% yield. The corresponding alkene by-
product was observed by 
1
H NMR spectroscopy of the crude mixture, but unfortunately 
could not be isolated cleanly. However, a surprisingly high 91:9 er was achieved.  
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Scheme 4.20 Asymmetric lithiation/trapping of 241 with s-BuLi/(–)-sparteine 
Synthesis of the opposite enantiomeric series of compounds through the asymmetric 
lithiation of N-Boc-N′-cumyl piperazine 241 was undertaken (using s-BuLi and the (+)-
sparteine surrogate (+)-26 at –78 °C for 1 h). Trapping with a range of electrophiles 
gave (S)-259, (R)-263, (S)-264 and (S)-267 in 54-99% yield and 86:14-88:12 er 
(Scheme 4.21). Oxazolidinone (S)-267 was isolated in 73% yield; a small amount of the 
SET alkene by-product was formed. As seen with N-Boc-N′-t-butyl piperazine 152 it 
appears that increasing the steric bulk of the protecting group decreases the problematic 
SET side-reactions. The yield of amide (S)-264 was only 54%, due to the formation of 
cyclised products that could not be isolated cleanly.  
 
  
Scheme 4.21 Asymmetric lithiation/trapping of 241 with s-BuLi/(+)-26 
The absolute stereochemistry of methyl ester (S)-259 was determined by conversion to 
known carboxylic derivate (S)-322. Direct displacement of the cumyl group with benzyl 
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chloroformate was unsuccessful and so a two-step procedure to convert cumyl 
piperazine (S)-259 into Cbz protected piperazine (S)-322 was undertaken (Scheme 
4.22). Removal of the cumyl group was achieved using transfer hydrogenolysis with 
Pd(OH)2/C and ammonium formate at reflux for 2 h, giving secondary amine (S)-321 in 
97% yield. Then, acylation with benzyl chloroformate was accomplished and following 
saponification of the methyl ester, carboxylic acid (S)-322 was isolated in 62% yield 
over two steps. The absolute stereochemistry was confirmed by comparison of the 
optical rotation of (S)-322 ([α]D –14.9 (c 0.7 in CHCl3)) with a known sample 
synthesised from serine ([α]D –17.5 (c 1.0 in CHCl3 for a sample of >99:1 er)).
190
 
 
Scheme 4.22 
The use of N-Boc-N′-cumyl piperazine 241 prevented the ring fragmentation side-
reaction. Crucially, lithiation/trapping methodology applied to 241 allowed the 
synthesis of both enantiomeric series of α-substituted piperazines in high yield and good 
enantiomeric ratios, unlike when using other protected N-Boc piperazines. Additionally, 
the cumyl group could be easily removed by hydrogenolysis (see Scheme 3.27) or 
transfer hydrogenolysis, allowing further derivatisation of the substituted piperazines to 
interesting target molecules.  
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4.3 Chiral Auxiliary Approach to Enantiopure N-Boc Piperazines  
4.3.1 Synthesis of Enantiopure Monosubstituted N-Boc Piperazines 
The use of N-Boc-N′-cumyl piperazine 241 as a substrate allowed access to both 
enantiomeric series of α-substituted N-Boc piperazines in 86:14-91:9 er. These levels of 
enantioselectivity are in line with results published by McDermott
108
 and with earlier 
research carried out within the O’Brien group.184 However, with N-Boc pyrrolidine 12, 
enantioselectivity was as high as 98:2 er.
42
 Unfortunately, with N-Boc piperazines 
stereoselectivities at this level are difficult to achieve though enantioselective 
deprotonation using the currently available chiral diamines. 
The chiral auxiliary approach pioneered by Guerrini and co-workers allowed access to 
single enantiomers of α-substituted piperazines (see Scheme 4.3).183 It was envisaged 
that this methodology could be developed further by using chiral diamines to affect an 
asymmetric deprotonation. If the auxiliary and diamine both favour the removal of the 
same proton, high yields of enantiomerically pure α-substituted N-Boc piperazines 
could be achieved. 
The first challenge was to develop a practical multi-gram scale synthesis of N-Boc-N′-
(S)-α-methyl benzyl piperazine (S)-308. A method for the synthesis of piperazines from 
primary amines developed by D’Ambra and co-workers was used.191,192 Reaction 
between commercially available N-tosyl amine 323 and enantiomerically pure (S)-(−)-
α-methylbenzylamine in DIPEA gave tosyl piperazine (S)-324 in 84% yield (Scheme 
4.23). Removal of the tosyl group with HBr in the presence of 4-hydroxy benzoic acid 
gave secondary amine (S)-325 in 95% yield without the need for purification. Boc 
protection under standard conditions gave the desired substrate (S)-308 in 93% yield as 
a single enantiomer. Overall, synthesis of 13.4 g of (S)-308 was achieved in 74% total 
yield over three steps, a significant improvement on the literature method (20% over 5 
steps).
183
 Importantly, only one purification operation was required; (S)-308 was 
purified by flash column chromatography. 
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Scheme 4.23 
In order to facilitate the development of asymmetric lithiation/trapping methodology, 
the length of time required for the complete lithiation of (S)-308 with s-BuLi and a 
range of ligands was ascertained by in situ ReactIR
™
 spectroscopic studies (Scheme 
4.24). As expected, complete lithiation of (S)-308 with s-BuLi and TMEDA was rapid, 
proceeding via pre-lithiation complex 326 to give lithiated intermediate 327 within 7 
min (Scheme 4.24a). Lithiation in the presence of the (+)-sparteine surrogate (+)-26 was 
also fast, reaching completion within 2 min (Scheme 4.24c). Lithiation in the presence 
of (–)-sparteine was nearing completion after 2 h (Scheme 4.24b), as was diamine-free 
lithiation in THF to 328 (Scheme 4.24d). The lithiation of N-Boc-N′-(S)-α-methyl 
benzyl piperazine (S)-308 took longer to reach completion than lithiations of N-Boc-N′-
benzyl piperazine 117, but was faster than the lithiation of N-Boc-N′-t-butyl piperazine 
152 (see Table 2.1). This supports the idea that increasing the steric bulk of the 
protecting group increases the time required for complete lithiation of the substrate to 
occur.  
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Scheme 4.24 Lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308 with s-BuLi 
and ligands, (a) TMEDA, (b) (–)-sparteine, (c) (+)-26, (d) THF 
These ReactIR
™
 spectroscopic studies showed that the lithiation conditions employed 
by Guerrini, specifically the warming of the reaction mixture (s-BuLi, TMEDA, THF, –
78 °C then –35 °C for 2 h), were overly complicated and unnecessary. Therefore, the 
investigation began by optimising the racemic lithiation and trapping with 
benzophenone (Table 4.6). Diamine-free lithiation of N-Boc-N′-(S)-α-methyl benzyl 
piperazine (S)-308 with s-BuLi in THF at –78 °C for 3 h resulted in a slight preference 
for the removal of the pro-(S) proton, a 60:40 dr in favour of (S,S)-309 was observed. 
Products (S,S)-309 and (R,S)-310 were isolated in 52% and 32% yield respectively 
(Table 4.6, entry 1). The same degree of diastereoselectivity was observed by Guerrini 
when performing the lithiation using s-BuLi/TMEDA in THF. Interestingly, when using 
TMEDA in Et2O, (S,S)-309 and (R,S)-310 were formed with improved 
(b) 
(d) (c) 
(a) 
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diastereoselectivity (70:30 dr) (entry 2). The yields of the isolated oxazolidinones were 
good, with (S,S)-309 being obtained in 58% yield and (R,S)-310 in 15% yield. Changing 
the solvent to MTBE gave similar results to those with Et2O, products (S,S)-309 and 
(R,S)-310 formed in 70:30 dr and with yields of 56% and 20% yield respectively (entry 
3). 
 
Entry Diamine Solvent Time (h) 
dr 
(309:310)
a
 
Yield 309 
(%)
b
 
Yield 310 
(%)
b
 
1 - THF 3  60:40 52 32 
2 TMEDA Et2O 1 70:30 58 15 
3 TMEDA MTBE 1 70:30 56 20 
a
 Dr determined by analysis of 
1
H NMR spectrum of the crude reaction mixture.
 b
 Yield 
after flash column chromatography. 
Table 4.6 Effect of solvent and diamine on the lithiation of N-Boc-N′-(S)-α-
methylbenzyl piperazine (S)-308 
Lithiation of (S)-308 using s-BuLi and TMEDA in ethereal solvents provided a good 
combined yield of oxazolidinones (S,S)-309 and (R,S)-310 (73-84%). Knowing that the 
chiral auxiliary could induce modest levels of diastereoselectivity, the compounded 
effect of chiral diamines on the reaction was investigated. Since the chiral auxiliary 
induces a preference for the removal of the pro-(S) proton, a chiral diamine that also 
favoured the removal of the pro-(S) proton should give a ‘matched’ case. It was 
anticipated that upon trapping, oxazolidinones (S,S)-309 and (R,S)-310 would be formed 
with a high diastereomeric ratio, and hence (S,S)-309 could be isolated as a single 
stereoisomer in high yield. The effects of chiral diamines on the lithiation/trapping of α-
methylbenzyl-substituted N-Boc piperazine (S)-308 with benzophenone are detailed in 
Table 4.7. It has been observed that the s-BuLi/(+)-sparteine surrogate (+)-26 complex 
preferentially removed the pro-(S) proton of N-Boc heterocycles. Therefore, lithiation of 
(S)-308 under these conditions resulted in the formation of (S,S)-309 and (R,S)-310 in a 
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90:10 dr (Table 4.7, entry 1). Gratifyingly, this increase in diastereoselectivity shows 
that the diamine and auxiliary are matched, in that they both favour removal of the pro-
(S) proton. However, an even higher diastereomeric ratio was expected. 
Disappointingly, the yields of (S,S)-309 and (R,S)-310 were low (31% and 4% 
respectively). When (–)-sparteine was used, a mismatch between the diamine and 
auxiliary was observed with (R,S)-310 and (S,S)-309 formed in 60:40 dr (entry 2). 
Similarly, the isolated yields of (R,S)-310 (29%) and (S,S)-309 (16%) were 
disappointing. The use of the Alexakis diamine (S,S)-27 led to the formation of the 
products (S,S)-309 and (R,S)-310 in 90:10 dr and 32% and 2% isolated yields (entry 3). 
The mismatched enantiomer (R,R)-27 gave the products (R,S)-310 and (S,S)-309 in 
70:30 dr and 15% and 6% isolated yields (entry 4). 
 
Entry Diamine Time (h) 
dr 
(309:310)
a
 
Yield 309 
(%)
b
 
Yield 310 
(%)
b
 
1 (+)-26 1  90:10 31 4 
2 (–)-sparteine 3 40:60 16 29 
3 (S,S)-27 1 90:10 32 2 
4 (R,R)-27 1 30:70 6 15 
a
 Dr determined by analysis of 
1
H NMR spectrum of the crude reaction mixture.
 b
 Yield 
after flash column chromatography. 
Table 4.7 Effect of chiral diamines on the lithiation of N-Boc-N′-(S)-α-methylbenzyl 
piperazine (S)-308 
Although the matched/mis-matched effect was clearly demonstrated, both the yields and 
diastereomeric ratios were disappointing. This was probably due to competing SET 
processes, as is often observed with benzophenone. The yields are poor due to the 
formation of alkene (S)-329 (Figure 4.1), present in significant quantities in all cases (by 
analysis of 
1
H NMR spectra of the crude reaction mixtures). A small portion of (S)-329 
was isolated cleanly in the reaction with (–)-sparteine and the structure confirmed (entry 
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2). Additionally, it is possible that the observed diastereomeric ratio of the products is 
lower than the diastereomeric ratio of lithiated intermediates. Planar radical formation 
on the piperazine and subsequent single electron transfer mediated electrophile trapping 
could cause erosion of dr post-lithiation.  
 
Figure 4.1 
With the benefit of hindsight, the decision to use benzophenone as an electrophile for 
the development of this chiral auxiliary/chiral diamine methodology was misguided. 
Although there was precedent for using benzophenone from Guerrini’s work, and the 
absolute and relative stereochemistry of the products were known, the single electron 
transfer problems complicated the initial development of this methodology. 
To by-pass these problems, trapping with methyl chloroformate was investigated. 
Lithiation with s-BuLi/TMEDA in Et2O followed by trapping formed esters (S,S)-330 
and (R,S)-331 in 68:32 dr (Scheme 4.25). Isolated yields of 19% and 8% respectively 
were low due to the formation of diester (S)-332 (24%). The relative stereochemistry of 
(S,S)-330 was confirmed using the same method as detailed for the cumyl protected 
analogue (see Scheme 4.22). 
 
Scheme 4.25 
As reported earlier (Scheme 3.22 and Table 3.1, entry 1), the formation of diester by-
products occurs frequently when using s-BuLi/TMEDA. Due to the fact that these by-
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products are generally not observed when using chiral diamines, the investigation of the 
matched chiral auxiliary/chiral diamine system was investigated. Pleasingly, lithiation 
of N-Boc-N′-(S)-α-methyl benzyl piperazine (S)-308 with s-BuLi/(+)-sparteine 
surrogate (+)-26 for 10 min at –78 °C followed by trapping with methyl chloroformate 
formed (S,S)-330 and (R,S)-331 in 95:5 dr. The major diastereomer, (S,S)-330, was 
isolated in 90% yield and the minor diastereomer (R,S)-331 in 4% yield (Scheme 4.26). 
Additionally, no ring fragmentation by-products or diester (S)-332 were observed. 
Analysis of (S,S)-330 by CSP-HPLC, in comparison with a racemic sample, showed 
that no racemisation had occurred and that (S,S)-330 had been formed in 99:1 er. 
 
Scheme 4.26 
Lithiation of (S)-308 using s-BuLi/(–)-sparteine results in a mismatch between the chiral 
auxiliary and the chiral diamine. When trapping with methyl chloroformate (R,S)-331 
and (S,S)-330 were formed in a 63:37 dr with yields of 49% and 27% respectively 
(Scheme 4.27). 
 
Scheme 4.27 
In order to access the opposite enantiomeric series of α-substituted piperazines in high 
yield, the opposite enantiomer of the substrate was required. N-Boc-N′-(R)-α-methyl 
benzyl piperazine (R)-308 was synthesised in an analogous fashion to the (S) 
enantiomer. Subsequent lithiation of N-Boc-N′-(R)-α-methyl benzyl piperazine (R)-308 
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with s-BuLi/(–)-sparteine for 3 h at –78 °C followed by trapping with methyl 
chloroformate formed (R,R)-330 and (S,R)-331 in >95:5 dr; ester (R,R)-330 was isolated 
91% yield (Scheme 4.28). 
 
Scheme 4.28 
To demonstrate the scope of this matched chiral auxiliary/chiral diamine methodology, 
a small selection of electrophiles were investigated. Initially, racemic lithiation of (S)-
308 was performed using s-BuLi/TMEDA in Et2O at –78 °C followed by trapping with 
electrophiles and the results are presented in Table 4.8. In all but one case, 
diastereoselectivities (68:32-71:29 dr) were similar to that obtained with methyl 
chloroformate (68:32 dr, see Scheme 4.25). However, the dr obtained with methyl 
iodide (63:27 dr) was marginally lower, possibly due to slow trapping of the lithiated 
intermediate at low temperatures (Table 4.8, entry 3). Overall total yields were good, 
ranging from 79-98%. 
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Entry E
+
 Products dr
a
 Yields (%)
b
 
1 PhCONMe(OMe) 
 
71:29 62, 17 
2 (p-TolS)2 
 
69:31 67, 27 
3 MeI 
 
63:37 62, 35 
4 AllylBr
c
 
 
68:32 56, 23 
a
 Dr determined by analysis of 
1
H NMR spectrum of the crude reaction mixture.
 b
 Yield 
after flash column chromatography. 
c 
via Li/Cu transmetallation using CuCN.2LiCl. 
 
Table 4.8 Racemic lithiation/trapping of (S)-308 with s-BuLi/TMEDA and a range of 
electrophiles 
Next, lithiation of (S)-308 was performed using s-BuLi/(+)-sparteine surrogate (+)-26 
followed by trapping with a similar set of electrophiles, the results are presented in 
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Table 4.9. In all cases the reactions proceeded with good diastereoselectivity (>92:8 dr). 
Importantly, no ring-fragmentation by-products were observed.  
 
Entry E
+
 Products dr
a
 Yields (%)
b
 
1 PhCONMe(OMe) 
 
93:7 86, 6 
2 (p-TolS)2 
 
95:5 86, 4 
3 Bu3SnCl 
 
93:7
d
 94
e
 
4 AllylBr
c
 
 
95:5 79, 5 
a
 Dr determined by analysis of 
1
H NMR spectrum of the crude reaction mixture. 
b
 Yield 
after flash column chromatography. 
c 
via Li/Cu transmetallation using CuCN.2LiCl. 
d 
Determined by conversion into (S,S)-330 and (S,R)-331. 
e 
Combined yield. 
 
Table 4.9 Asymmetric lithiation/trapping of (S)-308 with s-BuLi/(+)-26 and a range of 
electrophiles 
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Diastereoselective lithiation followed by trapping with the Weinreb amide N-methoxy-
N-methylbenzamide gave (S,S)-333 and (R,S)-334 in 93:7 dr. The major diastereomer 
(S,S)-333 was isolated in 86% yield (Table 4.9, entry 1). Trapping with p-tolyl disulfide 
resulted in the diastereomers (R,S)-335 and (R,S)-336 being formed in 95:5 dr (entry 2). 
The major diastereomer, thioether (R,S)-335 was isolated in 86% yield. When trapping 
with Bu3SnCl, an inseparable mixture of diastereomers (R,S)-341 and (S,S)-342 was 
formed in 94% combined yield and 93:7 dr (entry 3). Due to the complexity of the 
1
H 
NMR spectrum of the mixture of stannanes, the diastereomeric ratio of (R,S)-341 and 
(S,S)-342 had to be determined by conversion into a mixture of diastereomeric esters 
(S,S)-330 and (S,R)-331. Sn/Li exchange was accomplished using n-BuLi and TMEDA 
in THF at –78 °C for 10 min before trapping with methyl chloroformate (Scheme 4.29). 
Esters (S,S)-330 and (S,R)-331 were obtained in a combined 64% yield and 93:7 dr, thus 
giving the diastereomeric ratio of stannanes (R,S)-341 and (S,S)-342. 
 
Scheme 4.29 
Allyl piperazines (R,S)-339 and (S,S)-340 were formed in 95:5 dr when using Dieter’s 
Li/Cu transmetalation
93
 method followed by trapping with allyl bromide (Table 4.9, 
entry 4). Major diastereomer (R,S)-339 was isolated in 79% yield.  
Lithiation/trapping of (S)-308 with a range of electrophiles allowed the synthesis of a 
variety of enantiopure α-substituted N-Boc piperazines with excellent levels of 
diastereoselectivity and high isolated yields. However, when trapping with methyl 
iodide, (R,S)-337 and (S,S)-338 were formed in a relatively poor 76:24 dr, with yields of 
53% and 15% respectively (Scheme 4.30). 
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Scheme 4.30 
The low dr is attributed to slow trapping by methyl iodide at low temperatures and the 
initially high dr is thus compromised. The diamine displacement strategy (see Chapter 
4.2.3) was employed to improve the diastereoselectivity of trapping with methyl iodide. 
As it is known that TMEDA cannot displace the (+)-sparteine surrogate (+)-26 from the 
lithiated intermediates but it can displace (–)-sparteine, the strategy was applied to the 
antipode of the starting material (R)-308. Lithiation was initially accomplished using    
s-BuLi/(–)-sparteine at –78 °C. Without using an excess of TMEDA to effect a diamine 
displacement, (S,R)-337 and (R,R)-338 were formed in a 55:45 dr and 32% and 27% 
isolated yields (Table 4.10, entry 1). This showed that warming of the reaction to a 
temperature at which the organolithium was configurationally unstable was occurring, 
before a significant degree of trapping occurred. Interestingly, the dr is lower than the 
enantiomeric reaction using (+)-sparteine surrogate (+)-26. When the diamine 
displacement method was employed (entry 2), a marked improvement was observed. α-
Methyl piperazines (S,R)-337 and (R,R)-338 were formed in a 90:10 dr and isolated in 
70% and 3% yield respectively. 
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Entry Diamines dr 337:338
a
 Yield 337 (%)
b
  Yield 338 (%)
b
 
1 (–)-sparteine 55:45 32 27 
2 
(–)-sparteine 
then TMEDA 
90:10 70 3 
a
 Dr determined by analysis of 
1
H NMR spectrum of the crude reaction mixture.
 b
 Yield 
after flash column chromatography. 
Table 4.10 Effect of diamine displacement on the lithiation/trapping of N-Boc-N′-(R)-α-
methylbenzyl piperazine (R)-308  
An alternative strategy was investigated to improve the yield of methylated piperazine 
(R,S)-337. A Sn/Li exchange procedure from the diastereomeric mixture of stannanes 
(R,S)-341 and (S,S)-342 was performed. As with the diamine displacement strategy, this 
procedure removes the requirement for a bulky chiral diamine in the trapping with 
methyl iodide, thus speeding up trapping at low temperatures and allowing (R,S)-337 
and (S,S)-338 to be formed without loss of diastereoselectivity. Transmetalation was 
achieved using n-BuLi/TMEDA in THF at –78 °C for 10 min before addition of methyl 
iodide. 2-Methyl piperazines (R,S)-337 and (S,S)-338 were formed without loss of 
diastereoselectivity in 93:7 dr. Major isomer (R,S)-337 was isolated in 69% yield 
(Scheme 4.31). The minor diastereomer was observed by analysis of the 
1
H NMR of the 
crude mixture but was not isolated due to the small scale of the reaction. 
. 
Scheme 4.31 
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Although the diamine displacement and Sn/Li exchange strategies led to an 
improvement in the yield of major diastereomer (R,S)-337, a more direct method was 
desired. Therefore, the use of methyl triflate as an electrophile was investigated. It is 
know than methyl triflate is 10
4
 times more reactive then methyl iodide in the alkylation 
of pyridines.
193
 It was envisaged that trapping with methyl triflate would be much 
quicker than with methyl iodide at low temperatures, thus trapping would occur without 
epimerisation of the organolithium intermediate. When lithiation of (S)-308 with s-
BuLi/TMEDA in Et2O was followed by trapping with methyl triflate, (R,S)-337 and 
(S,S)-338 were formed in 72:28 dr and isolated in 72% and 23% yield respectively 
(Scheme 4.32).  
 
Scheme 4.32 Lithiation/trapping of (S)-308 with methyl triflate 
In contrast, when lithiation of (S)-308 was carried out with s-BuLi/(+)-sparteine 
surrogate (+)-26 followed by trapping with methyl triflate, the desired α-methyl 
piperazines were not formed. Ring-fragmented by-product (S)-343 was isolated in 46% 
yield (Scheme 4.32). This is the only electrophile investigated that caused the ring 
fragmentation of N-Boc-N′-(S)-α-methyl benzyl piperazine (S)-308. The speed of 
trapping of the organolithium intermediate is slowed in the presence of a bulky diamine 
thus allowing the fragmentation pathway to predominate. Assuming that the lone pair of 
the nitrogen attacks methyl triflate in an SN2 process, the small size of the electrophile 
coupled with its high reactivity could explain the observed fragmentation. Despite the 
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ring fragmentation encountered with methyl triflate when using s-BuLi/(+)-26, (R,S)-
337 can still be isolated in 72% yield as a single enantiomer when using s-
BuLi/TMEDA to effect lithiation.  
To demonstrate the applicability of the chiral auxiliary/chiral diamine methodology, a 
formal synthesis of the antiretroviral drug Indinavir (see Figure 3.1) was undertaken. 
Lithiation of (S)-308 using s-BuLi/(+)-26 followed by trapping with t-butyl isocyanate 
was performed in an attempt introduce the t-butyl amide functionality. However, the 
reaction resulted in a complex mixture of cyclised and uncyclised products that could 
not be separated. Since the amide functionality could not be introduced directly, 
manipulation of ester (S,S)-330 was carried out. Saponification of the ester proceeded 
smoothly to give acid (S,S)-344 in 94% yield (Scheme 4.33). Synthesis of the t-butyl 
amide moiety of (S,S)-345 was completed in 98% yield through amidation with             
t-butylamine, using HATU as the coupling agent. Hydrogenolysis of the cumyl 
protecting group was unsuccessful, presumably due to the presence of the amide 
functionality. Therefore, protecting group removal was achieved by reaction with 1-
chloroethyl chloroformate, followed by MeOH, to give piperazine hydrochloride (S)-
346 in 84% yield. The formal synthesis was completed by removal of the Boc group 
using HCl in Et2O, giving piperazine dihydrochloride (S)-347 in 98% yield.
194
 
Alternatively, a partial synthesis of Indinavir was achieved by alkylating (S)-346 with 3-
(chloromethyl)pyridine in the presence of Et3N to give (S)-348 in 69% yield. 
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Scheme 4.33 Formal synthesis of Indinavir 
 
4.3.2 Synthesis of Enantiopure Disubstituted N-Boc Piperazines 
With methodology developed to construct enantiopure α-substituted piperazines, further 
elaboration of these products to synthesise 2,6- and 2,5-disubstituted piperazines was 
investigated. The synthesis of disubstituted piperidines through two consecutive 
lithiation/trapping reactions was pioneered by Beak
74,75
 and examples were provided 
Chapter 1.2.5.  
2-Methyl N-Boc piperazine (R,S)-337 was initially chosen due to the lack of reactive 
functional groups. Lithiation with s-BuLi/TMEDA in Et2O at –78 °C for 1 h before 
trapping with benzophenone gave (R,S,S)-349 in 49% as a single diastereomer (Scheme 
4.34). Based on the analysis of the 
1
H NMR spectrum of the crude product a 77:23 
mixture of (R,S,S)-349 and alkene by-product (R,S)-350 was formed, thus accounting 
for the moderate yield of (R,S,S)-349. Interestingly, this is the only encounter of the 
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formation of SET by-products when using s-BuLi/TMEDA in the work disclosed within 
this thesis.  
 
Scheme 4.34 
Benzophenone was chosen as the electrophile because the product (oxazolidinone 
(R,S,S)-349) does not have the Boc group. This eliminated rotamers from the 
1
H NMR 
spectrum, allowing structural assignment by evaluation of the coupling constants. A 
large vicinal axial-axial coupling of 11.0 Hz is evident between H
2
 the adjacent axial 
proton, placing the oxazolidinone group in an equatorial orientation as expected. 
Coupling constants could not be resolved for H
6
 but a 2D COSY experiment showed 
that H
6
 and H
5ax
 were coupled. Analysis of the coupling constants for H
5ax
 showed a 4.0 
Hz axial-equatorial coupling to H
6
, indicating that H
6
 is in an equatorial orientation and 
hence the methyl substituent is in an axial orientation. The observed diastereoselectivity 
arises due to the fact that the 2-methyl substituent adopts an axial conformation to avoid 
A
1,3
-type strain with the Boc group. Subsequent Boc-directed equatorial lithiation and 
retentive trapping results in a 2,6-trans-relationship (see Scheme 1.40). 
In an analogous reaction, lithiation of 2-methyl N-Boc piperazine (R,S)-337 and 
trapping with methyl chloroformate gave (S,R,S)-351 in 77% as a single diastereomer 
(Scheme 4.35). The relative stereochemistry was assigned by analogy with (R,S,S)-349 
as it was not possible to fully analyse the 
1
H NMR spectrum due to the presence of 
rotamers.  
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Scheme 4.35 
Unsymmetrical N-Boc heterocycles can possibly exist as two different rotameric forms. 
As shown previously with 2-phenyl N-Boc pyrrolidine 39 (see Scheme 2.7), N-Boc 
tetrahydroisoquinoline 135 (see Scheme 2.10) and N-Boc imidazolidine 154 (see 
Scheme 2.23) the barrier to rotation of the N-Boc group is often high at low 
temperatures, resulting in low yields of substituted products. However the relatively 
high yield of (S,R,S)-351 (77%) suggests that rotamers (R,S)-337a and (R,S)-337b 
readily interconvert at low temperatures (Scheme 4.36). Similarly, it is known that the 
rotamers of 2-phenyl N-Boc piperidine convert rapidly at –78 °C in THF.115 Lithiation 
would only be expected at the least hindered position of (R,S)-337b to give lithiated 
intermediate (R,R,S)-352. However, closer inspection of the lithiation event using 
ReactIR
™
 or variable temperature NMR would be necessary to definitively prove that 
rotamers (R,S)-337a and (R,S)-337b readily interconvert at low temperatures on the 
reaction timescale. 
 
Scheme 4.36 Lithiation of rotameric forms of (R,S)-337  
van Maarseveen and co-workers assigned a cis-relationship between the allyl groups of 
racemic 2,6-diallyl piperazine 200 (see Scheme 3.6), but this assignment is at odds with 
previous work on 2,6-disubstitited N-Boc piperidines and the work disclosed within this 
section. In order to investigate the stereochemical relationship between two allyl groups, 
enantiopure diallyl piperazine (R,R,S)-353 was synthesised. Lithiation of allyl 
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piperazine (R,S)-339 was accomplished using s-BuLi/TMEDA. After transmetallation 
to copper (using CuCN.2LiCl) and trapping with allyl bromide, diallyl piperazine 
(R,R,S)-353 was isolated in 57% yield (Scheme 4.37). Removal of the α-methyl benzyl 
protecting group was accomplished using 1-chloroethyl chloroformate followed by 
MeOH to give (R,R)-354 in 55% yield. The optical rotation of (R,R)-354 was found to 
be [α]D –34.9 (c 0.7 CHCl3). The non-zero optical rotation proves the trans-relationship 
between the allyl groups; the cis-compound is meso (achiral) and would have an optical 
rotation of zero. It is still possible, although unlikely, that van Maarseveen’s synthesis 
of the N-methyl diallyl derivative 200 did result in the formation of a cis-disubstituted 
piperazine. 
 
Scheme 4.37 
Next, the synthesis of 2,5-disubsituted piperazines was investigated. The requisite 
substrate, 3-methyl piperazine (R)-356 was synthesised in three steps from enantiopure 
2-methyl piperazine (R,S)-337 (Scheme 4.38). Reduction of the Boc group with LiAlH4 
in THF at reflux gave tertiary amine (R,S)-355 in 88% yield. Then, removal of the α-
methyl benzyl protecting group was accomplished using hydrogenation with Pd/C in 
acidic MeOH. Following Boc protection of the resulting secondary amine, 3-methyl 
piperazine (R)-356 was isolated in 87% yield. 
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Scheme 4.38 
N-Boc-N′-methyl piperazine 151 was shown to undergo ring-fragmentation side-
reactions with the majority of electrophiles (see Chapter 3.2). However, benzophenone 
reacted with the intermediate organolithium without fragmentation (see Scheme 3.33). 
Therefore, lithiation/trapping of 3-methyl piperazine (R)-356 was performed with         
s-BuLi/TMEDA and benzophenone. Oxazolidinone (R,R)-357 was isolated in 53% 
yield as a single diastereomer (Scheme 4.39). The trans-relationship between the 
substituents was determined by analysis of the coupling constants from the 
1
H NMR 
spectrum of (R,R)-357. H
2
 shows a large axial coupling of 11.0 Hz, indicating that the 
oxazolidinone is in an equatorial orientation. H
6eq
 shows a large geminal coupling and 
an equatorial-axial coupling of 3.5 Hz. Additionally H
6ax
 shows a large axial-axial 
coupling of 11.5 Hz. The trans-relationship arises due to the methyl group adopting an 
equatorial orientation before equatorial deprotonation and retentive trapping (see 
Scheme 1.43). 
 
Scheme 4.39 
The work presented in this section shows the synthesis of enantiomerically pure trans-
2,6- and trans-2,5-disubstitiuted N-Boc piperazines using the chiral auxiliary approach.  
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4.4 Conclusions and Future Work 
Preliminary investigations into the asymmetric lithiation/trapping of N-Boc-N′-benzyl 
piperazine 117 revealed a series of problems. Specifically, ring fragmentation side-
reactions were encountered with a range of electrophiles, whist other slow trapping 
electrophiles resulted in either ring fragmentation or near-racemic products being 
isolated, or both. 
Increasing the steric bulk of the piperazine protecting group prevented the lone pair 
attacking electrophiles and thus minimised or eliminated the ring fragmentation side-
reaction. Additionally, use of a large protecting group reduced the SET side-reactions 
with benzophenone. A range of piperazines protected with sterically large protecting 
groups were investigated. The use of N-Boc-N′-t-butyl piperazine 152, N-Boc-N′-trityl 
piperazine 203 and N-Boc-N′-PhFl piperazine 240 was moderately successful. However, 
each of these substrates had drawbacks. Finally, the use of N-Boc-N′-cumyl piperazine 
241 allowed the synthesis of a range of α-substituted N-Boc piperazines in good yields 
and er, in both enantiomeric series. As far as it can be known, this is the first report of 
the cumyl protecting group for the protection, manipulation and deprotection of amines. 
The development of an asymmetric lithiation/trapping method using an N-Boc 
piperazine substrate protected with an α-methyl benzyl chiral auxiliary 308 allowed the 
synthesis of enantiopure α-substituted N-Boc piperazines in excellent yield. Both 
enantiomeric series are attainable in high yield by matching the sense of induction from 
the chiral auxiliary and the chiral diamine. A representative selection of piperazines 
synthesised is shown in Figure 4.2. Further work could focus on expanding the 
electrophile scope of this reaction. 
 
Figure 4.2  
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The α-methyl benzyl protecting group could be removed using several different 
conditions allowing further derivatisation of the piperazine scaffold, with a formal 
synthesis of the antiretroviral drug Indinavir being completed.  
The synthesis of enantiopure trans-disubstituted piperazines has been accomplished 
using two consecutive stereoselective lithiation/trapping reactions. The selection of 
compounds formed is shown in Figure 4.3. 
 
Figure 4.3 
Further elaboration of the piperazine scaffold could be achieved using the methodology 
developed, with the synthesis of tri- and tetrasubstituted piperazines 358 and 359 being 
feasible (Scheme 4.40). The third lithiation would need to employ a chiral diamine to 
control the regioselectivity of the lithiation/trapping. Additionally, in order to obtain 
good yields, the reactions would need to be performed at a temperature at which N-Boc 
rotamers could interconvert readily. 
Scheme 4.40 Possible synthesis of tri- and tetrasubstituted piperazines 358 and 359 
Piperazines are ubiquitous within drug molecules, but very few examples exist with the 
piperazine substituted at carbon. The methodology developed within this chapter would 
allow medicinal chemists to synthesise a range of enantiopure mono- and disubstituted 
piperazines that are differentially protected, for incorporation into potential drug 
molecules. 
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Chapter Five: Synthesis of the (–)-Sparteine Surrogate 
The (+)-sparteine surrogate (+)-26 (Figure 5.1) has been used with great success in the 
s-BuLi-mediated asymmetric lithiation of N-Boc heterocycles.
48,57,60,63,68,95,195,196
 It has 
found utility in the lithiation of other substrates including O-alkyl carbamates
48,197
 as 
first reported by Hoppe,
41
 the lithiation of phosphine boranes,
198,199
 ferrocene 
derivatives,
200
 and diaryl-methane derivatives.
201
 Additionally, it has been employed as 
a ligand for transition metals with palladium catalysed oxidative kinetic resolution of 
secondary alcohols,
202
 copper(II)-mediated resolution of BINOL,
203
 and oxidative 
dearomatisation of benzaldehyde derivatives being reported.
204
 A review of the 
chemistry of the (+)-sparteine surrogate (+)-26 was published in 2008.
205
  
As shown by previous work in the O’Brien group53,95 and in Chapter 2, the lithiation 
times of N-Boc heterocycles are much shorter using s-BuLi and the (+)-sparteine 
surrogate (+)-26 than with (–)-sparteine. This itself creates an opportunity for the (–)-
sparteine surrogate (–)-26 (Figure 5.1) in synthesis. Furthermore, the unreliable supply 
of naturally occurring (–)-sparteine,206,207 makes access to the (–)-sparteine surrogate   
(–)-26 critical. However, the reliance on (–)-cytisine, itself a natural product, as a 
starting material for the synthesis of (+)-26 precludes the synthesis of the enantiomer in 
an analogous fashion. 
 
Figure 5.1 
Thus, gram-scale synthetic routes to the (–)-sparteine surrogate (–)-26 were explored. 
This chapter details two approaches for synthesis of the (–)-sparteine surrogate (–)-26. 
The first involved the synthesis and resolution of racemic 26, and the second, aimed to 
develop a fully stereoselective synthesis wherein an enzymatic kinetic resolution of an 
early stage intermediate would give the required enantiopure building block.   
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5.1 Previous Syntheses of the Sparteine Surrogate  
To date, all syntheses of enantioenriched sparteine surrogate 26 have relied on one of 
three strategies: use of an enantiopure starting material from the chiral pool, resolution 
of racemic surrogate 26 or asymmetric synthesis. This section reviews the current 
published methods for the synthesis of the sparteine surrogate 26. 
 
5.1.1 Use of Chiral Pool Starting Materials: Synthesis of the (+)-Sparteine 
Surrogate from (–)-Cytisine 
The wide adoption of O’Brien’s (+)-sparteine surrogate (+)-26 is a testament to its 
success as a ligand. Its acceptance by the synthetic community has been facilitated by 
the fact that it is easy to synthesise in high yield from (–)-cytisine (Scheme 5.1) using a 
procedure developed in the O’Brien group.48,51 This was made possible by Lasne’s 
development of a straightforward and low cost procedure for the extraction of (–)-
cytisine from Laburnum anagyroides seeds on a multi-gram scale.
208
  
Scheme 5.1 Synthesis of (+)-26 from (–)-cytisine 
Using Lasne’s method, workers in the O’Brien group extracted (–)-cytisine from 
Laburnum anagyroides seeds in 1.1% mass yield. With (–)-cytisine in hand, methyl 
carbamate 360 was formed in 92% yield by reaction with methyl chloroformate in the 
presence of triethylamine. Then, diastereoselective hydrogenation on the least hindered 
exo-face, employing Adams’s catalyst, followed by global reduction with LiAlH4 gave 
the (+)-sparteine surrogate (+)-26 in 86% yield. Chiral shift 
1
H NMR spectroscopy 
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showed (+)-26 to be >98:2 er. Thus, an efficient multi-gram synthesis of (+)-26 from (–
)-cytisine was completed in three steps in 79% overall yield. 
 
5.1.2 Synthesis and Resolution of Racemic Sparteine Surrogate 
Scheiber and Nemes reported the first synthesis of racemic sparteine surrogate 26 in 
1994 before its use as a sparteine-like diamine was even considered (Scheme 5.2).
209
 2-
Quinolizinone 361 (synthesised using previously reported procedures
210,211
) was 
transformed into bispidone 362 as a single diastereomer via a double Mannich reaction 
in 56% yield. Reduction of the carbonyl group was accomplished using the Huang-
Minlon modification of the Wolff-Kishner reduction to give 26 in 99% yield.  
 
Scheme 5.2 
The stereoselectivity in the double Mannich reaction can be explained as shown in 
Scheme 5.3. It is a result of a preferred double chair conformation of bicyclic ketone 
361 and the fact that the second Mannich reaction can only occur when the iminium ion 
is orientated axially, as in 363. 
 
Scheme 5.3 Stereoselectivity in the double Mannich reaction of 361 
Work within the O’Brien group was initially focussed on accessing the (+)-sparteine 
surrogate (+)-26 via Scheiber and Nemes’ route using enantiopure bicyclic ketone (R)-
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361.
212
 Unfortunately, preliminary studies on related bicyclic amino ketones showed 
that racemisation occurred under the harsh acidic conditions required for the double 
Mannich reaction. This presumably occurred through either a retro-Mannich or retro-
Michael reaction. Further experimentation did not identify racemisation free double 
Mannich conditions and attention was turned to the resolution of 26 for the attainment 
of (+)-26.  
To facilitate this goal, an optimised synthesis of racemic sparteine surrogate 26 was 
developed (Scheme 5.4).
213
 Hydrogenation of ethyl-2-pyridyl acetate 364 using 
Adams’s catalyst under acidic conditions gave crude piperidine ester 365 which was 
reacted with ethyl acrylate in the presence of triethylamine to give di-ester 366 in 69% 
overall yield. A Dieckmann condensation was accomplished using LHMDS at –78 °C, 
followed by decarboxylation under acidic conditions to give bicyclic ketone 361 in 87% 
yield. The synthesis was completed using the double Mannich/Wolff-Kishnner protocol 
developed by Scheiber and Nemes, with bispidone 362 being isolated in 58% yield and 
26 in 68% yield. In summary, the synthesis of racemic sparteine surrogate 26 was 
completed in 24% yield over five steps. 
 
Scheme 5.4 O’Brien’s synthesis of racemic sparteine surrogate 26  
Classical resolution of 26 was attempted using a range of chiral acids (Figure 5.2) as 
resolving agents in acetone.
214
 Literature precedent suggested this was a viable strategy. 
Leonard had reported the total synthesis of racemic sparteine and resolution with (+)-
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camphorsulfonic acid (+)-367 in acetone in 1950.
215
 Several other chiral acids that are 
often used in the resolution of amines were also investigated, including tartaric acid 
derivatives (–)-368 and (–)-369,216,217 (S)-malic acid (S)-370 and (S)-mandelic acid (S)-
371. 
 
Figure 5.2  
Acetone was chosen as the solvent due to the literature precedent of the resolution of 
sparteine, and 1.0 eq. of the resolving agent was employed. Mixtures of a chiral acid 
and sparteine surrogate 26 were formed at 60 °C and allowed to cool over 12 h. The 
results of this investigation are shown in Table 5.1.  
 
Entry Resolving agent Yield (%) er
a
 
1 (+)-367 - - 
2 (–)-368 - - 
3 (–)-369 69 0 
4 (S)-370 - - 
5 (S)-371 - - 
a
 Er of the free base, determined by 
1
H NMR spectroscopy in the presence of a chiral 
shift reagent. 
Table 5.1 Attempted resolution of racemic sparteine surrogate 26 using chiral acids 
Crystals were observed in only one case, when (–)-369 was employed as the resolving 
agent (Table 5.1, entry 3). No enantioenrichment was observed. It is possible that the 
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use of 1.0 equivalent of resolving agent (–)-369 led to the high yield (69%) and racemic 
nature of the isolated material. 
The O’Brien group then turned their attention to resolution via lattice inclusion, a 
technique pioneered by Schlenk.
218
 In 1983, Toda and co-workers showed that racemic 
sparteine could be resolved using enantiopure acetylenic alcohols including (R)-372 
(Scheme 5.5).
219
 An equimolar mixture of (R)-372 and racemic sparteine in acetone 
gave crystals that, upon treatment with aqueous HCl, resulted in the isolation of (–)-
sparteine in 24% yield and 90:10 er. Importantly, when complexation of 90:10 er (–)-
sparteine and (R)-372 was repeated, enantiopure (–)-sparteine was obtained. 
 
Scheme 5.5 
Due to the similarity in structure of (–)-sparteine and the sparteine surrogate 26 it was 
hypothesised by O’Brien and co-workers that resolution of the latter could be 
accomplished using enantiopure acetylenic alcohols.
213
 To this end a sample of 
enantiopure (R)-373 was prepared by resolution with (–)-sparteine using Toda’s 
method. Treatment of racemic surrogate 26 with (R)-373 in acetone gave crystals that, 
upon treatment with aqueous HCl, liberated enantioenriched (–)-26 in 23% yield and 
81:19 er (Scheme 5.6).  
  
Scheme 5.6 
To summarise, enantioenrichment of the sparteine surrogate 26 by resolution with 
acetylenic alcohol (R)-373 was possible. However, since two resolutions would be 
required to produce (–)-26 in high enantiomeric ratio the overall yield of the resolution 
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would be prohibitively low. Additionally, (–)-sparteine was required for the resolution 
of racemic 373. 
More recently, Canipa and O’Brien developed a novel synthesis of racemic sparteine 
surrogate 26.
220
 The route involved three key reactions: (i) the diastereoselective 
alkylation of cyclic β-amino esters, (ii) annulation via an intramolecular conjugate 
addition, followed by stereoselective protonation and (iii) formation of the bispidine 
framework via double displacement of a di-mesylate with methylamine. The first three 
steps of the synthetic route are shown in Scheme 5.7. As with the previous route to 26, 
the synthesis began with hydrogenation of pyridine 364 to piperidine 365 using 
Adams’s catalyst. The crude piperidine was then transformed into N-Boc ester 374 
using Boc2O in the presence of triethylamine in 73% overall yield.  
 
Scheme 5.7 
The next step was a diastereoselective alkylation of N-Boc ester 374. Treatment of 374 
with LHMDS in THF at –78 °C followed by addition of (α-bromomethyl)acrylate 375 
(synthesised according to a known procedure
221
) gave di-ester 376 in 79% yield as a 
single diastereomer. Stereoselectivity in the alkylation of protected piperidine derived 
cyclic β-amino esters, such as 374, is well precedented from the work of Knight,222,223 
Lhommet,
224
 and others.
45,225-227
 A rationale for the stereoselectivity observed in the 
alkylation has been proposed by Knight and is shown in Scheme 5.8. It is assumed that 
the enolate 377 adopts the E configuration shown, and that the lithium coordinates to 
the carbonyl of the Boc group. The electrophile then approaches from the least hindered 
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back face, avoiding interactions with the sterically demanding Boc group. This leads to 
formation of 376 as the major diastereomer.  
 
Scheme 5.8 Rationale for stereoselectivity in the alkylation of 377 
The next key step was a sequential Boc deprotection/intramolecular conjugate addition 
reaction. Removal of the N-Boc protecting group from di-ester 376 was accomplished 
using TFA under standard conditions. The crude secondary amine 378 was treated with 
K2CO3 in EtOH at room temperature for 16 h, resulting in intramolecular conjugate 
addition to give 379 as a single diastereomer in 90% yield (Scheme 5.9). 
Scheme 5.9 
The ring-closing conjugate addition proceeded stereoselectively to give the cis-
diastereomer of 379. This can be rationalised as shown in Scheme 5.10. Intramolecular 
conjugate addition of the secondary amine of 378 onto the α,β-unsaturated ester gave 
intermediate enolate 380. Protonation of the enolate by EtOH from the less hindered 
exo-face gave the desired cis-stereochemistry. 
 
Scheme 5.10 Rationale for stereoselectivity in the synthesis of 379 
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Analysis of the 
1
H NMR spectrum of di-ester 379 suggested that the bicyclic compound 
adopted the conformation 379b and not 379a (Scheme 5.11). This conformation was 
favoured as it places the two ester groups in an equatorial positions, avoiding 
unfavourable 1,3 diaxial interactions, and the ring-flip was made possible by nitrogen 
inversion. 
 
Scheme 5.11 
With the requisite stereocentres formed in two completely diastereoselective steps, the 
synthesis was completed in three problem free transformations (Scheme 5.12). 
Reduction of di-ester 379 to diol 381 using LiAlH4 was followed by the application of 
standard sulfonylation conditions to give di-mesylate 382 in 72% yield over two steps. 
Finally, double displacement with methylamine in EtOH completed the synthesis of 26 
in 72% yield. Precedent for this double displacement came from Breuning’s work on 
the synthesis of oxa-bispidines via double displacement of a di-mesylate with 
methylamine.
228,229
  
 
Scheme 5.12 
In summary, synthesis of racemic sparteine surrogate 26 was completed in eight steps 
(five isolation steps) in 27% overall yield. This route is unpublished to date. 
Importantly, the synthesis is completely diastereoselective and potentially scalable. The 
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major disadvantages of this route are that it starts with the relatively expensive ethyl-2-
pyridyl acetate 364 and it is relatively labour intensive, requiring four chromatographic 
separations of intermediates and a final distillation of 26.  
Although racemic sparteine surrogate 26 was synthesised using this route, it was 
identified that there was potential for this method to be used in the synthesis of 
enantioenriched sparteine surrogate 26. This would require the preparation of 
enantioenriched N-Boc ester 374. To this end, a preliminary investigation into the 
resolution of secondary amine 365 was undertaken (Scheme 5.13). β-Amino ester 365 
was dissolved in acetone with (R)-mandelic acid (R)-371 (1.0 eq.) and stirred for 24 h. 
The resulting white precipitate was filtered off and then treated with base to release (R)-
365, in 31% yield and 90:10 er. Although this preliminary investigation was partially 
successful, (R)-365 was not obtained with a sufficient degree of enantioenrichment to be 
of practical use in the preparation of (–)-sparteine surrogate (–)-26.  
 
Scheme 5.13 
 
5.1.3 Asymmetric Synthesis of the Sparteine Surrogate  
To date, three syntheses of enantiopure sparteine surrogate 26 have been accomplished 
using asymmetric synthesis. In 2002, Lesma reported the synthesis of (–)-26 starting 
from enantiopure piperidine mono-acetate 383 (both enantiomers of which are available 
by enzymatic desymmetrization of the corresponding meso-diol or meso-di-acetate
230
) 
(Scheme 5.14).
231
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Scheme 5.14 Lesma’s asymmetric synthesis of (–)-sparteine surrogate (–)-26 
Swern oxidation of mono-alcohol 383 gave aldehyde 384 in 90% yield. Then, in the key 
step, benzyl imine 385 was formed in situ before a Sc(OTf)3 catalysed hetero-Diels 
Alder reaction with Danishefsky's diene gave a 50:50 mixture of diastereomeric 
piperidines 386 in 89% yield. Saponification and mesylation gave a mixture of 
mesylates 387. Subsequent hydrogenation of the alkene and concurrent hydrogenolysis 
of the benzyl and Cbz groups, followed by heating in basic media, completed the 
formation of the tricyclic core, giving 388 in 65% yield. Then, reduction of the ketone 
gave 389 in 75% yield. The synthesis was completed through reductive amination to 
methylate the secondary amine and then, finally, separation of the diastereomeric 
mixture. The sparteine surrogate (–)-26 was obtained in 38% yield, and its epimer 390 
in 44% yield. Although this synthetic route does allow for the preparation of both 
enantiomers of the sparteine surrogate 26, the length of the route, the complete lack of 
diastereoselectivity in the Diels-Alder reaction and the need to separate the 
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diastereomeric tricycles (–)-26 and 390 probably precludes this route from being used to 
generate useful quantities of sparteine surrogate (–)-26. 
In 2005, Lesma reported a more efficient and selective synthesis of the (+)-sparteine 
surrogate (+)-26, starting from enantiopure piperidine mono-acetate ent-383 (Scheme 
5.15).
232
 
 
Scheme 5.15 Lesma’s asymmetric synthesis of (+)-sparteine surrogate (+)-26 
Using a previously reported procedure, azide 392 was prepared in four steps.
233
 Swern 
oxidation of ent-383 proceeded smoothly to give aldehyde ent-384 in 91% yield. 
Stereoselective Brown allylation proceeded in 91:9 dr and upon separation of the 
diastereomers, allyl alcohol 391 was obtained in 65% yield. Azide 392 was formed in 
87% yield by mesylation of the alcohol followed by displacement with NaN3. 
Subsequent Staudinger reduction of the azide followed by Boc protection and N-
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allylation gave the RCM precursor 393 in 39% yield over three steps. Diene 393 
underwent RCM using Grubbs’ first generation catalyst to form 394 in 89% yield. Then, 
Boc deprotection, ester saponification and mesylation of the resulting alcohol were 
completed to give 395 in 60% yield. Base promoted cyclisation formed the tricyclic 
core, with 396 being isolated in 67% yield. Finally, hydrogenation of the alkene and 
removal of the Cbz group was accomplished in the presence of Pd/C. Subsequent 
reductive amination affected N-methylation to give the (+)-sparteine surrogate (+)-26 in 
63% yield. In summary, enantiopure (+)-26 was synthesised in 4% overall yield from 
ent-383. Although the Brown allylation resulted in good levels of diastereoselectivity, 
the route is too long to be used for the synthesis of (+)-26 on a multi-gram scale.  
More recently, a higher yielding synthesis of (–)-26 has been reported by the O’Brien 
group starting from iodo ester 397, itself synthesised in three steps from 5-
chloropentanol (Scheme 5.16).
225
 Piperidine 398 was formed by treatment of iodo ester 
397 with (S)-α-methylbenzylamine. The amine first displaced the iodide in an SN2 
reaction then the resulting secondary amine added to the α,β-unsaturated ester moiety in 
a diastereoselective manner. Piperidine 397 was isolated in 68% yield after separation 
of a 75:25 diastereomeric mixture of products. 
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Scheme 5.16 O’Brien’s asymmetric synthesis of (–)-sparteine surrogate (–)-26 
Then, stereoselective alkylation of 398 by treatment with LHMDS and ethyl (α-
bromomethyl)acrylate 375 gave di-ester 399 as a single diastereomer in 93% yield. 
Conjugate addition of N-methyl hydroxylamine to α,β-unsaturated ester of 399 resulted 
in a 50:50 mixture of diastereomeric hydroxylamines 400 in 85% yield. Subsequent 
cleavage of both the N-α-methylbenzyl and N-O bonds using transfer hydrogenolysis 
was performed, to give 401 in 48% yield. Since only one diastereomer of 400 has the 
correct stereochemistry to undergo bis-lactamisation, 401 was formed as a single 
diastereomer. The synthesis of (–)-26 was completed by reduction with LiAlH4 in 68% 
yield. Overall, enantiopure (–)-26 was synthesised in 18% yield over only five steps, 
starting from iodo ester 397. Unfortunately, the formation and separation of by-products 
in the conversion of diastereomeric hydroxylamines 400 to tricycle 401 precludes this 
route being used for the synthesis of multi-gram quantities of (–)-26.  
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5.1.4 Conclusions 
To date, the most efficient, and hence useful synthesis of the sparteine surrogate 26 is 
O’Brien’s synthesis of (+)-26 from naturally occurring (–)-cytisine over three steps (see 
Scheme 5.1). This method allows the facile preparation of gram quantities of (+)-26. 
However, due to the reliance on (–)-cytisine as a starting material, only one enantiomer 
(+)-26 can be made via this route. Although the antipode (–)-26 has been synthesised by 
Lesma and by O’Brien, these routes are not amenable to the synthesis of enantiopure   
(–)-26 on a multi-gram scale due to the number of steps involved, or problems 
encountered with purification. 
Recently, it has become apparent that the (+)-sparteine surrogate (+)-26 out-performs  
(–)-sparteine in many aspects of asymmetric lithiation chemistry. For example, Chapter 
2 shows several examples where the time required for lithiation of N-Boc heterocycles 
is an order of magnitude shorter with s-BuLi/(+)-26 than with (–)-sparteine. This 
increase in the rate of deprotonation allows the asymmetric lithiation of N-Boc 
piperidine 10 with s-BuLi/(+)-26 to give α-substituted products in good yield and er 
(see Scheme 1.32). The analogous reaction with s-BuLi/(–)-sparteine gives <10% yield 
due to the slow rate of lithiation. There are more subtle advantages to the use of 26 over 
(–)-sparteine. Recent work within the O’Brien group has shown that the (+)-sparteine 
surrogate (+)-26 is compatible with THF as a solvent whereas when (–)-sparteine is 
employed in THF, racemic products were isolated.
57
 Additionally, it has been shown 
that for the s-BuLi mediated lithiation at higher temperature (–30 °C) (+)-26 
outperforms (–)-sparteine in terms of yield and enantioselectivity.60 
These reasons, coupled with the fact that (–)-sparteine is currently difficult to obtain, 
make the need for an efficient synthesis of (–)-26 apparent. Thus, new methods for the 
gram-scale synthesis of enantiopure (–)-26 were sought. The first approach was via a 
classical resolution of racemic sparteine surrogate 26 and secondly, via the formation of 
an enantiomerically pure intermediate and subsequent diastereoselective synthesis 
building on Canipa and O’Brien’s unpublished route.220 
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5.2 Improved Synthesis and Classical Resolution of the Sparteine 
Surrogate 
5.2.1 Synthesis of Racemic Sparteine Surrogate  
The moderate success enjoyed by O’Brien and co-workers in the synthesis and 
resolution of 26 (see Schemes 5.4 and 5.6)
214
 inspired a re-investigation, with a view to 
improving the resolution procedure to allow the acquisition of either enantiomer of the 
sparteine surrogate 26 on gram-scale in >99:1 er. Due to the relatively high cost of the 
initial starting material used by O’Brien, ethyl-2-pyridyl acetate 364, the first objective 
was to develop a synthesis of pyridine ester 364 using cheaper starting materials. In 
1953, Goldberg et al. published a synthesis of 364 that involved the treatment of 2-
picoline 402 with phenyllithium followed by subsequent trapping with diethyl carbonate 
(Scheme 5.17).
234
 However, lengthy reaction times and awkward procedures were 
required and 364 was obtained in only 44% yield.  
 
Scheme 5.17 
Building on work by Liu,
235
 optimisation studies on the synthesis of 364 were focussed 
around replacing phenyllithium with LDA, resulting in a simplified procedure (Scheme 
5.18). Lithiation of 2-picoline 402 with 2.05 eq. of LDA at –78 °C in the presence of 
diethyl carbonate gave 364 in 89% yield on a multi-gram scale after distillation. In this 
reaction 14.7 g of 364 was produced. 2 eq. of LDA are required due to 364 being 
deprotonated in preference to 2-picoloine 402 once it has formed.  
 
Scheme 5.18 
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With a simple, scalable synthesis of 364 developed, attention was turned to the 
synthesis of bicyclic ketone 361 using the method previously reported by O’Brien and 
co-workers.
213
 Starting with 25 g (150 mmol) of ethyl-2-pyridyl acetate 364, 
hydrogenation in the presence of Adams’s catalyst gave piperidine 365 in 90% yield 
(pure by 
1
H NMR spectroscopy) (Scheme 5.19). Subsequent treatment with ethyl 
acrylate in the presence of triethylamine gave 31.3 g of di-ester 366 in 94% yield. 
Dieckmann condensation effected by LHMDS followed by decarboxylation in aqueous 
acid gave bicyclic ketone 361 in 79% yield after distillation. Overall, 7.2 g of 361 was 
obtained, without the need for chromatography, in 59% yield over four steps from the 
cheap, commercially available starting material 2-picoline 402. 
 
Scheme 5.19 
The next challenge was optimisation of the double Mannich reaction to generate 
bispidone 362 from bicyclic ketone 361. Scheiber and Nemes originally reported a 58% 
yield for this reaction,
209
 as did workers in the O’Brien group213 using Beak’s modified 
conditions for the preparation of bispidines.
46
 However, in this study, scale-up to multi-
gram quantities resulted in the yield dropping significantly (Scheme 5.20). Starting with 
7.1 g of bicyclic ketone 361, bispidone 362 was isolated in a disappointing 34% yield. 
 
Scheme 5.20 
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The low yield was attributed to problems with purification by distillation of the high 
boiling product 362 on scale. In fact, 
1
H NMR spectroscopy of the solid black residue 
remaining after distillation showed that significant amounts of 362 remained. In an 
attempt to remedy this situation, different methods of purification were attempted. 
Purification by forming a crystalline acid salt of 362 met with failure. A range of acids 
were trialled but crystalline solids failed to form in all cases. An attempt at purification 
by flash column chromatography was prohibitively labour intensive and the yield was 
still low.  
In order to develop a cleaner reaction that might allow for easier purification of 
bispidone 362, optimisation of the double Mannich reaction was investigated. Standard 
reaction conditions were applied (1.5 eq. of methylamine and AcOH, 3.0 eq. of 
paraformaldehyde in MeOH at reflux) and the reaction was monitored by GC (Scheme 
5.21 and Figure 5.3). In Figure 5.3 reaction progress is depicted with the relative 
proportion of ketone 361 shown in blue and bispidone 362 in red. It was observed that 
half of the ketone 362 was consumed by the first time point, within the first 10 min. 
However, the reaction stalled at this point and took over 24 h (not shown) for complete 
consumption of 362. Importantly, the relative proportion of bispidone 361 decreased 
after 4 h as the amount of by-products (not shown) increased.  
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Scheme 5.21 
 
Figure 5.3 GC monitoring of the double Mannich reaction of 361 to 362 
A second experiment using a stoichiometric quantity of the reagents (1.0 eq. of 
methylamine and AcOH, 2.0 eq. of paraformaldehyde in MeOH at reflux) was studied 
using GC to investigate the hypothesis that excess reagents were adversely affecting the 
reaction (Scheme 5.22 and Figure 5.4). Similarly, it was observed that half of 361 was 
consumed within 10 min and that the reaction stalled, requiring 24 h for complete 
consumption of 362. It is unknown why the formation of bispidone 362 is fast at the 
outset and then orders of magnitude slower thereafter. However, product inhibition of 
the reaction could have occurred. 
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Scheme 5.22 
 
Figure 5.4 GC monitoring of the double Mannich reaction of 361 to 362 
This study of the conversion of ketone 361 into bispidone 362 failed to provide a 
method for the generation of an easily separable crude mixture of 362 on scale. Despite 
this, it was observed that performing the double Mannich reaction using only 1.0 eq. of 
the reagents gave a marginally cleaner reaction profile than the use of Beak’s 
conditions. 
In an effort to improve the yield and operational simplicity of the double Mannich 
reaction, alternative conditions for the conversion of ketone 361 into bispidone 362 
were sought. In 2004, Cordova reported the (S)-proline-catalysed enantioselective 
Mannich reaction between simple ketones, formaldehyde and aryl amines.
236
 In one 
example, reaction using cyclohexanone, formaldehyde and aniline gave the β-amino 
ketone (S)-403 in 90% yield with >99:1 er (Scheme 5.23). 
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Scheme 5.23 
It was envisaged that this type of methodology could be applied to the double Mannich 
reaction of bicyclic ketone 361 by altering the stoichiometry of the reaction. 
Additionally, it was foreseeable that the mild nature of this reaction may also have 
enabled the use of an enantioenriched bicyclic ketone 361 without racemisation 
occurring under the reaction conditions. To this end, bicyclic ketone 361 was subjected 
to modified Mannich conditions (Scheme 5.24). Disappointingly, a complex mixture of 
products was observed, with no bispidone 404 formed.  
 
Scheme 5.24 
With the failure of the organocatalytic double Mannich reaction, the synthesis of several 
grams of the racemic sparteine surrogate 26 was completed by resorting to the slightly 
modified acidic double Mannich conditions. Disappointingly, no real improvement in 
yield was seen on scale-up. Double Mannich reaction on 8.0 g of ketone 361 resulted in 
bispidone 362 being isolated in 37% yield (Scheme 5.25). Subsequent Wolff-Kishner 
reduction using hydrazine monohydrate and KOH proceeded in 68% yield completing 
the synthesis of 26. 
 
Scheme 5.25 
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To conclude, an optimised synthesis of intermediate bicyclic ketone 361 has been 
developed allowing access to multi-gram quantities of 361 in 59% yield over four steps 
from cheap materials. Attempts to improve the yield of isolated bispidone 362 obtained 
from the subsequent double Mannich reaction were less successful. Nevertheless, 
several grams of racemic 26 were synthesised in preparation for investigation into the 
classical resolution of the sparteine surrogate 26. 
 
5.2.2 Classical Resolution of the Sparteine Surrogate 
Previous work on the resolution of 26 within the O’Brien group used 1H NMR 
spectroscopy in the presence of a chiral shift reagent to ascertain the enantiomeric ratio 
of the sparteine surrogate generated from the diastereomeric salts.
214
 A more accurate 
and operationally simple procedure was desired. To this end, a CSP-GC method for the 
determination of the enantiomeric ratio of 26 was developed by the analytical team at 
AstraZeneca.
237
 The CSP-GC method developed utilised a Cyclodex B column at oven 
temperatures of 110 °C to 140 °C (ramp rate 1 °C min
-1
).  
With an improved analytical method in hand, the resolution of 26 using chiral acids was 
re-investigated. Previous attempts in the O’Brien group had used 1.0 eq. of the chiral 
resolving agents (367-371) and only one solvent, acetone (see Table 5.1).
214
 It was felt 
that the use of only one solvent limited the chance of obtaining crystalline salts, and that 
the use of greater than 0.5 eq. of the resolving agent could result in a poor resolution of 
26. To remedy these limitations, an initial screen of four resolving agents 367-370 (0.5 
eq.) with 19 mg (0.1 mmol) of racemic sparteine surrogate 26 in four different solvents 
(acetone, MeCN, IPA and MTBE) was undertaken. The results are presented in Table 
5.2 with yields of the diastereomeric salts given. The diastereomeric salts were treated 
with KOH(aq) to release sparteine surrogate 26, the enantiomeric ratio of which was 
determined by CSP-GC. The absolute stereochemistry of the major enantiomer was 
determined by comparison with a pure sample of (+)-sparteine surrogate (+)-26 
synthesised from (–)-cytisine.  
Chapter Five: Synthesis of the (–)-Sparteine Surrogate 
 
187 
 
 
 
 Resolving agent 
Entry Solvent (+)-367 (–)-368 (–)-369 (S)-370 
1 Acetone - 20%
a
, 73:27 er
b
 32%, 28:72 er - 
2 MeCN - - 12%, 2:98 er - 
3 IPA - - - - 
4 MTBE 43%, 50:50 er 26%, 64:36 er 49%, 45:55 er - 
a
 Yield of the diastereomeric salts. 
b
 Er of the free base determined by CSP-GC [(+)-
26:(–)-26].  
Table 5.2 Classical resolution of racemic sparteine surrogate 26 
Whereas the successful resolution of racemic sparteine using (+)-camphorsulfonic acid 
(+)-367 in acetone was reported by Leonard,
215
 the use of (+)-367 for the resolution of 
sparteine surrogate 26 was a resounding failure (entries 1–4). Of the four solvents used, 
only resolution in MTBE gave any crystals (43%) and the re-isolated surrogate 26 was 
determined to be racemic (entry 4). Use of (S)-malic acid (S)-370 failed to give any 
isolatable solid (entries 1-4). Solids were formed in several solvents using tartaric acid 
derivatives (–)-368 and (–)-369. It is noteworthy that the use of 0.5 eq. of (–)-O,O'-di-p-
toluoyl-L-tartaric acid (–)-369 in acetone gave a 32% yield of a diastereomeric salt 
which gave (–)-26 in 72:28 er (entry 1). Previous work using 1.0 eq. of (–)-369 in 
acetone gave the salt in 69% yield but the resulting diamine 26 was racemic (see Table 
5.1). This observation lends weight to the hypothesis that the use of >0.5 eq. of the 
resolving agent is detrimental to the enantiomeric ratio of the final diamine.  
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The standout result from this initial small screen of conditions was the formation of a 
diastereomeric salt between 26 and (–)-369 with the salt being isolated in 12% yield 
(entry 2). After release of the diamine using aqueous base, (–)-26 was obtained in 98:2 
er. Although the yield was low, the er of (–)-26 was excellent (98:2 er). Encouraged by 
this result, and the fact that isolatable solids were formed in three of the four cases with 
(–)-369, a wide solvent screen using (–)-369 as the resolving agent was initiated with a 
view to improving the yield, whilst maintaining the high er. The results are shown in 
Table 5.3, with the yields of the diastereomeric salts given along with the enantiomeric 
ratio, determined by CSP-GC of the reformed  (–)-sparteine surrogate (–)-26.  
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Entry Solvent Yield (%)
a
 Er
b
 
1 MeOAc 33 77:23 
2 EtOAc 40 80:20 
3 
n
PrOAc 35 77:23 
4 
i
PrOAc 33 69:31 
5 BuOAc 38 66:34 
6 MEK – – 
7 MIBK – – 
8 Et2O 25 63:27 
9 THF 31 81:19 
10 2-Me THF 25 67:33 
11 CPME 28 74:26 
12 Toluene 40 57:43 
13 Cyclohexane – – 
14 BuCN – – 
15 PhCN – – 
16 19:1 MeCN:H2O – – 
17 9:1 MeCN:H2O – – 
18 4:1 MeCN:H2O – – 
19 4:1 MeCN:acetone 23 97:3 
20 1:1 MeCN:acetone 23 90:10 
a
 Yield of the diastereomeric salts. 
b
 Er of the free base determined by CSP-GC [(–)-
26:(+)-26].  
Table 5.3 Solvent screen for the resolution of 26 with (–)-369 
Fifteen solvents were initially assessed for their ability to facilitate the resolution of 26 
with (–)-369 (Table 5.3, entries 1-15). The solvents chosen principally composed of 
esters (entries 1-5), ketones (entries 6 and 7), ethers (entries 8-11) and nitriles (entries 
14 and 15). Of the 15 solvents tested, diastereomeric salts were isolated in ten cases, 
with yields ranging from 25% (entry 10) to 40% (entries 2 and 12). Disappointingly, the 
enantiomeric ratios of (–)-26 were only modest, ranging from 57:43 er (entry 12) to 
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80:20 er (entry 2). Although yields were improved over the resolution in MeCN (12%, 
see Table 5.2, entry 2) the enantiomeric ratios were greatly reduced, being of no 
practical benefit for the synthesis of (–)-26 for use in asymmetric lithiation chemistries. 
Attention was then focussed on improving the yield by using a co-solvent with MeCN 
(entries 16-20). The addition of water resulted in failure to form crystals (entries 16-18). 
More promisingly, the use of a 4:1 mixture of MeCN-acetone (entry 19) gave the 
diastereomeric salts in an improved 23% yield and the (–)-sparteine surrogate (–)-26 in 
97:3 er, a comparable level of enantioenrichment as seen with neat MeCN. Increasing 
the amount of co-solvent to a 1:1 mixture of MeCN-acetone also resulted in the 
diastereomeric salts being obtained in 23% yield, although the enantiomeric ratio of (–)-
26 dropped to 90:10 er (entry 20).  
The use of a small amount of acetone as a co-solvent resulted in an increase in yield, 
without significant loss of enantioenrichment. It was felt that this system could be used 
to access significant quantities of (–)-26 in high er. To demonstrate the suitability of (–)-
acid (–)-369 for the resolution of 26 in 4:1 MeCN-acetone, scale-up of the procedure 
was undertaken (Scheme 5.26). When the resolution was performed using 1.0 mmol of 
26 (the volume of solvent was scaled equally), the diastereomeric salts were isolated in 
27% yield, and free diamine (–)-26 in 95:5 er. On a 10 mmol scale, resolution gave the 
salts in 33% yield and free diamine (–)-26 in 93:7 er. Unfortunately, scale-up of this 
procedure led to less selective resolution, with an increase in yield of the isolated salt 
and a related drop in enantioenrichment. 
  
Scheme 5.26 Resolution of 26 with (–)-369 in 4:1 MeCN-acetone 
In summary, the resolution of racemic sparteine surrogate 26 was revisited with a 
moderate level of success. After a small screen of resolving agents (367-370) and a 
wide solvent screen, it was found that, on a small scale (0.1 mmol), 26 could be 
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resolved using (–)-O,O'-di-p-toluoyl-L-tartaric acid (–)-369 in 4:1 MeCN-acetone, 
producing enantioenriched (–)-26 in 97:3 er (23% yield of the diastereomeric salt).  
The reduction in enantiomeric ratio with increasing scale was disappointing. 
Nevertheless, this procedure serves as a good preliminary result, and future work may 
be able to improve the resolution process. 
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5.3 Development of a Scalable Synthesis of Enantiopure (–)-Sparteine 
Surrogate 
The route to racemic sparteine surrogate 26 recently developed by Canipa and 
O’Brien220 was thought to be a promising starting point for the synthesis of enantiopure 
(–)-sparteine surrogate (–)-26. The synthetic route is summarised in Scheme 5.27. 
 
Scheme 5.27 O’Brien and Canipa’s synthesis of racemic sparteine surrogate 26 
Due to several promising factors, this route was chosen for further investigation with a 
view to developing a high yielding, scalable and operationally simple synthesis of (–)-
26. The major advantage of this route was that the two key steps, the alkylation of 374 
with LHMDS and bromoacrylate 375 to give di-ester 376, and the subsequent 
intramolecular conjugate addition to 379, proceeded with full diastereoselectivity. 
Additionally, all steps are operationally straightforward and generally high yielding, 
with racemic sparteine surrogate 26 being isolated in 27% overall yield. The main 
drawback of this route is that it involved many purification steps, with compounds 374, 
376, 379 and 382 isolated by flash column chromatography, and the sparteine surrogate 
26 isolated by vacuum distillation. It was envisaged that this synthesis could be 
streamlined by removing some of the purification steps.  
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5.3.1. Synthesis of an Enantiopure β-Amino Ester Intermediate by Resolution 
The first challenge in the synthesis enantiopure sparteine surrogate (–)-26 was the 
generation of an enantiopure β-amino ester such as 365 or the N-Boc protected β-amino 
ester 374. The preparation of such enantioenriched homopipecolinic acid derivatives has 
been reported through the homologation of pipecolic esters,
238,239
 the conjugate addition 
of chiral amine derivatives to α,β-unsaturated esters and subsequent cyclisation,240-243 
SN2 displacement–cyclisation of α,β-unsaturated esters using a chiral amine,
45,225,244
 
hydrogenation of enamide esters using a chiral auxiliary
245,246
 and the diastereoselective 
allylation of a chiral iminium ion.
226
 Additionally, classical resolution of a piperidinyl 
ethanol derivative and subsequent oxidation has been described.
223,247
  
Although preliminary work into the resolution of β-amino ester 365 was undertaken 
within the O’Brien group220 (see Scheme 5.13), a procedure that gave greater levels of 
er was desired. In 2009, workers at Solvay reported the resolution of cyclic β-amino 
methyl ester 405 using carboxylic acid (S)-406 in IPA (Scheme 5.28).
248
 Diastereomeric 
salt 405.(S)-406 was isolated in 40% yield and release of the amine with HCl(aq) gave 
405 in a 97:3 ratio of D:L isomers. Recrystallisation of the salt from IPA gave 405.(S)-
406 in 28% overall yield and subsequently gave 405 in >99:1 D:L.   
 
Scheme 5.28 
Using this work by researchers at Solvay, the resolution of ethyl ester analogue 365 was 
attempted. First, the synthesis of chiral acid (R)-406 was accomplished in two steps 
from unnatural (R)-glutamic acid (Scheme 5.29). Tosylation of (R)-glutamic acid 
proceeded in 46% yield to give (R)-407,
249
 followed by DCC facilitated intramolecular 
amidation to give tosyl pyroglutamic acid (R)-406 in 86% yield and 40% yield over two 
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steps. Resolving agent (R)-406 was shown to be enantiopure by CSP-HPLC by 
comparison of the methyl ester derivative with a racemic sample.  
 
Scheme 5.29 
Next, the resolution of β-amino ester 365 was performed (Scheme 5.30). Diastereomeric 
salt formation between 365 and chiral acid (R)-406 at 5 °C was successful, with the salt 
(R)-365.(R)-406 being isolated in 36% yield. After derivatisation, (R)-365 was found to 
have 93:7 er. Recrystallisation of the salt from IPA resulted in (R)-365.(R)-406 being 
isolated in an overall 29% yield; after derivatisation (R)-365 was shown to have 99:1 er.  
 
Scheme 5.30 
The enantiomeric ratio was determined using a laborious process. A small portion of the 
salt (R)-365.(R)-406 was treated with NaOH(aq) to release (R)-365. Then, Boc protection 
under standard conditions gave (R)-374 which was analysed by CSP-HPLC. The 
absolute configuration of (R)-374 was determined by comparison of the optical rotation 
([α]D +7.5 (c 1.0 in CHCl3)) with a known sample ([α]D +7.4 (c 1.0 in CHCl3)).
225
 
The resolution process of 365 was comparable with that reported for the methyl ester 
analogue 405, giving enantiopure ester (R)-365 in 29% yield after one recrystallisation 
from IPA. Although this material was of sufficient quality for the synthesis of 
enantiopure sparteine surrogate (–)-26 there were several prohibitive drawbacks. The 
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yield of (R)-365.(R)-406 was relatively low (29%) and the procedure was laborious, 
requiring the synthesis of the resolving agent (R)-406 (from the relatively expensive 
unnatural (R)-glutamic acid). Additionally, recrystallisation of the diastereomeric salt 
and a lengthy procedure to determine the enantiomeric excess of the resolved cyclic β-
amino ester (R)-365 were required. An alternative, simpler resolution procedure for 
acquiring an enantiopure cyclic β-amino ester was desired and attention was turned to 
enzymatic methods. 
Enzymatic kinetic resolution of homopipecolinic esters through selective hydrolysis of 
the ester functionality using pig liver esterase has been reported. However, the er of 
both the ester and acid products was low.
250,251
 Recently, a highly enantioselective 
lipase-catalysed transesterification procedure was reported, although flash column 
chromatography was required to separate the resulting esters.
252
 Lipases are commonly 
used in the kinetic resolution of racemates
253
 and, in 2004, Pousset and co-workers 
reported the enzymatic kinetic resolution of N-Boc protected methyl ester 408 using a 
lipase from Burkholderia cepacia.
254
 Selective hydrolysis of (S)-408 in phosphate buffer 
(pH 7.0) and THF was performed at 35 °C for 96 h, with the pH maintained through 
addition of NaOH(aq) using a pH stat (Scheme 5.31). Residual β-amino ester (R)-408 
was recovered with 99:1 er and acid (S)-409 was formed in >99:1 er. Although no 
yields were given, the high levels of er in this reaction were manifested by a high 
conversion. In fact, the E factor (a measure of the selectivity of the enzyme)
253,255,256
 
was >100 for this reaction. The products were isolated simply by removal of the enzyme 
by filtration through Celite
®
 followed by a simple acid/base workup gave ester (R)-408 
and acid (S)-409. 
 
Scheme 5.31 
It was envisaged that this enzymatic resolution procedure could be used to access 
significant quantities of a highly enantioenriched β-amino methyl ester or ethyl ester 
(R)-408 or (R)-374. Synthesis of requisite the N-Boc methyl ester 408 was 
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accomplished on a multi-gram scale from 2-picoline 402 (Scheme 5.32). In an 
analogous fashion to the reaction already detailed (see Scheme 5.18), methyl 2-piperidyl 
acetate 410 was synthesised in 76% yield by deprotonation of 402 and trapping with 
dimethyl carbonate. Subsequent hydrogenation in the presence of platinum(IV) oxide in 
MeOH gave piperidine 405 in 83% yield. Finally N-Boc protection was accomplished 
using Boc2O giving 408 in 97% after chromatography. 
 
Scheme 5.32 
Similarly, N-Boc ethyl ester 374 was synthesised by Boc protection of piperidine 365 
(synthesis detailed in Scheme 5.19) giving N-Boc ester 374 in 95% yield after 
chromatography (Scheme 5.33). It was found that the need for chromatography could be 
eliminated by using 1.0 eq. of Boc2O, with 374 being obtained in 99% yield on >10 g 
scale. 
 
Scheme 5.33 
With significant amounts of starting material in hand, a study into the enzymatic 
resolution of racemic cyclic N-Boc esters 408 and 374 was undertaken with a view to 
generating enantiopure cyclic N-Boc esters. The results are presented in Table 5.4. Due 
to the unavailability of a pH stat, the investigation was conducted without the use of 
such an instrument.  
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Entry Substrate 
Temp / 
°C 
Time / 
h 
(R)-408 / (R)-374  (S)-409 
E
c
 
Yield (%) er
a
 Yield (%) er
b
 
1 408 rt 48 41 88:12 42 87:13 16 
2 408 35 48 47 97:3 40 >99:1 >100 
3 408 50 28 45 90:10 39 96:4 29 
4 374 rt 24 47 97:3 44 98:2 >100 
5 374 rt 48 42 >99:1 46 92:8 >100 
6 374 35 24 42 >99:1 42 96:4 >100 
7 374 35 72
d
 42 >99:1 44 95:5 >100 
8 374 35 48
e
 45 >99:1 48 96:4 >100 
9 374 35 64
f
 46 >99:1 44 96:4 >100 
a
 Er determined by CSP-HPLC (R)-408/374:(S)-408/374. 
b
 Er determined by CSP-
HPLC of methyl ester derivative (S)-408, (S)-408:(R)-408. 
c
 E = ln[ees(1- eep)]/(ees + 
eep)/ln[ees(1 + ees)]/(eep + ees).
254,255
 
d
 Half the amount of lipase (125 mg). 
e
 10 mmol 
scale, 2.5 g lipase. 
f
 50 mmol scale, 12.5 g lipase. 
Table 5.4 Enzymatic resolution of cyclic N-Boc esters 408 and 374 
When enzymatic resolution of 1.0 mmol of methyl ester 408 was performed at room 
temperature in 8:1 buffered water-THF, using 250 mg of lipase for 48 h, residual ester 
(R)-408 was isolated in 41% yield and 88:12 er and the acid (S)-409 was isolated in 
42% yield and 87:13 er (Table 5.4, entry 1). The E factor
254,255
 for this reaction, a 
measure of the selectivity of the enzyme under specific conditions, was only 16. The er 
of ester (R)-408 was measured directly by CSP-HPLC, whereas acid (S)-409 had to be 
converted into the corresponding methyl ester (S)-408 using trimethylsilyldiazomethane 
before CSP-HPLC analysis could be performed.  
Next, the resolution was repeated at 35 °C and 50 °C (entries 2 and 3) to assess the 
effect of temperature on the selectivity of the resolution. When performed at 35 °C (the 
temperature at which Pousset and co-workers ran resolutions
248
) for 48 h, residual ester 
(R)-408 was isolated in 47% yield and 97:3 er and acid (S)-409 was isolated in 40% 
yield and >99:1 er, with the E factor being >100. Resolution of methyl ester 408 was 
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much more selective at 35 °C than at room temperature (entries 1 and 2). The results 
obtained when the resolution was run at 35 °C for 48 h indicate that the resolution was 
not left for sufficient time to generate enantiopure ester (R)-408 (Pousset left a similar 
reaction for 96 h to reach completion). Although the use of a pH stat was not essential 
for the resolution, it would have the advantage of allowing the user to know when the 
resolution reached completion (by monitoring the amount of NaOH that has been added 
to the mixture). At 50 °C (entry 3), resolution of 408 was much less selective (E = 29).  
Then, enzymatic resolution of the preferred substrate, ethyl ester 374 was investigated. 
Resolution at room temperature, for 24 h (entry 4), was highly selective (E >100) 
resulting in residual ethyl ester (R)-374 being isolated in 47% yield and 97:3 er. The 
acid (S)-409 was isolated in 44% yield and 98:2 er. Extending the reaction time to 48 h 
at room temperature (entry 5) led to enantiopure (R)-374 being isolated in 42% yield 
(>99:1 er). Fortuitously, kinetic resolution of ethyl ester 374 was much more selective 
than with methyl ester 408 (entries 1 and 5), and optimisation of this result was pursued 
to generate an efficient process. Elevation of the temperature to 35 °C (entry 6) led to 
isolation of enantiopure (R)-374, in 42% yield in 24 h. The resolution of ethyl ester 374 
was not only more selective than the resolution of methyl ester 408 but also faster 
(entries 2 and 6). The time required for complete hydrolysis of (S)-374 was determined 
by CSP-HPLC of aliquots of the reaction mixture after filtration and work-up. 
In order to increase the efficiency of the process, an attempt was made to lower the 
amount of lipase required. Reducing the amount of lipase by half (entry 7) increased the 
time to reach completion to 72 h. This time was prohibitively long. As the enzyme was 
relatively cheap the high enzyme loading was not an issue. 
With a high yielding method for the resolution of ethyl ester 374 on a small scale 
established, the process was scaled up to 10 mmol (entry 8). The resolution took longer 
to reach completion (48 h), but nevertheless 1.2 g of enantiopure N-Boc ester (R)-374 
(>99:1 er) was isolated in 45% yield (entry 8). Scaling the process to 50 mmol, using 
12.5 g of lipase resulted in 6.2 g of (R)-374 being isolated in 46% yield and >99:1 er 
after 64 h (entry 9 and Scheme 5.34). Acid (S)-409 was obtained in 44% yield, and 96:4 
er. The increase in the time required for complete hydrolysis of (S)-374 on increasing 
scale may be due to the increasing concentration of the reaction, which was changed 
due to the large volumes of solvent required on scale. 
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Scheme 5.34 
In summary, the enzymatic resolution of cyclic N-Boc ethyl ester 374 using lipase from 
Burkholderia cepacia at 35 °C is highly selective (E >100) and high yielding. 
Importantly, the process is cheap, operationally simple, scalable and requires no 
purification of the enantioenriched ester (R)-374. The optimised method is highly 
suitable for the generation of significant quantities of enantiopure N-Boc ester (R)-374 
for the synthesis of the (–)-sparteine surrogate (–)-26. It is envisaged that if the opposite 
enantiomer of N-Boc ester (S)-374 was required for the synthesis of (+)-26, it could be 
obtained by running the resolution for a shorter amount of time to generate enantiopure 
acid (S)-409. Subsequent esterification could then form ethyl ester (S)-374.  
 
5.3.2 Synthesis of Enantiopure (–)-Sparteine Surrogate  
Synthesis of enantiopure cyclic N-Boc ester (R)-374 was achieved in three steps from 
ethyl-2-pyridyl acetate 364, without the need for chromatography, in 41% overall yield. 
Focus was turned to improving the synthesis of (–)-sparteine surrogate (–)-26 by further 
reducing the number of isolation operations needed.
220
 First, synthesis of ethyl (α-
bromomethyl)acrylate 375 was required as an electrophile for use in the 
diastereoselective alkylation of cyclic N-Boc ester (R)-374. This was accomplished 
using the reported procedure.
221
 Treatment of triethyl phosphonoacetate 411 with 
aqueous K2CO3 and formaldehyde gave alcohol 412 which, without isolation, was 
treated with PBr3 to give ethyl (α-bromomethyl)acrylate 375 in 63% after distillation 
(Scheme 5.35). 
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Scheme 5.35 
With bromo acrylate 375 in hand, alkylation of (R)-374 using O’Brien and Canipa’s 
conditions of 1.4 eq. LHMDS in THF at –78 ° C for 1 h followed by 1.4 eq. of 375 
resulted in di-ester (R,R)-376 being formed as a single diastereomer (by 
1
H NMR 
spectroscopy). Isolation by chromatography gave (R,R)-376 in 97% yield (Scheme 
5.36). The relative stereochemistry has previously been established by Canipa via 
conversion into the sparteine surrogate 26, and explanation of the observed 
diastereoselectivity was shown in Scheme 5.8. Analysis of di-ester (R,R)-376 by CSP-
HPLC, in comparison with a racemic sample of 376 (prepared in an analogous fashion, 
full details in Chapter 6.6), showed that no epimerisation had occurred during this step. 
. 
Scheme 5.36 
Next, annulation was performed as previously described, through N-Boc deprotection of 
di-ester (R,R)-376 using TFA, followed by diastereoselective base-mediated 
intramolecular conjugate addition of the resulting secondary amine (R,R)-378 onto the 
α,β-unsaturated ester. Bicyclic di-ester (R,S,R)-379 was obtained in 81% yield as a 
single diastereomer (Scheme 5.37). The stereoselectivity was fully in line with that 
noted by Canipa and was rationalised using the model shown in Scheme 5.10. 
Chapter Five: Synthesis of the (–)-Sparteine Surrogate 
 
201 
 
  
Scheme 5.37 
It was found that the enolate alkylation, deprotection and annulation steps could be 
telescoped without any loss of overall yield. Alkylation of (R)-374 was performed using 
a decreased amount (1.2 eq.) of both LHMDS and bromo acrylate 375, followed by Boc 
deprotection and base-mediated intramolecular Michael addition to give di-ester 
(R,S,R)-379 as a single diastereomer in 80% yield over the three steps (Scheme 5.38). 
From pyridine ester 364, bicyclic diester (R,S,R)-379 was synthesised in 33% yield and 
>99:1 er over six steps. Only one purification operation was required with bicyclic 
diester (R,S,R)-379 being purified by flash column chromatography. 
 Scheme 5.38 
With the requisite stereocentres and functionality in place, attention was focussed on the 
end game. Canipa and O’Brien reduced di-ester 379 to diol 381 with LiAlH4 and then 
formed bis mesylate 382 under standard conditions. Following isolation by flash 
column chromatography, double displacement of the di-mesylate 382 with methylamine 
in EtOH gave sparteine surrogate 26 (see Scheme 5.12). It was envisaged that it may be 
possible to streamline the process by telescoping the three steps, removing the need for 
purification of di-mesylate 382 by flash column chromatography.  
Optimisation studies were carried out on a racemic system. Reduction of di-ester 379 
with LiAlH4 and subsequent mesylation to di-mesylate 382 occurred without 
complication (Scheme 5.39). However, treatment of crude di-mesylate 382 with a 
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commercial solution of methylamine in EtOH (8 M) at reflux under an argon 
atmosphere led to an 80:20 mixture (by 
1
H NMR spectroscopy of the crude product) of 
the desired sparteine surrogate 26 and tetrahydropyran 413, whose structure was 
tentatively assigned by 
1
H NMR spectroscopy and mass spectrometry.  
 
Scheme 5.39 
Confirmation of the structure of the by-product was accomplished by synthesising a 
pure sample of tetrahydropyran 413 using a related procedure (Scheme 5.40).
257
 
Refluxing di-mesylate 382 in 20% aqueous KOH, resulted in tetrahydropyran 413 being 
isolated in 25% yield, which gave an identical 
1
H NMR spectrum to the impurity 
previously observed.  
 
Scheme 5.40 
It was hypothesised that tetrahydropyran 413 may have been formed during the 
mesylation step by initial formation of a monomesylate and intramolecular 
displacement. Careful analysis of the 
1
H NMR spectrum of crude 382 indicated that this 
was not the case. Nevertheless, in an endeavour to eliminate the unwanted side reaction, 
di-mesylate 382 was purified by flash column chromatography before the double 
displacement was undertaken, with di-mesylate 382 being isolated cleanly in 85% yield  
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(Scheme 5.41). Disappointingly, treatment of pure 382 with ethanolic methylamine at 
reflux led to a 90:10 mixture of surrogate 26 and the tetrahydropyran by-product 413.  
 
Scheme 5.41 
Attempts to separate the sparteine surrogate 26 from tetrahydropyran 413 by vacuum 
distillation or selective salt formation with (–)-O,O'-di-p-toluoyl-L-tartaric acid (–)-369 
were unsuccessful.  
Figure 5.5 shows the 
1
H NMR spectra of: (i) the 90:10 mixture of sparteine surrogate 26 
and tetrahydropyran 413, (ii) pure (+)-sparteine surrogate (+)-26 derived from (–)-
cytisine and (iii) pure tetrahydropyran 413. Analysis of these three spectra showed that 
the sparteine surrogate 26 synthesised from di-ester 379 was contaminated with 
tetrahydropyran 413. The characteristic signals of 413, specifically the four signals for 
the OCH protons between 4.2-3.5 ppm are evident in Figure 5.5 (i). 
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Figure 5.5 
1
H NMR spectra of i) 90:10 mixture of 26:413, ii) sparteine surrogate 26 and 
iii) tetrahydropyran 413  
Canipa’s previous work on the synthesis of the sparteine surrogate 26 by double 
displacement of di-mesylate 382 led to the formation of only a trace amount (2-3%) of 
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the tetrahydropyran by-product 413.
220
 However, in this investigation, a 90:10 to 80:20 
inseparable mixture of sparteine surrogate 26 and tetrahydropyran 413 was routinely 
obtained when using commercial ethanolic methylamine. Previous work by Breuning on 
the synthesis of oxa-bispidines via double displacement of a di-mesylate with 
methylamine was also reported to proceed without issue.
228,229
  
Significant effort was thus applied to the problem of tetrahydropyran formation, with 
efforts to change both the leaving group and amine source proving futile. The results of 
these investigations are briefly summarised in Table 5.5. Ratios of products were 
determined from analysis of the 
1
H NMR spectra of crude reaction mixtures.  
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Entry Substrate Conditions Outcome 
1 414 MeNH2 (8 M, EtOH), reflux, 16 h 65:35 26:413 
2 415 MeNH2 (8 M, EtOH), reflux, 16 h 
95:5 26:413, unidentified by-
products 
3 382 MeNH2 (8 M, EtOH), rt, 4 d 90:10 26:413 
4 382 
MeNH2 (8 M, EtOH), 4Å MS, reflux, 
16 h 
80:20 26:413 
5 382 MeNH2 (2.0 M, THF), reflux, 16 h No reaction 
6 382 
MeNH2 (2.0 M, THF), 70 °C, 
pressure tube, 5 d 
Decomposition 
7 382 
MeNH2 (2.0 M, THF), 70 °C, EtOH, 
pressure tube, 16 h 
No Reaction 
8 382 MeNH2 (2.0 M, MeOH), reflux, 16 h 90:10 26:413 
9 382 
MeNH2.HCl (10 eq.), Et3N (10 eq.), 
EtOH, reflux, 16 h 
No reaction 
10 382 
NH3 (0.5 M, dioxane), 70 °C, 
pressure tube, 5 d 
No Reaction 
11 382 
NH3 (7 M, MeOH), 70 °C, pressure 
tube, 3 d 
No Reaction 
12 382 
Methoxyamine.HCl (5 eq.), Et3N (7 
eq.), THF, reflux, 16 h 
No Reaction 
Table 5.5 Attempts to prevent the formation of tetrahydropyran 413 
It was thought that the di-mesylate 382 may have been undergoing decomposition under 
the reaction conditions through deprotonation α to sulfur. Attempts at changing the 
leaving group to either a tosylate (Table 5.5, entry 1) or iodide (entry 2) did not improve 
the reaction outcome. Employing di-tosylate 414 under standard conditions (8 M 
methylamine in EtOH, reflux, 16 h) gave a 65:35 mixture of 26 and tetrahydropyran 
413 (entry 1). Di-iodide 415 resulted in an improved 95:5 mixture of 26 and 413 
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although other unidentified by-products were formed (entry 2). It was hypothesised that 
the methylamine may have been evaporating under the reaction conditions and 
subsequent thermal decomposition of the residual di-mesylate 382 may have been 
leading to the formation of tetrahydropyran 413. To test this, pure di-mesylate 382 was 
stirred in 8 M ethanolic methylamine at room temperature in a sealed system for 4 d 
(entry 3). A 90:10 mixture of 26 and 413 was isolated, refuting this hypothesis.  
It may have been possible that the commercial methylamine solution contained either 
water or methylammonium hydroxide. Therefore, the reagent was dried over 4Å 
molecular sieves prior to the addition of 382. No improvement was seen with an 80:20 
mixture of 26 and 413 formed (entry 4). Several other commercial solutions of 
methylamine were obtained and their use investigated (entries 5-8). 2.0 M methylamine 
in THF gave no product using the standard reaction conditions (16 h, reflux, entry 5). 
An analogous reaction at 70 °C for 5 d in a sealed pressure tube was performed to 
prevent the possible evaporation of methylamine. This led only to decomposition 
products (entry 6). A solution of 382 in a 1:1 mixture of 2.0 M THF solution of 
methylamine and EtOH was heated at 70 °C for 16 h in a sealed pressure tube, but no 
reaction was observed. Next, a solution of 2.0 M methylamine in MeOH was used. 
However, this only gave an 80:20 mixture of 26 and 413 (entry 8). An attempt to derive 
anhydrous methylamine in situ from methylamine hydrochloride (previously flame-
dried under reduced pressure) and triethylamine in EtOH was undertaken. Subsequent 
heating of 382 to reflux for 16 h under these conditions gave no products (entry 9). 
Similarly, the use of anhydrous ammonia solutions (either 0.5 M in dioxane or 7 M in 
MeOH, entries 10 and 11 respectively) returned only unreacted starting material 382. 
Finally, the use of methoxyamine hydrochloride and triethylamine in THF at reflux also 
resulted in no reaction of 382 (entry 12).  
Although it should have been possible to perform a double displacement of di-mesylate 
382 using a methylamine solution as reported previously,
220
 the significant formation of 
the inseparable tetrahydropyran by-product 413 was insurmountable. An alternative 
strategy was thus sought. 
It was envisaged that a double reductive amination on di-aldehyde 416 using 
methylamine would result in formation of only the desired sparteine surrogate 26.
258-260
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Disappointingly, attempted oxidation of diol 381 with DMP to form the requisite di-
aldehyde 416 resulted in a complex mixture of products (Scheme 5.42). 
 
Scheme 5.42 
Other approaches for ring-closure were considered. In 2004 Fukuyama reported the 
formation of a nine-membered cyclic amine in the synthesis of strychnine via a double 
Mitsunobu reaction between a diol and nosyl amine.
261
 Inspired by this, an analogous 
reaction using diol 381 was undertaken (Scheme 5.43). Treatment of diol 381 with 
DIAD, PPh3 and nosyl amine in THF resulted in the formation of the desired bispidine 
417, isolated in 10% yield. Disappointingly, tetrahydropyran 413 was isolated in 63% 
yield. In this case the two products were easily separated, but the low yield of bispidine 
417 precluded this method being used for the synthesis of the sparteine surrogate 26. 
 
Scheme 5.43 
With the failure of both the reductive amination and Mitsunobu end-games, and the 
double displacement of di-mesylate 382 with methylamine proving problematic, an 
alternative amine source for the double displacement of 382 was investigated.  
It was found that displacement of enantiopure di-mesylate (R,S,R)-382, formed from di-
ester (R,S,R)-379, could be accomplished cleanly using neat allylamine (dried by 
distillation over CaH2) at 50 °C under an argon atmosphere to give crude bispidine 
(S,R,R)-418 (Scheme 5.44). Excess allylamine was easily removed under reduced 
pressure. There was no evidence of any tetrahydropyran 413 in the 
1
H NMR spectrum 
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of the crude product. Allyl bispidine (S,R,R)-418 was not purified. Instead, the allyl 
group was displaced using methyl chloroformate in CHCl3 at reflux to give methyl 
carbamate (S,S,R)-419 which, after purification by flash column chromatography, was 
isolated in 61% yield over four steps from di-ester (R,S,R)-379. Finally, reduction of 
methyl carbamate (S,S,R)-419 was accomplished using LiAlH4 in THF at reflux to give 
(–)-sparteine surrogate (–)-26 in 97% yield. Final distillation of (–)-26 was not 
necessary as it was pure by 
1
H NMR spectroscopy. 880 mg of (–)-26 was synthesised 
using this method and analysis by CSP-GC showed that (–)-26 had 99:1 er. The 
absolute stereochemistry of (–)-26 was determined unambiguously by CSP-GC and by 
comparison of the optical rotation of synthetic (–)-26 ([α]D –28.4 (c 1.0 in EtOH)) with 
a sample of (+)-26 derived from (–)-cytisine ([α]D +26.5 (c 1.0 in EtOH)).
213
  
 
Scheme 5.44 Synthesis of (–)-sparteine surrogate (–)-26 from (R,S,R)-379 
Although this end-game from di-ester (R,S,R)-379 was lengthy, it allowed the 
preparation of enantiopure (–)-26 uncontaminated with tetrahydropyran by-product 413. 
The synthesis was accomplished in nine steps with a 19% overall yield from 
commercially available ethyl 2-pyridyl acetate 364. Importantly, many of the steps were 
telescoped and only two purification steps required, with bicyclic ester (R,S,R)-379 and 
methyl carbamate (S,S,R)-419 being purified by flash column chromatography. This, 
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along with the fully diastereoselective nature of the two key steps (see Scheme 5.27), 
allowed the synthesis to be performed on scale, with 880 mg (99:1 er) of the (–)-
sparteine surrogate (–)-26 synthesised.  
 
5.3.3 Early Incorporation of Amine Functionality 
With the failure to effect the double displacement of di-mesylate 382 with a source of 
methylamine, and the resultant stepwise conversion of di-mesylate (R,S,R)-382 into 
sparteine surrogate (–)-26, alternative routes that allowed introduction of amine 
functionality earlier in the synthesis were investigated. It was envisaged that this tactic 
would allow a streamlined synthesis of the (–)-sparteine surrogate (–)-26. Scheme 5.45 
details the retrosynthesis of such a route. It was proposed that the bispidine framework 
of 26 could be constructed from amino alcohol 420 by selectively activating the primary 
alcohol, which itself could be prepared from 421 by reduction of both ester and amide 
groups followed by N-debenzylation. The bicyclic amide 421 could be accessed using 
N-Boc deprotection/intramolecular conjugate addition chemistry from compound 422, 
which in turn could be made by performing a diastereoselective alkylation on amide 423 
with LHMDS and bromoacrylate 375.  
 
Scheme 5.45 Retrosynthesis of sparteine surrogate 26 from amide 423 
A racemic synthesis was investigated. To start with amide 423 was synthesised from N-
Boc ester 374 (Scheme 5.46). Saponification of ester 374 was achieved under standard 
conditions using lithium hydroxide. Activation of the resulting carboxylic acid with 
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methyl chloroformate in the presence of triethylamine followed by addition of N-benzyl 
methylamine gave amide 423 in 83% yield over the three steps  
 
Scheme 5.46 
Alkylation of amide 423 with LHMDS and acrylate 375 at –78 °C in THF gave 
alkylation product 422 as an unconfirmed mixture of diastereomers in 69% yield 
(Scheme 5.47). The diastereomeric ratio was undeterminable due to the complexity of 
the 
1
H NMR spectrum of 422, caused by two sets of rotamers. An attempt to simplify 
the spectrum using high temperature NMR studies in DMSO-d6, forcing rotamers to 
interconvert on a NMR time scale, did not simplify the spectrum sufficiently. 
Nevertheless, the mixture of diastereomeric esters 422 was converted into bicyclic 
amides 421 and 424 by subjecting the mixture to TFA, to facilitate N-Boc deprotection, 
followed by base-mediated intramolecular conjugate addition. An 80:20 mixture of 
diastereomeric amides 421 and 424 was formed (by analysis of a 
1
H NMR spectrum of 
the crude product) and the amides isolated in 72% and 20% yield respectively. The 
relative stereochemistry of the major diastereomer was assigned by analogy with that 
observed in the intramolecular conjugate addition of di-ester 376 (see Scheme 5.9), and 
was confirmed by completion of the synthesis of sparteine surrogate 26 (see Scheme 
5.48). The relative stereochemistry of the minor diastereomer 424 is unknown. It is 
possible, but unlikely, that the enolate alkylation to 422 proceeds with complete 
stereoselectivity and the following Boc deprotection/intramolecular conjugate addition 
occurs with poor diastereoselectivity. 
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Scheme 5.47 
Synthesis of the sparteine surrogate 26 was completed from amido ester 421 as shown 
in Scheme 5.48. Reduction of both the ester and amide functionalities of 421 with 
LiAlH4 in THF at room temperature gave amino alcohol 425 in 92% yield. N-Benzyl 
deprotection of 425 was accomplished using transfer hydrogenation conditions 
(Pd(OH)2/C and ammonium formate in EtOH at reflux) to give secondary amino 
alcohol 420 in 81% yield. The synthesis was completed following activation of the 
primary alcohol of 420 using Appel conditions (CBr4, PPh3) and concurrent cyclisation 
in the presence of triethylamine. Racemic sparteine surrogate 26 was isolated in 76% 
after vacuum distillation. The completion of the synthesis proved the relative 
stereochemistry of 421. 
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Scheme 5.48 
Although this route was not fully diastereoselective, separation of diastereomers 421 
and 424 by flash column chromatography after the intramolecular conjugate addition 
was simple. Hence, it was thought that this route may be viable for the synthesis of 
significant quantities of pure sparteine surrogate (–)-26. When scale-up was undertaken, 
alkylation of amide 423 with LHMDS and bromo acrylate 375 on a 2 g scale returned 
the desired alkylation product 422 in only 23% yield with a number of unidentifiable 
by-products. All attempts to understand and control this reaction and develop a robust, 
reproducible procedure failed and the alkylation of 423 remained unpredictable. For this 
reason, and the fact that the route involved the formation and separation of 
diastereomers 421 and 424, attention was turned to an alternative synthesis of the 
sparteine surrogate (–)-26.  
It was envisaged that the amine functionality could be introduced earlier in the synthetic 
route by employing the use of a substituted acrylamide or acrylonitrile partner in the 
alkylation step. Literature precedent and the result obtained from the alkylation of 423 
(see Scheme 5.47) suggested that the presence of an ethyl ester group on the cyclic β-
amino ester partner 374 might be essential for complete diastereoselectivity within these 
alkylation reactions.
222,223
 Introducing the masked amine in the electrophile might result 
in high diastereoselectivity as an ester enolate could be used. The retrosynthesis of such 
a route is shown in Scheme 5.49. 
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Scheme 5.49 Retrosynthesis of sparteine surrogate 26 from amide 429 
It was proposed that the end-game to complete the synthesis of 26 would be analogous 
to that already described in Scheme 5.48. This involved activation of the alcohol 
functionality in amino alcohol 426, after synthesis from amide 427 by reduction of both 
ester and amide groups followed by N-debenzylation. The bicyclic amide 427 could be 
accessed using the N-Boc deprotection/intramolecular conjugate addition from 428, 
which in turn could be made by performing a possibly diastereoselective alkylation of 
cyclic β-amino ester 374 with LHMDS and acrylamide 429.  
The synthesis began with preparation of α-bromomethyl acrylamide 429 in three steps 
(Scheme 5.50). Treatment of acryloyl chloride 430 with N-methylbenzylamine in the 
presence of triethylamine gave acrylamide 431 in 62% yield. Subsequent alcohol 
catalysed Baylis-Hillman reaction (as investigated by Aggarwal and Lloyd-Jones
262
) 
with paraformaldehyde
263
 formed crude primary alcohol 432, which was converted into 
α-bromomethyl acrylamide 429 in 40% yield using PBr3. 
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Scheme 5.50 
With acrylamide 429 in hand, the key alkylation of cyclic β-amino ester 374 was 
investigated (Scheme 5.51). Gratifyingly, alkylation of 374 with 1.2 eq. LHMDS in 
THF at –78 °C, followed by addition of α-bromomethyl acrylamide 429 resulted in 
amido ester 428 being formed as a single diastereomer in 93% yield. Subsequent TFA-
mediated Boc deprotection was performed, followed by attempted base-mediated 
diastereoselective intramolecular conjugate addition. However, stirring the reaction in a 
mixture of K2CO3 and EtOH for 16 h gave bicyclic compound 427 in only 20% yield, 
with secondary amine 433 being recovered in 64% yield. It is assumed that the relative 
stereochemistry of 428 and 427 is the same as other examples, but this has not been 
confirmed. 
 
Scheme 5.51 
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It is clear that intramolecular conjugate addition into the acrylamide moiety of 433 is 
significantly slower than the comparable reaction with amino acrylate 377 (see Scheme 
5.37). Due to the low yield of the conjugate addition, this route was abandoned and 
alternative Michael acceptors were investigated. However, it is feasible that the 
intramolecular Michael addition of 433 could be optimised with future work. Initial 
studies showed heating 433 in a mixture of K2CO3 and EtOH at reflux resulted in 
epimerisation of at least one of the stereocentres.  
It was anticipated that use of α-bromomethyl acrylonitrile 436 would result in a more 
reactive Michael acceptor. Synthesis of 436 was accomplished according to a literature 
procedure
264
 and in an similar manner to α-bromomethyl acrylate 437. Treatment of 
diethyl cyanomethylphosphonate 434 with saturated aqueous K2CO3 and aqueous 
formaldehyde gave crude alcohol 435. Subsequent bromination using PBr3 formed α-
bromomethyl acrylonitrile 436 in 29% yield (Scheme 5.52).  
 
Scheme 5.52 
Diastereoselective alkylation of N-Boc ester 374 with 436 proceeded without issue, 
giving compound 437 as a single diastereomer in 72% yield (Scheme 5.53). Subsequent 
tandem N-deprotection/Michael addition occurred with complete stereoselectivity, 
giving bicyclic nitrile 438 in 70% yield. The relative stereochemistry of 437 and 438 
was assumed. As expected, the use of the more reactive Michael acceptor 437 resulted 
in the complete conversion into bicyclic compound 438. Unfortunately, an attempt at 
simultaneous reduction of ester and nitrile functionalities using LiAlH4 did not produce 
amino alcohol 439, and instead resulted in a complex mixture of decomposition 
products. 
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Scheme 5.53 
Although introduction of amine functionality earlier in the route through the use of 
acrylamide 429 and acrylonitrile 436 have not yet led to a practical, scalable route to the 
sparteine surrogate 26, it is possible with further experimentation that they might. More 
forcing conditions for the intramolecular Michael addition onto acrylamide 428 (see 
Scheme 5.51) or use of a suitable reducing agent for the reduction of nitrile 438 to 
amino alcohol 439 may allow development of a short, efficient synthesis of (–)-26. 
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5.4 Conclusions and Future Work 
A classical resolution of racemic sparteine surrogate 26 was successfully developed to 
give highly enantiomerically enriched (–)-26. After a wide screen of solvent systems, 
resolution of 26 was accomplished using (–)-369 in 4:1 MeCN-acetone. The 
diastereomeric salt of (–)-26 was isolated in 23% yield and (–)-26 in 97:3 er (Scheme 
5.54). Scale-up to 10 mmol resulted in a small drop in enantioenrichment, with the salt 
of (–)-26 isolated in 33% yield and (–)-26 in 93:7 er. Further optimisation studies may 
find an alternative solvent system that would allow (–)-26 to be isolated in greater yield 
and with a higher degree of enantioenrichment. 
 
Scheme 5.54 
Secondly, a synthesis of enantiopure (–)-sparteine surrogate (–)-26 has been 
accomplished using a modified procedure developed within the O’Brien group.220 A key 
intermediate, β-amino ester (R)-374 was obtained as a single enantiomer through both 
classical resolution and enzymatic resolution methods, with the latter procedure being 
the most useful. Ester (R)-374 was generated on a multi-gram scale using a lipase from 
Burkholderia cepacia, employing a modification of Pousset’s published method 
(Scheme 5.55).
254
 
 
Scheme 5.55 
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Although significant issues with formation of by-product tetrahydropyran 413 were 
encountered in the final step of the synthesis of (–)-26, this was overcome by modifying 
the route. The synthesis of (–)-26 was accomplished in 9 steps and 19% overall yield. 
Importantly, the synthetic steps are easy to perform, high yielding and scalable. 
Optimisation resulted in only two purification operations being required throughout the 
synthesis allowing the rapid synthesis of 880 mg (99:1 er) of the (–)-sparteine surrogate 
(–)-26. To date, this is the most practical synthesis of (–)-26 reported and could possibly 
be commercialised in the future.  
The main limitation of the method developed is that the end-game required for 
completion of the synthesis is lengthy. Future work may result in identification of 
reliable conditions for the double displacement of di-mesylate 382 with methylamine, 
without the formation of the tetrahydropyran by-product 413 (Figure 5.6). Alternatively, 
future work may be able to build upon the initial investigation into the incorporation of 
masked amine functionality earlier in the synthesis, resulting in a higher yielding, 
streamlined synthesis of (–)-26.  
 
Figure 5.6 
A purposeful, improved synthesis of tetrahydropyran 413 and other heteroatom 
derivatives from an enantiopure intermediate could be undertaken. The investigation of 
the use of these ligands as chiral ligands for metal-catalysed asymmetric reactions could 
be an interesting avenue of research.  
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Chapter Six: Experimental 
6.1 General Methods 
All-non aqueous reactions were carried out under oxygen free Ar or N2 using flame-
dried glassware. Et2O and THF were freshly distilled from sodium and benzophenone. 
MTBE and toluene were distilled over CaH2. Alkyllithiums were titrated against N-
benzylbenzamide before use.
265
 All diamines used in lithiation reactions were distilled 
over CaH2 before use. Petrol refers to the fraction of petroleum ether boiling in the 
range 40-60 °C and was purchased in Winchester quantities. Brine refers to a saturated 
solution. Water is distilled water. 
 
Flash column chromatography was carried out using Fluka Chemie GmbH silica (220-
440 mesh). Thin layer chromatography was carried out using commercially available 
Merck F254 aluminium backed silica plates. Proton (400 MHz) and carbon (100.6 MHz) 
NMR spectra were recorded on a Jeol ECX-400 instrument using an internal deuterium 
lock. For samples recorded in CDCl3, chemical shifts are quoted in parts per million 
relative to CHCl3 (δH 7.26) and CDCl3 (δC 77.0, central line of triplet). Carbon NMR 
spectra were recorded with broad band proton decoupling and assigned using DEPT 
experiments. Coupling constants (J) are quoted in Hertz. Melting points were carried 
out on a Gallenkamp melting point apparatus. Boiling points given for compounds 
purified by Kügelrohr distillation correspond to the oven temperature during distillation. 
Infrared spectra were recorded on an ATI Mattson Genesis FT-IR spectrometer or a 
Perkin Elmer UATR Two FT-IR spectrometer. Electrospray high and low resonance 
mass spectra were recorded at room temperature on a Bruker Daltronics microOTOF 
spectrometer. Optical rotations were recorded at room temperature on a Jasco DIP-370 
polarimeter (using sodium D line, 589 nm) and [α]D given in units of 10
-1
 deg cm
3
 g
-1
. 
Chiral stationary phase HPLC was performed on an Agilent 1200 series chromatograph. 
Chiral stationary phase GC was performed on a Hewlett Packard 6980 series 
chromatograph. In situ ReactIR
™
 infra-red spectroscopic monitoring was performed on 
a Mettler-Toledo ReactIR iC10 spectrometer with a silicon-tipped (SiComp) probe. 
Baseline correction was performed at 1737-1750 cm
-1
, with peak smoothing at 0-
29.8cm
-1
.  
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6.2 General Procedures 
General Procedure A: Racemic lithiation/trapping using s-BuLi/THF 
s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
N-Boc piperazine (1.0 eq.) in THF (4-7 mL) at –78 °C under Ar. The resulting solution 
was stirred at –78 °C for 1-3 h. Then, the electrophile (1.3-2.0 eq.) was added dropwise.  
The reaction mixture was stirred at –78 °C for 15 min and then allowed to warm to rt 
over 30 min. Then, saturated NH4Cl(aq) (10 mL) (and saturated NaHCO3(aq) (10 mL) or 
20% NaOH(aq) (10 mL) where used) was added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product 
 
General Procedure B: Racemic lithiation/trapping using s-BuLi/TMEDA 
 s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
N-Boc piperazine (1.0 eq.) and TMEDA (1.3 eq.) in solvent (4-7 mL) at –78 °C under 
Ar. The resulting solution was stirred at –78 °C for 10 min – 1 h. Then, the electrophile 
(1.3-2.0 eq.) was added dropwise. The reaction mixture was stirred at –78 °C for 15 min 
and then allowed to warm to rt over 30 min. Then, saturated NH4Cl(aq) (10 mL) (and 
saturated NaHCO3(aq) (10 mL) or 20% NaOH(aq) (10 mL) where used) was added and 
the two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). 
The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product 
 
General Procedure C: Asymmetric lithiation/trapping using s-BuLi/diamine with 
pre-mixing of diamine and s-BuLi 
s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
diamine (1.3 eq.) in Et2O (4-6 mL) at –78 °C under Ar. The resulting solution was 
stirred at –78 °C for 15 min. Then, a solution of N-Boc piperazine (1.0 eq.) in Et2O (1 
mL) was added dropwise. The resulting solution was stirred at –78 °C for 10 min – 6 h. 
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Then, the electrophile (1.3-2.0 eq.) was added dropwise. The reaction mixture was 
allowed to warm to rt over 16 h. Then, saturated NH4Cl(aq) (10 mL) (and saturated 
NaHCO3(aq) (10 mL) or 20% NaOH(aq) (10 mL) where used) was added and the two 
layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. 
 
General Procedure D: Asymmetric Lithiation/trapping using s-BuLi/diamine 
without pre-mixing of diamine and s-BuLi 
 s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
N-Boc piperazine (1.0 eq.) and diamine (1.3 eq.) in solvent (4-7 mL) at –78 °C under 
Ar. The resulting solution was stirred at –78 °C for 10 min – 3 h. Then, the electrophile 
(1.3-2.0 eq.) was added dropwise.  The reaction mixture was allowed to warm to rt over 
16 h. Then, saturated NH4Cl(aq) (10 mL) (and saturated NaHCO3(aq) (10 mL) or 20% 
NaOH(aq) (10 mL) where used) was added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product 
 
General Procedure E: Racemic lithiation/trapping using s-BuLi/TMEDA via 
cuprate 
 s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
N-Boc piperazine (1.0 eq.) and TMEDA (1.3 eq.) in solvent (5 mL) at –78 °C under Ar. 
The resulting solution was stirred at –78 °C for 1 h. Then a solution of CuCN.2LiCl (0.5 
eq.) in THF (1-2 mL) was added dropwise. The resulting solution was stirred at –78 °C 
for 1 h. Then, the electrophile (2.0 eq.) was added dropwise. The reaction mixture was 
stirred at –78 °C for 15 min and then allowed to warm to rt over 30 min. Then, saturated 
NH4Cl(aq) (10 mL) (and saturated NaHCO3(aq) (10 mL) or 20% NaOH(aq) (10 mL) where 
used) was added and the two layers were separated. The aqueous layer was extracted 
with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. 
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General Procedure F: Classical resolution of the sparteine surrogate 26 
A solution of resolving agent (0.05 mmol, 0.5 eq.) in minimum amount of solvent was 
added to a stirred solution of 26 (19 mg, 0.10 mmol, 1.0 eq.) in solvent (20 µL) at rt. 
The resulting mixtures were stirred at rt for 16 h. Solvent (0.2 mL) was added, crystals 
(if formed) were filtered, washed with solvent (0.6 mL) and dried under reduced 
pressure. Then, the crystals were dissolved in 20% KOH(aq) (3 mL) and MTBE (2 mL). 
The layers were separated and the aqueous layer was extracted with MTBE (2 × 2 mL). 
The combined organics were dried by passing through a PTFE membrane under gravity 
and evaporated under reduced pressure to give resolved surrogate 26. The er of 26 was 
determined by CSP-GC using cyclodex-B column (110-140 °C, 1 °C/min), (+)-26 22.8 
min, (–)-26 23.1 min 
 
General Procedure G: Lipase catalysed enzymatic resolution of alkyl 2-(pyridin-2-
yl)acetates 
A solution of alkyl 2-(pyridin-2-yl)acetate (1-50 mmol, 1.0 eq.) in THF (2-50 mL) was 
added in one portion to a gently stirred 1:1 mixture of 0.1 M phosphate buffer (pH 7.0) 
and H2O (16-400 mL). Lipase from Burkholderia cepacia (125 mg-12.5 g) was added in 
one portion and the reaction was stirred at the specified temperature (rt to 50 °C) for a 
specified time (24–120 h). Upon cooling to rt (if necessary) the mixture was filtered 
through Celite
®
 and washed with H2O (20-200 mL) and Et2O (20-200 mL). 20% 
NaOH(aq) (20-200 mL) was added to the filtrate and the resulting mixture was extracted 
with Et2O (3 × 10-100 mL). The combined organic layers were dried (MgSO4), filtered 
and evaporated under reduced pressure to give the ester. The aqueous layer was 
acidified with 1M HCl(aq) and extracted with Et2O (3 × 10-100 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the acid. 
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6.3 Experimental for Chapter Two 
 
tert-Butyl pyrrolidine-1-carboxylate 12 
 
Pyrrolidine (4.27 g, 5.01 mL, 60 mmol, 1.2 eq.) was added dropwise to a stirred 
solution of di-tert butyl dicarbonate (10.91 g, 50 mmol, 1.0 eq.) in CH2Cl2 (200 mL) at 
0 °C under Ar. The resulting colourless solution was allowed to warm to rt and stirred 
for 2 h. Then, 1 M HCl(aq) (100 mL) was added and the two layers were separated. The 
aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by Kugelrohr distillation gave N-Boc pyrrolidine 12 (8.38 g, 98%) 
as a colourless oil, bp 95-100 °C/2.7 mmHg (lit.,
266
 bp 70-75 °C/0.05 mmHg); 
1
H NMR 
(400 MHz, CDCl3) δ 3.32-3.28 (m, 4H, NCH2), 1.84-1.81 (m, 4H, CH2), 1.45 (s, 9H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 154.6 (C=O), 78.7 
(CMe3), 45.8 (NCH2), 45.6 (NCH2), 28.4 (CMe3), 25.6 (CH2), 24.9 (CH2). 
Spectroscopic data consistent with those reported in the literature.
266
 
Lab Book Reference: JDF6_532 
 
tert-Butyl piperazine-1-carboxylate 257 
 
A solution of di-tert-butyl dicarbonate (20.0 g, 91.6 mmol, 1.0 eq.) in CH2Cl2 (200 mL) 
was added dropwise over 3 h to a stirred solution of piperazine 253 (15.8 g, 183.2 
mmol, 2.0 eq.) in CH2Cl2 (500 mL) at rt. The resulting cloudy solution was stirred at rt 
for 16 h. Then, the solvent was evaporated under reduced pressure to give a white solid. 
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Water (250 mL) was added and the insoluble solids were removed by filtration and 
washed with water (100 mL). The aqueous filtrate was extracted with CH2Cl2 (3 × 100 
mL) and the combined organic extracts were evaporated under reduced pressure to give 
N-Boc piperazine 257 (14.1 g, 83%) as a white solid, mp 42-44 °C (lit.,
267
 42.5-45 °C); 
1
H NMR (400 MHz, CDCl3) δ 3.37 (t, J = 5.0 Hz, 4H, NCH2), 2.79 (t, J = 5.0 Hz, 4H, 
NCH2), 2.14 (s, 1H, NH), 1.41 (s, 9H, CMe3). 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 
(C=O), 79.38 (CMe3), 45.7 (NCH2), 44.8 (NCH2), 28.3 (CMe3). Spectroscopic data 
consistent with those reported in the literature.
267
  
Lab Book Reference: JDF2_126 
 
tert-Butyl 4-benzylpiperazine-1-carboxylate 117 
 
N-Boc piperazine 257 (7.30 g, 39.2 mmol, 1.0 eq.) and K2CO3 (10.85 g, 78.4 mmol, 2.0 
eq.) were added portionwise to a stirred solution of benzyl chloride (4.96 g, 4.51 mL, 
39.2 mmol 1.0 eq.) in EtOH (120 mL) at rt. The resulting white suspension was stirred 
and heated at reflux for 16 h. After cooling to rt, the solvent was evaporated under 
reduced pressure and the residue was partitioned between water (60 mL) and CH2Cl2 
(60 mL). The two layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 30 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 4:1 petrol-EtOAc as eluent gave N-Boc-N′-
benzyl piperazine 117 (9.18 g, 85%) as a white solid, mp 68-70 °C (lit.,
268
 72-75 °C); RF 
(7:3 petrol-EtOAc) 0.3; 
1
H NMR (400 MHz, CDCl3) δ 7.32-7.23 (m, 5H, Ph), 3.50 (s, 
2H, CH2Ph), 3.42 (t, J = 5.0 Hz, 4H, NCH2), 2.38 (t, J = 5.0 Hz, 4H, NCH2), 1.46 (s, 
9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 (C=O), 137.8 (ipso-Ph), 129.1 (Ph), 
128.2 (Ph), 127.1 (Ph), 79.4 (CMe3), 63.0 (CH2Ph), 52.8 (NCH2), 44.0 (NCH2), 28.4 
(CMe3). Spectroscopic data consistent with those reported in the literature.
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Lab Book Reference: JDF1_14 
 
tert-Butyl 4-methylpiperazine-1-carboxylate 151 
 
A solution of di-tert-butyl dicarbonate (21.6 g, 99.2 mmol, 1.1 eq.) in CH2Cl2 (50 mL) 
was added dropwise to a stirred solution of N-methyl piperazine (9.0 g, 10 mL, 90.2 
mmol, 1.0 eq.) in CH2Cl2 (150 mL) at 0 °C under Ar. The resulting solution was 
allowed to warm to rt and stirred for at rt for 16 h. Water (100 mL) and 20% NaOH(aq) 
(100 mL) were added and the layers separated. The aqueous layer was extracted with 
CH2Cl2 (3 × 100 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by Kugelrohr 
distillation gave N-Boc-N′-methyl piperazine 151 (16.54 g, 92%) as a colourless oil, bp 
105-110 °C / 0.9 mmHg; RF (9:1 CH2Cl2-MeOH) 0.2; 
1
H NMR (400 MHz, CDCl3) δ 
3.39 (t, J = 5.0 Hz, 4H, NCH2), 2.29 (t, J = 5.0 Hz, 4H, NCH2), 2.24 (s, 3H, NMe), 1.41 
(s, 9H, CMe3). 
13
C NMR (100.6 MHz, CDCl3) δ 154.6 (C=O), 79.5 (CMe3), 54.7 
(NCH2), 46.1 (NMe), 43.5 (NCH2), 28.3 (CMe3). Spectroscopic data consistent with 
those reported in the literature.
269
  
Lab Book Reference: JDF1_85 
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tert-Butyl 4-(2-cyanopropan-2-yl)piperazine-1-carboxylate 258 
 
HCl (40.3 mL of a 2.0 M in Et2O, 80.6 mmol, 1.5 eq.) was added dropwise to a stirred 
solution of N-Boc piperazine 257 (12.6 g, 53.7 mmol, 1.0 eq.) in MeOH (60 mL) and 
CH2Cl2 (60 mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 1 h. 
Then, the solvent was evaporated under reduced pressure and the residue was dissolved 
in water (150 mL). NaCN (2.63 g, 53.7 mmol, 1.0 eq.) and then a solution of acetone 
(9.4 g, 11.8 mL, 161.2 mmol, 3.0 eq.) in water (20 mL) were added sequentially. The 
resulting mixture was stirred at rt under air for 48 h. Then, water (100 mL) was added 
and the mixture was extracted with EtOAc (3 × 100 mL). The combined organics were 
dried (MgSO4), filtered and evaporated under reduced pressure to give N-Boc 
piperazine 258 (11.0 g, 81%) as a white solid which was sufficiently pure by 
1
H NMR 
spectroscopy, mp 108-110 °C; IR (CHCl3) 3018, 1686 (C=O), 1455, 1429, 1391, 1367, 
1307, 1290, 1266, 1242, 1215, 1172, 1130, 750, 667 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
δ 3.46 (t, J = 5.0 Hz, 4H, NCH2), 2.59 (t, J = 5.0 Hz, 4H, NCH2), 1.51 (s, 6H, CMe2), 
1.46 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.4 (C=O), 119.8 (CN), 79.9 
(CMe3), 55.8 (CMe2), 47.3 (NCH2), 44.0 (NCH2), 28.4 (CMe3), 26.1 (CMe2); MS (ESI) 
m/z 276 [(M + Na)
+
, 40], 254 [(M + H)
+
, 100], 198 [(M – CMe3)
+
, 50]; HRMS  m/z 
calcd for C13H23N3O2 (M + H)
+
 254.1863, found 254.1864 (–0.2 ppm error). 
Lab Book Reference: JDF5_447 
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tert-Butyl 4-tert-butylpiperazine-1-carboxylate 252 
 
Methyl magnesium bromide (31.3 mL of a 3.0 M in Et2O, 94.0 mmol, 3.0 eq.) was 
added dropwise to a stirred solution of N-Boc piperazine 258 (7.9 g, 31.3 mmol, 1.0 eq.) 
in THF (150 mL) at 0 °C under Ar. After being allowed to warm to rt the reaction was 
allowed to stir at rt for 16 h. Then, the mixture was cooled to 0 °C and water (20 mL) 
was added dropwise. The mixture was diluted with water (200 mL) and extracted with 
EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (200 mL), 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 98:2-94:6 CH2Cl2-
MeOH as eluent gave N-Boc-N′-tert-butyl piperazine 252 (6.0 g, 79%) as a white solid, 
mp 49-51 °C; RF (19:1 CH2Cl2-MeOH) 0.3; IR (CHCl3) 2977, 1682 (C=O), 1429, 1366, 
1288, 1267, 1247, 1169, 1128, 953, 864, 757 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 3.41 
(t, J = 5.0 Hz, 4H, NCH2), 2.50 (t, J = 5.0 Hz, 4H, NCH2), 1.46 (s, 9H, OCMe3), 1.06 (s, 
9H, NCMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.6 (C=O), 79.2 (OCMe3), 53.7 
(NCMe3), 45.8 (NCH2), 44.6 (NCH2), 28.3 (CMe3), 25.7 (CMe3); MS (ESI) m/z 243 (M 
+ H)
+
; HRMS  m/z calcd for C13H26N2O2 (M + H)
+
 243.2067, found 243.2073 (–1.9 
ppm error). 
Lab Book Reference: JDF2_183 
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tert-Butyl 4-phenylpiperidine-1-carboxylate 66 
 
A solution of di-tert-butyl dicarbonate (3.0 g, 13.6 mmol, 1.1 eq.) in CH2Cl2 (20 mL) 
was added dropwise a stirred solution of 4-phenyl piperidine (2.0 g, 12.4 mmol, 1.0 eq.) 
in CH2Cl2 (80 mL) at 0 °C under Ar. The resulting solution was allowed to warm to rt 
and stirred at rt for 16 h. Then, 1 M HCl(aq) (100 mL) was added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 
19:1-4:1 petrol-EtOAc as eluent gave N-Boc piperidine 66 (3.2 g, 99%) as a pale yellow 
oil, RF (9:1 petrol-EtOAc) 0.3;
 1
H NMR (400 MHz, CDCl3) δ 7.35–7.28 (m, 2H, Ph), 
7.23-7.19 (m, 3H, Ph), 4.29-4.20 (m, 2H, NCH), 2.80 (td, J = 13.0, 2.5 Hz, 2H, NCH), 
2.64 (tt, J = 12.0, 3.5 Hz, 1H, CHPh), 1.88-1.77 (m, 2H, CH), 1.64 (td, J = 12.5, 4.0 Hz, 
2H, CH), 1.49 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.9 (C=O), 145.8 
(ipso-Ph), 128.5 (Ph), 126.8 (Ph), 126.3 (Ph), 79.4 (CMe3), 44.5 (NCH2), 42.8 (CHPh), 
33.3 (NCH2CH2), 28.6 (CMe3). Spectroscopic data consistent with those reported in the 
literature.
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ReactIR
™
 monitoring of the lithiation of N-Boc-pyrolidine 12 (TMEDA) 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. 
The solution was stirred at –78 °C for 9 min. 
For N-Boc-pyrrolidine 12, a peak at 1702 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1679 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex 157. A new peak at 1650 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 25. After a lithiation time of 5 min, 
complete lithiation of N-Boc-pyrrolidine 12 to give the lithiated intermediate 25 was 
observed. 
Lab Book Reference: JDF6_545 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-pyrolidine 12 ((–)-sparteine) 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
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solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. 
The solution was stirred at –78 °C for 60 min. 
For N-Boc-pyrrolidine 12, a peak at 1702 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex 157. A new peak at 1643 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 25. After a lithiation time of 60 min, 
complete lithiation of N-Boc-pyrrolidine 12 to give the lithiated intermediate 25 was 
observed.  
Lab Book Reference: JDF3_239 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-pyrolidine 12 ((+)-sparteine 
surrogate (+)-26) 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 
1.3 eq.) was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 
eq.). The solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). 
Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise. The solution was stirred at –78 °C for 10 min. 
For N-Boc-pyrrolidine 12, a peak at 1704 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1679 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex 157. A new peak at 1647 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 25. After a lithiation time of 2 min, 
complete lithiation of N-Boc-pyrrolidine 12 to give the lithiated intermediate 25 was 
observed. 
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Lab Book Reference: JDF3_243 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-pyrolidine 12 (THF) 
 
THF (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) was added. The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –78 °C for 100 min. 
For N-Boc-pyrrolidine 12, a peak at 1697 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1649 cm
-1
 was observed which was assigned to νC=O 
in the lithiated intermediate 158. After a lithiation time of 90 min, complete lithiation of 
N-Boc-pyrrolidine 12 to give the lithiated intermediate 158 was observed. 
Lab Book Reference: JDF3_259 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-pyrolidine 12 (Et2O) 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) was added. The solution was stirred for 5 min (to verify the stability of readout 
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on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –78 °C for 90 min. 
For N-Boc-pyrrolidine 12, a peak at 1701 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex 159. A new peak at 1642 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 22. After a lithiation time of 90 min, 
incomplete lithiation of N-Boc-pyrrolidine 12 to give the lithiated intermediate 22 and 
N-Boc-pyrrolidine 12 was observed. 
Lab Book Reference: JDF3_258 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-benzyl piperazine 117 
(TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 7 min. 
For N-Boc-N′-benzyl piperazine 117, a peak at 1699 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 160. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 161. After a lithiation 
time of 5 min, complete lithiation of N-Boc-N′-benzyl piperazine 117 to give the 
lithiated intermediate 161 was observed. 
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Lab Book Reference: JDF3_220 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-benzyl piperazine 117 ((–)-
sparteine)  
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 
mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability 
of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 
mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 75 min. 
For N-Boc-N′-benzyl piperazine 117, a peak at 1702 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 160. A new peak at 1645 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 161. After a lithiation 
time of 1 h, complete lithiation of N-Boc-N′-benzyl piperazine 117 to give the lithiated 
intermediate 161 was observed. 
Lab Book Reference: JDF3_238 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-benzyl piperazine 117 ((+)-
sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of (+)-sparteine surrogate (+)-26 (252 mg, 
1.3 mmol, 1.3 eq.) in Et2O (2 mL) was added followed by a solution of N-Boc-N′-
benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was 
stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution 
was stirred at –78 °C for 5 min. 
For N-Boc-N′-benzyl piperazine 117, a peak at 1702 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1663 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 160. A new peak at 1644 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 161. After a lithiation 
time of 2 min, complete lithiation of N-Boc-N′-benzyl piperazine 117 to give the 
lithiated intermediate 161 was observed. 
Lab Book Reference: JDF5_428 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-benzyl piperazine 117 (THF) 
 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of N-Boc-N′-benzyl piperazine 117 (276 
mg, 1.0 mmol, 1.0 eq.) in THF (2 mL) was added. The solution was stirred for 5 min (to 
verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution 
in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C 
for 1 h. 
For N-Boc-N′-benzyl piperazine 117, a peak at 1696 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1645 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 162. After a lithiation time of 1 h, almost 
complete lithiation of N-Boc-N′-benzyl piperazine 117 to give the lithiated intermediate 
162 was observed. 
Lab Book Reference: JDF4_375 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-tert-butyl piperazine 152 
(TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution N-Boc-N′-tert-butyl piperazine 152 (242 mg, 1.0 mmol, 
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1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 15 min. 
For N-Boc-N′-tert-butyl piperazine 152, a peak at 1700 cm-1 was observed and assigned 
to νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 163. A new peak at 1644 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 164. After a lithiation 
time of 15 min, complete lithiation of N-Boc-N′-tert-butyl piperazine 152 to give the 
lithiated intermediate 164 was observed. 
Lab Book Reference: JDF3_228 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-tert-butyl piperazine 152 ((–)-
sparteine) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution N-Boc-N′-tert-butyl piperazine 152 (242 mg, 1.0 
mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability 
of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 
mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 5 h. 
For N-Boc-N′-tert-butyl piperazine 152, a peak at 1700 cm-1 was observed and assigned 
to νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 163. A new peak at 1644 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 164. After a lithiation 
time of 5 h, almost complete lithiation of N-Boc-N′-tert-butyl piperazine 152 to give the 
lithiated intermediate 164 and N-Boc-N′-tert-butyl piperazine 152 was observed. 
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Lab Book Reference: JDF6_564 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-tert-butyl piperazine 152 ((+)-
sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of (+)-sparteine surrogate (+)-26 (252 mg, 
1.3 mmol, 1.3 eq.) in Et2O (2 mL) was added followed by a solution N-Boc-N′-tert-
butyl piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was 
stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution 
was stirred at –78 °C for 7 min. 
For N-Boc-N′-tert-butyl piperazine 152, a peak at 1703 cm-1 was observed and assigned 
to νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex 163. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 164. After a lithiation 
time of 6 min, complete lithiation of N-Boc-N′-tert-butyl piperazine 152 to give the 
lithiated intermediate 164 was observed. 
Lab Book Reference: JDF5_427 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-tert-butyl piperazine 152 (THF) 
 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of N-Boc-N′-tert-butyl piperazine 152 
(242 mg, 1.0 mmol, 1.0 eq.) in THF (2 mL) was added. The solution was stirred for 5 
min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at 
–78 °C for 2 h. 
For N-Boc-N′-tert-butyl piperazine 152, a peak at 1694 cm-1 was observed and assigned 
to νC=O. After addition of s-BuLi, a new peak at 1645 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 165. After a lithiation time of 2 h, 
incomplete lithiation of N-Boc-N′-tert-butyl piperazine 152 to the give the lithiated 
intermediate 165 and N-Boc-N′-tert-butyl piperazine 152 was observed. 
Lab Book Reference: JDF4_372 
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3-(2-Hydroxyethyl)-4-methylene-5,5-diphenyloxazolidin-2-one 169  
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution of N-Boc morpholine 155 (187 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). A peak at 1706 cm
-1
 was observed and assigned to νC=O of N-Boc 
morpholine 155. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 
eq.) was added dropwise. A new peak at 1687 cm
-1
 was observed which was assigned to 
νC=O in the pre-lithiation complex. A new peak at 1638 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate 166. The solution was stirred at –78 °C for 
10 min. Complete lithiation of N-Boc morpholine 155 to give the lithiated intermediate 
166 had occurred within 1 min. Then, a solution of benzophenone (364 mg, 2.0 mmol, 
2.0 eq.) in Et2O (1 mL) was added dropwise. The reaction mixture was allowed to warm 
to rt over 30 min. Then, 1 M HCl(aq) (10 mL) was added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 1:1 
petrol-EtOAc as eluent gave oxazolidinone 169 (119 mg, 40%) as a white solid, mp 88-
91 °C; RF (1:1 petrol-EtOAc) 0.5; IR (CHCl3) 3624 (OH), 1761 (C=O), 1683 (C=C), 
1448, 1400, 1336, 1231, 1022, 699 cm
–1
;  
1
H NMR (400 MHz, CDCl3) δ 7.41-7.36 (m, 
10H, Ph), 4.64 (d, J = 3.0 Hz, 1H, C=CHAHB), 4.21 (d, J = 3.0 Hz, 1H, C=CHAHB), 3.88 
(q, J = 5.5 Hz, 2H, OCH2), 3.72 (t, J = 5.5 Hz, 2H, NCH2), 2.01 (br s, 1H, OH); 
13
C 
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NMR (100.6 MHz, CDCl3) δ 155.8 (C=O), 147.2 (C=CH2), 140.3 (ipso-Ph), 128.7 (Ph), 
128.3 (Ph), 127.1 (Ph), 89.3 (Ph2CO), 86.7 (C=CH2), 59.3 (NCH2), 44.3 (OCH2); MS 
(ESI) m/z 318 [(M + Na)
+
, 100], 296 [(M + H)
+
, 80], 252 [(M – CH2CH2OH)
+
, 70]; 
HRMS  m/z calcd for C18H17NO3 (M + H)
+
 296.1281, found 296.1285 (–1.0 ppm error). 
Lab Book Reference: JDF3_241 
 
ReactIR
™
 monitoring of the lithiation of tert-butyl 3-isopropylimidazolidine-1-
carboxylate 154 ((–)-sparteine) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution 3-isopropylimidazolidine-1-carboxylate 154 (214 mg, 
1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the 
stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 10 min. 
For 3-isopropylimidazolidine-1-carboxylate 154, a peak at 1709 cm
-1
 was observed and 
assigned to νC=O. After addition of s-BuLi, a new peak at 1693 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1647 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate 171. After a lithiation 
time of 2 min, complete partial lithiation of 3-isopropylimidazolidine-1-carboxylate 154 
to give the lithiated intermediate 171 and 3-isopropylimidazolidine-1-carboxylate 154 
was observed. 
Lab Book Reference: JDF3_240 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 4-(((2,4,6-
triisopropylphenyl)sulfonyl)oxy)piperidine-1-carboxylate 156 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (302 mg, 390 µL, 2.6 mmol, 1.3 eq.) was 
added followed by a solution of 4-trisyl-N-Boc piperidine 156 (467 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 2.6 eq.) 
was added dropwise. The solution was stirred at –78 °C for 16 min. 
For 4-trisyl-N-Boc piperidine 156, a peak at 1697 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1662 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 1 min, 
complete lithiation of 4-trisyl-N-Boc piperidine 156 to give the lithiated intermediate 
was observed. 
Lab Book Reference: JDF3_224 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 4-(((2,4,6-
triisopropylphenyl)sulfonyl)oxy)piperidine-1-carboxylate 156 ((–)-sparteine) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (610 mg, 598 µL, 2.6 mmol, 1.3 eq.)  
was added followed by a solution of 4-trisyl-N-Boc piperidine 156 (467 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). Then, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 
2.6 eq.) was added dropwise. The solution was stirred at –78 °C for 17 min. 
For 4-trisyl-N-Boc piperidine 156, a peak at 1704 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 10 
min, complete lithiation of 4-trisyl-N-Boc piperidine 156 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_225 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 4-chloropiperidine-1-
carboxylate 49 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (302 mg, 390 µL, 2.6 mmol, 1.3 eq.) was 
added followed by a solution of 4-chloro-N-Boc piperidine 49 (220 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 2.6 eq.) 
was added dropwise. The solution was stirred at –78 °C for 8 min. 
For 4-chloro-N-Boc piperidine 49, a peak at 1702 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1657 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate. After a lithiation time of 2 min, complete 
lithiation of 4-trisyl-N-Boc piperidine 49 to give the lithiated intermediate was 
observed. The pre-lithiation complex was not observed. 
Lab Book Reference: JDF3_229 
 
ReactIR
™
 monitoring of the lithiation of tert-butyl 4-chloropiperidine-1-
carboxylate 49 ((–)-sparteine)  
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (610 mg, 598 µL, 2.6 mmol, 1.3 eq.)  
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was added followed by a solution of 4-chloro-N-Boc piperidine 49 (220 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). Then, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 
2.6 eq.) was added dropwise. The solution was stirred at –78 °C for 25 min. 
For 4-trisyl-N-Boc piperidine 49, a peak at 1698 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1675 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1639 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 25 
min, almost complete lithiation of 4-trisyl-N-Boc piperidine 49 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_227 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-methyl piperazine 151 
(TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 12 min. 
For N-Boc-N′-methyl piperazine 151, a peak at 1702 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 5 min, 
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complete lithiation of N-Boc-N′-methyl piperazine 151 to give the lithiated intermediate 
was observed. 
Lab Book Reference: JDF4_362 
 
ReactIR
™
 monitoring of the lithiation of N-Boc-N′-methyl piperazine 151 ((–)-
sparteine) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution of N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 
mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability 
of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 
mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 90 min. 
For N-Boc-N′-methyl piperazine 151, a peak at 1702 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1644 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 90 
min, complete lithiation of N-Boc-N′-methyl piperazine 151 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF4_364 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-methyl piperazine 151 ((+)-
sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of (+)-sparteine surrogate (+)-26 (252 mg, 
1.3 mmol, 1.3 eq.) in Et2O (2 mL) was added followed by a solution of N-Boc-N′-
methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was 
stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution 
was stirred at –78 °C for 7 min. 
For N-Boc-N′-methyl piperazine 151, a peak at 1703 cm-1 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 4 min, 
complete lithiation of N-Boc-N′-methyl piperazine 151 to give the lithiated intermediate 
was observed. 
Lab Book Reference: JDF5_427 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 1,4-dioxa-8-
azaspiro[4.5]decane-8-carboxylate 68 ((+)-sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 
1.3 eq.) in Et2O (2 mL) was added followed by a solution of acetal 68 (243 mg, 1.0 
mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability 
of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 
mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 12 min. 
For acetal 68, a peak at 1705 cm
-1
 was observed and assigned to νC=O. After addition of 
s-BuLi, a new peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-
lithiation complex. A new peak at 1645 cm
-1
 was observed which was assigned to νC=O 
in the lithiated intermediate. After a lithiation time of 4 min, complete partial lithiation 
of acetal 68 to give the lithiated intermediate and acetal 68 was observed. 
Lab Book Reference: JDF3_245 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 4-
((triisopropylsilyl)oxy)piperidine-1-carboxylate 98 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of 4-OTIPS-N-Boc piperidine 98 (358 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –78 °C for 25 min. 
For 4-OTIPS-N-Boc piperidine 98, a peak at 1698 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1673 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 25 
min, almost complete lithiation of 4-OTIPS-N-Boc piperidine 98 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_230 
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ReactIR
™
 monitoring of the lithiation of tert-butyl 4-
((triisopropylsilyl)oxy)piperidine-1-carboxylate 98 ((+)-sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 
1.3 eq.) in Et2O (2 mL) was added followed by a solution of 4-OTIPS-N-Boc piperidine 
98 (358 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to 
verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution 
in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C 
for 30 min. 
For 4-OTIPS-N-Boc piperidine 98, a peak at 1702 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1673 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 30 
min, complete lithiation of 4-OTIPS-N-Boc piperidine 98 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_244 
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ReactIR
™
 monitoring of the lithiation of 4-phenyl-N-Boc piperidine 66 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of 4-phenyl-N-Boc piperidine 66 (261 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –78 °C for 60 min. 
For 4-phenyl-N-Boc piperidine 66, a peak at 1698 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1647 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 60 
min, complete lithiation of 4-phenyl-N-Boc piperidine 66 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_221 
 
ReactIR
™
 monitoring of the lithiation of 4-phenyl-N-Boc piperidine 66 ((+)-
sparteine surrogate (+)-26) 
 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 
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1.3 eq.) in Et2O (2 mL) was added followed by a solution of 4-phenyl-N-Boc piperidine 
66 (261 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to 
verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution 
in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C 
for 45 min. 
For 4-phenyl-N-Boc piperidine 66, a peak at 1699 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1679 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1642 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 20 
min, complete lithiation of 4-phenyl-N-Boc piperidine 66 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_265 
 
ReactIR
™
 monitoring of the lithiation of 4-methyl-N-Boc piperidine 97 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –60 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of 4-methyl-N-Boc piperidine 97 (199 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –60 °C for 50 min. 
For 4-methyl-N-Boc piperidine 97, a peak at 1694 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 45 
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min, complete lithiation of 4-methyl-N-Boc piperidine 97 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_261 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –50 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of 4-methyl-N-Boc piperidine 97 (199 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –50 °C for 25 min. 
For 4-methyl-N-Boc piperidine 97, a peak at 1694 cm
-1
 was observed and assigned to 
νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. After a lithiation time of 25 
min, complete lithiation of 4-methyl-N-Boc piperidine 97 to give the lithiated 
intermediate was observed. 
Lab Book Reference: JDF3_269 
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ReactIR
™
 monitoring of the lithiation of N-Boc piperidine 10 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –60 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of N-Boc piperidine 10 (185 mg, 1.0 mmol, 1.0 eq.) in 
Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout on 
ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –60 °C for 55 min. 
For N-Boc piperidine 10, a peak at 1695 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1673 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex. A new peak at 1639 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate. After a lithiation time of 50 min, complete 
lithiation of N-Boc piperidine 10 to give the lithiated intermediate was observed. 
Lab Book Reference: JDF3_260 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –50 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of N-Boc piperidine 10 (185 mg, 1.0 mmol, 1.0 eq.) in 
Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout on 
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ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –50 °C for 35 min. 
For N-Boc piperidine 10, a peak at 1698 cm
-1
 was observed and assigned to νC=O. After 
addition of s-BuLi, a new peak at 1679 cm
-1
 was observed which was assigned to νC=O 
in the pre-lithiation complex. A new peak at 1645 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate. After a lithiation time of 35 min, complete 
lithiation of N-Boc piperidine 10 to give the lithiated intermediate was observed. 
Lab Book Reference: JDF3_266 
 
ReactIR
™
 monitoring of the lithiation of N-Boc azepine 153 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –50 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of N-Boc azepine 153 (199 mg, 1.0 mmol, 1.0 eq.) in Et2O 
(2 mL). The solution was stirred for 5 min (to verify the stability of readout on 
ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) 
was added dropwise. The solution was stirred at –50 °C for 2 h. 
For N-Boc piperidine 1530, a peak at 1698 cm
-1
 was observed and assigned to νC=O. 
After addition of s-BuLi, a new peak at 1679 cm
-1
 was observed which was assigned to 
νC=O in the pre-lithiation complex. A new peak at 1644 cm
-1
 was observed which was 
assigned to νC=O in the lithiated intermediate. After a lithiation time of 2 h, complete 
lithiation of N-Boc piperidine 153 to give the lithiated intermediate was observed. 
Lab Book Reference: JDF3_268 
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tert-Butyl 2-(trimethylsilyl)pyrrolidine-1-carboxylate 13  
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1676 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1650 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate 25. The solution was stirred at –78 °C for 10 min. Complete 
lithiation of N-Boc-pyrrolidine 12 to give the lithiated intermediate 25 had occurred. 
Then, Me3SiCl (217 mg, 254 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak 
at 1695 cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc 
pyrrolidine 13. The solution was stirred at –78 °C for 15 min. Complete trapping of 
lithiated intermediate 25 to give substituted N-Boc pyrrolidine 13 was observed after 15 
min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1 petrol-Et2O as eluent gave N-Boc pyrrolidine 13 (189 mg, 81%) as a pale 
yellow oil, RF (9:1 petrol-Et2O) 0.3; 
1
H NMR (400 MHz, CDCl3) δ 3.55–3.43 (m, 1H, 
NCH), 3.30–3.20 (m, 1H, NCH), 3.20–3.10 (m, 1H, NCH), 2.07–1.91 (m, 1H, CH), 
1.83–1.67 (m, 3H, CH), 1.45 (s, 9H, CMe3), 0.04 (s, 9H, SiMe3); 
13
C NMR (100.6 
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MHz, CDCl3) (mixture of rotamers) δ 154.8 (C=O), 78.7 (CMe3), 47.7 (NCH), 46.9 
(NCH2), 28.6 (CMe3), 27.9 (CH2), 25.5 (CH2), 2.1 (SiMe3). Spectroscopic data 
consistent with those reported in the literature.
62
 
Lab Book Reference: JDF6_542 
 
cis-tert-Butyl 4-phenyl-2-(trimethylsilyl)piperidine-1-carboxylate cis-67 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-4-phenyl piperidine 66 (261 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). A peak at 1699 cm
-1
 was observed and assigned to νC=O of N-Boc-4-
phenyl piperidine 66. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. A new peak at 1677 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate 174. The solution was stirred at 
–78 °C for 90 min. Complete lithiation of N-Boc-4-phenyl piperidine 66 to give the 
lithiated intermediate 174 had occurred. Then, Me3SiCl (217 mg, 253 µL, 2.0 mmol, 2.0 
eq.) was added dropwise. A new peak at 1691 cm
-1
 was observed which was assigned to 
νC=O in the substituted N-Boc-4-phenyl piperidine cis-67. The solution was stirred at –
78 °C for 2 h. Incomplete trapping of lithiated intermediate 174 to give substituted N-
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Boc-4-phenyl piperidine 67 and lithiated N-Boc-4-phenyl piperidine 174 was observed. 
Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the two 
layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 19:1-1:1 petrol-Et2O as eluent gave cis-N-Boc piperidine cis-67 (130 mg, 
39%) as a colourless oil, RF (9:1 petrol-Et2O) 0.5; 
1
H NMR (400 MHz, CDCl3) δ 7.35-
7.29 (m, 2H, Ph), 7.24-7.18 (m, 3H, Ph), 4.11 (br d, J = 13.0 Hz, 1H, NCH), 2.96 (br t, J 
= 12.0 Hz, 1H, NCH), 2.72 (tt, J = 12.0, 4.0 Hz, 1H, CHPh), 2.42 (d, J = 12.0 Hz, 1H, 
NCH), 1.88-1.77 (m, 2H, CH), 1.68-1.54 (m, 2H, CH), 1.47 (s, 9H, CMe3), 0.08 (s, 9H, 
SiMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 155.1 (C=O), 146.2 (ipso-Ph), 128.5 (Ph), 
126.9 (Ph), 126.2 (Ph), 79.0 (CMe3), 50.0 (NCH), 47.9 (NCH2), 44.9 (CHPh), 34.2 
(CH2), 33.5 (CH2), 28.4 (CMe3), 0.7 (SiMe3) and N-Boc-4-phenyl piperidine 66 (129 
mg, 49%) as a colourless oil. Spectroscopic data for cis-67 consistent with those 
reported in the literature.
73
 
Lab Book Reference: JDF6_544 
 
tert-Butyl 4-benzyl-2-(trimethylsilyl)piperazine-1-carboxylate 175 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
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added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). A peak at 1698 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 10 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate 161 had occurred. Then, Me3SiCl (217 mg, 253 µL, 2.0 
mmol, 2.0 eq.) was added dropwise. A new peak at 1691 cm
-1
 was observed which was 
assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 175. The solution was 
stirred at –78 °C for 1 h. Incomplete trapping of lithiated intermediate 161 to give 
substituted N-Boc-N′-benzyl piperazine 175 and lithiated N-Boc-N′-benzyl piperazine 
161 was observed. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After 
warming to rt, saturated NaHCO3(aq) (10 mL) was added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 9:1-
1:1 petrol-EtOAc as eluent gave N-Boc piperazine 175 (20 mg, 6%) as a colourless oil, 
RF (9:1 petrol-EtOAc) 0.4; IR (CHCl3) 2977, 2804, 1673 (C=O), 1454, 1420, 1366, 
1296, 1168, 1111, 1027, 840 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.32-7.30 (m, 4H, Ph), 7.27-7.22 (m, 1H, Ph) 4.20 (br s, 0.6H, NCH), 3.80 
(br s, 0.4H, NCH), 3.61-3.55 (m, 1H, NCH), 3.44 (d, J = 13.0 Hz, 1H, CHAHBPh), 3.40 
(d, J = 13.0 Hz, 1H, CHAHBPh), 3.05 (br s, 0.4H, NCH), 2.92 (br s, 0.6H, NCH), 2.80 
(d, J = 12.0 Hz, 1H, NCH), 2.72 (m, 0.6H, NCH), 2.64 (br s, 0.4H, NCH), 2.24 (br s, 
1H, NCH), 1.93 (td, J = 12.0, 3.0 Hz, 1H, NCH), 1.46 (s, 9H, CMe3), 0.12 (s, 9H, 
SiMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 (C=O), 138.3 (ipso-Ph), 129.1 (Ph), 
128.1 (Ph), 127.0 (Ph), 79.1 (CMe3), 63.4 (NCH2), 54.3 (NCH2), 53.2 (NCH2), 45.3 
(NCH), 41.4 (NCH2), 28.4 (CMe3), 0.8 (SiMe3); MS (ESI) m/z 349 (M + H)
+
; HRMS  
m/z calcd for C19H32N2O2Si (M + H)
+
 349.2306, found 349.2297 (+1.7 ppm error). and 
N-Boc-N′-benzyl piperazine 117 (240 mg, 87%) as a colourless oil. Spectroscopic data 
consistent for 175 with those reported in the literature.
59
 
Lab Book Reference: JDF6_543 
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tert-Butyl 2-methylpyrrolidine-1-carboxylate 33 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1679 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1650 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 9 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, dimethyl 
sulfate (252 mg, 189 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 1698 
cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc pyrrolidine 33. 
The solution was stirred at –78 °C for 10 min. Complete trapping of lithiated 
intermediate to give substituted N-Boc pyrrolidine 33 was observed within 3 min. Then, 
saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 19:1 
petrol-EtOAc as eluent gave N-Boc pyrrolidine 33 (122 mg, 66%) as a colourless oil, RF 
(9:1 petrol-EtOAc) 0.2; 
1
H NMR (400 MHz, CDCl3) δ 3.97-3.80 (m, 1H, NCH), 3.42-
3.26 (m, 2H, NCH), 2.03-1.92 (m, 1H, CH), 1.91-1.82 (m, 1H, CH), 1.82-1.73 (m, 1H, 
CH), 1.57-1.46 (m, 1H, CH), 1.45 (s, 9H, CMe3), 1.14 (d, J = 6.5 Hz, 3H, NCHMe);
 13
C 
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NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 154.5 (C=O), 78.8 (CMe3), 52.7 
(NCH), 46.2 (NCH2), 33.0 (CH2), 28.5 (CMe3), 23.2 (CH2), 20.5 (CH2). Spectroscopic 
data consistent with those reported in the literature.
75
 
Lab Book Reference: JDF6_545 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1652 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 8 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, methyl 
iodide (284 mg, 195 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 1698 
cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc pyrrolidine 33. 
The solution was stirred at –78 °C for 7 min. Complete trapping of lithiated 
intermediate to give substituted N-Boc pyrrolidine 33 was observed within 3 min. Then, 
saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 19:1 
petrol-EtOAc as eluent gave N-Boc pyrrolidine 33 (60 mg, 33%) as a colourless oil. 
Lab Book Reference: JDF6_540 
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cis-tert-Butyl 2-methyl-4-phenylpiperidine-1-carboxylate cis-86 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-4-phenyl piperidine 66 (261 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). A peak at 1697 cm
-1
 was observed and assigned to νC=O of N-Boc-4-
phenyl piperidine 66. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. A new peak at 1676 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1643 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. The solution was stirred at –78 
°C for 90 min. Complete lithiation of N-Boc-4-phenyl piperidine 66 to give the lithiated 
intermediate had occurred. Then, dimethyl sulfate (252 mg, 189 µL, 2.0 mmol, 2.0 eq.) 
was added dropwise. A new peak at 1691 cm
-1
 was observed which was assigned to 
νC=O in the substituted N-Boc-4-phenyl piperidine cis-86. The solution was stirred at –
78 °C for 2 h. Incomplete trapping of lithiated intermediate to give substituted N-Boc-4-
phenyl piperidine cis-86 and N-Boc-4-phenyl piperidine 66 was observed. Then, 
saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 19:1 
petrol-EtOAc as eluent gave cis-N-Boc piperidine cis-86 (143 mg, 52%) as a colourless 
oil, RF (19:1 petrol-EtOAc) 0.2; 
1
H NMR (400 MHz, CDCl3) δ 7.33-7.27 (m, 2H, Ph), 
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7.23-7.17 (m, 3H, Ph), 4.02-3.90 (m, 1H, NCH), 3.81 (ddd, J = 14.0, 7.5, 3.0 Hz, 1H, 
NCH), 3.25 (ddd, J = 14.0, 10.0, 6.5 Hz, 1H, NCH), 2.82-2.68 (m, 1H, CHPh), 2.21-
2.10 (m, 1H, CH), 1.91 (dddd, J = 13.5, 6.0, 3.0, 1.5 Hz, 1H, CH), 1.66-1.55 (m, 2H, 
CH), 1.49 (s, 9H, CMe3), 1.20 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, 
CDCl3) δ 155.4 (C=O), 146.0 (ipso-Ph), 128.5 (Ph), 126.8 (Ph), 126.1 (Ph), 79.2 
(CMe3), 50.1 (NCH), 38.0 (CHPh), 37.6 (NCH2), 37.1 (CH2), 31.3 (CH2), 28.5 (CMe3), 
19.9 (CHMe). Spectroscopic data consistent with those reported in the literature.
271
 
Lab Book Reference: JDF6_547 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-4-phenyl piperidine 66 (261 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). A peak at 1698 cm
-1
 was observed and assigned to νC=O of N-Boc-4-
phenyl piperidine 66. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1647 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. The solution was stirred at –78 
°C for 60 min. Complete lithiation of N-Boc-4-phenyl piperidine 66 to give the lithiated 
intermediate had occurred. Then, methyl iodide (284 mg, 124 µL, 2.0 mmol, 2.0 eq.) 
was added dropwise. A new peak at 1694 cm
-1
 was observed which was assigned to 
νC=O in the substituted N-Boc-4-phenyl piperidine cis-86. The solution was stirred at –
78 °C for 45 min. Complete trapping of lithiated intermediate to give substituted N-Boc-
4-phenyl piperidine cis-86 was observed within 30 min. Then, saturated NH4Cl(aq) (10 
mL) was added at –78 °C. After warming to rt, the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
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dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 98:2-19:1 petrol-
EtOAc as eluent gave cis-N-Boc piperidine cis-86 (192 mg, 70%) as a colourless oil. 
Lab Book Reference: JDF6_541 
 
tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate 176 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). A peak at 1703 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1679 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 10 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, dimethyl sulfate (252 mg, 189 µL, 
2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 1693 cm
-1
 was observed which 
was assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 176. The solution 
was stirred at –78 °C for 2 h. Incomplete trapping of lithiated intermediate to give 
substituted N-Boc-N′-benzyl piperazine 176 and N-Boc-N′-benzyl piperazine 117 was 
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observed. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, 
saturated NaHCO3(aq) (10 mL) was added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-EtOAc 
as eluent gave N-Boc piperazine 176 (11 mg, 4%) as a colourless oil, RF (7:3 petrol-
EtOAc) 0.6; IR (ATR) 2973, 1688 (C=O), 1452, 1407, 1392, 1364, 1341, 1322, 1305, 
1279, 1247, 1223, 1158, 1107, 1059, 1039, 1028, 740, 700 cm
-1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.36-7.29 (m, 4H, Ph), 7.26-7.22 (m, 1H, Ph), 4.18 (br s, 1H, NCH), 3.80 (br 
d, J = 12.5 Hz, 1H, NCH), 3.53 (d, J = 13.0 Hz, 1H, CHAHBPh), 3.40 (d, J = 13.0 Hz, 
1H, CHAHBPh), 3.11 (td, J = 12.5, 3.5 Hz, 1H, NCH), 2.77-2.73 (m, 1H, NCH), 2.59 
(dt, J = 11.0, 1.5 Hz, NCH), 2.12 (dd, J = 11.0, 4.0 Hz, 1H, NCH), 2.00 (ddd, J = 12.5, 
11.5, 3.5 Hz, 1H, NCH), 1.45 (s, 9H, CMe3), 1.24 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR 
(100.6 MHz, CDCl3) δ 154.8 (C=O), 138.4 (ipso-Ph), 128.7 (Ph), 128.2 (Ph), 127.0 
(Ph), 79.3 (CMe3), 62.8 (NCH2), 57.3 (NCH2), 53.2 (NCH2), 47.0 (NCH), 39.1 (NCH2), 
28.4 (CMe3), 15.9 (Me); MS (ESI) m/z 291 (M + H)
+
. Spectroscopic data consistent 
with those reported in the literature.
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Lab Book Reference: JDF6_554 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). A peak at 1698 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which 
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was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, methyl iodide (284 mg, 124 µL, 2.0 
mmol, 2.0 eq.) was added dropwise. A new peak at 1693 cm
-1
 was observed which was 
assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 176. The solution was 
stirred at –78 °C for 2 h. Complete trapping of lithiated intermediate to give substituted 
N-Boc-N′-benzyl piperazine 176 was observed within 2 h. Then, saturated NH4Cl(aq) (10 
mL) was added at –78 °C. After warming to rt, saturated NaHCO3(aq) (10 mL) was 
added and the two layers were separated. The aqueous layer was extracted with Et2O (3 
× 10 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-EtOAc as eluent gave N-Boc piperazine 176 
(218 mg, 75%) as a colourless oil. 
Lab Book Reference: JDF6_539 
 
 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of N-Boc-N′-benzyl piperazine 117 (276 
mg, 1.0 mmol, 1.0 eq.) in THF (2 mL) was added. The solution was stirred for 5 min (to 
verify the stability of readout on ReactIR
™
). A peak at 1695 cm
-1
 was observed and 
assigned to νC=O of N-Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1642 cm
-1
 
was observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 210 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, methyl iodide (284 mg, 124 µL, 2.0 
mmol, 2.0 eq.) was added dropwise. A new peak at 1695 cm
-1
 was observed which was 
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assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 176. The solution was 
stirred at –78 °C for 1 h. Complete trapping of lithiated intermediate to give substituted 
N-Boc-N′-benzyl piperazine 176 was observed within 1 h. Then, saturated NH4Cl(aq) (10 
mL) was added at –78 °C. After warming to rt, the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 8:2 petrol-EtOAc 
as eluent gave N-Boc piperazine 176 (217 mg, 75%) as a colourless oil. 
Lab Book Reference: JDF7_604 
 
 (S)-tert-Butyl 2-(trimethylsilyl)pyrrolidine-1-carboxylate (S)-13  
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1701 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1646 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 90 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, Me3SiCl 
(217 mg, 254 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 1694 cm
-1
 was 
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observed which was assigned to νC=O in the substituted N-Boc pyrrolidine (S)-13. The 
solution was stirred at –78 °C for 90 min. Incomplete trapping of lithiated intermediate 
to give substituted N-Boc pyrrolidine (S)-13 and N-Boc pyrrolidine 12 was observed. 
Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the two 
layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 4:1-1:1 petrol-Et2O as eluent gave N-Boc pyrrolidine (S)-13 (30 mg, 12%, 
98:2 er by CSP-GC) as a pale yellow oil, [α]D +66.0 (c 1.3 in CHCl3) (lit.,
62
 [α]D +71.8 
(c 2.6 in CHCl3) for (S)-13 of 98:2 er); CSP-GC: β-cyclodextrin (100 °C) (S)-13 45.7 
min, (R)-13 48.6 min, and N-Boc pyrrolidine 12 (144 mg, 84%) as a clear oil. 
Lab Book Reference: JDF6_584 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1700 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1678 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1646 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 80 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, the 
solution warmed to –40 °C and stirred for 10 min (to verify the stability of readout on 
ReactIR
™
). Then, Me3SiCl (217 mg, 254 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A 
new peak at 1694 cm
-1
 was observed which was assigned to νC=O in the substituted N-
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Boc pyrrolidine (S)-13. The solution was stirred at –40 °C for 25 min. Complete 
trapping of lithiated intermediate to give substituted N-Boc pyrrolidine (S)-13 was 
observed within 10 min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After 
warming to rt, the two layers were separated. The aqueous layer was extracted with 
Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 4:1-1:1 petrol-Et2O as eluent gave N-Boc 
pyrrolidine (S)-13 (178 mg, 73%, 98:2 er by CSP-GC) as a pale yellow oil, [α]D +71.8 
(c 1.0 in CHCl3) (lit.,
62
 [α]D +71.8 (c 2.6 in CHCl3) for (S)-13 of 98:2 er); CSP-GC: β-
cyclodextrin (100 °C) (S)-13 45.7 min, (R)-13 48.6 min. 
Lab Book Reference: JDF7_602 
 
tert-Butyl 2-(1-hydroxycyclobutyl)pyrrolidine-1-carboxylate 177 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1649 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 6 min. Complete lithiation 
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of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, 
cyclobutanone (140 mg, 149 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 
1687 cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc 
pyrrolidine 177. The solution was stirred at –78 °C for 4 min. Complete trapping of 
lithiated intermediate to give substituted N-Boc pyrrolidine 177 was observed within 1 
min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1-8:2 petrol-EtOAc as eluent gave N-Boc pyrrolidine 177 (180 mg, 74%) 
as a white solid, mp 104-105 °C; RF (8:2 petrol-EtOAc) 0.2; IR (CHCl3) 3266 (OH), 
2970, 2953, 1639 (C=O), 1453, 1378, 1346, 1199, 1147, 1099, 909, 769, 726, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 4.07 (br s, 1H, OH), 3.95 (dd, J = 8.0, 5.5 Hz, 1H, NCH), 
3.69-3.53 (m, 1H, NCH), 3.33-3.21 (m, 1H, NCH), 2.39-2.25 (m, 1H, CH), 2.15-1.81 
(m, 7H, CH), 1.78-1.67 (m, 1H, CH), 1.59-1.50 (m, 1H, CH), 1.45 (s, 9H, CMe3); 
13
C 
NMR (100.6 MHz, CDCl3) δ 156.7 (C=O), 80.0 (C), 78.7 (C), 64.0 (NCH), 48.3 
(NCH2), 34.0 (CH2), 32.2 (CH2), 28.4 (CMe3), 27.7 (CH2), 24.3 (CH2), 13.0 (CH2); MS 
(ESI) m/z 264 [(M + Na)
+
, 40], 242 [(M + H)
+
, 100], 186 [(M – CMe3)
+
, 70]; HRMS 
m/z calcd for C13H23NO3 (M + H)
+
 242.1751, found 242.1748 (+1.5 ppm error) and N-
Boc pyrrolidine 12 (20 mg, 12%) as a clear oil. 
Lab Book Reference: JDF6_551 
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cis-tert-Butyl 2-(1-hydroxycyclobutyl)-4-phenylpiperidine-1-carboxylate cis-178 
and 1'-hydroxybi(cyclobutan)-2-one 180 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-4-phenyl piperidine 66 (261 mg, 1.0 mmol, 1.0 
eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of readout 
on ReactIR
™
). A peak at 1699 cm
-1
 was observed and assigned to νC=O of N-Boc-4-
phenyl piperidine 66. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which was 
assigned to νC=O in the pre-lithiation complex. A new peak at 1644 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate. The solution was stirred at –78 
°C for 90 min. Complete lithiation of N-Boc-4-phenyl piperidine 66 to give the lithiated 
intermediate had occurred. Then, cyclobutanone (140 mg, 149 µL, 2.0 mmol, 2.0 eq.) 
was added dropwise. A new peak at 1694 cm
-1
 was observed which was assigned to 
νC=O in the substituted N-Boc-4-phenyl piperidine cis-178. The solution was stirred at –
78 °C for 10 min. Complete trapping of lithiated intermediate to give substituted N-Boc-
4-phenyl piperidine cis-178 was observed within 1 min. Then, saturated NH4Cl(aq) (10 
mL) was added at –78 °C. After warming to rt, the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 8:2-3:7 petrol-Et2O 
as eluent gave cis-N-Boc piperidine cis-178 (185 mg, 56%) as a colourless oil, RF (7:3 
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petrol-Et2O) 0.2; IR (CHCl3) 3281 (OH), 2936, 2894, 1648 (C=O), 1454, 1430, 1402, 
1346, 1315, 1268, 1227, 1139, 1046, 1026, 745, 690 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
δ 7.33-7.27 (m, 2H, Ph), 7.24-7.17 (m, 3H, Ph), 5.36 (br s, 1H, OH), 4.09 (dt, J = 13.5, 
4.0 Hz, 1H, NCH), 3.41 (dd, J = 11.0, 2.5 Hz, 1H, NCH), 3.16-3.04 (m, 1H, NCH), 
2.86-2.74 (m, 1H, CHPh), 2.32-2.21 (m, 1H, CH), 2.19-2.01 (m, 2H, CH), 2.00-1.80 (m, 
5H, CH), 1.67-1.51 (m, 2H, CH), 1.48 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 
155.7 (C=O), 145.4 (ipso-Ph), 128.4 (Ph), 126.8 (Ph), 126.3 (Ph), 80.2 (C), 75.1 (C), 
65.8 (NCH), 47.9 (NCH2), 42.7 (CHPh), 34.0 (CH2), 33.8 (CH2), 33.5 (CH2), 28.4 
(CMe3), 12.7 (CH2); MS (ESI) m/z 354 [(M + Na)
+
, 80], 332 [(M + H)
+
, 100], 276 [(M – 
CMe3)
+
, 20]; HRMS m/z calcd for C20H29NO3 (M + H)
+
 332.2220, found 332.2205 
(+4.2 ppm error) and hydroxy ketone 180 (44 mg, 24%) as a colourless oil, RF (7:3 
petrol-Et2O) 0.1; IR (CHCl3) 3425 (OH), 2942, 1747 (C=O), 1365, 1217, 1154, 1071, 
1000, 932, 687, 653 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 3.61 (ddt, J = 10.0, 7.0, 2.5 
Hz, 1H, CHC=O), 3.07-2.86 (m, 2H, CH2C=O), 2.35-2.24 (m, 1H, CH), 2.18-1.95 (m, 
6H, CH + OH), 1.87-1.75 (m, 1H, CH), 1.63-1.51 (m, 1H, CH); 
13
C NMR (100.6 MHz, 
CDCl3) δ 211.3 (C=O), 74.3 (COH), 67.5 (CHC=O), 45.4 (CH2C=O), 35.1 (CH2), 34.8 
(CH2), 12.7 (CH2), 12.0 (CH2); MS (ESI) m/z 163 [(M + Na)
+
, 100], 141 [(M + H)
+
, 40]; 
HRMS m/z calcd for C8H12O2 (M + H)
+
 141.0910, found 141.0911 (–1.1 ppm error) and 
N-Boc-4-phenyl piperidine 66 (80 mg, 31%) as a clear oil. 
Lab Book Reference: JDF6_553 
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tert-Butyl 4-benzyl-2-(1-hydroxycyclobutyl)piperazine-1-carboxylate 179 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). A peak at 1701 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, cyclobutanone (140 mg, 149 µL, 2.0 
mmol, 2.0 eq.) was added dropwise. A new peak at 1692 cm
-1
 was observed which was 
assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 179. The solution was 
stirred at –78 °C for 6 min. Complete trapping of lithiated intermediate to give 
substituted N-Boc-N′-benzyl piperazine 179 was observed within 1 min. Then, saturated 
NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, saturated NaHCO3(aq) (10 
mL) was added and the two layers were separated. The aqueous layer was extracted 
with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 9:1-8:2 petrol-EtOAc as eluent gave N-Boc 
piperazine 179 (206 mg, 59%) as a colourless oil, RF (8:2 petrol-EtOAc) 0.2; IR 
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(CHCl3) 2973, 1653 (C=O), 1394, 1354, 1274, 1197, 1151, 1106, 1015, 749, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 7.35-7.23 (m, 5H, Ph), 6.82 
(br s, 1H, OH), 4.28 (br s, 0.4H, NCH), 4.13-4.04 (m, 1.2H, NCH), 3.90 (br d, J = 12.5 
Hz, 0.4H, NCH), 3.60-3.35 (m, 3H, NCH), 3.18-3.06 (m, 1H, NCH), 2.85-2.71 (m, 1H, 
NCH), 2.40-2.28 (m, 1H, NCH), 2.15-2.02 (m, 2H, NCH + CH), 2.01-1.83 (m, 3H, 
CH), 1.72-1.61 (m, 1H, CH), 1.61-1.49 (m, 1H, CH), 1.47 (s, 5.4H, CMe3), 1.45 (s, 
3.6H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 155.2 (C=O), 
154.8 (C=O), 136.4 (ipso-Ph), 136.3 (ipso-Ph), 129.0 (Ph), 128.5 (Ph), 127.6 (Ph), 80.4 
(C), 80.3 (C), 79.7 (C), 62.8 (NCH2Ph), 53.3 (NCH), 52.9 (NCH2), 52.8 (NCH2), 52.3 
(NCH), 52.2 (NCH2), 52.0 (NCH2), 41.6 (NCH2), 40.3 (NCH2), 36.3 (CH2), 36.1 (CH2), 
32.7 (CH2), 28.4 (CMe3), 28.3 (CMe3), 11.3 (CH2), 11.2 (CH2); MS (ESI) m/z 347 (M + 
H)
+
; HRMS m/z calcd for C20H30N2O3 (M + H)
+
 347.2329, found 347.2328 (+0.1 ppm 
error) and N-Boc-N′-benzyl piperazine 117 (81 mg, 29%) as a white solid. 
Lab Book Reference: JDF6_552 
 
tert-Butyl 2-(tributylstannyl)pyrrolidine-1-carboxylate 21 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
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peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1649 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 8 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, 
tributyltin chloride (650 mg, 542 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new 
peak at 1677 cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc 
pyrrolidine 21. The solution was stirred at –78 °C for 4 min. Complete trapping of 
lithiated intermediate to give substituted N-Boc pyrrolidine 21 was observed within 1 
min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 98:2 petrol-EtOAc as eluent gave N-Boc pyrrolidine 21 (276 mg, 60%) as a 
pale yellow oil, RF (98:2 petrol-EtOAc) 0.2; 
1
H NMR (400 MHz, CDCl3) (70:30 
mixture of rotamers) δ 3.73-3.69 (m, 0.3H, NCH), 3.42-3.27 (m, 1.7H, NCH), 3.20-3.12 
(m, 1H, NCH), 2.24-2.04 (m, 1H, CH), 1.95-1.73 (m, 3H, CH), 1.55-1.40 (m, 6H, CH), 
1.48 (s, 2.7H, CMe3), 1.44 (s, 6.3H, CMe3), 1.31-1.24 (m, 6H, CH2), 0.93-0.81 (m, 15H, 
CH2 + Me); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 154.1 (C=O), 78.2 
(CMe3), 46.7 (NCH), 46.4 (NCH), 30.4 (NCH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 
28.7 (CMe3), 28.6 (CMe3), 27.9 (CH2), 27.7 (CH2), 27.2 (CH2), 13.8 (Me), 10.0 (CH2), 
9.5 (CH2). Spectroscopic data consistent with those reported in the literature.
62
  
Lab Book Reference: JDF6_571 
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tert-Butyl 2-(hydroxydiphenylmethyl)pyrrolidine-1-carboxylate 36 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1701 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1646 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 8 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, a solution 
of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) was added dropwise. A 
new peak at 1668 cm
-1
 was observed which was assigned to νC=O in the substituted N-
Boc pyrrolidine 36. The solution was stirred at –78 °C for 5 min. Complete trapping of 
lithiated intermediate to give substituted N-Boc pyrrolidine 36 was observed within 1 
min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1-7:3 petrol-Et2O as eluent gave N-Boc pyrrolidine 36 (241 mg, 68%) as a 
white solid, mp 106-108 °C (lit.,
272
 101-103 °C); RF (7:3 petrol-Et2O) 0.3; 
1
H NMR 
(400 MHz, CDCl3) δ 7.42-7.36 (m, 4H, Ph), 7.34-7.23 (m, 6H, Ph), 6.44 (br s, 1H, OH), 
4.90 (dd, J = 9.0, 3.5 Hz, 1H, NCH), 3.42-3.26 (m, 1H, NCH), 2.86 (br s, 1H, NCH), 
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2.16-2.03 (m, 1H, CH), 1.96-1.88 (m, 1H, CH), 1.48-1.42 (m, 1H, CH), 1.44 (s, 9H, 
CMe3), 0.76 (br s, 1H, CH); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
157.8 (C=O), 146.4 (ipso-Ph), 143.7 (ipso-Ph), 128.5 (Ph), 128.2 (Ph), 127.8 (Ph), 
127.7 (Ph), 127.3 (Ph), 127.1 (Ph), 127.0 (Ph), 126.5 (Ph), 81.6 (Ph2COH), 80.6 
(CMe3), 65.7 (NCH), 47.8 (NCH2), 29.7 (CH2), 28.5 (CMe3), 28.3 (CMe3), 22.8 (CH2). 
Spectroscopic data consistent with those reported in the literature.
272
 
Lab Book Reference: JDF6_567 
 
2-(Hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid tert-butyl ester syn-31 and 
anti-32 
 
  
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1701 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1647 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 8 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, 
benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 
1676 cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc 
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pyrrolidines syn-31 and anti-32. The solution was stirred at –78 °C for 10 min. 
Complete trapping of lithiated intermediate to give substituted N-Boc pyrrolidines syn-
31 and anti-32 was observed within 1 min. Then, saturated NH4Cl(aq) (10 mL) was 
added at –78 °C. After warming to rt, the two layers were separated. The aqueous layer 
was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 98:2 CH2Cl2-acetone as 
eluent gave N-Boc pyrrolidine syn-31 (165 mg, 59%) as a colourless oil, RF (98:2 
CH2Cl2-acetone) 0.3; 
1
H NMR (400 MHz, CDCl3) δ 7.38-7.24 (m, 5H, Ph), 4.69 (br s, 
1H, CHOH), 4.54 (d, J = 9.0 Hz, 1H, CHOH), 4.11-4.06 (m, 1H, NCH), 3.49-3.43 (m, 
1H, NCH), 3.40-3.26 (m, 1H, NCH), 1.76-1.64 (m, 2H, CH), 1.64-1.45 (m, 1H, CH), 
1.52 (s, 9H, CMe3), 1.36-1.25 (m, 1H, CH); 
13
C NMR (100.6 MHz, CDCl3) δ 158.3 
(C=O), 142.4 (ipso-Ph), 128.3 (Ph), 127.7 (Ph), 127.2 (Ph), 80.7 (CMe3), 76.3 (CHOH), 
64.0 (NCH), 47.5 (NCH2), 28.6 (CH2), 28.5 (CMe3), 23.6 (CH2) and N-Boc pyrrolidine 
anti-32 (94 mg, 34%) as a colourless oil, RF (98:2 CH2Cl2-acetone) 0.2; 
1
H NMR (400 
MHz, CDCl3) δ 7.38-7.21 (m, 5H, Ph), 4.94 (br s, 1H, CHOH), 4.23 (br s, 1H, NCH), 
3.81 (br s, 1H, CHOH), 3.39-3.33 (m, 1H, NCH), 2.94 (br s, 1H, NCH), 1.94-1.72 (m, 
2H, CH), 1.63-1.47 (m, 2H, CH), 1.52 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 
157.1 (C=O), 141.2 (ipso-Ph), 128.0 (Ph), 127.3 (Ph), 126.7 (Ph), 80.3 (CMe3), 76.2 
(CHOH), 63.3 (NCH), 47.7 (NCH2), 28.5 (CMe3), 26.9 (CH2), 23.5 (CH2). 
Spectroscopic data consistent with those reported in the literature.
67
 The total yield of 
syn-31 and anti-32 was 93%. 
Lab Book Reference: JDF6_566 
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tert-Butyl 4-benzyl-2-(tributylstannyl)piperazine-1-carboxylate 181 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
readout on ReactIR
™
). A peak at 1702 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1675 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, tributyltin chloride (650 mg, 542 µL, 
2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 1671 cm
-1
 was observed which 
was assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 181. The solution 
was stirred at –78 °C for 6 min. Complete trapping of lithiated intermediate to give 
substituted N-Boc-N′-benzyl piperazine 181 was observed within 1 min. Then, saturated 
NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, saturated NaHCO3(aq) (10 
mL) was added and the two layers were separated. The aqueous layer was extracted 
with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 19:1 petrol-EtOAc as eluent gave N-Boc 
piperazine 181 (324 mg, 57%) as a colourless oil, RF (9:1 petrol-EtOAc) 0.2; IR 
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(CHCl3) 2961, 2911, 2881, 2827, 1647 (C=O), 1433, 1395, 1395, 1344, 1278, 1231, 
1151, 1088, 1055, 1007, 850, 688 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 7.38–7.21 (m, 5H, Ph), 4.13 (s, 0.5H, NCH), 4.03 (br d, J = 13.0 Hz, 0.5H, 
NCH), 3.80–3.16 (m, 4H, NCH), 2.82–2.37 (m, 3H, NCH), 2.21 (br s, 0.5H, NCH), 
1.96–1.80 (m, 0.5H, NCH), 1.55–1.35 (m, 15H, CH2 + CMe3), 1.35–1.23 (m, 6H, CH2), 
0.99–0.78 (m, 15H, CH2 + Me); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
154.6 (C=O), 154.2 (C=O), 138.2 (ipso-Ph), 129.4 (Ph), 128.3 (Ph), 127.2 (Ph), 79.5 
(CMe3), 79.4 (CMe3), 63.3 (NCH2), 58.1 (NCH2), 53.2 (NCH2), 53.0 (NCH2), 46.5 
(NCH), 45.5 (NCH), 44.8 (NCH2), 42.6 (NCH2), 29.3 (CH2), 29.3 (CH2), 28.5 (CMe3), 
27.9 (CH2), 27.7 (CH2), 13.8 (Me), 11.1 (CH2), 10.4 (CH2); MS (ESI) m/z 567 (M + 
H)
+
; HRMS m/z calcd for C28H50N2O2Sn (M + H)
+
 567.2972, found 567.2945 (+3.9 
ppm error). 
Lab Book Reference: JDF6_572 
 
tert-Butyl 4-benzyl-2-(hydroxydiphenylmethyl)piperazine-1-carboxylate 182 and 7-
benzyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 183 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
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readout on ReactIR
™
). A peak at 1702 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1676 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, a solution of benzophenone (364 mg, 
2.0 mmol, 2.0 eq.) in Et2O (1 mL) was added dropwise. A new peak at 1666 cm
-1
 was 
observed which was assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine 182 
and oxazolidinone 183. The solution was stirred at –78 °C for 4 min. Complete trapping 
of lithiated intermediate to give substituted N-Boc-N′-benzyl piperazine 182 and 
oxazolidinone 183 was observed within 1 min. Then, saturated NH4Cl(aq) (10 mL) was 
added at –78 °C. After warming to rt, saturated NaHCO3(aq) (10 mL) was added and the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 19:1-7:3 petrol-EtOAc as eluent gave N-Boc piperazine 182 (230 mg, 50%) 
as a colourless oil, RF (9:1 petrol-EtOAc) 0.3; IR (CHCl3) 3117 (OH), 2960, 2782, 1654 
(C=O), 1430, 1394, 1345, 1320, 1282, 1197, 1150, 1107, 1049, 1002, 849, 746, 690 cm
–
1
; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.77 (br s, 0.5H, OH), 
7.67-7.43 (m, 4.5H, Ph + OH), 7.36-7.04 (m, 11H, Ph), 5.17 (d, J = 3.0 Hz, 0.5H, 
NCH), 4.85 (d, J = 3.0 Hz, 0.5H, NCH), 4.16 (dd, J = 13.5, 3.5 Hz, 0.5H, NCH), 3.90-
3.70 (m, 1.5H, NCH), 3.45-3.27 (m, 2H, NCH), 3.00 (dd, J = 11.5, 6.0 Hz, 1H, NCH), 
2.94 (d, J = 11.5Hz, 0.5H, NCH), 2.85 (d, J = 11.5 Hz, 0.5H, NCH), 2.36-2.25 (m, 1H, 
NCH), 2.21-2.07 (m, 1H, NCH), 1.26 (s, 4.5H, CMe3), 1.20 (s, 4.5H, CMe3); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 154.6 (C=O), 154.2 (C=O), 147.1 (ipso-
Ph), 146.5 (ipso-Ph), 144.8 (ipso-Ph), 144.5 (ipso-Ph), 136.1 (ipso-Ph), 129.2 (Ph), 
129.1 (Ph), 128.5 (Ph), 128.4 (Ph), 128.1 (Ph), 128.0 (Ph), 127.6 (Ph), 127.3 (Ph), 126.8 
(Ph), 126.7 (Ph), 126.6 (Ph), 126.5 (Ph), 126.4 (Ph), 126.3 (Ph), 126.1 (Ph), 125.8 (Ph), 
83.6 (Ph2COH), 83.5 (Ph2COH), 79.8 (CMe3), 62.8 (NCH2Ph), 55.6 (NCH), 54.5 
(NCH2), 53.9 (NCH), 53.7 (NCH2), 52.6 (NCH2), 52.5 (NCH2), 41.6 (NCH2), 40.6 
(NCH2), 28.2 (CMe3), 27.9 (CMe3); MS (ESI) m/z 459 (M + H)
+
; HRMS m/z calcd for 
C29H34N2O3 (M + H)
+
 459.2642, found 459.2626 (+3.9 ppm error) and oxazolidinone 
183 (40 mg, 10%) as a white solid, mp 146-149 °C; RF (7:3 petrol-Et2O) 0.2; IR 
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(CHCl3) 3020, 2400, 1751 (C=O), 1422, 1215, 929, 759, 669 cm
–1
; NMR (400 MHz, 
CDCl3) δ 7.53-7.50 (m, 2H, Ph), 7.40-7.21 (m, 13H, Ph), 4.54 (dd, J = 11.0, 3.5 Hz, 1H, 
NCH), 3.80 (ddd, J = 13.0, 3.5, 1.5 Hz, 1H, NCH), 3.50 (d, J = 13.0 Hz, 1H, 
CHAHBPh), 3.31 (d, J = 13.0 Hz, 1H, CHAHBPh), 3.09 (ddd, J = 13.0, 12.0, 3.5 Hz, 1H, 
NCH), 2.70-2.66 (m, 1H, NCH), 2.55 (ddd, J = 11.0, 3.5, 1.5 Hz, 1H, NCH), 1.93 (td, J 
= 12.0, 3.5 Hz, 1H, NCH), 1.57 (t, J = 11.0 Hz, 1H, NCH); 
13
C NMR (100.6 MHz, 
CDCl3) δ 156.5 (C=O), 142.7 (ipso-Ph), 139.1 (ipso-Ph), 137.6 (ipso-Ph), 129.1 (Ph), 
128.8 (Ph), 128.7 (Ph), 128.6 (Ph), 128.5 (Ph), 128.1 (Ph), 127.6 (Ph), 126.2 (Ph), 126.0 
(Ph), 85.3 (Ph2CO), 62.9 (NCH2), 61.1 (NCH), 55.7 (NCH2), 50.7 (NCH2), 41.5 
(NCH2); MS (ESI) m/z 385 (M + H)
+
; HRMS  m/z calcd for C25H24N2O2 (M + H)
+
 
385.1911, found 385.1899 (+3.6 ppm error). Spectroscopic data consistent with those 
reported in the literature.
59
  The total yield of 182 and 183 was 60%. 
Lab Book Reference: JDF6_569 
 
tert-Butyl 4-benzyl-2-(hydroxy(phenyl)methyl)piperazine-1-carboxylate anti-185 
and syn-184 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution of  N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 
1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability of 
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readout on ReactIR
™
). A peak at 1702 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1646 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) was added dropwise. A new peaks at 1665 cm
-1
 was observed which was 
assigned to νC=O in the substituted N-Boc-N′-benzyl piperazines anti-185 and syn-184. 
The solution was stirred at –78 °C for 7 min. Complete trapping of lithiated 
intermediate to give substituted N-Boc-N′-benzyl piperazines anti-185 and syn-184 was 
observed within 1 min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After 
warming to rt, saturated NaHCO3(aq) (10 mL) was added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 
19:1-7:3 Et2O-CH2Cl2 as eluent gave N-Boc piperazine anti-185 (45 mg, 12%) as a 
white solid, mp 100-102 °C; RF (9:1 Et2O-CH2Cl2) 0.3; IR (CHCl3) 3215 (OH), 2971, 
2783, 1658 (C=O), 1429, 1385, 1345, 1302, 1197, 1151, 1101, 1000, 744, 691, 658 cm
–
1
; 
1
H NMR (400 MHz, CDCl3) δ 7.44-7.36 (m, 3H, Ph), 7.36-7.31 (m, 2H, Ph), 7.21-
6.99 (m, 5H, Ph), 6.42 (br s, 1H, CHOH), 5.08 (br s, 1H, CHOH), 4.01-3.85 (m, 1H, 
NCH), 3.80-3.67 (m, 1H, NCH), 3.63 (d, J = 12.5 Hz, 1H, CHAHBPh), 3.28 (d, J = 12.0 
Hz, 1H, NCH2), 3.08-2.94 (m, 1H, NCH2), 2.95 (d, J = 12.5 Hz, 1H, CHAHBPh), 2.33-
2.16 (m, 1H, NCH), 2.00 (dd, J = 12.0, 3.5 Hz, 1H, NCH), 1.70-1.55 (m, 1H, NCH), 
1.51 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 155.0 
(C=O), 154.8 (C=O), 143.2 (ipso-Ph), 136.3 (ipso-Ph), 129.7 (Ph), 128.7 (Ph), 128.0 
(Ph), 127.8 (Ph), 126.6 (Ph), 126.5 (Ph), 125.5 (Ph), 125.5 (Ph), 80.3 (CMe3), 80.1 
(CMe3), 79.0 (CHOH), 63.0 (NCH2Ph), 55.6 (NCH), 54.8 (NCH), 53.0 (NCH2), 50.5 
(NCH2), 42.3 (NCH2), 41.2 (NCH2), 28.5 (CMe3); MS (ESI) m/z 383 (M + H)
+
; HRMS 
m/z calcd for C23H30N2O3 (M + H)
+
 383.2329, found 383.2319 (+3.0 ppm error) and N-
Boc piperazine syn-184 (151 mg, 40%) as a white solid, mp 118-119 °C; RF (9:1 Et2O-
CH2Cl2) 0.2; IR (CHCl3) 2963, 1656 (C=O), 1431, 1393, 1345, 1281, 1229, 1196, 1150, 
1109, 1000, 848, 744, 689 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 mixture of 
rotamers) δ 7.43-7.14 (m, 10H, Ph), 6.01 (br s, 1H, OH), 5.28-4.97 (m, 1H, CHOH), 
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4.31 (s, 0.45H, NCH), 4.20-4.09 (m, 1.1H, NCH), 3.89 (d, J = 13.5 Hz, 0.45H, NCH), 
3.72-3.43 (m, 3H, NCH + CH2Ph), 3.12 (d, J = 11.5 Hz, 0.55H, NCH2), 3.01-2.80 (m, 
1.45H, NCH2), 2.43 (dd, J = 11.5, 3.5 Hz, 0.55H, NCH), 2.29 (d, J = 11.5 Hz, 0.45H, 
NCH), 2.24-2.07 (m, 1H, NCH), 1.30 (s, 4H, CMe3), 1.08 (s, 5H, CMe3); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 154.5 (C=O), 141.6 (ipso-Ph), 137.0 (ipso-
Ph), 136.6 (ipso-Ph), 129.2 (Ph), 128.6 (Ph), 128.5 (Ph), 128.2 (Ph), 128.0 (Ph), 127.7 
(Ph), 127.4 (Ph), 127.2 (Ph), 126.6 (Ph), 126.5 (Ph), 79.9 (CMe3), 79.6 (CHOH), 63.0 
(NCH2Ph), 56.4 (NCH2), 54.8 (NCH), 54.5 (NCH), 52.6 (NCH2), 52.5 (NCH2), 41.7 
(NCH2), 40.9 (NCH2), 28.2 (CMe3), 27.8 (CMe3); MS (ESI) m/z 383 (M + H)
+
; HRMS 
m/z calcd for C23H30N2O3 (M + H)
+
 383.2329, found 383.2315 (+3.9 ppm error). The 
total yield of anti-185 and syn-184 was 52%. 
Lab Book Reference: JDF6_568 
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tert-Butyl 4-benzyl-2-(hydroxy(phenyl)methyl)piperazine-1-carboxylate syn-184 
 
Crystal data and structure refinement for syn-184 
Identification code paob1204 
Empirical formula C23H30N2O3 
Formula weight 382.49 
Temperature/K 110.00(10) 
Crystal system triclinic 
Space group P-1 
a/Å 9.2272(3) 
b/Å 10.4025(3) 
c/Å 11.5915(4) 
α/° 102.908(3) 
β/° 98.613(3) 
γ/° 96.263(3) 
Volume/Å
3
 1060.48(6) 
Z 2 
ρcalc mg/mm
3
 1.198 
m/mm
-1
 0.079 
F(000) 412.0 
Crystal size/mm
3
 0.3921 × 0.2964 × 0.1735 
2Θ range for data collection 6.1 to 64.44° 
Index ranges -13 ≤ h ≤ 13, -14 ≤ k ≤ 15, -17 ≤ l ≤ 17 
Reflections collected 52490 
Independent reflections 7110[R(int) = 0.0404] 
Data/restraints/parameters 7110/0/266 
Goodness-of-fit on F
2
 1.046 
Final R indexes [I>=2σ (I)] R1 = 0.0424, wR2 = 0.1068 
Final R indexes [all data] R1 = 0.0520, wR2 = 0.1144 
Largest diff. peak/hole / e Å
-3
 0.41/-0.23 
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 (R)-tert-Butyl 2-(hydroxydiphenylmethyl)pyrrolidine-1-carboxylate (R)-36 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1702 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1680 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1645 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 80 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, a solution 
of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) was added dropwise. A 
new peak at 1667 cm
-1
 was observed which was assigned to νC=O in the substituted N-
Boc pyrrolidine (R)-36. The solution was stirred at –78 °C for 10 min. Complete 
trapping of lithiated intermediate to give substituted N-Boc pyrrolidine (R)-36 was 
observed within 1 min. Then, saturated NH4Cl(aq) (10 mL) was added at –78 °C. After 
warming to rt, the two layers were separated. The aqueous layer was extracted with 
Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 9:1-17:3 petrol-Et2O as eluent gave N-Boc 
pyrrolidine (R)-36 (260 mg, 74%, 94:6 er by CSP-HPLC) as a white solid, [α]D +121.5 
(c 1.0 in CHCl3) (lit.,
62
 [α]D +132.1 (c 1.97 in CHCl3) for (R)-36 of 95:5 er); CSP-
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HPLC: Chiralcel OD-H (95:5 hexane:i-PrOH, 0.5 mL min
-1
) (R)-36 12.8 min, (S)-36 
15.6 min. 
Lab Book Reference: JDF6_587 
 
 (R)-tert-Butyl 2-((R)-hydroxy(phenyl)methyl)pyrrolidine-1-carboxylate (R,R)-31 
and (R)-tert-butyl 2-((S)-hydroxy(phenyl)methyl)pyrrolidine-1-carboxylate (R,S)-
32 
 
 
Et2O (14 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by N-Boc-pyrrolidine 12 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.). The 
solution was stirred for 5 min (to verify the stability of readout on ReactIR
™
). A peak at 
1701 cm
-1
 was observed and assigned to νC=O of N-Boc-pyrrolidine 12. Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. A new 
peak at 1681 cm
-1
 was observed which was assigned to νC=O in the pre-lithiation 
complex. A new peak at 1646 cm
-1
 was observed which was assigned to νC=O in the 
lithiated intermediate. The solution was stirred at –78 °C for 75 min. Complete lithiation 
of N-Boc-pyrrolidine 12 to give the lithiated intermediate had occurred. Then, 
benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) was added dropwise. A new peak at 
1668 cm
-1
 was observed which was assigned to νC=O in the substituted N-Boc 
pyrrolidines (R,R)-31 and (R,S)-32. The solution was stirred at –78 °C for 10 min. 
Complete trapping of lithiated intermediate to give substituted N-Boc pyrrolidines 
(R,R)-31 and (R,S)-32 was observed within 1 min. Then, saturated NH4Cl(aq) (10 mL) 
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was added at –78 °C. After warming to rt, the two layers were separated. The aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 98:2 CH2Cl2-acetone as 
eluent gave N-Boc pyrrolidine (R,R)-31 (181 mg, 66%, 97:3 er by CSP-HPLC) as a 
colourless oil, [α]D –0.3 (c 1.0 in CHCl3) (lit.,
67
 [α]D –1.9 (c 1.0 in CHCl3) for (R,R)-31 
of 95:5 er); CSP-HPLC: Chiralcel OD (98:2 hexane:i-PrOH, 0.5 mL min
-1
) (R,R)-31 
23.9 min, (S,S)-32 30.4 min and (R,S)-32 (58 mg, 21%, 92:8 er by CSP-HPLC) as a 
colourless oil, [α]D +85.8 (c 1.0 in CHCl3) (lit.,
67
 [α]D +95.3 (c 1.0 in CHCl3) for (R,S)-
32 of 97:3 er); CSP-HPLC: Chiralcel OD (99:1 hexane:i-PrOH, 0.5 mL min
-1
) (R,S)-32 
40.6 min, (S,R)-32 46.6 min. The total yield of (R,R)-31 and (R,S)-32 was 87%. 
Lab Book Reference: JDF6_589 
 
(S)-tert-Butyl 4-benzyl-2-(hydroxydiphenylmethyl)piperazine-1-carboxylate (R)-
182 and (R)-7-benzyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 
(S)-183 
 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 
mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the stability 
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of readout on ReactIR
™
). A peak at 1702 cm
-1
 was observed and assigned to νC=O of N-
Boc-N′-benzyl piperazine 117. Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. A new peak at 1680 cm
-1
 was observed which 
was assigned to νC=O in the pre-lithiation complex. A new peak at 1644 cm
-1
 was 
observed which was assigned to νC=O in the lithiated intermediate. The solution was 
stirred at –78 °C for 8 min. Complete lithiation of N-Boc-N′-benzyl piperazine 117 to 
give the lithiated intermediate had occurred. Then, a solution of benzophenone (364 mg, 
2.0 mmol, 2.0 eq.) in Et2O (1 mL) was added dropwise. A new peaks at 1664 cm
-1
 was 
observed which was assigned to νC=O in the substituted N-Boc-N′-benzyl piperazine (S)-
182 and oxazolidinone (R)-183. The solution was stirred at –78 °C for 15 min. 
Complete trapping of lithiated intermediate to give substituted N-Boc-N′-benzyl 
piperazine (R)-182 and oxazolidinone (R)-183 was observed within 1 min. Then, 
saturated NH4Cl(aq) (10 mL) was added at –78 °C. After warming to rt, saturated 
NaHCO3(aq) (10 mL) was added and the two layers were separated. The aqueous layer 
was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 9:1-7:3 petrol-EtOAc as 
eluent gave N-Boc piperazine (R)-182 (176 mg, 38%) as a colourless oil, and 
oxazolidinone (R)-183 (52 mg, 14%, 81:19 er by CSP-HPLC) as a white solid; CSP-
HPLC: Chiralcel OD (90:10 hexane:i-PrOH, 1.0 mL min
-1
) (S)-183 12.3 min, (R)-183 
16.3 min. 
 Lab Book Reference: JDF6_585 
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6.4 Experimental for Chapter Three 
tert-Butyl 4-benzyl-2-(trimethylsilyl)piperazine-1-carboxylate 175 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and Me3SiCl (217 mg, 254 µL, 2.0 mmol, 2.0 eq.) worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 9:1 petrol-EtOAc as eluent gave N-Boc piperazine 175 (236 mg, 68%) as 
a colourless oil. 
Lab Book Reference: JDF3_211 
 
tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate 176 
 
Using general procedure A, s-BuLi (3.0 mL of a 1.3 M solution in hexanes, 3.9 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (829 mg, 3.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and methyl iodide (852 mg, 374 µL, 6.0 mmol, 2.0 eq.) worked up with 20% 
NaOH(aq) (20 mL) gave the crude product. Purification by flash column chromatography 
on silica with 9:1 petrol-EtOAc as eluent gave N-Boc piperazine 176 (645 mg, 74%) as 
a colourless oil. 
 Lab Book Reference: JDF3_205 
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Using general procedure A, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (415 mg, 1.5 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h, and dimethyl sulfate (378 mg, 284 µL, 3.0 mmol, 2.0 eq.) worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 9:1 petrol-EtOAc as eluent gave N-Boc piperazine 176 (300 mg, 69%) as 
a colourless oil.  
Lab Book Reference: JDF1_36 
 
tert-Butyl 4-benzyl-2-(tributylstannyl)piperazine-1-carboxylate 181 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and Bu3SnCl (650 mg, 542 µL, 2.0 mmol, 2.0 eq.) worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 19:1 petrol-EtOAc as eluent gave N-Boc piperazine 181 
(387 mg, 68%) as a colourless oil. 
Lab Book Reference: JDF5_445 
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7-Benzyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 183 
 
Using general procedure A, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (415 mg, 1.5 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and a solution of benzophenone (547 mg, 3.0 mmol, 2.0 eq.) in THF (1 mL), 
worked up with 20% NaOH(aq) (10 mL) gave the crude product. Purification by flash 
column chromatography on silica with 4:1-7:3 petrol-EtOAc as eluent gave 
oxazolidinone 183 (520 mg, 90%) as a white solid.  
Lab Book Reference: JDF1_13 
 
1-tert-Butyl 2-methyl 4-benzylpiperazine-1,2-dicarboxylate 208  
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and methyl chloroformate (190 mg, 155 µL, 2.0 mmol, 2.0 eq.) worked up 
saturated NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 9:1-7:3 petrol-EtOAc as eluent gave N-Boc piperazine 
208 (200 mg, 60%) as a colourless oil, RF (7:3 petrol-EtOAc) 0.7; IR (CHCl3) 2979, 
1744 (C=O, CO2Me), 1691 (C=O, Boc), 1408, 1366, 1301, 1169, 1119, 1046, 976, 867 
cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) δ 7.32-7.24 (m, 5H, Ph), 
4.71 (br s, 0.55H, NCH), 4.54 (br s, 0.45H, NCH), 3.85 (br d, J = 13.0 Hz, 0.55H, 
NCH), 3.77-3.75 (m, 0.45H, NCH), 3.73 (s, 1.35H, OMe), 3.71 (s, 1.65H, OMe), 3.58 
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(d, J = 13.0 Hz, 0.45H, CHAHBPh), 3.58 (d, J = 13.0 Hz, 0.55H, CHAHBPh), 3.45 (d, J = 
13.0 Hz, 0.55H, CHAHBPh), 3.41 (d, J = 13.0 Hz, 0.45H, CHAHBPh),  3.34-3.27 (m, 
1.55H, NCH), 3.18 (td, J = 13.0,  3.0 Hz, 0.45H, NCH), 2.79 (br d, J = 11.0 Hz, 0.45H, 
NCH), 2.74 (d, J = 11.0 Hz, 0.55H, NCH), 2.18 (td, J = 11.0, 4.0 Hz, 1H, NCH), 2.11 
(br d, J = 11.0 Hz, 0.55H, NCH), 2.11 (br d, J = 11.0 Hz, 0.45H, NCH), 1.47 (s, 4.9H, 
CMe3), 1.42 (s, 4.1H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
171.3 (CO2Me), 171.1 (CO2Me), 155.8 (NC=O), 155.3 (NC=O), 137.6 (ipso-Ph), 128.7 
(Ph), 128.1 (Ph), 127.2 (Ph), 80.2 (CMe3), 62.3 (NCH2), 55.5 (NCH), 54.3 (NCH), 53.5 
(NCH2), 52.4 (NCH2), 52.3 (NCH2), 51.9 (OMe), 42.0 (NCH2), 41.0 (NCH2), 28.3 
(CMe3); MS (ESI) m/z 335 (M + H)
+
; HRMS  m/z calcd for C18H26N2O4 (M + H)
+
 
335.1965, found 335.1974 (–2.7 ppm error). Spectroscopic data consistent with those 
reported in the literature.
59
  
Lab Book Reference: JDF2_117 
 
tert-Butyl 4-benzyl-2-(dimethyl(phenyl)silyl)piperazine-1-carboxylate 242 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and PhMe2SiCl (341 mg, 335 µL, 2.0 mmol, 2.0 eq.) worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 9:1 petrol-EtOAc as eluent gave N-Boc piperazine 242 (190 mg, 46%) as 
a colourless oil, RF (9:1 petrol-EtOAc) 0.3; IR (CHCl3) 3019, 2400, 1679 (C=O), 1421, 
1366, 1294, 1215, 759, 669 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.53-7.44 (m, 2H, Ph), 7.35-7.28 (m, 8H, Ph), 4.05 (br d, J = 12.0 Hz, 0.6H, 
NCH), 3.87 (br s, 0.4H, NCH), 3.76 (br s, 1H, NCH), 3.40 (d, J = 13.0 Hz, 1H, 
CHAHBPh),  3.36 (d, J = 13.0 Hz, 1H, CHAHBPh), 3.00-3.90 (m, 1H, NCH), 2.79-2.72 
(m, 1.6H, NCH), 2.62 (br s, 0.4H, NCH), 2.25-2.16 (m, 1H, NCH), 1.92 (td, J = 11.5, 
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3.5 Hz, 1H, NCH), 1.42 (s, 9H, CMe3), 0.48 (s, 3H, SiMe), 0.37 (br s, 3H, SiMe); 
13
C 
NMR (100.6 MHz, CDCl3) δ 154.5 (C=O), 138.2 (ipso-Ph), 138.0 (ipso-Ph), 133.9 (Ph), 
129.3 (Ph), 129.0 (Ph), 128.1 (Ph), 127.7 (Ph), 127.1 (Ph), 79.3 (CMe3), 66.4 (NCH2), 
54.2 (NCH2), 53.1 (NCH2), 46.1 (NCH), 41.4 (NCH2), 28.3 (CMe3), 1.6 (SiMe), 2.8 
(SiMe); MS (ESI) m/z 411 (M + H)
+
; HRMS  m/z calcd for C24H34N2O2Si (M + H)
+
 
411.2462, found 411.2472 (–0.4 ppm error). 
Lab Book Reference: JDF3_252 
tert-Butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate 243 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (6 mL) 
for 1 h and a suspension of paraformaldehyde (60 mg, 2.0 mmol, 2.0 eq.) in THF (1 
mL) worked up with saturated NaHCO3(aq) (10 mL) gave the crude product. Purification 
by flash column chromatography on silica with 7:3-1:1 petrol-EtOAc as eluent gave N-
Boc piperazine 243 (197 mg, 64%) as a colourless oil, RF (1:1 petrol-EtOAc) 0.2; IR 
(CHCl3) 3280 (OH), 2971, 2913, 2781 1658 (C=O), 1433, 1390, 1345, 1302, 1197, 
1152, 1103, 1060, 1035, 997, 743 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.36-7.24 (m, 
5H, Ph), 4.07 (br s, 1H, NCH), 3.96-3.81 (m, 3H, CH2O + NCH), 3.51 (d, J = 13.0 Hz, 
1H, CHAHBPh), 3.47 (d, J = 13.0 Hz, 1H CHAHBPh), 3.40 (br s, 1H, NCH), 2.98 (dt, J = 
11.5, 2.0 Hz, 1H, NCH), 2.83 (br d, J = 10.0 Hz, 1H, NCH), 2.31 (ddd, J = 11.5, 4.0, 1.0 
Hz, 1H, NCH), 2.09 (ddd, J = 12.5, 11.5, 4.0 Hz, 1H, NCH), 1.45 (CMe3), OH not 
resolved; 
13
C NMR (100.6 MHz, CDCl3) δ 155.1 (C=O), 137.0 (ipso-Ph), 129.0 (Ph), 
128.5 (Ph), 127.5 (Ph), 80.0 (CMe3), 66.7 (CH2OH), 63.0 (CH2Ph), 55.1 (NCH2), 52.5 
(NCH2), 51.1 (NCH), 41.4 (NCH2), 28.4 (CMe3); MS (ESI) m/z 307 (M + H)
+
; HRMS 
m/z calcd for C17H26N2O3 (M + H)
+
 307.2016, found 307.2023 (–2.2 ppm error). 
Spectroscopic data consistent with those reported in the literature.
273
  
Lab Book Reference: JDF5_481 
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7'-Benzyltetrahydrospiro[cyclohexane-1,1'-oxazolo[3,4-a]pyrazin]-3'(5'H)-one 244  
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
for 1 h and cyclohexanone (196 mg, 207 µL 2.0 mmol, 2.0 eq.) worked up with 
saturated NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 1:1 petrol-EtOAc as eluent gave oxazolidinone 244 (131 
mg, 44%) as a white solid, mp 64-66 °C; RF (1:1 petrol-EtOAc) 0.1; IR (CHCl3) 2896, 
1710 (C=O), 1428, 1331, 1286, 1074, 1025, 961, 890, 745 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.35-7.25 (m, 5H, Ph), 3.76 (dd, J = 13.0, 3.5 Hz, 1H, NCH), 3.61-3.49 (m, 
2H, CH2Ph), 3.39 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.05 (td, J = 12.5, 3.5 Hz, 1H, 
NCH), 2.77-2.73 (m, 2H, NCH), 2.05-1.97 (m, 2H, NCH), 1.89-1.20 (m, 10H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 156.4 (C=O), 137.3 (ipso-Ph), 128.8 (Ph), 128.3 (Ph), 
127.3 (Ph), 80.7 (CO), 63.0 (NCH2), 61.7 (NCH), 52.8 (NCH2), 51.7 (NCH2), 41.0 
(NCH2), 36.7 (CH2), 30.7 (CH2), 28.3 (CH2), 25.0 (CH2), 21.9 (CH2); MS (ESI) m/z 301 
(M + H)
+
; HRMS m/z calcd for C18H25N2O2 (M + H)
+
 301.1905, found 301.1911 (+1.6 
ppm error). 
Lab Book Reference: JDF4_482 
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1-tert-Butyl 2-methyl 4-tert-butylpiperazine-1,2-dicarboxylate 245 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-t-butyl piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.), TMEDA (232 
mg, 195 µL, 1.3 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and methyl chloroformate (189 
mg, 155 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 7:3 petrol-EtOAc 
as eluent gave N-Boc piperazine 245 (135 mg, 45%) as a colourless oil, RF (7:3 petrol-
EtOAc) 0.4; IR (CHCl3) 2976, 1745 (C=O, CO2Me), 1689 (C=O, Boc), 1455, 1393, 
1367, 1304, 1253, 1170, 1119, 1041, 965, 865, 761 cm
–1
;  
1
H NMR (400 MHz, CDCl3) 
(50:50 mixture of rotamers) δ 4.70 (br s, 0.5H, NCH), 4.53 (br s, 0.5H, NCH), 3.83 (br 
d, J = 12.5 Hz, 0.5H, NCH), 3.75-3.73 (m, 0.5H, NCH), 3.73 (s, 1.5H, OMe), 3.72 (s, 
1.5H, OMe), 3.52-3.45 (m, 1H, NCH), 3.13 (td, J = 12.5, 3.5 Hz, 0.5H, NCH), 3.03 (td, 
J = 12.5, 3.5 Hz, 0.5H, NCH), 2.92 (br d, J = 11.0 Hz, 0.5H, NCH), 2.84 (br d, J = 11.0 
Hz, 0.5H, NCH), 2.28-2.23 (m, 1H, NCH), 2.11 (td, J = 11.0, 3.5 Hz, 1H, NCH), 1.46 
(s, 4.5H, OCMe3), 1.42 (s, 4.5H, OCMe3), 0.96 (s, 9H, NCMe3); 
13
C NMR (100.6 MHz, 
CDCl3) (mixture of rotamers) δ 171.6 (CO2Me), 171.3 (CO2Me), 155.8 (NC=O), 155.4 
(NC=O), 80.0 (OCMe3), 56.3 (NCH), 55.0 (NCH), 53.3 (NCMe3), 51.9 (OMe), 47.6 
(NCH2), 45.2 (NCH2), 42.9 (NCH2), 42.0 (NCH2), 28.3 (CMe3), 25.8 (CMe3); MS (ESI) 
m/z 301 (M + H)
+
; HRMS  m/z calcd for C15H28N2O4 (M + H)
+
 301.2122, found 
301.2122 (+0.3 ppm error). 
Lab Book Reference: JDF2_123 
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7-tert-Butyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 246 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-t-butyl piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.), TMEDA (232 
mg, 195 µL, 1.3 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and a solution of benzophenone 
(364 mg, 2.0 mmol, 2.0 eq.) in THF (1 mL) worked up with 20% NaOH(aq) (10 mL) 
gave the crude product. Purification by flash column chromatography on silica with 
99:1-98:2 CH2Cl2-MeOH as eluent gave oxazolidinone 246 (200 mg, 57%) as a white 
solid, mp 193-195 °C; RF (99:1 CH2Cl2-MeOH) 0.2; IR (CHCl3) 2975, 1750 (C=O), 
1449, 1363, 1302, 1255, 1203, 1036, 984 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.53-
7.50 (m, 2H, Ph), 7.39-7.24 (m, 8H, Ph), 4.43 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.85 
(ddd, J = 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.08 (ddd, J = 13.0, 12.0, 3.5 Hz, 1H, NCH), 
2.92-2.88 (m, 1H, NCH), 2.62 (ddd, J = 12.0, 3.5, 1.0 Hz, 1H, NCH), 2.06 (td, J = 12.0, 
3.5 Hz, 1H, NCH), 1.51 (t, J = 11.0 Hz, 1H, NCH), 0.93 (s, 9H, CMe3); 
13
C NMR 
(100.6 MHz, CDCl3) δ 156.1 (C=O), 142.4 (ipso-Ph), 138.8 (ipso-Ph), 128.5 (Ph), 128.4 
(Ph), 128.2 (Ph), 127.8 (Ph), 126.0 (Ph), 125.7 (Ph), 85.4 (Ph2CO), 61.9 (NCH), 54.3 
(CMe3), 48.8 (NCH2), 44.8 (NCH2), 42.6 (NCH2), 26.0 (CMe3); MS (ESI) m/z 351 (M + 
H)
+
; HRMS  m/z calcd for C23H26N2O2 (M + H)
+
 351.2067, found 351.2062 (+0.7 ppm 
error). 
Lab Book Reference: JDF4_327  
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4-Tritylpiperazine-1-carboxylic acid tert-butyl ester 203 
 
Triphenylmethyl chloride (2.06 g, 7.4 mmol 1.1 eq.) was added to a stirred solution of 
Et3N (748 mg, 1.03 mL, 7.4 mmol, 1.1 eq.) and N-Boc piperazine 257 (1.25 g, 6.7 
mmol, 1.0 eq.) in CHCl3 (40 mL) at rt under Ar. The resulting mixture was stirred at rt 
for 16 h. Then, saturated NaHCO3(aq) (50 mL) was added and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic 
layers were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 9:1 petrol-
Et2O as eluent gave N-Boc-N′-trityl piperazine 203 (2.29 g, 80%) as a white solid, mp 
137-140 °C, RF (9:1 petrol-Et2O) 0.2; IR (CHCl3) 1693 (C=O), 1410, 1364, 1169, 1115, 
1003 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.46 (br s, 6H, Ph), 7.37-7.21 (m, 6H, Ph), 
7.15 (t, J = 7.5 Hz, 3H, p-Ph), 3.54 (br s, 4H, NCH2), 2.25 (br s, 4H, NCH), 1.38 (s, 9H, 
CMe3); 
13
C NMR (400 MHz, CDCl3) δ 154.9 (C=O), 146.9 (ipso-Ph), 127.9 (Ph), 127.6 
(Ph), 126.1 (Ph), 79.4 (CMe3), 76.9 (CPh3), 47.8 (NCH2), 44.4 (NCH2), 28.3 (CMe3); 
MS (ESI) m/z 451 (M + na)
+
; HRMS (ESI) m/z calcd for C28H32N2O2 (M + Na)
+
 
451.2355, found 451.2356.  
Lab Book Reference: JDF5_433  
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1-tert-Butyl 2-methyl 4-tritylpiperazine-1,2-dicarboxylate 247 and 1-tert-Butyl 2,2-
dimethyl 4-tritylpiperazine-1,2,2-tricarboxylate 248 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 
97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl chloroformate (95 mg, 77 
µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-Et2O as 
eluent gave N-Boc piperazine 247 (86 mg, 35%) as a white solid, mp 189-192 °C; RF 
(4:1 petrol-Et2O) 0.3; IR (CHCl3) 3020, 2399, 1746 (C=O, CO2Me), 1688 (C=O, Boc), 
1410, 1215, 1120, 1010, 762, 669 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.42 (br s, 6H, Ph), 7.29-7.20 (m, 6H, Ph), 7.17 (br s, 3H, Ph), 4.61 (br s, 
0.6H, NCH), 4.46 (br s, 0.4H, NCH), 3.92 (s, 3H, OMe), 3.82 (d, J = 12.0 Hz, 0.4H, 
NCH), 3.74-3.62 (m, 1.6H, NCH), 3.59-3.44 (m, 2H, NCH), 3.09 (d, J = 11.0 Hz, 0.4H, 
NCH), 3.02 (d, J = 11.0 Hz, 0.6H, NCH), 1.88-1.80 (m, 1H, NCH), 1.43 (s, 5.4H, 
CMe3), 1.39 (s, 3.6H, CMe3); 
13
C NMR (400 MHz, CDCl3) (mixture of rotamers) δ 
171.9 (CO2Me), 155.8 (NC=O), 155.2 (NC=O), 137.9 (ipso-Ph), 129.2 (Ph), 127.5 (Ph), 
126.3 (Ph), 80.2 (CMe3), 76.9 (CPh3),  55.4 (NCH or OMe), 54.2 (NCH or OMe), 51.9 
(NCH or OMe), 48.9 (NCH2), 47.8 (NCH2), 44.2 (NCH2), 42.5 (NCH2), 41.5 (NCH2), 
28.3 (CMe3); MS (ESI) m/z 509 (M + Na)
+
; MS (ESI) m/z 509 (M + Na)
+
; HRMS  m/z 
calcd for C30H33N2O4Na (M + Na)
+
 509.2411, found 509.2417 (–0.9 ppm error) and N-
Boc piperazine 248 (80 mg, 29%) as a white solid, mp 83-86 °C; RF (4:1 petrol-Et2O) 
0.2; IR (CHCl3) 2971, 1743 (C=O, CO2Me) 1660 (C=O, Boc), 1465, 1425, 1380, 1346, 
1262, 1200, 1150, 1102, 1065, 1008, 920, 756 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.49 
(br s, 6H, Ph), 7.32-7.20 (m, 6H, Ph), 7.22-7.10 (m, 3H, Ph), 4.02 (br s, 1H, NCH), 3.88 
(s, 3H, CO2Me), 3.80 (br s, 1H, NCH), 3.68 (s, 3H, CO2Me), 3.25 (br s, 1H, NCH), 3.01 
(br s, 1H, NCH), 1.82-1.50 (m, 2H, NCH), 1.36 (s, 9H, CMe3); 
13
C NMR (400 MHz, 
CDCl3) (mixture of rotamers) δ 153.2 (br, NC=O), 152.6 (br, NC=O), 146.5 (ipso-Ph), 
142.0 (br, ipso-Ph), 129.4 (Ph), 127.6 (Ph), 126.2 (Ph), 80.2 (CMe3), 77.1 (CPh3), 58.1 
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(CO2Me), 55.5 (CO2Me), 48.1 (NCH2), 46.6 (NCH2), 44.7 (NCH2), 28.1 (CMe3), 28.0 
(CMe3) (CO2Me and CCO2Me not resolved); MS (ESI) m/z 567 (M + Na)
+
; HRMS m/z 
calcd for C32H36N2O6 (M + Na)
+
 567.2466, found 567.2460 (+0.6 ppm error). 
Lab Book Reference: JDF5_496 
 
tert-Butyl 2-(hydroxydiphenylmethyl)-4-tritylpiperazine-1-carboxylate 250 and 
1,1-Diphenyl-7-trityltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 249 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 
97 µL, 0.65 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and , a solution of benzophenone 
(182 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 9:1-6:4 petrol-Et2O as eluent gave N-Boc piperazine 250 (35 mg, 11%) as a white 
solid, mp 105-108 °C; RF (8:2 petrol-Et2O) 0.2;
 
IR (CHCl3) 2963, 1654 (C=O), 1468, 
1425, 1396, 1345, 1328, 1286, 1266, 1218, 1150, 1099, 967, 892, 757 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) (55:45 mixture of rotamers) δ 8.26 (s, 0.55H, OH), 8.03 (s, 0.45H, 
OH), 7.74-7.69 (m, 1H, Ph), 7.66-7.56 (m, 2H, Ph), 7.54-7.06 (m, 19H, Ph), 6.91-6.68 
(m, 3H, Ph), 5.23 (d, J = 3.0 Hz, 1H, NCH), 4.93 (d, J = 3.0 Hz, 1H, NCH), 4.26-4.06 
(m, 1.45H, NCH), 3.79 (d, J = 12.0 Hz, 0.55H, NCH), 3.68 (d, J = 12.0 Hz, 1H, NCH), 
3.11 (d, J = 12.0 Hz, 0.45H, NCH), 3.05 (d, J = 12.0 Hz, 0.55H, NCH), 2.27 (dd, J = 
12.0, 4.0 Hz, 0.55H, NCH), 2.14 (dd, J = 12.0, 4.0 Hz, 0.45H, NCH), 1.25-1.21 (m, 1H, 
NCH), 1.08 (s, 5H, CMe3), 1.06 (s, 4H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture 
of rotamers) δ 154.0 (C=O), 153.8 (C=O), 146.7 (ipso-Ph), 146.6 (ipso-Ph), 145.3 (ipso-
Ph), 145.0 (ipso-Ph), 144.5 (ipso-Ph), 143.4 (ipso-Ph), 128.5 (Ph), 128.4 (Ph), 128.4 
(Ph), 127.9 (Ph), 127.8 (Ph), 127.7  (Ph), 127.5 (Ph), 127.2 (Ph), 127.0 (Ph), 126.8 (Ph), 
126.7 (Ph), 126.5 (Ph), 126.5 (Ph), 126.4 (Ph), 126.3 (Ph), 126.1 (Ph), 84.0 (COH), 79.7 
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(CMe3 or CPh3), 79.6 (CMe3 or CPh3), 78.7 (CMe3 or CPh3), 55.0 (NCH), 53.3 (NCH), 
49.8 (NCH2), 49.4 (NCH2), 49.1 (NCH2), 41.8 (NCH2), 40.5 (NCH2), 28.0 (CMe3), 27.8 
(CMe3); MS (ESI) m/z 611 (M + H)
+
; HRMS m/z calcd for C41H42N2O3 (M + H)
+
 
611.3268, found 611.3284 (–3.1 ppm error) and oxazolidinone 249 (132 mg, 50%) as a 
white solid, mp 238-241 °C (decomposed); RF (8:2 petrol-Et2O) 0.1; IR (CHCl3) 2964, 
1743 (C=O), 1467, 1426, 1398, 1341, 1280, 1214, 1164, 1107, 1017, 973, 929, 889, 
747, 700, 690 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.53-7.48 (m, 2H, Ph), 7.44-7.28 (m, 
9H, Ph), 7.25-7.20 (m, 6H, Ph), 7.18-7.12 (m, 6H, Ph), 7.05-702 (m, 2H, Ph), 4.74 (dd, 
J = 11.0, 3.5 Hz, 1H, NCH), 3.86-3.75 (m, 1H, NCH), 3.38 (td, J = 12.0, 3.5 Hz, 1H, 
NCH), 3.10-3.01 (m, 1H, NCH), 2.88-2.81 (m, 1H, NCH), 1.38 (td, J = 12.0, 3.5 Hz, 
1H, NCH), 0.82-0.74 (m, 1H, NCH); NMR (100.6 MHz, CDCl3) δ 156.1 (C=O), 142.2 
(ipso-Ph), 138.6 (ipso-Ph), 128.8 (Ph), 128.5 (Ph), 128.4 (Ph), 127.9 (Ph), 127.7 (Ph), 
127.7 (Ph), 126.4 (Ph), 126.0 (Ph), 125.6 (Ph), 85.3 (Ph2CO), 77.2 (CPh3), 62.0 (NCH), 
52.0 (NCH2), 47.0 (NCH2), 42.0 (NCH2); MS (ESI) m/z 559 (M + Na)
+
; HRMS m/z 
calcd for C37H32N2O2 (M + Na)
+
 559.2356, found 559.2376 (–3.6 ppm error). 
Lab Book Reference: JDF5_497 
 
tert-Butyl 2-(tributylstannyl)-4-tritylpiperazine-1-carboxylate 251 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 
97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and Bu3SnCl (325 mg, 271 µL, 1.0 
mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude product. 
Purification by flash column chromatography on silica with 98:2 petrol-Et2O as eluent 
gave N-Boc piperazine 251 (308 mg, 86%) as a pale yellow oil, RF (19:1 petrol-EtOAc) 
0.4; IR (CHCl3) 2911, 2879, 1646 (C=O), 1465, 1428, 1402, 1344, 1277, 1232, 1196, 
1134, 1092, 987, 744, 698 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (75:25 mixture of 
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rotamers) δ 7.46 (br s, 6H, Ph), 7.32-7.20 (m, 6H, Ph), 7.20-7.06 (m, 3H, Ph), 4.06 (s, 
0.25H, NCH), 3.82 (s, 0.75H, NCH), 3.50-2.46 (m, 4H, NCH), 2.09-1.48 (m, 2H, 
NCH), 1.49-1.29 (m, 15H, CH2 + CMe3), 1.29-1.14 (m, 6H, CH2), 0.95-0.61 (m, 15H, 
CH2 + Me); 
13
C NMR (100.6 MHz, CDCl3) δ 155.6 (C=O), 142.8 (ipso-Ph), 129.3 (Ph), 
127.4 (Ph), 126.0 (Ph), 79.3 (CMe3), 77.1 (CPh3), 52.4 (NCH2), 48.5 (NCH2), 46.6 
(NCH2), 45.4 (NCH), 29.2 (CH2), 28.2 (CMe3), 27.6 (CH2), 13.7 (Me), 11.9 (CH2); MS 
(ESI) m/z 719 (M + H)
+
; HRMS m/z calcd for C40H58N2O2Sn (M + H)
+
 719.3601, found 
719.3605 (–0.6 ppm error). 
Lab Book Reference: JDF5_499 
 
7'-Trityltetrahydrospiro[cyclohexane-1,1'-oxazolo[3,4-a]pyrazin]-3'(5'H)-one 252 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 
97 µL, 0.65 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and cyclohexanone (98 mg, 104 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 8:2-4:6 petrol-Et2O 
as eluent gave N-Boc piperazine 252 (84 mg, 37%) as a white solid, mp 74-76 °C; RF 
(8:2 petrol-EtOAc) 0.2; IR (CHCl3) 2973, 1709 (C=O), 1466, 1426, 1341, 1288, 1262, 
1197, 1053, 1018, 992, 967, 914, 895, 748 cm
–1
; NMR (400 MHz, CDCl3) δ 7.44 (br s, 
6H, Ph), 7.30-7.26 (m, 6H, Ph), 7.20-7.16 (m, 3H, Ph), 3.77-3.73 (m, 1H, NCH), 3.69 
(dd, J = 11.0, 3.0 Hz, 1H, NCH), 3.31 (td, J = 12.5, 3.5 Hz, 1H, NCH), 3.07-3.04 (m, 
2H, NCH), 1.94-1.91 (m, 1H, NCH), 1.75-1.71 (m, 1H, NCH), 1.62-1.31 (m, 10H, 
CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 156.5 (C=O), 129.0 (Ph), 127.8 (Ph), 126.4 
(Ph), 80.8 (CO), 77.4 (CPh3), 62.6 (NCH), 48.8 (NCH2), 47.6 (NCH2), 41.7 (NCH2), 
36.9 (CH2), 30.6 (CH2), 25.0 (CH2), 22.0 (CH2), 21.9 (CH2) (ipso-Ph not resolved); MS 
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(ESI) m/z 453 (M + H)
+
; HRMS m/z calcd for C30H32N2O2 (M + H)
+
 453.2537, found 
453.2536 (–0.4 ppm error). 
Lab Book Reference: JDF6_509 
 
tert-Butyl 4-(9-phenyl-9H-fluoren-9-yl)piperazine-1-carboxylate 240 
 
A mixture of 9-bromo-9-phenyl fluorene (3.21 g, 10 mmol, 1.0 eq.), piperazine 253 
(4.31 g, 50 mmol, 5.0 eq.), Pb(NO3)2 (3.97 g, 12 mmol, 1.2 eq.) and K3PO4 (3.18 g, 15 
mmol, 1.5 eq.) in MeCN (40 mL) was stirred at rt under Ar for 48 h. The solids were 
removed by filtration through Celite
®
 and washed with MeCN (50 mL), EtOAc (100 
mL) and CH2Cl2 (100 mL). The filtrate was evaporated under reduced pressure. Then, 
CH2Cl2 (50 mL) and water (50 mL) were added and the two layers were separated. The 
aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
N-fluorophenyl piperazine 254 (2.70 g, 83%) as a beige solid, 
1
H NMR (400 MHz, 
CDCl3) δ 7.70-7.67 (m, 2H, Ar), 7.51 (br s, 2H, Ar), 7.41-7.32 (m, 5H, Ar), 7.27-7.22 
(m, 4H, Ar), 2.84 (t, J = 5.0 Hz, 4H, NCH2), 2.42 (br s, 4H, NCH2), 1.72 (br s, 1H, NH). 
The crude product was used in the next step without further purification (≥95% purity 
by 
1
H NMR spectroscopy). 
Lab Book Reference: JDF6_528 
 
A solution of di-tert-butyl dicarbonate (2.17 g, 9.93 mmol, 1.2 eq.) in CH2Cl2 (20 mL) 
was added dropwise to a stirred solution of crude N-fluorophenyl piperazine 254 (2.0 g, 
8.27 mmol, 1.0 eq.) in CH2Cl2 (80 mL) at 0 °C under Ar. The resulting solution was 
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allowed to warm to rt and stirred for at rt for 16 h. Then, water (100 mL) was added and 
the two layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 19:1 as eluent gave N-Boc piperazine 240 (3.24 g, 92%) 
as a white solid, mp 198-201 °C; RF (9:1 petrol-EtOAc) 0.2; IR (CHCl3) 3008, 1681 
(C=O), 1451, 1429, 1429, 1366, 1287, 1253, 1169, 1129, 1000, 756 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) δ 7.69-7.67 (m, 2H, Ar), 7.49 (br s, 2H, Ar), 7.39-7.34 (m, 4H, Ar), 
7.28-7.23 (m, 5H, Ar), 3.39 (br s, 4H, NCH2), 2.40 (br s, 4H, NCH2), 1.39 (s, 9H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 (C=O), 146.6 (ipso-Ar), 142.6 (ipso-
Ar), 140.6 (ipso-Ar), 128.4 (Ar), 128.2 (Ar), 127.4 (Ar), 127.3 (Ar), 127.0 (Ar), 126.1 
(Ar), 119.9 (Ar), 79.3 (CMe3 or NCPh), 77.9 (CMe3 or NCPh), 47.3 (NCH2), 28.4 
(CMe3) (one NCH2 resonance not resolved); MS (ESI) m/z 427 (M + H)
+
; HRMS  m/z 
calcd for C28H30N2O2 (M + H)
+
 427.2380, found 427.2391 (–1.7 ppm error). 
Lab Book Reference: JDF6_529 
 
1-tert-Butyl 2-methyl 4-(9-phenyl-9H-fluoren-9-yl)piperazine-1,2-dicarboxylate 255 
and 1-tert-Butyl 2,2-dimethyl 4-(9-phenyl-9H-fluoren-9-yl)piperazine-1,2,2-
tricarboxylate 256 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 240 (213 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 mg, 97 µL, 
0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl chloroformate (95 mg, 77 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 8:2-1:1 petrol-Et2O 
as eluent gave N-Boc piperazine 255 (86 mg, 36%) as a white solid mp, 165-167 °C; RF 
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(7:3 petrol-Et2O) 0.2; IR (CHCl3) 3018, 2980, 1745 (C=O, CO2Me), 1691 (C=O, Boc), 
1451, 1408, 1367, 1304, 1216, 1170, 1119, 746, 668 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 7.72-7.67 (m, 2H, Ar), 7.40-7.35 (m, 4H, Ar), 7.30-7.22 
(m, 7H, Ar), 4.56 (br s, 0.6H, NCH), 4.39 (br s, 0.4H, NCH), 3.83-3.78 (m, 0.4H, 
NCH), 3.80 (s, 3H, OMe), 3.70 (br d, J = 12.5 Hz, 0.6H, NCH), 3.41 (td, J = 12.5, 3.5 
Hz, 0.6H, NCH), 3.30 (td, J = 12.5, 3.5 Hz, 0.4H, NCH), 3.15 (br d, J = 11.5 Hz, 0.6H, 
NCH), 3.07 (br d, J = 11.5 Hz, 0.4H, NCH), 2.94 (br d, J = 11.0 Hz, 0.4H, NCH), 2.84 
(br d, J = 11.0 Hz, 0.6H, NCH), 2.26-2.16 (m, 2H, NCH), 1.42 (s, 5.4H, CMe3), 1.37 (s, 
3.6H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.4 (CO2Me), 
155.9 (NC=O), 155.3 (NC=O), 156.6 (ipso-Ar), 155.7 (ipso- Ar), 142.3 (ipso- Ar), 
141.1 (ipso- Ar), 140.3 (ipso- Ar), 128.5 (Ar), 128.4 (Ar), 127.6 (Ar), 127.4 (Ar), 127.3 
(Ar), 127.0 (Ar), 126.4 (Ar), 126.2 (Ar), 126.1 (Ar), 126.0 (Ar), 120.2 (Ar), 120.0 (Ar), 
80.1 (CMe3), 77.6 (NCPh), 55.7 (NCH or OMe), 54.6 (NCH or OMe), 51.8 (NCH or 
OMe), 48.6 (NCH2), 47.3 (NCH2), 42.7 (NCH2), 41.7 (NCH2), 28.3 (CMe3), 28.2 
(CMe3);  MS (ESI) m/z 485 (M + H)
+
; HRMS  m/z calcd for C30H32N2O4 (M + H)
+
 
485.2435, found 485.2442 (–1.4 ppm error), and N-Boc piperazine 256 (46 mg, 17%), 
RF (8:2 petrol-Et2O) 0.1; IR (CHCl3) 3014, 2931, 1754, (C=O, CO2Me), 1662 (C=O, 
Boc), 1427, 1380, 1345, 1261, 1150, 1104, 1078, 1012, 974, 922 cm
–1
; 
1
H NMR (400 
MHz, CDCl3) (50:50 mixture of rotamers) δ δ 7.70 (d, J = 7.5 Hz, 2H, Ar), 7.66-7.43 
(m, 2H, Ar), 7.43-7.32 (m, 4H, Ar), 7.32-7.15 (m, 5H, Ar), 3.99 (br s, 0.5H, NCH), 3.85 
(s, 3H, CO2Me), 3.90-3.71 (m, 1.5H, NCH), 3.55 (br s, 3H, CO2Me), 3.05 (br s, 1H, 
NCH), 2.79 (br s, 1H, NCH), 2.36 (br s, 1H, NCH), 2.23 (br s, 1H, NCH), 1.37 (s, 9H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.2 (CO2Me), 171.0 
(CO2Me), 155.8 (NC=O), 155.3 (NC=O), 143.4 (ipso-Ar), 143.2 (ipso-Ar), 128.1 (Ar), 
127.4 (Ar), 127.0 (Ar), 80.1 (CMe3), 77.6 (NCPh), 64.1 (OMe), 55.6 (OMe), 54.4 
(OMe), 53.4 (CCO2Me), 51.7 (NCH2), 51.5 (NCH2), 49.2 (NCH2), 42.2 (NCH2), 41.2 
(NCH2), 28.3 (CMe3), 28.2 (CMe3) (several Ar signals not resolved); MS (ESI) m/z 543 
(M + H)
+
; HRMS m/z calcd for C32H34N2O6 (M + H)
+
 543.2490, found 543.2470 (+3.7 
ppm error), and N-Boc piperazine 240 (92 mg, 43%) as a white solid. 
Lab Book Reference: JDF6_520  
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1-tert-Butyl 2-methyl 4-(9-phenyl-9H-fluoren-9-yl)piperazine-1,2-dicarboxylate 255 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 240 (213 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 mg, 97 µL, 
0.65 mmol, 1.3 eq.) in MTBE (7 mL) for 1 h and methyl chloroformate (95 mg, 77 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 4:1-1:1 petrol-Et2O 
as eluent gave N-Boc piperazine 255 (140 mg, 58%) as a white solid and N-Boc 
piperazine 240 (43 mg, 20%) as a white solid. 
Lab Book Reference: JDF6_521 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 240 (213 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 mg, 97 µL, 
0.65 mmol, 1.3 eq.) in toluene (5 mL) for 1 h and methyl chloroformate (95 mg, 77 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 4:1-1:1 petrol-Et2O 
as eluent gave N-Boc piperazine 255 (186 mg, 77%) as a white solid and N-Boc 
piperazine 240 (49 mg, 23%) as a white solid. 
Lab Book Reference: JDF6_522 
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tert-Butyl 4-(2-phenylpropan-2-yl)piperazine-1-carboxylate 241 
 
Phenyl magnesium chloride (26.6 mL of a 2.0 in THF, 53.3 mmol, 3.0 eq.) was added 
dropwise to a stirred solution of nitrile 258 (4.5 g, 17.8 mmol, 1.0 eq.) in THF (100 mL) 
at 0 °C under Ar. The reaction was allowed to warm to rt and stirred at rt for 16 h. Then, 
the mixture was cooled to 0 °C and water (20 mL) was added dropwise. The mixture 
was diluted with water (200 mL) and extracted with EtOAc (3 x 100 mL). The 
combined organic extracts were washed with brine (200 mL), dried (MgSO4), filtered 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 8:2 Et2O-petrol and then with 98:2-94:6 CH2Cl2-
MeOH as eluent gave N-Boc-N′-cumyl piperazine 241 (4.2 g, 77%) as a colourless 
viscous oil, RF (8:2 petrol-Et2O) 0.2; IR (CHCl3) 2932, 1655 (C=O), 1404, 1370, 1345, 
1283, 1268, 1245, 1228, 1152, 1109, 989, 949, 850, 745, 691 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.55–7.49 (m, 2H, Ph), 7.34–7.27 (m, 2H, Ph), 7.24–7.17 (m, 1H, Ph), 3.36 (t, 
J = 4.5 Hz, 4H, NCH2), 2.41 (br s, 4H, NCH2), 1.44 (s, 9H, CMe3), 1.33 (s, 6H, 
CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 154.8 (C=O), 148.8 (ipso-Ph), 128.0 (Ph), 
126.2 (Ph), 126.0 (Ph), 79.3 (CMe3), 59.7 (CMe2Ph), 46.0 (NCH2), 44.3 (NCH2), 28.4 
(CMe3), 24.0 (CMe2Ph); MS (ESI) m/z 305 (M + H)
+
; HRMS m/z calcd for C18H28N2O2 
(M + H)
+
 305.2224, found 305.2230 (–1.1 ppm error). 
Lab Book Reference: JDF7_623 
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tert-Butyl piperazine-1-carboxylate 257 
 
10% Pd/C (10 mg) was added to a stirred solution of N-Boc-N′-cumyl piperazine 241 
(50 mg, 0.16 mmol, 1.0 eq.) in MeOH (5 mL). Then, the reaction flask evacuated under 
reduced pressure and back filled with Ar three times. After a final evacuation, a balloon 
of H2 was attached and the reaction mixture was stirred vigorously at rt under H2 for 48 
h. The mixture was filtered through Celite
®
 and washed with Et2O (20 mL). The filtrate 
was evaporated under reduced pressure to give N-Boc piperazine 257 (30 mg, 98%) as a 
white solid. 
Lab Book Reference: JDF6_596 
 
1-tert-Butyl 2-methyl 4-(2-phenylpropan-2-yl)piperazine-1,2-dicarboxylate 259 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl chloroformate (95 
mg, 77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 97:3-8:2 
CH2Cl2-Et2O as eluent gave N-Boc piperazine 259 (119 mg, 66%) as a pale yellow oil, 
RF (19:1 CH2Cl2-Et2O) 0.2; IR (CHCl3) 2972, 2933, 1718 (C=O, CO2Me), 1662 (C=O, 
Boc), 1469, 1452, 1391, 1369, 1346, 1331, 1310, 1284, 1195, 1155, 1101, 1016, 951, 
736, 692 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) δ 7.42–7.37 
(m, 2H, Ph), 7.31–7.25 (m, 2H, Ph), 7.23–7.17 (m, 1H, Ph), 4.66 (br s, 0.55H, NCH), 
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4.50 (br s, 0.45H, NCH), 3.80 (d, J = 11.0 Hz, 0.55H, NCH), 3.72 (s, 1.35H, OMe), 
3.70 (s, 1.65H, OMe), 3.72-3.69 (m, 0.45H, NCH), 3.35–3.19 (m, 1.55H, NCH), 3.13 
(td, J = 12.0, 3.0 Hz, 0.45H, NCH), 2.74 (d, J = 10.5 Hz, 0.45H, NCH), 2.67 (d, J = 
10.5 Hz, 0.55H, NCH), 2.37 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 2.18 (td, J = 11.5, 3.5 Hz, 
1H, NCH), 1.46 (s, 5H, CMe3), 1.41 (s, 4H, CMe3), 1.31 (s, 6H, CMe2Ph); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 171.6 (CO2Me), 171.4 (CO2Me), 156.0 
(NC=O), 155.4 (NC=O), 148.4 (ipso-Ph), 148.3 (ipso-Ph), 127.9 (Ph), 126.3 (Ph), 125.9 
(Ph), 80.1 (CMe3), 59.2 (CMe2Ph), 56.0 (NCH), 54.9 (NCH), 51.8 (OMe), 47.8 (NCH2), 
45.7 (NCH2), 42.7 (NCH2), 41.7 (NCH2), 28.3 (CMe3), 28.2 (CMe3), 24.0 (CMe2Ph), 
23.9 (CMe2Ph), 23.7 (CMe2Ph); MS (ESI) m/z 363 (M + H)
+
; HRMS m/z calcd for 
C20H30N2O4 (M + H)
+
 363.2278, found 363.2277 (0.0 ppm error). 
Lab Book Reference: JDF6_600 
 
tert-Butyl 2-methyl-4-(2-phenylpropan-2-yl)piperazine-1-carboxylate 260 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl iodide (142 mg, 62 
µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 8:2 petrol-Et2O as 
eluent gave N-Boc piperazine 260 (152 mg, 95%) as a colourless oil, RF (8:2 petrol-
Et2O) 0.3; IR (CHCl3) 2931, 1652 (C=O), 1427, 1393, 1345, 1300, 1263, 1214, 1152, 
1093, 1005, 691 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.54-7.51 (m, 2H, Ph), 7.33-7.27 
(m, 2H, Ph), 7.23-7.18 (m, 1H, Ph), 4.12 (br s, 1H, NCH), 3.75 (br d, J = 13.0 Hz, 1H, 
NCH), 3.04 (td, J = 12.5, 3.5 Hz, 1H, NCH), 2.76-2.67 (m, 1H, NCH), 2.52 (dt, J = 
11.0, 2.0 Hz, 1H, NCH), 2.31 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 2.14 (td, J = 12.5, 3.5 
Hz, 1H, NCH), 1.44 (s, 9H, CMe3), 1.33 (s, 3H, CMe2Ph), 1.30 (s, 3H, CMe2Ph), 1.22 
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(d, J = 7.0 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 154.9 (C=O), 149.2 (ipso-
Ph), 128.0 (Ph), 126.3 (Ph), 126.2 (Ph), 79.3 (CMe3), 59.4 (CMe2Ph), 50.8 (NCH2), 
47.6 (NCH), 46.5 (NCH2), 39.9 (NCH2), 28.5 (CMe3), 24.3 (CMe2Ph), 23.6 (CMe2Ph), 
15.8 (CHMe); MS (ESI) m/z 319 (M + H)
+
; HRMS  m/z calcd for C19H30N2O2 (M + H)
+
 
319.2380, found 319.2369 (+3.5 ppm error). 
Lab Book Reference: JDF7_655 
 
tert-Butyl 4-(2-phenylpropan-2-yl)-2-(trimethylsilyl)piperazine-1-carboxylate 261 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and Me3SiCl (109 mg, 127 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-Et2O as 
eluent gave N-Boc piperazine 261 (184 mg, 98%) as a colourless oil, RF (9:1 petrol-
Et2O) 0.3; IR (CHCl3) 2965, 2931, 1645 (C=O), 1428, 1399, 1344, 1277, 1261, 1228, 
1197, 1154, 1094, 916, 825, 749, 691 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture 
of rotamers) δ 7.52-7.47 (m, 2H, Ph), 7.34-7.28 (m, 2H, Ph), 7.24-7.18 (m, 1H, Ph), 
3.95 (br s, 0.6H, NCH), 3.72 (br s, 0.4H, NCH), 3.63-3.56 (br m, 1H, NCH), 2.95 (dt, J 
= 11.5, 2.0 Hz, 1H, NCH), 2.93 (br s, 0.4H, NCH), 2.84 (br s, 0.6H, NCH), 2.45 (br s, 
2H, NCH), 2.03 (td, J = 11.5, 3.0 Hz, 1H, NCH), 1.43 (s, 9H, CMe3), 1.35 (s, 6H, 
CMe2Ph), 0.13 (s, 9H, SiMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
154.5 (C=O), 154.4 (C=O), 148.4 (ipso-Ph), 127.9 (Ph), 126.3 (Ph), 126.3 (Ph), 79.1 
(CMe3), 59.9 (CMe2Ph), 47.1 (NCH2), 46.9 (NCH2), 46.5 (NCH2), 45.7 (NCH), 44.7 
(NCH), 43.7 (NCH2), 42.0 (NCH2), 28.4 (CMe3), 26.7 (CMe2Ph), 20.4 (CMe2Ph), –0.6 
(SiMe3); MS (ESI) m/z 377 (M + H)
+
; HRMS  m/z calcd for C21H36N2O2Si (M + H)
+
 
377.2619, found 377.2601 (+4.3 ppm error). 
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Lab Book Reference: JDF7_656 
 
7'-(2-Phenylpropan-2-yl)tetrahydrospiro[cyclohexane-1,1'-oxazolo[3,4-a]pyrazin]-
3'(5'H)-one 262 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and cyclohexanone (97 mg, 104 
µL 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 9:1-7:3 petrol-
EtOAc as eluent gave oxazolidinone 262 (95 mg, 58%) as a pale yellow oil, RF (8:2 
petrol-EtOAc) 0.2; IR (CHCl3) 2972, 2930, 2895, 1708 (C=O), 1497, 1425, 1404, 1342, 
1263, 1199, 1162, 913, 771, 726, 691, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.49 (d, 
J = 7.5 Hz, 2H, Ph), 7.31 (t, J = 7.5 Hz, 2H, Ph), 7.22 (t, J = 7.5 Hz, 1H, Ph), 3.73 (dd, J 
= 13.0, 2.0 Hz, 1H, NCH), 3.31 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 2.97 (td, J = 12.0, 3.5 
Hz, 1H, NCH), 2.76-2.67 (m, 2H, NCH), 2.19-2.06 (m, 2H, NCH), 1.91-1.40 (m, 10H, 
CH2), 1.33 (s, 6H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 156.5 (C=O), 148.5 
(ipso-Ph), 128.2 (Ph), 126.4 (Ph), 125.8 (Ph), 80.8 (CO), 62.7 (NCH), 60.3 (CMe2Ph), 
46.7 (NCH2), 45.4 (NCH2), 41.9 (NCH2), 36.8 (CH2), 30.7 (CH2), 25.0 (CH2), 24.4 
(CMe2Ph), 24.1 (CMe2Ph), 22.0 (CH2), 21.9 (CH2); MS (ESI) m/z 329 (M + H)
+
; HRMS  
m/z calcd for C20H28N2O2 (M + H)
+
 329.2224, found 329.2207 (+4.6 ppm error). 
 Lab Book Reference: JDF7_642  
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tert-Butyl 4-(2-phenylpropan-2-yl)-2-(tributylstannyl)piperazine-1-carboxylate 263 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and Bu3SnCl (325 mg, 271 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 19:1 petrol-EtOAc 
as eluent gave N-Boc piperazine 263 (260 mg, 80%) as a pale yellow oil, RF (19:1 
petrol-EtOAc) 0.3; IR (CHCl3) 2971, 2913, 2881, 2827, 1645 (C=O), 1432, 1397, 1344, 
1280, 1197, 1152, 1090, 1002, 947, 908, 849, 743, 691, 658 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 7.49 (d, J = 7.5 Hz, 2H, Ph), 7.29 (t, J = 7.5 Hz, 
2H, Ph), 7.23-7.16 (m, 1H, Ph), 4.21-4.12 (m, 0.5H, NCH), 3.97 (br d, J = 12.0 Hz, 
0.5H, NCH), 3.60-3.25 (m, 1.5H, NCH), 2.86-2.52 (m, 2.5H, NCH), 2.31 (br s, 1H, 
NCH), 2.06-1.84 (m, 1H, NCH), 1.55-1.37 (m, 15H, CMe3 + CH2), 1.33-1.22 (m, 12H, 
CMe2Ph + CH2), 0.95-0.83 (m, 15H, CH2 + Me); 
13
C NMR (100.6 MHz, CDCl3) 
(mixture of rotamers) δ 154.6 (C=O), 153.9 (C=O), 148.3 (ipso-Ph), 148.2 (ipso-Ph), 
128.0 (Ph), 126.3 (Ph), 79.3 (CMe3), 79.0 (CMe3), 60.0 (CMe2Ph), 50.2 (NCH2), 46.9 
(NCH2), 45.9 (NCH2), 45.6 (NCH2), 43.0 (NCH), 29.2 (CH2), 28.4 (CMe3), 27.9 (CH2), 
27.8 (CH2), 27.6 (CH2), 27.3 (CH2), 26.8 (CH2), 25.7 (CH2), 22.1 (CMe2Ph), 20.7 
(CMe2Ph), 13.7 (Me), 11.1 (CH2), 10.4 (CH2); MS (ESI) m/z 595 (M + H)
+
; HRMS m/z 
calcd for C30H54N2O2Sn (M + H)
+
 595.3285, found 595.3261 (+3.6 ppm error). 
Lab Book Reference: JDF7_607 
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tert-Butyl 2-(tert-butylcarbamoyl)-4-(2-phenylpropan-2-yl)piperazine-1-
carboxylate 264 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and tert-butyl isocyanate (64 mg, 
74 µL, 0.65 mmol, 1.3 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 9:1-8:2 
petrol-EtOAc as eluent gave N-Boc piperazine 264 (55 mg, 27%) as a white solid, mp 
61-64 °C;  RF (8:2 petrol-EtOAc) 0.3; IR (CHCl3) 2933, 1651 (C=O), 1524, 1488, 1430, 
1371, 1345, 1283, 1152, 1102, 951, 742 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.47-7.42 
(m, 2H, Ph), 7.31-7.24 (m, 2H, Ph), 7.23-7.17 (m, 1H, Ph), 5.88 (br s, 1H, NH), 4.47 (br 
s, 1H, NCH), 3.86 (br s, 1H, NCH), 3.59 (d, J = 11.5 Hz, 1H, NCH), 2.92 (br s, 1H, 
NCH), 2.49 (br s, 1H, NCH), 2.30 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 2.09 (td, J = 11.5, 
3.5 Hz, 1H, NCH), 1.45 (s, 9H, CMe3), 1.41 (s, 9H, CMe3), 1.35 (s, 3H, CMe2Ph), 1.33 
(s, 3H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 169.4 (C=O, CONH), 155.1 (C=O, 
Boc), 148.5 (ipso-Ph), 128.1 (Ph), 126.5 (Ph), 126.1 (Ph), 80.6 (OCMe3), 59.7 
(CMe2Ph), 57.3 (br, NCH), 51.8 (NCH2), 51.2 (NCMe3), 46.5 (NCH2), 42.1 (br, NCH2), 
28.9 (OCMe3), 28.4 (OCMe3), 27.8 (NCMe3), 20.3 (CMe2Ph); MS (ESI) m/z 404 (M + 
H)
+
; HRMS  m/z calcd for C23H37N3O3 (M + H)
+
 404.2908, found 404.2914 (+2.2 ppm 
error). 
Lab Book Reference: JDF7_643 
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tert-Butyl 2-(hydroxydiphenylmethyl)-4-(2-phenylpropan-2-yl)piperazine-1-
carboxylate 266 and 1,1-diphenyl-7-(2-phenylpropan-2-yl)tetrahydro-1H-
oxazolo[3,4-a]pyrazin-3(5H)-one 267 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone 
(182 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 9:1-8:2 petrol-EtOAc as eluent gave N-Boc piperazine 266 (55 mg, 23%) as a 
white solid, mp 54-56 °C; RF (7:3 petrol-EtOAc) 0.2; IR (CHCl3) 2961, 2934, 1655 
(C=O), 1427, 1395, 1345, 1326, 1284, 1232, 1151, 1096, 1001, 957, 690, 628 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 8.25 (s, 0.5H, OH), 8.10 (s, 
0.5H, OH), 7.70 (d, J = 7.5 Hz, 2H, Ph), 7.62 (t, J = 7.5 Hz, 2H, Ph), 7.46 (d, J = 7.5 
Hz, 1H, Ph), 7.42-7.07 (m, 10H, Ph), 5.16 (d, J = 3.0 Hz, 0.5H, NCH), 4.84 (d, J = 3.0 
Hz, 0.5H, NCH), 4.09 (dd, J = 13.5, 3.0 Hz, 0.5H, NCH), 3.82-3.62 (m, 1.5H, NCH), 
3.27-3.16 (m, 1H, NCH), 2.69 (d, J = 11.0 Hz, 0.5H, NCH), 2.61 (d, J = 11.0 Hz, 0.5H, 
NCH), 2.46 (dd, J = 11.5, 4.0 Hz, 0.5H, NCH), 2.41 (dd, J = 11.5, 4.0 Hz, 0.5H, NCH), 
2.25-2.09 (m, 1H, NCH), 1.32 (s, 1.5H, CMe2Ph), 1.29 (s, 1.5H, CMe2Ph), 1.24 (s, 
1.5H, CMe2Ph), 1.22 (s, 4.5H, CMe3), 1.16 (s, 1.5H, CMe2Ph), 1.15 (s, 4.5H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 154.5 (C=O), 154.2 (C=O), 
147.1 (ipso-Ph), 146.5 (ipso-Ph), 145.7 (ipso-Ph), 145.5 (ipso-Ph), 145.0 (ipso-Ph), 
144.7 (ipso-Ph), 128.4 (Ph), 128.1 (Ph), 128.0 (Ph), 127.6 (Ph), 127.5 (Ph), 127.3 (Ph), 
126.9 (Ph), 126.9 (Ph), 126.8 (Ph), 126.7 (Ph), 126.5 (Ph), 126.4 (Ph), 126.4 (Ph), 126.2 
(Ph), 126.2 (Ph), 126.0 (Ph), 126.0 (Ph), 83.9 (Ph2COH), 83.8 (Ph2COH), 79.6 (CMe3), 
60.3 (CMe2Ph), 60.3 (CMe2Ph), 55.6 (NCH), 54.0 (NCH), 48.5 (NCH2), 47.5 (NCH2), 
46.8 (NCH2), 46.7 (NCH2), 42.2 (NCH2), 41.2 (NCH2), 28.1 (CMe3), 27.9 (CMe3), 26.4 
(CMe2Ph), 26.3 (CMe2Ph), 19.7 (CMe2Ph), 19.6 (CMe2Ph); MS (ESI) m/z 487 (M + 
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H)
+
; HRMS m/z calcd for C30H38N2O3 (M + H)
+
 487.2955, found 487.2944 (+2.4 ppm 
error) and oxazolidinone 267 (152 mg, 74%) as a white solid, mp 122-124 °C; RF (7:3 
petrol-EtOAc) 0.1; IR (CHCl3) 2963, 2931, 1723 (C=O), 1470, 1426, 1390, 1342, 1282, 
1241, 1159, 1100, 1059, 1016, 971, 895, 690 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.49–
7.43 (m, 4H, Ph), 7.39–7.19 (m, 11H, Ph), 4.42 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.83–
3.72 (m, 1H, NCH), 3.04 (td, J = 12.0, 4.0 Hz, 1H, NCH), 2.69–2.63 (m, 1H, NCH), 
2.56 (ddd, J = 11.5, 3.5, 2.0 Hz, 1H, NCH), 2.09 (td, J = 11.5, 3.5 Hz, 1H, NCH), 1.55 
(t, J = 11.0 Hz, 1H, NCH), 1.24 (s, 3H, CMe2Ph), 1.18 (s, 3H, CMe2Ph); 
13
C NMR 
(100.6 MHz, CDCl3) δ 156.2 (C=O), 148.3 (ipso-Ph), 142.5 (ipso-Ph), 138.9 (ipso-Ph), 
128.5 (Ph), 128.3 (Ph), 128.2 (Ph), 128.1 (Ph), 127.8 (Ph), 126.5 (Ph), 125.9 (Ph), 125.8 
(Ph), 125.7 (Ph), 88.3 (Ph2CO), 62.4 (NCH), 60.2 (CMe2Ph), 49.3 (NCH2), 45.3 
(NCH2), 42.5 (NCH2), 25.0 (CMe2Ph), 23.3 (CMe2Ph);  MS (ESI) m/z 413 (M + H)
+
; 
HRMS m/z calcd for C27H28N2O2 (M + H)
+
 413.2224, found 413.2216 (+2.6 ppm error). 
Lab Book Reference: JDF7_606 
 
tert-Butyl 2-(hydroxymethyl)-4-(2-phenylpropan-2-yl)piperazine-1-carboxylate 268 
and 7-(2-Phenylpropan-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 269 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-cumyl piperazine 241 (152 mg, 0.50 mmol, 1.0 eq.), TMEDA (76 
mg, 97 µL, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and a suspension of 
paraformaldehyde (30 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 7:3-1:1 petrol-EtOAc as eluent gave N-Boc piperazine 
268 (96 mg, 57%) as a pale yellow oil, RF (7:3 petrol-EtOAc) 0.2; IR (CHCl3) 2972, 
2933, 1655 (C=O), 1392, 1370, 1345, 1290, 1196, 1152, 1100, 995, 895, 767, 747, 728, 
692, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 7.5 Hz, 2H, Ph), 7.32 (t, J = 
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7.5 Hz, 2H, Ph), 7.25-7.20 (m, 1H, Ph), 4.19-3.57 (m, 5H, NCH + CH2OH + CH2OH), 
3.26 (br s, 1H, NCH), 2.94 (d, J = 11.0 Hz, 1H, NCH), 2.72 (br s, 1H, NCH), 2.41 (dd, J 
= 11.5, 4.0 Hz, 1H, NCH), 2.19 (td, J = 11.5, 3.0 Hz, 1H, NCH), 1.44 (s, 9H, CMe3), 
1.38 (s, 6H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 155.0 (C=O), 147.4 (ipso-Ph), 
128.3 (Ph), 126.7 (Ph), 125.9 (Ph), 79.8 (CMe3), 65.4 (CH2OH), 59.9 (CMe2Ph), 52.0 
(NCH), 52.0 (NCH2), 46.2 (NCH2), 42.1 (NCH2), 28.5 (CMe3), 24.2 (CMe2Ph), 22.7 
(CMe2Ph); MS (ESI) m/z 335 (M + H)
+
; HRMS  m/z calcd for C19H30N2O3 (M + H)
+
 
335.2329, found 335.2325 (+1.2 ppm error) and oxazolidinone 269 (34 mg, 26%) as a 
pale yellow oil, RF (7:3 petrol-EtOAc) 0.1; IR (CHCl3) 2973, 1720 (C=O), 1496, 1545, 
1404, 1194, 1045, 914, 771, 725, 659, 617 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.53-
7.47 (m, 2H, Ph), 7.35-7.29 (m, 2H, Ph), 7.26-7.20 (m, 1H, Ph), 4.32 (t, J = 8.0 Hz, 1H, 
CHAHBO), 3.88-3.72 (m, 3H, CHAHBO + NCH), 3.05 (td, J = 12.0, 3.5 Hz, 1H, NCH), 
2.85-2.74 (m, 2H, NCH), 2.21 (td, J = 12.0, 3.5 Hz, 1H, NCH), 2.04 (t, J = 11.0 Hz, 1H, 
NCH), 1.34 (s, 6H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 157.0 (C=O), 148.3 
(ipso-Ph), 128.2 (Ph), 126.5 (Ph), 125.9 (Ph), 65.5 (CH2O), 60.2 (CMe2Ph), 54.0 
(NCH), 51.3 (NCH2), 45.4 (NCH2), 42.0 (NCH2), 25.2 (CMe2Ph), 23.1 (CMe2Ph); MS 
(ESI) m/z 261 (M + H)
+
; HRMS  m/z calcd for C15H20N2O2 (M + H)
+
 261.1598, found 
261.1587 (+3.9 ppm error). 
Lab Book Reference: JDF7_641 
 
tert-Butyl 2-allyl-4-(2-phenylpropan-2-yl)piperazine-1-carboxylate 270 
 
Using general procedure E, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 97 µL, 
0.65 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h, CuCN.2LiCl (0.25 mmol, 0.5 eq.) in THF (1 
mL) and allyl bromide (121 mg, 87 µL, 1.0 mmol, 2.0 eq.), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
Chapter Six: Experimental 
 
317 
 
chromatography on silica with 8:2 petrol-Et2O as eluent gave N-Boc piperazine 270 
(138 mg, 80%) as a colourless oil, RF (8:2 petrol-Et2O) 0.3; IR (CHCl3) 2972, 2930, 
2776, 1658 (C=O), 1397, 1344, 1305, 1197, 1153, 1092, 972, 950, 907, 761, 732, 691, 
658 cm
–1
; 1H NMR (400 MHz, CDCl3) δ 7.55-7.48 (m, 2H, Ph), 7.34-7.28 (m, 2H, Ph), 
7.24-7.18 (m, 1H, Ph), 5.73-5.63 (m, 1H, CH=CH2), 5.09-5.02 (m, 1H, CH=CHAHB), 
4.99-4.94 (m, 1H, CH=CHAHB), 4.01 (br s, 1H, NCH), 3.80 (br s, 1H, NCH), 2.98 (t, J 
= 11.5 Hz, 1H, NCH), 2.67 (br s, 2H, NCH or CH2), 2.57- 2.37 (m, 2H, NCH or CH2), 
2.26 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 2.21-2.08 (m, 1H, NCH), 1.43 (s, 9H, CMe3), 
1.33 (s, 3H, CMe2Ph), 1.30 (s, 3H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 154.8 
(C=O), 148.9 (ipso-Ph), 125.7 (CH=CH2), 128.0 (Ph), 126.3 (Ph), 126.0 (Ph), 116.8 
(CH=CH2), 79.3 (CMe3), 59.4 (CMe2Ph), 52.0 (br, NCH), 48.0 (NCH2), 46.4 (NCH2), 
39.6 (br, NCH2), 34.5 (CH2), 28.4 (CMe3), 24.5 (CMe2Ph), 23.2 (CMe2Ph); MS (ESI) 
m/z 345 (M + H)
+
; HRMS m/z calcd for C21H33N2O2 (M + H)
+
 345.2537, found 
345.2526 (+3.1 ppm error). 
Lab Book Reference: JDF7_666 
 
2-Methylbutan-2-yl N-ethenyl-N-(2-
[(methoxycarbonyl)(methyl)amino]ethyl)carbamate 271 and Methyl 2-(tert-
butoxycarbonyl(2-(methoxycarbonyl(methyl)amino)ethyl)amino)acrylate 272 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) and methyl 
chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 7:3-1:1 petrol-EtOAc as eluent gave vinyl carbamate 271 (88 mg, 34%) as a 
colourless oil, RF (7:3 petrol-EtOAc) 0.4; IR (CHCl3) 2983, 1697 (C=O), 1630 (C=O), 
1486, 1423, 1393, 1368, 1233, 1216, 1155, 575 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
(50:50 mixture of rotamers) δ 7.11 (dd, J =15.0, 10.0 Hz, 0.5H, CH=CH2), 6.95 (dd, J = 
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15.0, 10.0 Hz, 0.5H, CH=CH2), 4.48 (m, 0.5H, CH=CHAHB), 4.46-4.18 (m, 1.5H, 
CH=CHAHB + CH=CH2), 3.69 (s, 3H, OMe), 3.69-3.57 (m, 2H, NCH2), 3.39-3.35 (m, 
2H, NCH2), 2.93 (s, 1.5H, NMe), 2.91 (s, 1.5H, NMe), 1.50 (s, 9H, CMe3); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 156.6 (C=O), 152.9 (C=O), 152.5 (C=O), 
132.9 (CH=CH2), 132.6 (CH=CH2), 91.1 (CH=CH2), 90.6 (CH=CH2), 81.4 (CMe3), 
81.2 (CMe3), 52.6 (OMe), 52.5 (OMe), 45.9 (NCH2), 45.6 (NCH2), 41.2 (NCH2), 40.4 
(NCH2), 35.5 (NMe), 28.1 (CMe3); MS (ESI) m/z 281 [(M + Na)
+
 100], 159 [(M – 
Boc)
+
, 40]; HRMS m/z calcd for C12H22N2O4 (M + Na)
+
 281.1476, found 281.1472 (–
1.0 ppm error); and vinyl carbamate 272 (35mg, 11%) as a colourless oil, RF (7:3 petrol-
EtOAc) 0.2; IR (CHCl3) 3023, 1734 (C=O, CO2Me), 1699 (C=O, Boc), 1486, 1439, 
1395, 1369, 1236, 1161, 765; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) 
δ 5.92 (br s, 1H, C=CHAHB), 5.56 (br s, 0.5H, C=CHAHB), 5.40 (br s, 0.5H, C=CHAHB), 
3.78 (s, 1.5H, OMe), 3.77 (s, 1.5H, OMe), 3.67 (s, 3H, OMe), 3.62-3.55 (m, 2H, 
NCH2), 3.48-3.45 (m, 2H, NCH2), 3.95 (s, 1.5H, NMe), 3.94 (s, 1.5H, NMe), 1.41 (br s, 
9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 166.2 (C=O), 157.0 
(C=O), 156.7 (C=O), 153.7 (C=O), 153.6 (C=O), 140.5 (C=CH2), 140.0 (C=CH2), 
117.7 (C=CH2), 81.4 (CMe3), 81.2 (CMe3), 52.6 (OMe), 52.5 (OMe), 52.3 (OMe), 52.2 
(OMe), 47.9 (NCH2), 47.1 (NCH2), 35.2 (NMe), 34.8 (NMe), 28.0 (CMe3); MS (ESI) 
m/z 339 [(M + Na)
+
 100], 217 [(M – Boc)+, 20]; HRMS  m/z calcd for C14H24N2O6 (M + 
Na)
+
 339.1527, found 339.1526 (+0.2 ppm error). 
Lab Book Reference: JDF2_186 
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tert-Butyl 2-(1-methyl-3-phenyl-3-(phenylcarbamoyl)ureido)ethyl(vinyl)carbamate 
275 and tert-Butyl 2-(1-methyl-3-phenylureido)ethyl(vinyl)carbamate 274 and tert-
Butyl 4-methyl-2-(phenylcarbamoyl)piperazine-1-carboxylate 273 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) and phenyl 
isocyanate (238 mg, 218 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 mL) 
gave the crude product. Purification by flash column chromatography on silica with 9:1-
1:1 petrol-EtOAc and then EtOAc as eluent gave vinyl carbamate 275 (127 mg, 29%) as 
a colourless gum, RF (3:1 petrol-EtOAc) 0.2;  IR (CHCl3) 3346 (NH), 3006, 1701 (C=O, 
Boc), 1629 (C=O, urea), 1597, 1533, 1498, 1444, 1381, 1368, 1315, 1278, 1247, 1215, 
1154, 1056, 908, 856, 757 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (70:30 mixture of 
rotamers) δ 8.63 (br s, 0.7H, NH), 8.55 (br s, 0.3H, NH), 7.54-7.27 (m, 9H, Ph), 7.07-
6.92 (m, 2H, Ph + CH=CH2), 4.44 (d, J = 15.5 Hz, 1H, CH=CHAHB), 4.25 (d, J = 9.0 
Hz, 1H, CH=CHAHB), 3.85 (br s, 1.3H, NCH2), 3.68 (br s, 0.7H, NCH2), 3.42 (t, J = 6.5 
Hz, 2H, NCH2), 2.79 (s, 3H, NMe), 1.48 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) 
δ 158.1 (C=O), 152.8 (C=O), 152.5 (C=O), 138.4 (ipso-Ph), 137.8 (ipso-Ph), 132.5 
(CH=CH2), 129.1 (Ph), 128.7 (Ph), 127.7 (Ph), 126.8 (Ph), 123.3 (Ph), 119.7 (Ph), 91.4 
(CH=CH2), 81.9 (CMe3), 46.8 (NCH2), 40.0 (NCH2), 36.9 (NMe), 28.1 (CMe3); MS 
(ESI) m/z 339 [(M – Boc)+]; HRMS m/z calcd for C14H23N4O2 339.1816, found 
339.1809 (+1.6 ppm error), vinyl carbamate 274 (77 mg, 24%) as a pale yellow oil, RF 
(3:1 petrol-EtOAc) 0.1; IR (CHCl3) 3010, 1704 (C=O, Boc), 1629 (C=O, urea), 1500, 
1421, 1368, 1245, 1154, 692 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.51-7.39 (m, 3H, Ph 
+ NH), 7.28 (t, J = 7.0 Hz, 2H, Ph), 7.03-7.00 (m, 2H, Ph + CH=CH2), 4.47 (d, J = 16.0 
Hz, 1H, CH=CHAHB), 4.47 (br d, J = 8.0 Hz, 1H, CH=CHAHB), 3.72 (t, J = 6.5 Hz, 2H, 
NCH2), 3.46 (br s, 2H, NCH2), 3.06 (s, 3H, NMe), 1.50 (s, 9H, CMe3); 
13
C NMR (100.6 
MHz, CDCl3) δ 153.2 (C=O), 148.8 (C=O), 133.7 (ipso-Ph), 132.8 (CH=CH2), 129.4 
(Ph), 128.8 (Ph), 128.5 (Ph), 91.4 (CH=CH2), 82.3 (CMe3), 46.1 (NCH2), 40.9 (NCH2), 
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35.5 (NMe), 28.3 (CMe3); MS (ESI) m/z 342 [(M + Na)
+
 100], 320 [(M + H)
+
, 20], 220 
[(M – Boc)+, 80]; HRMS  m/z calcd for C17H25N3O3 (M + H)
+
 320.1974 , found 
320.1958 (+0.6 ppm error) and N-Boc piperazine 273 (111 mg, 35%) as a white solid, 
mp 135-137 °C; RF (EtOAc) 0.3; IR (CHCl3) 3008, 2981, 2948, 2804, 1686 (C=O), 
1599, 1524, 1498, 1442, 1411, 1368, 1296, 1168, 1142 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) δ 8.72 (br s, 1H, NH), 7.54-7.51 (m, 2H, Ph), 7.31 (t, J = 8.0 Hz, 2H, Ph), 7.09 
(t, J = 7.0 Hz, 1H, Ph), 4.76 (br s, 1H, NCH), 4.11 (br s, 1H, NCH), 3.39 (br d, J = 11.5 
Hz, 1H, NCH), 3.17 (td, J = 13.0, 2.0 Hz, 1H, NCH), 2.77 (br d, J = 11.5 Hz, 1H, 
NCH), 2.33 (s, 3H, NMe), 2.15 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 2.07-2.01 (m, 1H, 
NCH), 1.51 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 168.1 (NHC=O), 155.3 
(NC=O) 137.6 (ipso-Ph), 128.8 (Ph), 124.1 (Ph), 119.7 (Ph), 81.4 (CMe3), 54.5 (NCH2), 
54.2 (NCH2), 46.0 (NMe), 28.2 (CMe3); MS (ESI) m/z 320 [(M + H)
+
, 20], 264 [(M – 
CMe3)
+
, 30]; HRMS  m/z calcd for C17H25N3O3 (M + H)
+
 320.1974, found 320.1981 
(+2.4 ppm error). 
Lab Book Reference: JDF2_187 
 
7-Methyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 276 and 
tert-Butyl 2-(hydroxydiphenylmethyl)-4-methylpiperazine-1-carboxylate 277 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in THF (1 mL) worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 98:2-95:5 CH2Cl2-MeOH as eluent gave oxazolidinone 276 (263 mg, 
83%) as a white solid, mp 96-98 °C; RF (19:1 CH2Cl2-MeOH) 0.4; IR (CHCl3) 2948, 
2804, 1751 (C=O), 1450, 1409, 1360, 1301, 1255, 1138, 1032, 988, 757 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) δ 7.52-7.47 (m, 2H, Ph), 7.37-7.23 (m, 8H, Ph), 4.50 (dd, J = 11.0, 
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3.5 Hz, 1H, NCH), 3.83 (ddd, J = 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.12 (ddd, J = 13.0, 
12.0, 3.5 Hz, 1H, NCH), 2.68-2.64 (m, 1H, NCH), 2.43 (ddd, J = 12.0, 3.5, 1.0 Hz, 1H, 
NCH), 2.18 (s, 3H, NMe), 1.93 (td, J = 12.0, 3.5 Hz, 1H, NCH), 1.43 (t, J = 11.0 Hz, 
1H, NCH); 
13
C NMR (100.6 MHz, CDCl3) δ 158.8 (C=O), 142.2 (ipso-Ph), 138.6 (ipso-
Ph), 128.5 (Ph), 128.3 (Ph), 128.2 (Ph), 127.8 (Ph), 125.8 (Ph), 125.6 (Ph), 85.1 
(Ph2CO), 60.9 (NCH), 56.9 (NCH2), 53.2 (NCH2), 46.3 (NMe), 41.5 (NCH2); MS (ESI) 
m/z 309 (M + H)
+
; HRMS  m/z calcd for C19H20N2O2 (M + H)
+
 309.1598, found 
309.1599 (+0.1 ppm error) and N-Boc piperazine 277 (45 mg, 12%) as a pale yellow oil, 
RF (9:1 CH2Cl2-MeOH) 0.5; IR (CHCl3) 3680 (OH), 3019, 2980, 2855, 2807, 1681 
(C=O), 1461, 1417, 1367, 1350, 1304, 1287, 1215, 1169, 1146, 1027, 765 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.70-7.07 (m, 10H, Ph), 5.23 
(br d, J = 4.0 Hz, 0.5H, NCH), 4.90 (br d, J = 4.0 Hz, 0.5H, NCH), 4.17-4.11 (m, 0.5H, 
NCH), 3.86-3.72 (m, 1.5H, NCH), 2.97-2.92 (m, 1H, NCH), 2.87-2.84 (m, 0.5H, NCH), 
2.78-2.76 (m, 0.5H, NCH), 2.28 (dd, J = 12.0, 4.0 Hz, 0.5H, NCH), 2.24 (dd, J = 12.0, 
4.0 Hz, 0.5H, NCH), 2.17 (s, 1.5H, NMe), 2.14 (s, 1.5H, NMe), 2.10-1.98 (m, 1H, 
NCH), 1.25 (s, 4.5H, CMe3), 1.21 (s, 4.5H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) 
(mixture of rotamers) δ 154.6 (C=O), 154.2 (C=O), 147.7 (ipso-Ph), 147.2 (ipso-Ph), 
145.0 (ipso-Ph), 144.7 (ipso-Ph), 128.3 (Ph), 128.1 (Ph), 127.5 (Ph), 127.3 (Ph), 126.7 
(Ph), 126.6 (Ph), 126.5 (Ph) 126.3 (Ph), 126.1 (Ph), 126.0 (Ph), 83.5 (Ph2COH), 83.4 
(Ph2COH), 79.8 (CMe3), 79.7 (CMe3), 56.6 (NCH2), 55.8 (NCH2), 55.2 (NCH), 54.4 
(NCH2), 54.3 (NCH2), 53.5 (NCH), 45.8 (NMe), 45.7 (NMe), 41.4 (NCH2), 40.3 
(NCH2), 28.2 (CMe3), 28.0 (CMe3); MS (ESI) m/z 383 (M + H)
+
; HRMS  m/z calcd for 
C23H30N2O3 (M + H)
+
 383.2329, found 383.2317 (+3.6 ppm error). 
Lab Book Reference: JDF1_28 
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tert-Butyl 2-(methylamino)ethyl(1-(trimethylsilyl)vinyl)carbamate 279 and tert-
Butyl 2-(methylamino)ethyl(vinyl)carbamate 278 
 
s-BuLi (1.85 mL of a 1.3 M solution in hexanes, 2.4 mmol, 2.4 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) and 
TMEDA (278 mg, 360 µL, 2.4 mmol, 2.4 eq.) in Et2O (7 mL) at –78 °C under Ar. The 
resulting solution was warmed to –10 °C and stirred for 1 h. The solution was cooled to 
–78 °C then Me3SiCl (361 mg, 305 µL, 2.4 mmol, 2.4 eq.) was added dropwise. The 
reaction mixture was warmed to –60 °C, stirred for 1 h then allowed to warm to rt over 
16 h. Then, saturated NH4Cl(aq) (10 mL) and 20% NaOH(aq) (10 mL) were added and the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude products. Purification by flash column chromatography on 
silica with 9:1 CH2Cl2-MeOH as eluent gave silane 279 (86 mg, 32%) as a pale yellow 
oil, RF (9:1 CH2Cl2-MeOH) 0.2; IR (CHCl3) 2972, 1656 (C=O), 1432, 1372, 1346, 
1228, 1197, 1136, 831, 742 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 5.38 (br s, 1H, 
C=CHAHB), 5.13 (br s, 1H, C=CHAHB), 3.59 (t, J = 7.0 Hz, 2H, NCH2), 2.79 (t, J = 7.0 
Hz, 2H, NCH2), 2.53 (br s, 1H, NH), 2.49 (s, 3H, Me), 1.47 (s, 9H, CMe3), 0.15 (s, 9H, 
SiMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.4 (C=O or C=CH2), 153.3 (C=O or 
C=CH2), 112.7 (br, C=CH2), 80.6 (CMe3), 49.5 (NCH2), 46.7 (NCH2), 35.6 (NMe), 28.5 
(CMe3), 0.5 (SiMe3); MS (ESI) m/z 273 [(M + H)
+
, 100], 217 [(M – CMe3)
+
, 40], 173 
[(M – Boc), 20]; HRMS m/z calcd for C17H24N2O2 (M + H)
+
 273.1993, found 273.2000 
(–1.9 ppm error) and vinyl carbamate 278 (75 mg, 37%) as a pale oil, RF (9:1 CH2Cl2-
MeOH) 0.1; IR (CHCl3) 3513 (NH), 2978, 1698 (C=O), 1629 (C=C), 1456, 1368, 1152, 
862, 759 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.01 (br s, 1H, CH=CH2), 4.35 (d, J = 
16.0 Hz, 1H, CH=CHAHB), 4.21 (br s, 1H, CH=CHAHB), 3.65 (br s, 2H, NCH2), 2.79 (t, 
J = 7.0 Hz, 2H, NCH2), 2.47 (s, 3H, NMe), 2.11 (br s, 1H, NH), 1.49 (s, 9H, CMe3); 
13
C 
NMR (100.6 MHz, CDCl3) δ 152.9 (C=O), 132.9 (CH=CH2), 90.8 (CH=CH2), 81.3 
(CMe3), 48.2 (NCH2), 41.9 (NCH2), 36.0 (NMe),  28.2 (CMe3);  MS (ESI) m/z 201 [(M 
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+ H)
+
, 100], 145 [(M – CMe3)
+
, 100], 101 [(M – Boc)+, 50]; HRMS  m/z calcd for 
C10H20N2O2 (M + H)
+
 201.1598, found 201.1595 (+2.0 ppm error). 
Lab Book Reference: JDF5_414 
 
tert-Butyl 4-allylpiperazine-1-carboxylate 239 
 
Allyl bromide (3.57 g, 2.56 mL, 29.5 mmol, 1.1 eq.) was added dropwise to a stirred 
suspension of N-Boc piperazine 257 (5.0 g, 26.8 mmol, 1.0 eq.) and K2CO3 (2.98 g, 
53.7 mmol, 2.0 eq.) in acetone (60 mL) at rt under Ar. The resulting mixture was stirred 
and heated at reflux for 16 h. After being allowed to cool to rt, the solids were removed 
by filtration and washed with acetone (100 mL). The filtrate was evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 3:1 petrol-acetone as eluent gave N-Boc-N′-allyl 
piperazine 239 (5.15 g, 85%) as a pale yellow oil, RF (3:1 petrol-acetone) 0.3; IR 
(CHCl3) 2815, 2368, 1685 (C=O), 1457, 1427, 1366, 1287, 1248, 1169, 1002 cm
–1
; 
1
H 
NMR (400 MHz, CDCl3) δ 5.90-5.79 (m, 1H, CH=CH2), 5.21-5.15 (m, 2H, CH=CH2), 
3.43 (br s, 4H, NCH2), 3.00-2.98 (m, 2H, NCH2), 2.38 (br s, 4H, NCH2), 1.45 (s, 9H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 154.6 (C=O), 134.6 (CH=CH2), 118.2 
(CH=CH2), 79.5 (CMe3), 61.7 (NCH2), 52.8 (NCH2), 43.9 (NCH2), 28.3 (CMe3); MS 
(ESI) m/z 227 [(M + H)
+
, 100], 171 [(M – CMe3)
+
, 40], 127 [(M – Boc)+, 20] ; HRMS  
m/z calcd for C12H22N2O2 (M + H)
+
 227.1754, found 227.1758 (–1.1 ppm error). 
Lab Book Reference: JDF1_74 
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1-tert-Butyl 2-methyl 4-allylpiperazine-1,2-dicarboxylate 280 and Methyl 2-((2-
(allyl(methoxycarbonyl)amino)ethyl)(tert-butoxycarbonyl)amino)acrylate 281  
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-allyl piperazine 239 (226 mg, 1.0 mmol, 1.0 eq.) and methyl 
chloroformate (190 mg, 154 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 8:2 petrol-EtOAc as eluent gave N-Boc piperazine 280 (70 mg, 25%) as a 
colourless oil, RF (1:1 petrol-EtOAc) 0.4; IR (CHCl3) 3019, 2981, 2954, 1743 (C=O, 
CO2Me), 1692 (C=O, Boc), 1476, 1456, 1436, 1408, 1368, 1328, 1302, 1222, 1211, 
1168, 1118, 1047, 785, 738, 667 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 5.77 (dddd, J = 16.5, 10.0, 6.5, 6.0 Hz, 1H, CH=CH2), 5.20-5.18 (m, 0.5H, 
CH=CHAHB), 5.16-5.13 (m, 1.5H, CH=CHAHB + CH=CHAHB), 4.73 (br s, 0.5H, NCH), 
4.55 (br s, 0.5H, NCH), 3.86 (br d, J = 14.0 Hz, 0.5H, NCH), 3.77-3.71 (m, 0.5H, 
NCH), 3.74 (s, 1.5H, OMe), 3.71 (s, 1.5H, OMe), 3.37 (br t, J = 13.0 Hz, 1H, NCH), 
3.24 (td, J = 13.0, 3.5 Hz, 0.5H, NCH), 3.14 (td, J = 13.0, 3.5 Hz, 0.5H, NCH), 3.04 (d, 
J = 12.0 Hz, 0.5H, NCH), 3.03 (d, J = 12.0 Hz, 0.5H, NCH), 2.90 (d, J = 13.0 Hz, 0.5H, 
NCH), 2.89 (d, J = 13.0 Hz, 0.5H, NCH), 2.81 (d, J = 10.0 Hz, 0.5H, NCH), 2.73 (d, J = 
10.0 Hz, 0.5H, NCH), 2.13-2.10 (m, 1H, NCH), 2.02 (td, J = 12.0, 3.5 Hz, 1H, NCH), 
1.47 (s, 4.5H, CMe3), 1.43 (s, 4.5H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of 
rotamers) δ 171.5 (C=O, CO2Me), 171.1 (C=O, CO2Me), 155.7 (C=O, Boc), 155.3 
(C=O, Boc), 135.4 (CH=CH2), 118.0 (CH=CH2), 80.2 (CMe3), 61.1 (NCH2), 55.4 
(NCH), 54.2 (NCH), 53.3 (NCH2), 52.4 (NCH2), 52.2 (OMe), 41.9 (NCH2), 41.0 
(NCH2), 28.2 (CMe3); MS (ESI) m/z 285 [(M + H)
+
, 100], 229 [(M – CMe3)
+
, 30], 185 
[(M – Boc)+, 10]; HRMS  m/z calcd for C14H24N2O4 (M + H)
+
 285.1809, found 
285.1821 (–1.9 ppm error) and vinyl carbamate 281 (55 mg, 16%) as a pale yellow oil, 
RF (1:1 petrol-EtOAc) 0.5; IR (CHCl3) 3018, 2818, 1744 (C=O), 1688 (C=O), 1455, 
1409, 1366, 1329, 1301, 1223, 1205, 1170, 1119, 1046, 788, 668 cm
–1
; 
1
H NMR (400 
Chapter Six: Experimental 
 
325 
 
MHz, CDCl3) (50:50 mixture of rotamers) δ 5.90 (s, 1H, C=CHAHB), 5.81-5.73 (m, 1H, 
CH=CH2), 5.56 (s, 0.5H, C=CHAHB), 5.40 (s, 0.5H, C=CHAHB), 5.19-5.13 (m, 2H, 
C=CH2), 3.92 (d, J = 5.0 Hz, 1H, NCH), 3.88 (d, J = 5.0 Hz, 1H, NCH), 3.77 (s, 3H, 
OMe), 3.69 (s, 3H, OMe), 3.63-3.55 (m, 2H, NCH2), 3.45-3.39 (m, 2H, NCH2), 1.42 (br 
s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 165.3 (C=O), 
156.7 (C=O), 156.6 (C=O), 153.6 (C=O), 153.5 (C=O), 140.5 (C=CH2), 140.2 
(C=CH2), 133.5 (CH=CH2), 133.3 (CH=CH2), 117.3 (C=CH2 or CH=CH2), 116.6 
(C=CH2 or CH=CH2), 81.2 (CMe3), 52.6 (OMe), 52.3 (OMe), 50.3 (NCH2), 50.1 
(NCH2), 48.2 (NCH2), 47.5 (NCH2), 45.3 (NCH2), 44.4 (NCH2), 28.0 (CMe3); MS (ESI) 
m/z 365 [(M + Na)
+
, 60], 343 [(M + H)
+
, 30], 243 [(M – Boc)+, 100]; HRMS  m/z calcd 
for C16H26N2O6 (M + H)
+
 343.1864, found 343.1850 (+3.9 ppm error). 
Lab Book Reference: JDF2_127 
 
tert-Butyl 4-allyl-2-(phenyl(phenylcarbamoyl)carbamoyl)piperazine-1-carboxylate 
282 and tert-Butyl 2-(1-allyl-3-phenyl-3-
(phenylcarbamoyl)ureido)ethyl(vinyl)carbamate 283 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-allyl piperazine 239 (226 mg, 1.0 mmol, 1.0 eq.) and phenyl 
isocyanate (238 mg, 218 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 mL) 
gave the crude product. Purification by flash column chromatography on silica with 9:1-
1:1 petrol-EtOAc as eluent gave N-Boc piperazine 282 (192 mg, 41%) as a colourless 
oil, RF (7:3 petrol-EtOAc) 0.4; IR (CHCl3) 3684 (NH), 3015, 2814, 1718 (C=O), 1596, 
1551, 1449, 1366, 1307, 1164, 1042, 991, 760 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 11.35 (s, 1H, NH), 7.56-7.54 (m, 2H, Ph), 7.49-7.27 (m, 
7H, Ph), 7.10-7.06 (m, 1H, Ph), 5.83 (dddd, J = 17.5, 10.0, 7.5, 5.5 Hz, 1H, CH=CH2), 
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5.23 (br d, J = 10.0 Hz, 1H, CH=CHAHB), 5.17 (dd, J = 17.5, 1.5 Hz, 1H, CH=CHAHB), 
4.68 (br s, 1H, NCH), 3.87 (br d, J = 12.0 Hz, 0.4H, NCH), 3.75-3.67 (m, 1.6H, NCH), 
3.10 (dd, J = 13.5, 5.0 Hz, 1H, NCH), 2.99 (td, J = 12.0, 1.5 Hz, 1H, NCH), 2.88-2.79 
(m, 1H, NCH), 2.73-2.68 (m, 1H, NCH),  2.00 (td, J = 12.0, 5.0 Hz, 1H, NCH), 1.76-
1.68 (m, 1H, NCH), 1.51 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of 
rotamers) δ 176.1 (C=O), 175.7 (C=O), 156.2 (C=O), 155.2 (C=O), 152.9 (C=O), 152.0 
(C=O), 137.8 (ipso-Ph), 136.8 (ipso-Ph), 134.6 (CH=CH2), 129.9 (Ph), 129.4 (Ph), 
129.1 (Ph), 128.9 (Ph), 124.0 (Ph), 120.2 (Ph), 118.5 (CH=CH2), 80.5 (CMe3), 61.2 
(NCH2), 55.6 (NCH), 54.5 (NCH), 53.0 (NCH2), 52.8 (NCH2), 52.1 (NCH2), 42.6 
(NCH2), 41.6 (NCH2), 25.4 (CMe3); MS (ESI) m/z 465 (M + H)
+
; HRMS  m/z calcd for 
C26H32N4O4 (M + H)
+
 465.2496, found 465.2491 (+1.8 ppm error) and vinyl carbamate 
283 (66 mg, 14%) as a colourless oil, RF (1:1 petrol-EtOAc) 0.4; IR (CHCl3) 3685 (NH), 
3347 (NH), 3032, 2402, 1682 (C=O), 1630 (C=O), 1600, 1537, 1502, 1444, 1368, 1311, 
1245, 1166, 930, 851, 693 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.81 (br s, 1H, NH), 
7.62-6.91 (m, 10H, Ph), 5.88 (ddt, J = 17.0, 10.0, 5.5 Hz, 1H, NCH=CH2), 5.31-5.05 
(m, 3H, CH=CH2 + CH=CH2), 4.42 (d, J = 16.0 Hz, 1H, CH=CH2), 4.25 (d, J = 9.0 Hz, 
1H, CH=CH2), 4.04-3.87 (m, 2H, NCH2), 3.76-3.66 (m, 2H, NCH2), 3.49-3.32 (m, 2H, 
NCH2), 1.52 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 155.2 (C=O), 153.4 
(C=O), 153.2 (C=O), 139.9 (CH=CH2), 137.2 (CH=CH2), 134.7 (ipso-Ph), 132.6 (ipso-
Ph), 130.5 (Ph), 129.7 (Ph), 128.9 (Ph), 128.7 (Ph), 122.4 (Ph), 119.4 (Ph), 117.3 
(CH=CH2), 91.3 (CH=CH2), 82.3 (CMe3), 50.5 (NCH2), 43.8 (NCH2), 41.4 (NCH2), 
28.2 (CMe3); MS (ESI) m/z 465 [(M + H)
+
, 20], 346 [(M - CONHPh)
+
, 100]; HRMS  
m/z calcd for C26H32N4O4 (M + H)
+
 465.2496, found 465.2539 (–9.8 ppm error). 
Lab Book Reference: JDF2_128 
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tert-Butyl 4-methylpiperazine-1-carboxylate 151 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-methyl piperazine 151 (200 mg, 1.0 mmol, 1.0 eq.) in 
THF (7 mL) at –78 °C under Ar. The resulting solution was stirred for 1 h at –78 °C. 
Then, the solution was warmed to 0 °C and stirred at 0 °C for 1 h. Saturated NH4Cl(aq) 
(10 mL) and 20% NaOH(aq) (10 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
products. Purification by flash column chromatography on silica with 9:1 CH2Cl2-
MeOH as eluent gave N-Boc piperazine 151 (176 mg, 88%) as a pale yellow oil, RF (9:1 
CH2Cl2-MeOH) 0.2. 
Lab Book Reference: JDF2_115 
 
tert-Butyl 4-benzyl-3-phenylpiperazine-1-carboxylate 295 and tert-butyl 4-benzyl-
2-phenylpiperazine-1-carboxylate 295 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in 
THF (7 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
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rt and stirred at rt for 30 min. Then, bromobenzene (207 mg, 140 μL, 1.3 mmol, 1.3 eq.) 
was added, followed by the addition of Pd(OAc)2 (11 mg, 0.05 mmol, 0.05 eq.) and 
t
Bu3PHBF4 (18 mg, 0.06 mmol, 0.06 eq.) in one portion. The reaction was stirred at rt 
for 16 h. Then, 35% NH4OH(aq) (0.2 mL) was added and the solution stirred at rt for 30 
min. The solids were removed by filtration through Celite
®
 and washed with Et2O (20 
mL). The filtrate was washed with H2O (20 mL), dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 19:1 petrol-EtOAc as eluent gave a 67:33 
mixture of N-Boc piperazine 295 and N-Boc piperazine 294 (by 
1
H NMR spectroscopy) 
(147 mg, 42%) as a colourless oil, RF (9:1 petrol-EtOAc) 0.3; 
1
H NMR (400 MHz, 
CDCl3) δ 7.51-7.47 (m, 1.34H, Ph), 7.31-7.19 (m, 8.66H, Ph), 5.23 (br s, 0.33H, NCH), 
4.10-3.89 (m, 1.67, NCH), 3.79 (d, J = 13.5 Hz, 0.67H, NCH), 3.57 (d, J = 13.0 Hz, 
0.33H, CHAHBPh), 3.45 (d, J = 13.0 Hz, 0.33H, CHAHBPh), 3.30-3.27 (m, 1H, NCH), 
3.03 (td, J = 12.5, 3.5 Hz, 0.33H, NCH), 3.02-2.76 (m, 3H, NCH), 2.41 (dd, J = 12.0, 
4.0 Hz, 0.33H, NCH), 2.16 (td, J = 12.0, 3.5 Hz, 0.33H, NCH), 2.07 (td, J = 12.0, 3.0 
Hz, 0.67H, NCH), 1.47 (s, 3H, CMe3), 1.45 (s, 6H, CMe3). 
Lab Book Reference: JDF7_618 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in 
THF (7 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
rt and stirred at rt for 30 min. Then, bromobenzene (207 mg, 140 μL, 1.3 mmol, 1.3 eq.) 
was added, followed by the addition of Pd(dba)2 (29 mg, 0.05 mmol, 0.05 eq.) and 
RuPhos (23 mg, 0.05 mmol, 0.05 eq.) in one portion. The reaction was stirred at rt for 
16 h. Then, saturated NH4Cl(aq) (10 mL) and saturated NaHCO3(aq) (10 mL) were added 
and the two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude products. Purification by flash column 
chromatography on silica with 9:1 petrol-EtOAc as eluent gave a 60:40 mixture of N-
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Boc piperazine 295 and N-Boc piperazine 294 (by 
1
H NMR spectroscopy) (223 mg, 
63%) as a colourless oil. 
Lab Book Reference: JDF7_628 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in 
THF (7 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
rt and stirred at rt for 30 min. Then, bromobenzene (207 mg, 140 μL, 1.3 mmol, 1.3 eq.) 
was added, followed by the addition of PEPPSI-
i
Pr (34 mg, 0.05 mmol, 0.05 eq.) in one 
portion. The reaction was stirred at rt for 16 h. Then, saturated NH4Cl(aq) (10 mL) and 
saturated NaHCO3(aq) (10 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
products. Purification by flash column chromatography on silica with 19:1 petrol-
EtOAc as eluent gave a 95:5 mixture (by 
1
H NMR) of N-Boc piperazine 295 and N-Boc 
piperazine 294 (by 
1
H NMR spectroscopy) (38%) as a colourless oil. 
Lab Book Reference: JDF7_617 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-benzyl piperazine 117 (138 mg, 0.5 mmol, 1.0 eq.) in 
THF (4 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.3 mL of a 1.0 M solution in Et2O, 0.3 mmol, 0.6 eq.) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
rt and stirred at rt for 30 min. Then, bromobenzene (104 mg, 70 μL, 0.65 mmol, 1.3 eq.) 
was added followed by the addition of PEPPSI-
i
Pr (34 mg, 0.05 mmol, 0.05 eq.) in one 
portion. The reaction was heated and stirred at reflux for 16 h. Upon cooling, saturated 
NH4Cl(aq) (10 mL) and saturated NaHCO3(aq) (10 mL) were added and the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude products. Purification by flash column chromatography on silica with 
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9:1-7:3 petrol-EtOAc as eluent gave a 90:10 mixture (by 
1
H NMR) of N-Boc piperazine 
295 and N-Boc piperazine 294 (by 
1
H NMR spectroscopy) (66 mg, 37%) as a colourless 
oil and N-Boc piperazine 117 (52 mg, 37%).  
Lab Book Reference: JDF10_967 
 
tert-Butyl (2-(benzylamino)ethyl)(vinyl)carbamate 299 
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-benzyl piperazine 117 (138 mg, 0.5 mmol, 1.0 eq.) in 
THF (4 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.3 mL of a 1.0 M solution in Et2O, 0.3 mmol, 0.6 eq.) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
rt and stirred at rt for 30 min. Then, bromobenzene (104 mg, 70 μL, 0.65 mmol, 1.3 eq.) 
was added. This mixture was added to a stirred suspension of Pd(dba)2 (14 mg, 0.025 
mmol, 0.05 eq.) and DavePhos (10 mg, 0.025 mmol, 0.05 eq.) in THF (1 mL) at rt under 
Ar. The reaction was stirred at rt for 16 h. Then, saturated NH4Cl(aq) (10 mL) and 
saturated NaHCO3(aq) (10 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
products. Purification by flash column chromatography on silica with 7:3-1:1 petrol-
EtOAc as eluent gave N-Boc piperazine 117 (67 mg, 49%) as a white solid and alkene 
299 (64 mg, 46%) as a colourless oil, RF (7:3 petrol-EtOAc) 0.2; IR (ATR) 2978, 2936, 
2821, 1702 (C=O), 1625 (C=C), 1452, 1421, 1364, 1327, 1247, 1213, 1163, 1137, 1028, 
977, 836, 769, 733 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.35-7.29 (m, 4H, Ph), 7.29-
7.21 (m, 1H, Ph), 7.04 (br s, 1H, CH=CH2), 4.33 (d, J = 16.0 Hz, 1H, CH=CHAHB), 
4.20 (br s, 1H, , CH=CHAHB), 3.82 (s, 2H, CH2Ph), 3.65 (br s, 2H, NCH2), 2.83 (t, J = 
6.5 Hz, 2H, NCH2), 1.47 (s, 9H, CMe3) (NH not resolved); 
13
C NMR (100.6 MHz, 
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CDCl3) δ 153.0 (C=O), 140.0 (ipso-Ph), 133.0 (CH=CH2), 128.3 (Ph), 128.0 (Ph), 127.0 
(Ph), 90.8 (CH=CH2), 81.2 (CMe3), 53.9 (CH2Ph), 46.0 (NCH2), 42.5 (NCH2), 28.1 
(CMe3); MS (ESI) m/z 277 [(M + H)
+
, 100], 221 [(M – CMe3)
+
, 20]; HRMS  m/z calcd 
for C16H25N2O2 (M + H)
+
 277.1911, found 277.1910 (+0.5 ppm error). 
Lab Book Reference: JDF10_963 
 
tert-Butyl 2-phenyl-4-(2-phenylpropan-2-yl)piperazine-1-carboxylate 300 and tert-
butyl (2-((2-phenylpropan-2-yl)amino)ethyl)(vinyl)carbamate 301 
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc-N′-cumyl piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in 
THF (4 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 2 h. 
Then, ZnCl2 (0.3 mL of a 1.0 M solution in Et2O, 0.3 mmol, 0.6 eq.) was added and the 
resulting solution was stirred at –78 °C for 30 min. The solution was allowed to warm to 
rt and stirred at rt for 30 min. Then, bromobenzene (104 mg, 70 μL, 0.65 mmol, 1.3 eq.) 
was added, followed by the addition of Pd(dba)2 (14 mg, 0.025 mmol, 0.05 eq.) and 
RuPhos (12 mg, 0.025 mmol, 0.05 eq.) in one portion. The reaction was stirred at rt for 
16 h. Then, saturated NH4Cl(aq) (10 mL) and saturated NaHCO3(aq) (10 mL) were added 
and the two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude products. Purification by flash column 
chromatography on silica with 85:15 petrol-Et2O then 4:1 petrol:EtOAc as eluent gave 
N-Boc piperazine 300 (23 mg, 12%) as a pale yellow oil, RF (4:1 petrol-Et2O) 0.3; IR 
(ATR) 2974, 1689 (C=O), 1494, 1448, 1412, 1390, 1364, 1295, 10251, 1230, 1164, 
1113, 1029, 1012, 975, 956, 762, 697 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.36-7.17 
(m, 10H, Ph), 5.17 (br s, 1H, NCH), 3.90 (d, J = 13.0 Hz, 1H, NCH), 3.26 (d, J = 12.0 
Hz, 1H, NCH), 3.07 (td, J = 12.5, 3.5 Hz, 1H, NCH), 2.71 (d, J = 8.5 Hz, 1H, NCH), 
Chapter Six: Experimental 
 
332 
 
2.63 (dd, J = 12.0, 4.0 Hz, 1H, NCH), 2.29 (td, J = 12.0, 3.5 Hz, 1H, NCH), 1.43 (s, 9H, 
CMe3), 1.35 (s, 3H, CMe2Ph), 1.33 (s, 3H, CMe2Ph); 
13
C NMR (100.6 MHz, CDCl3) δ 
155.2 (C=O), 148.4 (ipso-Ph), 140.9 (ipso-Ph), 128.0 (Ph), 127.9 (Ph), 127.2 (Ph), 
126.4 (Ph), 126.2 (Ph), 79.7 (CMe3), 59.8 (CMe2Ph), 54.2 (NCH), 49.2 (NCH2), 46.4 
(NCH2), 41.0 (NCH2), 28.4 (CMe3), 24.0 (CMe2Ph), 23.3 (CMe2Ph) (Ph not resolved); 
MS (ESI) m/z 381 (M + H)
+
; HRMS m/z calcd for C24H32N2O2 (M + H)
+
 381.2537, 
found 381.2533 (+0.8 ppm error), and alkene 301 (46 mg, 30%) as a pale yellow oil, RF 
(4:1 petrol-Et2O) 0.1; IR (ATR) 2974, 2930, 1703 (C=O), 1625 (CH=CH2), 1454, 1421, 
1358, 1327, 1249, 1215, 1155, 1129, 1029, 835, 763, 699 cm
-1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.42 (d, J = 7.5 Hz, 2H, Ph), 7.34-7.28 (m, 2H, Ph), 7.23-7.17 (m, 1H, Ph), 
7.14-6.80 (br m, 1H, CH=CH2), 4.16 (br s, 2H, CH=CH2), 3.53 (br s, 2H NCH2), 2.51 
(t, J = 7.0 Hz, 2H, NCH2), 1.47-1.42 (br m, 15H, CMe3 + CMe2Ph) (NH not resolved); 
13
C NMR (100.6 MHz, CDCl3) δ 153.1 (C=O), 147.8 (ipso-Ph), 133.0 (CH=CH2), 128.3 
(Ph), 126.3 (Ph), 125.8 (Ph), 90.8 (CH=CH2), 81.2 (CMe3), 55.9 (CMe2Ph), 43.6 
(NCH2), 40.5 (NCH2), 29.7 (CMe2Ph), 28.3 (CMe3); MS (ESI) m/z 305 (M + H)
+
; 
HRMS m/z calcd for C18H28N2O2 (M + H)
+
 305.2224, found 305.2213 (+3.9 ppm error) 
and N-Boc piperazine 241 (80 mg, 53%). 
Lab Book Reference: JDF11_1006 
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6.5 Experimental for Chapter Four 
 (R)-7-Benzyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (R)-183 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (–)-sparteine (457 mg, 448 µL, 1.95 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 7:3 petrol-EtOAc as eluent gave oxazolidinone (R)-183 (310 mg, 54%, 
81:19 er by CSP-HPLC) as a white solid, [α]D +145.9 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel OD (90:10 hexane:i-PrOH, 1.0 mL min
–1
) (S)-183 14.4 min, (R)-183 18.9 
min. 
 Lab Book Reference: JDF1_35 
 
(S)-7-Benzyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (S)-183 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
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on silica with 7:3 petrol-EtOAc as eluent gave oxazolidinone (S)-183 (137 mg, 36%, 
75:25 er by CSP-HPLC) as a white solid, [α]D –114.9 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel OD (90:10 hexane:i-PrOH, 1.0 mL min
–1
) (S)-183 14.4 min, (R)-183 18.9 
min. 
 Lab Book Reference: JDF1_61 
 
Using general procedure C, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 
1.3 eq.), diamine (S,S)-27 (606 mg, 1.95 mmol, 1.3 eq.), N-Boc-N′-benzyl piperazine 
117 (415 mg, 1.5 mmol, 1.0 eq.) in Et2O (10 mL) for 1 h and a solution of 
benzophenone (547 mg, 3.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with 20% 
NaOH(aq) (10 mL) gave the crude product. Purification by flash column chromatography 
on silica with 7:3 petrol-EtOAc as eluent gave oxazolidinone (S)-183 (345 mg, 60%, 
86:14 er by CSP-HPLC) as a white solid, [α]D –157.7 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel OD (90:10 hexane:i-PrOH, 1.0 mL min
–1
) (S)-183 14.4 min, (R)-183 18.9 
min. 
Lab Book Reference: JDF1_49 
 
(R)-1-tert-butyl 2-methyl 4-benzylpiperazine-1,2-dicarboxylate (R)-208 and tert-
Butyl N-[2-[benzyl(methoxycarbonyl)amino]ethyl]-N-ethenylcarbamate 314 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (–)-sparteine (457 mg, 448 µL, 1.95 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 90 min and methyl 
chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 9:1-7:3 petrol-EtOAc as eluent gave N-Boc piperazine (R)-208 (236 mg, 71%, 
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88:12 er by CSP-HPLC) as a colourless oil, [α]D +27.5 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel AD-H (95:5 hexane:i-PrOH, 1.0 mL min
-1
) (R)-208 5.4 min, (S)-208 6.3 min, 
and vinyl carbamate 314 (39 mg, 12%) as a colourless oil, RF (8:2 petrol-EtOAc) 0.4; IR 
(CHCl3) 2973, 2934, 1672 (C=O), 1485, 1454, 1430, 1387, 1371, 1346, 1225, 1200, 
1148, 769, 725 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.34-
7.19 (m, 5H, Ph), 7.10-6.94 (br m, 1H, CH=CH2), 4.58-4.37 (br m, 2.5H, CH=CH2 + 
NCH2), 4.30-4.17 (m, 1.5H, NCH2), 3.77 (s, 1.5H, OMe), 3.44 (br s, 1.5H, OMe), 3.68-
3.59 (br m, 2H, NCH2), 3.38 (br s, 1H, NCH2), 3.30 (br s, 1H, NCH2), 1.49 (s, 9H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 157.6 (C=O), 157.3 
(C=O), 156.0 (C=O), 155.8 (C=O), 137.4 (ipso-Ph), 128.6 (CH=CH2), 127.8 (Ph), 127.4 
(Ph), 127.1 (Ph), 79.2 (CMe3), 52.8 (CO2Me), 50.9 (NCH2Ph), 50.5 (NCH2Ph), 46.4 
(NCH2), 45.7 (NCH2), 39.0 (NCH2), 28.3 (CMe3) (CH=CH2 not resolved), MS (ESI) 
m/z 357 [(M + Na)
+
, 100], 335 [(M + H)
+
, 10], 220 [(M – Boc)+, 80], HRMS  m/z calcd 
for C18H26N2O4 (M + H)
+
 335.1965, found 335.1972 (–2.6 ppm error).  
Lab Book Reference: JDF5_451 
 
 (S)-1-tert-Butyl 2-methyl 4-benzylpiperazine-1,2-dicarboxylate (S)-208 and tert-
Butyl N-[2-[benzyl(methoxycarbonyl)amino]ethyl]-N-ethenylcarbamate 314 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (152 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and methyl 
chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 8:2-7:3 petrol-EtOAc as eluent gave N-Boc piperazine 
(S)-208 (295 mg, 88%, 85:15 er by CSP-HPLC) as a colourless oil, [α]D –28.7 (c 1.0 in 
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CHCl3);  CSP-HPLC: Chiralcel AD-H (95:5 hexane:i-PrOH, 1.0 mL min
-1
) (R)-208 5.4 
min, (S)-208 6.3 min, and vinyl carbamate 314 (28 mg, 8%) as a colourless oil.  
Lab Book Reference: JDF5_469 
 
tert-Butyl (2-(benzylamino)ethyl)(vinyl)carbamate 299 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc piperazine 117 (138 
mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and Me3SiOTf (222 mg, 181 µL, 1.0 
mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude product. 
Purification by flash column chromatography on silica with 97:3 CH2Cl2:MeOH as 
eluent gave alkene 299 (71 mg, 51%) as a colourless oil, RF (97:3 CH2Cl2:MeOH) 0.1. 
Lab Book Reference: JDF10_941 
 
(R)-tert-Butyl 4-benzyl-2-(tributylstannyl)piperazine-1-carboxylate (R)-181 
  
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 10 min and Bu3SnCl 
(650 mg, 542 µL, 2.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) 
gave the crude product. Purification by flash column chromatography on silica with 
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19:1 petrol-EtOAc as eluent gave N-Boc piperazine (R)-181 (96 mg, 17%, 77:23 er by 
CSP-HPLC) as a colourless oil, [α]D –26.0 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel OD-
H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (S)-181 7.2 min, (R)-181 7.8 min. 
Lab Book Reference: JDF5_468 
 
tert-Butyl 4-benzyl-2-(trimethylsilyl)piperazine-1-carboxylate 175 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (152 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and Me3SiCl (217 
mg, 253 µL, 2.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 8:2 petrol-
EtOAc as eluent gave N-Boc piperazine 175 (186 mg, 53%, 50:50 er by CSP-HPLC) as 
a colourless oil, CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 1.0 mL min
-1
) (R)-
175 3.0 min, (S)-175 3.4 min. 
Lab Book Reference: JDF5_474 
 
 (R)-tert-Butyl 4-benzyl-2-(trimethylsilyl)piperazine-1-carboxylate (R)-175 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (S,S)-27 (404 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl piperazine 117 
Chapter Six: Experimental 
 
338 
 
(276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and Me3SiCl (217 mg, 254 µL, 2.0 
mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) gave the crude product. 
Purification by flash column chromatography on silica with 19:1-9:1 petrol-EtOAc as 
eluent gave N-Boc piperazine (R)-175 (37 mg, 9%, 52:48 er by CSP-HPLC) as a 
colourless oil, [α]D –0.1 (c 0.65 in CHCl3); CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-
PrOH, 1.0 mL min
-1
) (R)-175 3.1 min, (S)-175 3.4 min. The major enantiomer is 
assumed to be the expected (R) configuration. 
Lab Book Reference: JDF3_231 
 
tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate 176 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc-N′-benzyl piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.), TMEDA (232 
mg, 195 µL, 1.3 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and dimethyl sulfate (252 mg, 
189 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-EtOAc 
as eluent gave N-Boc piperazine 176 (190 mg, 65%) as a colourless oil.   
Lab Book Reference: JDF3_250 
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(S)-tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate (S)-176 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (S,S)-27 (404 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl piperazine 117 
(276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and methyl iodide (284 mg, 125 µL, 
2.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) gave the crude product. 
Purification by flash column chromatography on silica with 9:1 petrol-EtOAc as eluent 
gave N-Boc piperazine (S)-176 (395 mg, 45%, 55:45 er by CSP-HPLC) as a colourless 
oil, RF (7:3 petrol-EtOAc) 0.6; [α]D +4.8 (c 1.0 in EtOH) (lit.,
150
 [α]D +56 (c 0.44 in 
EtOH) for (S)-176 of >99:1 er); CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 0.5 
mL min
–1
) (R)-176 9.6 min, (S)-176 10.2 min.  
Lab Book Reference: JDF2_192 
 
tert-Butyl 2-(benzyl(methyl)amino)ethyl(vinyl)carbamate 315 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (S,S)-27 (404 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl piperazine 117 
(276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and dimethyl sulfate (252 mg, 189 
µL, 2.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) gave the crude product. 
Purification by flash column chromatography on silica with 17:3-7:3 petrol-EtOAc as 
eluent gave vinyl carbamate 315 (140 mg, 51%) as colourless oil, RF (4:1 petrol-EtOAc) 
0.4; IR (CHCl3) 3019, 2980, 2793, 2399, 1698 (C=O), 1627 (C=C), 1521, 1494, 1423, 
1391, 1217, 1152, 1018, 928, 847, 761, 699 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.33-
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7.22 (m, 5H, Ph), 7.10-6.95 (br m, 1H, CH=CH2), 4.23-4.10 (m, 2H, CH=CH2), 3.68-
3.51 (m, 2H, NCH2), 3.55 (s, 2H, CH2Ph), 2.53 (br s, 2H, NCH2), 2.29 (s, 3H, NMe), 
1.45 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 153.1 
(C=O), 139.0 (ipso-Ph), 132.8 (CH=CH2), 128.9 (Ph), 128.2 (Ph), 127.0 (Ph), 90.5 
(CH=CH2), 81.1 (CMe3), 62.7 (NCH2Ph), 62.5 (NCH2Ph), 53.3 (NCH2), 53.1 (NCH2), 
42.7 (NMe), 42.5 (NMe), 41.4 (NCH2), 40.9 (NCH2), 28.2 (CMe3); MS (ESI) m/z 291 
[(M + H)
+
, 100], 235 [(M – CMe3)
+
, 20], 191 [(M – Boc)+, 10]; HRMS m/z calcd for 
C17H26N2O2 (M + H)
+
 291.2067, found 291.2072 (–1.0 ppm error). 
Lab Book Reference: JDF3_232 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (276 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 10 min and dimethyl 
sulfate (252 mg, 189 µL, 2.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) 
gave the crude product. Purification by flash column chromatography on silica with 8:2 
petrol-EtOAc as eluent gave vinyl carbamate 315 (145 mg, 50%) as a colourless oil. 
Lab Book Reference: JDF5_475  
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of (+)-sparteine surrogate (+)-26 (126 mg, 0.5 mmol, 1.3 eq.) in 
Et2O (5 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 15 
min. Then, a solution of N-Boc-N′-benzyl piperazine 117 (138 mg, 0.5 mmol, 1.0 eq.) in 
Et2O (1 mL) was added dropwise. The resulting solution was stirred at –78 °C for 10 
min. Then, TMEDA (280 mg, 375 µL, 2.5 mmol, 5.0 eq.) was added dropwise and the 
resulting solution was stirred at –78 °C for 30 min. Then, dimethyl sulfate (126 mg, 97 
µL, 1.0 mmol, 2.0 eq.) was added dropwise. The reaction mixture was allowed to warm 
to rt over 16 h. Then, saturated NH4Cl(aq) (10 mL) and 20% NaOH(aq) (10 mL) were 
added and the two layers were separated. The aqueous layer was extracted with Et2O (3 
× 10 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
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chromatography on silica with 8:2 petrol-EtOAc as eluent gave vinyl carbamate 315 (50 
mg, 34%) as a colourless oil. 
Lab Book Reference: JDF5_480 
 
(S)-tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate (S)-176 and tert-butyl 2-
(benzyl(methyl)amino)ethyl(vinyl)carbamate 315 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc-N′-benzyl 
piperazine 117 (138 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 90 min and methyl 
iodide (142 mg, 62 µL, 1.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) gave 
the crude product. Purification by flash column chromatography on silica with 19:1-8:2 
petrol-EtOAc as eluent gave N-Boc piperazine (S)-176 (43 mg, 33%, 61:39 er by CSP-
HPLC) as a colourless oil, CSP-HPLC: Chiralcel IC (99:1 hexane:i-PrOH, 1.0 mL min
–
1
) (R)-176 12.3 min, (S)-176 14.7 min, and vinyl carbamate 315 (19 mg, 13%) as a 
colourless oil. 
Lab Book Reference: JDF7_619 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 0.65 mmol, 1.3 eq.), N-Boc-N′-benzyl piperazine 117 
(138 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 90 min and dimethyl sulfate (126 mg, 
97 µL, 1.0 mmol, 2.0 eq.), worked up with 20% NaOH(aq) (10 mL) gave the crude 
product. Purification by flash column chromatography on silica with 19:1-8:2 petrol-
EtOAc as eluent gave N-Boc piperazine (S)-176 (16 mg, 11%, 58:42 er by CSP-HPLC) 
as a colourless oil, CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) 
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(R)-176 6.8 min, (S)-176 7.3 min, and vinyl carbamate 315 (63 mg, 43%) as a 
colourless oil. 
Lab Book Reference: JDF5_485 
 
(S)-tert-Butyl 4-benzyl-2-methylpiperazine-1-carboxylate (S)-176  
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of (–)-sparteine (152 mg, 0.65 mmol, 1.3 eq.) in Et2O (5 mL) at –78 
°C under Ar. The resulting solution was stirred at –78 °C for 15 min. Then, a solution of 
N-Boc-N′-benzyl piperazine 117 (138 mg, 0.5 mmol, 1.0 eq.) in Et2O (1 mL) was added 
dropwise. The resulting solution was stirred at –78 °C for 90 min. Then, TMEDA (280 
mg, 375 µL, 2.5 mmol, 5.0 eq.) was added dropwise and the resulting solution was 
stirred at –78 °C for 30 min. Then, methyl iodide (142 mg, 62 µL, 1.0 mmol, 2.0 eq.) 
was added dropwise. The reaction mixture was allowed to warm to rt over 16 h. Then, 
saturated NH4Cl(aq) (10 mL) and 20% NaOH(aq) (10 mL) were added and the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 9:1-
8:2 petrol-EtOAc as eluent gave N-Boc piperazine (S)-176 (70 mg, 48%, 87:13 er by 
CSP-HPLC) as a colourless oil, CSP-HPLC: Chiralcel IC (99:1 hexane:i-PrOH, 1.0 mL 
min
–1
) (R)-176 12.4 min, (S)-176 15.3 min. 
Lab Book Reference: JDF7_620 
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(R)-1-tert-Butyl 2-methyl 4-tert-butylpiperazine-1,2-dicarboxylate (R)-245 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc-N′-tert-butyl 
piperazine 152 (121 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 6 h and methyl 
chloroformate (95 mg, 77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
with 8:2 petrol-EtOAc as eluent gave N-Boc piperazine (R)-245 (108 mg, 72%, 89:11 er 
by CSP-HPLC) as a pale yellow oil, [α]D +22.2 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel 
AD (99:1 hexane:i-PrOH, 1.0 mL min
-1
) (R)-245 16.0 min, (S)-245 21.8 min. 
Lab Book Reference: JDF2_153 
 
 (S)-1-tert-Butyl 2-methyl 4-tert-butylpiperazine-1,2-dicarboxylate (S)-245  
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-tert-butyl 
piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 10 min and methyl 
chloroformate (190 mg, 155 µL, 2.0 mmol, 2.0 eq.) worked up with 20% NaOH(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 8:2 petrol-EtOAc as eluent gave N-Boc piperazine (S)-245 (270 mg, 90%, 89:11 er 
by CSP-HPLC) as a colourless oil, CSP-HPLC: Chiralcel AD (99:1 hexane:i-PrOH, 1.0 
mL min
-1
) (R)-245 14.6 min, (S)-245 23.4 min. 
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Lab Book Reference: JDF5_470 
 
(S)-7-tert-Butyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (S)-
246 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (S,S)-27 (403 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-tert-butyl piperazine 
152 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone 
(364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) worked up with saturated NaHCO3(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 99:1-97:3 CH2Cl2-MeOH as eluent gave oxazolidinone (S)-246 (125 mg, 36%, 
85:15 er by CSP-HPLC) as a white solid, CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-
PrOH, 0.5 mL min
-1
) (S)-246 13.4 min, (R)-246 17.3 min. 
Lab Book Reference: JDF4_398 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (252 mg, 1.3 mmol, 1.3 eq.), N-Boc-N′-tert-butyl 
piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 99:1-97:3 CH2Cl2-MeOH as eluent gave oxazolidinone 
(S)-246 (265 mg, 76%, 86:14 er by CSP-HPLC) as a white solid, [α]D –179.3 (c 1.0 in 
CHCl3); CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-PrOH, 0.5 mL min
-1
) (S)-246 
13.4 min, (R)-246 17.7 min. 
Lab Book Reference: JDF4_400 
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(R)-7-tert-Butyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (R)-
246 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.), N-Boc-N′-tert-butyl 
piperazine 152 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 6 h and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 99:1-97:3 CH2Cl2-MeOH as eluent gave oxazolidinone 
(R)-246 (252 mg, 72%, 90:10 er by CSP-HPLC) as a white solid, [α]D +184.1 (c 1.0 in 
CHCl3); CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-PrOH, 0.5 mL min
-1
) (S)-246 
13.4 min, (R)-246 16.5 min. 
Lab Book Reference: JDF4_392 
 
(S)-1-tert-Butyl 2-methyl 4-tritylpiperazine-1,2-dicarboxylate (S)-247 
 
Using general procedure D, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), (+)-sparteine 
surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl 
chloroformate (95 mg, 77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
with 9:1-7:3 petrol-Et2O as eluent gave N-Boc piperazine (S)-247 (196 mg, 81%, 81:19 
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er by CSP-HPLC) as a white solid, [α]D –24.0 (c 1.0 in CHCl3); CP-HPLC: Chiralcel 
AD (95:5 hexane:i-PrOH, 0.2 mL min
-1
) (R)-247 38.4 min, (S)-247 50.4 min. 
Lab Book Reference: JDF5_416 
 
(S)-1,1-Diphenyl-7-trityltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (S)-249 
 
Using general procedure D, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), (+)-sparteine 
surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and a solution of 
benzophenone (182 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 9:1-7:3 petrol-Et2O as eluent gave N-Boc piperazine (S)-
249 (215 mg, 80%, 73:27 by CSP-HPLC) as a white solid, [α]D –121.8 (c 1.0 in CHCl3); 
CSP-HPLC: Chiralcel AD-H (95:5 hexane:i-PrOH, 1.0 mL min
-1
) (S)-249 5.6 min, (R)-
249 6.7 min. 
Lab Book Reference: JDF6_504 
 
(R)-tert-Butyl 2-(tributylstannyl)-4-tritylpiperazine-1-carboxylate (R)-251 
 
Using general procedure D, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc-N′-trityl piperazine 203 (214 mg, 0.5 mmol, 1.0 eq.), (+)-sparteine 
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surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and Bu3SnCl (325 
mg, 271 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 9:1-7:3 
petrol-Et2O as eluent gave N-Boc piperazine (S)-251 (265 mg, 74%, 82:18 er by CSP-
HPLC) as a pale yellow oil, [α]D –27.4 (c 1.1 in CHCl3); CSP-HPLC: Chiralcel OD-H 
(99:1 hexane:i-PrOH, 0.5 mL min
-1
) (R)-251 6.7 min, (S)-251 7.6 min. 
Lab Book Reference: JDF6_505 
 
 (S)-1-tert-Butyl 2-methyl 4-(9-phenyl-9H-fluoren-9-yl)piperazine-1,2-
dicarboxylate (S)-255  
 
Using general procedure D, s-BuLi (0.39 mL of a 1.3 M solution in hexanes, 0.50 
mmol, 1.3 eq.), N-Boc piperazine 240 (165 mg, 0.39 mmol, 1.0 eq.), (+)-sparteine 
surrogate (+)-26 (99 mg, 0.50 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl 
chloroformate (74 mg, 60 µL, 0.78 mmol, 2.0 eq.), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 9:1-7:3 petrol-Et2O as eluent gave N-Boc piperazine (S)-
255 (129 mg, 68%, 84:16 er by CSP-HPLC) as a white solid, [α]D –100.7 (c 1.0 in 
CHCl3); CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 1.0 mL min
-1
) (S)-255 25.1 
min, (S)-255 30.4 min. 
Lab Book Reference: JDF5_417 
 
Using general procedure D, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 240 (213 mg, 0.50 mmol, 1.0 eq.), (+)-sparteine surrogate 
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(+)-26 (126 mg, 0.65 mmol, 1.3 eq.) in MTBE (10 mL) for 1 h and methyl 
chloroformate (95 mg, 77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
with 9:1-7:3 petrol-Et2O as eluent gave N-Boc piperazine (S)-255 (144 mg, 59%, 85:15 
er by CSP-HPLC) as a white solid, CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 
1.0 mL min
-1
) (S)-255 25.1 min, (S)-255 30.4 min. 
Lab Book Reference: JDF6_526 
 
Using general procedure D, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine 240 (213 mg, 0.50 mmol, 1.0 eq.), (+)-sparteine surrogate 
(+)-26 (126 mg, 0.65 mmol, 1.3 eq.) in toluene (5 mL) for 1 h and methyl chloroformate 
(95 mg, 77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave 
the crude product. Purification by flash column chromatography on silica with 9:1-7:3 
petrol-Et2O as eluent gave N-Boc piperazine (S)-255 (98 mg, 40%, 81:19 er by CSP-
HPLC) as a white solid, CSP-HPLC: Chiralcel AD-H (99:1 hexane:i-PrOH, 1.0 mL 
min
-1
) (S)-255 25.1 min, (S)-255 30.4 min. 
Lab Book Reference: JDF6_526 
 
(R)-1-tert-Butyl 2-methyl 4-(2-phenylpropan-2-yl)piperazine-1,2-dicarboxylate (R)-
259  
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 6 h and methyl 
chloroformate (95 mg, 77 µL, 1.0 mmol, 2.0 eq.) worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
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with 19:1-8:2 CH2Cl2-Et2O as eluent gave N-Boc piperazine (R)-259 (128 mg, 71%, 
90:10 er by CSP-HPLC) as a colourless oil, [α]D +39.0 (c 0.85 in CHCl3); CSP-HPLC: 
Chiralcel OD-H (95:5 hexane:i-PrOH, 0.5 mL min
–1
) (R)-259 11.5 min, (S)-259 19.5 
min. 
Lab Book Reference: JDF7_603 
 
(S)-tert-Butyl 4-(2-phenylpropan-2-yl)-2-(tributylstannyl)piperazine-1-carboxylate 
(S)-263 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 6 h and Bu3SnCl (325 
mg, 271 µL, 1.0 mmol, 2.0 eq.) worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 19:1 petrol-
EtOAc as eluent gave N-Boc piperazine (S)-263 (180 mg, 61%, 89:11 er by CSP-HPLC 
of a derivative (R)-259) as a yellow oil, [α]D +32.6 (c 1.0 in CHCl3).  
Lab Book Reference: JDF7_626 
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(R)-1-tert-Butyl 2-methyl 4-(2-phenylpropan-2-yl)piperazine-1,2-dicarboxylate (R)-
259  
 
n-BuLi (35 µL of a 2.2 M solution in hexanes, 0.08 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of stannane (S)-263 (35 mg, 0.06 mmol, 1.0 eq.) and TMEDA (9 
mg, 12 µL, 0.08 mmol, 1.3 eq.) in Et2O (3 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 10 min. Then, methyl chloroformate (11 mg, 9 µL, 
0.12 mmol, 2.0 eq.) was added dropwise. The reaction mixture was stirred at –78 °C for 
15 min and then allowed to warm to rt over 30 min. Then, saturated NH4Cl(aq) (5 mL) 
and saturated NaHCO3(aq) (5 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 5 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 8:2 petrol-Et2O as 
eluent gave N-Boc piperazine (R)-259 (15 mg, 69%, 89:11 er by CSP-HPLC) as a 
colourless oil, CSP-HPLC: Chiralcel OD-H (95:5 hexane:i-PrOH, 0.5 mL min
–1
) (R)-
259 11.2 min, (S)-259 18.7 min. 
Lab Book Reference: JDF7_661 
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(R)-1,1-Diphenyl-7-(2-phenylpropan-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-
3(5H)-one (R)-267 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 6 h and a solution of 
benzophenone (182 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL) worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 19:1-8:2 petrol-EtOAc as eluent gave oxazolidinone (R)-
267 (110 mg, 53%, 91:9 er by CSP-HPLC) as a white solid, [α]D +144.7 (c 1.0 in 
CHCl3); CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-PrOH, 0.5 mL min
–1
) (S)-267 
19.7 min, (R)-267 27.7 min. 
 Lab Book Reference: JDF7_625 
 
 (S)-1-tert-Butyl 2-methyl 4-(2-phenylpropan-2-yl)piperazine-1,2-dicarboxylate (S)-
259  
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.5 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and methyl 
chloroformate (95 mg, 77 µL, 1.0 mmol, 2.0 eq.) worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
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with 19:1-8:2 CH2Cl2-Et2O as eluent gave N-Boc piperazine (S)-259 (151 mg, 83%, 
88:12 er by CSP-HPLC) as a colourless oil, [α]D –36.1 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel OD-H (95:5 hexane:i-PrOH, 0.5 mL min
–1
) (R)-259 11.5 min, (S)-259 19.3 
min. 
Lab Book Reference: JDF7_646 
 
(R)-tert-Butyl 4-(2-phenylpropan-2-yl)-2-(tributylstannyl)piperazine-1-carboxylate 
(R)-263 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.5 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and Bu3SnCl (325 
mg, 271 µL, 1.0 mmol, 2.0 eq.) worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 19:1 petrol-
EtOAc as eluent gave N-Boc piperazine (R)-263 (294 mg, 99%, 86:14 er by CSP-HPLC 
of a derivative (S)-259) as a yellow oil, [α]D –32.8 (c 1.0 in CHCl3);  
Lab Book Reference: JDF7_648 
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(S)-1-tert-Butyl 2-methyl 4-(2-phenylpropan-2-yl)piperazine-1,2-dicarboxylate (S)-
259  
 
n-BuLi (35 µL of a 2.2 M solution in hexanes, 0.08 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of stannane (R)-263 (35 mg, 0.06 mmol, 1.0 eq.) and TMEDA (9 
mg, 12 µL, 0.08 mmol, 1.3 eq.) in Et2O (3 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 10 min. Then, methyl chloroformate (11 mg, 9 µL, 
0.12 mmol, 2.0 eq.) was added dropwise. The reaction mixture was stirred at –78 °C for 
15 min and then allowed to warm to rt over 30 min. Then, saturated NH4Cl(aq) (5 mL) 
and saturated NaHCO3(aq) (5 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 5 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 8:2 petrol-Et2O as 
eluent gave N-Boc piperazine (S)-259 (15 mg, 69%, 86:14 er by CSP-HPLC) as a 
colourless oil, CSP-HPLC: Chiralcel OD-H (95:5 hexane:i-PrOH, 0.5 mL min
–1
) (R)-
259 11.2 min, (S)-259 18.7 min. 
Lab Book Reference: JDF7_660 
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(S)-tert-Butyl 2-(tert-butylcarbamoyl)-4-(2-phenylpropan-2-yl)piperazine-1-
carboxylate (S)-264 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.5 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and tert-butyl 
isocyanate (64 mg, 74 µL, 0.65 mmol, 1.3 eq.) worked up with saturated NaHCO3(aq) 
(10 mL) gave the crude product. Purification by flash column chromatography on silica 
with 17:3-1:1 petrol-Et2O as eluent gave N-Boc piperazine (S)-264 (108 mg, 54%, 
87:13 er by CSP-HPLC) as a white solid, [α]D –33.2 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel OD-H (98:2 hexane:i-PrOH, 0.5 mL min
–1
) (R)-264 14.3 min, (S)-264 16.6 
min. 
Lab Book Reference: JDF7_651 
 
(S)-1,1-Diphenyl-7-(2-phenylpropan-2-yl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-
3(5H)-one (S)-267 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.5 mmol, 1.3 eq.), N-Boc-N′-cumyl 
piperazine 241 (152 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and a solution of 
benzophenone (182 mg, 1.0 mmol, 2.0 eq.) in Et2O (1 mL) worked up with saturated 
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NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 8:2 petrol-EtOAc as eluent gave oxazolidinone (S)-267 
(150 mg, 73%, 87:13 er by CSP-HPLC) as a white solid, [α]D –106.0 (c 1.0 in CHCl3); 
CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-PrOH, 0.5 mL min
–1
) (S)-267 19.7 min, 
(R)-267 28.9 min. 
 Lab Book Reference: JDF7_647 
 
 (S)-1-tert-Butyl 2-methyl piperazine-1,2-dicarboxylate (S)-321 
 
10% Pd/C (5 mg) was added to a stirred solution of N-Boc-piperazine (S)-259 (20 mg, 
0.055 mmol, 1.0 eq.) in MeOH (5 mL). Then, the reaction flask evacuated under 
reduced pressure and back filled with Ar three times. After a final evacuation, a balloon 
of H2 was attached and the reaction mixture was stirred vigorously at rt under H2 for 48 
h. The mixture was filtered through Celite
®
 and washed with MeOH (20 mL). The 
filtrate was evaporated under reduced pressure to give N-Boc piperazine (S)-321 (14 
mg, quant.) as a pale yellow oil, [α]D –45.9 (c 0.95 in CHCl3); IR (ATR) 3352 (NH), 
2975, 1743 (C=O, CO2Me), 1692 (C=O), 1454, 1391, 1364, 1340, 1317, 1290, 1252, 
1223, 1201, 1112, 1072, 1038, 975, 917, 862, 829, 776, 731 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 4.73 (s, 0.5H, NCH), 4.55 (s, 0.5H, NCH), 3.87 
(br d, J = 13.0 Hz, 0.5H, NCH), 3.72-3.82 (m, 0.5H, NCH), 3.77 (s, 3H, CO2Me), 3.49-
3.59 (m, 1H, NCH), 3.11-3.21 (m, 0.5H, NCH), 2.86-3.08 (m, 2.5H, NCH), 2.65-2.79 
(m, 1H, NCH), 1.47 (s, 4.5H, CMe3), 1.43 (s, 4.5H, CMe3) (NH not resolved); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 171.6 (CO2Me), 155.9 (NC=O), 155.5 
(NC=O), 80.4 (CMe3), 55.5 (NCH), 54.2 (NCH), 52.3 (CO2Me), 47.3 (NCH2), 47.1 
(NCH2), 45.3 (NCH2), 42.7 (NCH2), 41.5 (NCH2), 28.4 (CMe3); MS (ESI) m/z 267 [(M 
+ Na)
+
, 30], 245 [(M + H)
+
, 50], 189 [(M – CMe3)
+
, 100], 145 [(M – Boc)+, 80]; HRMS  
m/z calcd for C11H20N2O4 (M + H)
+
 245.1493, found 245.1496 (+1.7 ppm error).  
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Lab Book Reference: JDF7_674  
20% Pd(OH)2/C (5 mg) was added to a stirred solution of N-Boc-piperazine (S)-259 (35 
mg, 0.097 mmol, 1.0 eq.) and ammonium formate (30 mg, 0.48 mmol, 5.0 eq.) in EtOH 
(5 mL) at rt under Ar. The resulting solution was stirred and heated at reflux for 2 h. 
After cooling to rt, the mixture was filtered through Celite
®
 and washed with EtOH (20 
mL). The filtrate was evaporated under reduced pressure to give N-Boc piperazine (S)-
321 (23 mg, 97%) as a colourless oil.  
Lab Book Reference: JDF10_1053  
 
10% Pd/C (5 mg) was added to a stirred solution of N-Boc-piperazine (S,S)-330 (20 mg, 
0.057 mmol, 1.0 eq.) in MeOH (5 mL). Then, the reaction flask evacuated under 
reduced pressure and back filled with Ar three times. After a final evacuation, a balloon 
of H2 was attached and the reaction mixture was stirred vigorously at rt under H2 for 48 
h. The mixture was filtered through Celite
®
 and washed with MeOH (20 mL). The 
filtrate was evaporated under reduced pressure to give N-Boc piperazine (S)-321 (14 
mg, quant.) as a pale yellow oil. 
Lab Book Reference: JDF7_675  
 
(S)-4-(Benzyloxycarbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
(S)-322 
 
Benzyl chloroformate (15 mg, 12 µL, 0.086 mmol, 1.5 eq.) was added to a stirred 
solution of N-Boc piperazine (S)-321 (14 mg, 0.055 mmol, 1.0 eq.) and Et3N (9 mg, 12 
µL, 0.086 mmol, 1.5 eq.) in CH2Cl2 at rt. The resulting solution was stirred for 16 h. 
Water (5 mL) was added and the layers separated. The aqueous was extracted with 
CH2Cl2 (2 x 5 mL). The combined organic layers were dried (MgSO4), filtered and 
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evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave N-Boc 
piperazine (16 mg, 74%) as a colourless oil, RF (7:3 petrol-EtOAc) 0.3; [α]D –3.4 (c 0.75 
in CHCl3); IR (CHCl3) 2973, 1718 (C=O, CO2Me), 1672 (C=O), 1492, 1409, 1346, 
1302, 1203, 1193, 1094, 1025, 914, 776, 741, 721, 659 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) (45:55 mixture of rotamers) δ 7.28-7.40 (5H, m, Ph), 5.17 (br d, J = 12.0 Hz, 
1H, CHAHBPh), 5.08 (d, J = 12.0 Hz, 1H, CHAHBPh), 4.76 (br s, 0.45H, NCH), 4.65 (br 
d, J = 13.5 Hz, 0.55H, NCH), 4.58 (br d, J = 12.0 Hz, 1H, NCH), 3.98-4.17 (m, 1H, 
NCH), 3.80-3.93 (m, 1H, NCH), 3.71 (br s, 1.35H, OMe), 3.59 (br s, 1.65H, OMe), 
3.04-3.32 (m, 2H, NCH), 2.89 (br s, 1H, NCH), 1.47 (s, 5H, CMe3), 1.43 (s, 4H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 170.5 (CO2Me), 170.3 
(CO2Me), 155.5 (NC=O), 155.0 (NC=O), 136.3 (ipso-Ph), 128.4 (Ph), 128.0 (Ph), 127.8 
(Ph), 80.9 (CMe3), 67.4 (CH2Ph), 54.8 (NCH), 53.4 (CO2Me), 52.3 (CO2Me), 44.7 
(NCH2), 43.2 (NCH2), 42.9 (NCH2), 40.0 (NCH2), 28.2 (CMe3); MS (ESI) m/z 401 [(M 
+ Na)
+
, 100], 323 [(M – Boc)+, 30]; HRMS  m/z calcd for C19H26N2O6Na (M + Na)
+
 
401.1683, found 401.1670 (+3.1 ppm error).  
Lab Book Reference: JDF7_682 
 
LiOH (3 mg, 0.13 mmol, 3.0 eq.) was added to a stirred solution of ester (16 mg, 0.042 
mmol, 1.0 eq.) in 4:1:1 THF-MeOH-water (2 mL) at rt under air. The reaction was 
stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure. The 
residue was partitioned between 1M HCl (5 mL) and CH2Cl2 (5 mL) and the two layers 
were separated. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 66:33:1 CH2Cl2-EtOAc-AcOH as eluent gave carboxylic acid (S)-322 (14 
mg, 84%) as a pale yellow oil.  RF (66:33:1 CH2Cl2-EtOAc-AcOH); 0.2; [α]D –14.9 (c 
0.7 in CHCl3) (lit.,
190
 [α]D –17.5 (c 1.02 in CHCl3); 
1
H NMR (400 MHz, CDCl3) (45:55 
mixture of rotamers) δ 7.27-7.40 (5H, m, Ph), 5.07-5.21 (m, 2H, CH2Ph), 4.82 (br s, 
0.45H, NCH), 4.63-4.72 (m, 1.55H, NCH), 4.60-4.74 (m, 2H, NCH), 3.09-3.27 (m, 2H, 
NCH), 2.93 (br s, 1H, NCH), 1.48 (s, 5H, CMe3), 1.44 (s, 4H, CMe3); 
13
C NMR (100.6 
MHz, CDCl3) (mixture of rotamers) δ 187.6 (COOH), 155.8 (NC=O), 155.4 (NC=O), 
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155.1 (NC=O), 136.0 (ipso-Ph), 128.6 (Ph), 128.2 (Ph), 128.0 (Ph), 81.2 (CMe3), 67.8 
(NCH), 54.6 (CH2Ph), 53.4 (CH2Ph), 44.5 (NCH2), 44.5 (NCH2), 44.3 (NCH2), 43.2 
(NCH2), 41.4 (NCH2), 40.2 (NCH2), 28.3 (CMe3). Spectroscopic data consistent with 
those reported in the literature.
190
 
Lab Book Reference: JDF7_693 
 
Benzyl chloroformate (15 mg, 12 µL, 0.086 mmol, 1.5 eq.) was added to a stirred 
solution of N-Boc piperazine (S)-321 (14 mg, 0.057 mmol, 1.0 eq.) and Et3N (9 mg, 12 
µL, 0.086 mmol, 1.5 eq.) in CH2Cl2 at rt. The resulting solution was stirred for 16 h. 
Water (5 mL) was added and the layers separated. The aqueous was extracted with 
CH2Cl2 (2 x 5 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave N-Boc 
piperazine (16 mg, 74%) as a colourless oil. 
Lab Book Reference: JDF7_683 
 
LiOH (3 mg, 0.13 mmol, 3.0 eq.) was added to a stirred solution of ester (16 mg, 0.042 
mmol, 1.0 eq.) in 4:1:1 THF-MeOH-water (2 mL) at rt under air. The reaction was 
stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure. The 
residue was partitioned between 1M HCl (5 mL) and CH2Cl2 (5 mL) and the two layers 
were separated. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 66:33:1 CH2Cl2-EtOAc-AcOH as eluent gave carboxylic acid (S)-322 (14 
mg, 84%) as a pale yellow oil,  RF (66:33:1 CH2Cl2-EtOAc-AcOH); 0.2; [α]D –14.3 (c 
0.7 in CHCl3) (lit.,
190
 [α]D –17.5 (c 1.02 in CHCl3).  
Lab Book Reference: JDF7_694 
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 (S)-1-(1-Phenylethyl)-4-methylbenzenesulfonylpiperazine (S)-324 
 
A mixture of N,N-bis(2-chloroethyl)-4-methylbenzenesulfonamide 323 (17.8 g, 60.0 
mmol, 1.1 eq.), (S)-(−)-α-methylbenzylamine (6.6 g, 7.0 mL, 54.5 mmol, 1.0 eq., 
>99.5:0.5 er) and i-Pr2NEt (15.5 g, 20.9 mL, 120 mmol, 2.2 eq.) was stirred and heated 
at 120 °C for 16 h. After being allowed to cool to rt, 7:3 H2O-EtOH (200 mL) was 
added and the suspension was stirred for 16 h at rt. Then, the solids were removed by 
filtration and washed with 1:1 H2O-EtOH (2 × 100 mL) and then cyclohexane (3 × 50 
mL) to give N-tosyl piperazine (S)-324 (17.9 g, 84%) as an-off white solid, mp 152-153 
°C; [α]D +48.7 (c 1.0 in CHCl3); IR (CHCl3) 2978, 2818, 1598, 1492, 1452, 1348, 1304, 
1166, 1136, 1093, 951, 908, 851, 733 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.63-7.60 
(m, 2H, Ar), 7.32-7.20 (m, 8H, Ar), 3.35 (q, J = 6.5 Hz, 1H, CHMe), 2.97 (br s, 4H, 
NCH), 2.58-2.53 (m, 2H, NCH), 2.47-2.43 (m, 2H, NCH), 2.43 (s, 3H, ArMe), 1.31 (d, 
J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 143.6 (ipso-Ar), 143.2 (ipso-
Ar), 132.4 (ipso-Ar), 129.6 (Ar), 128.3 (Ar), 127.9 (Ar), 127.4 (Ar), 127.1 (Ar), 64.4 
(NCHPh), 49.5 (NCH2), 46.3 (NCH2), 21.5 (Me), 19.4 (Me); MS (ESI) m/z 345 (M + 
H)
+
; HRMS m/z calcd for C19H24N2O2S (M + H)
+
 345.1631, found 345.1628 (+0.0 ppm 
error).  
Lab Book Reference: JDF5_422 
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 (R)-1-(1-Phenylethyl)-4-methylbenzenesulfonylpiperazine (R)-324 
 
Using the above procedure, a mixture of N,N-bis(2-chloroethyl)-4-
methylbenzenesulfonamide 323 (4.0 g, 13.3 mmol, 1.1 eq.), (R)-(−)-α-
methylbenzylamine (1.47 g, 1.56 mL, 12.1 mmol, 1.0 eq., >98:2 er) and i-Pr2NEt (3.4 g, 
4.7 mL, 26.7 mmol, 2.2 eq.) gave N-tosyl piperazine (R)-324 (3.5 g, 83%) as an off-
white solid, [α]D –46.3 (c 1.0 in CHCl3). 
Lab Book Reference: JDF6_533 
  
 (S)-1-(1-Phenylethyl)piperazine (S)-325 
 
A suspension of to tosyl piperazine (S)-324 (17.9 g, 52 mmol, 1.0 eq.) and 4-
hydroxybenzoic acid (21.6 g, 156 mmol, 3.0 eq.) in HBr (33 wt. % in AcOH, 125 mL) 
was stirred for at rt for 3 d under air. Then, H2O (150 mL) was added and the mixture 
was stirred for 2 h. The resulting white precipitate was removed by filtration and 
washed with H2O (200 mL). The aqueous filtrate was extracted with toluene (3 × 100 
mL). The aqueous layer was cooled to 0 °C and basified with solid KOH. Then, the 
basic solution was extracted with EtOAc (3 × 100 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give piperazine 
(S)-325 (9.4 g, 95%) as a pale yellow oil, [α]D –31.8 (c 1.0 in CHCl3); IR (CHCl3) 2985, 
2363, 1498, 1428, 1301, 1214, 1180, 1012, 913, 801, 692, 650, 616 cm
–1
; 
1
H NMR (400 
MHz, CDCl3) δ 7.31-7.20 (m, 5H, Ph), 3.34 (q, J = 6.5 Hz, 1H, CHMe), 2.86 (t, J = 5.0 
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Hz, 4H, NCH), 2.40 (br s, 2H, NCH), 2.37-2.33 (m, 2H, NCH), 1.94 (br s, 1H, NH), 
1.35 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 143.8 (ipso-Ph), 
128.1 (Ph), 127.6 (Ph), 126.8 (Ph), 65.3 (NCHPh), 51.8 (NCH2), 46.3 (NCH2), 19.5 
(CHMe); MS (ESI) m/z 191 (M + H)
+
; HRMS m/z calcd for C12H18N2 (M + H)
+
 
191.1543, found 191.1549 (–1.9 ppm error). 
Lab Book Reference: JDF5_424 
 
 (R)-1-(1-Phenylethyl)piperazine (R)-325 
 
Using the above procedure, tosyl piperazine (R)-324 (3.5 g, 10 mmol, 1.0 eq.) and 4-
hydroxybenzoic acid (4.1 g, 30 mmol, 3.0 eq.) in HBr (33 wt. % in AcOH, 30 mL) gave 
piperazine (R)-325 (1.5 g, 80%) as a pale yellow oil, [α]D +32.6 (c 1.0 in CHCl3). 
Lab Book Reference: JDF6_537 
 
(S)-tert-Butyl 4-(1-phenylethyl)piperazine-1-carboxylate (S)-308 
 
A solution of di-tert-butyl dicarbonate (14.0 g, 64.2 mmol, 1.3 eq.) in CH2Cl2 (50 mL) 
was added dropwise to a stirred solution of piperazine (S)-325 (9.4 g, 49.4 mmol, 1.0 
eq.) in CH2Cl2 (100 mL) at 0 °C under Ar. The resulting solution was allowed to warm 
to rt and stirred at rt for 16 h. Then, saturated NaHCO3(aq) (100 mL) was added and the 
two layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). 
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The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1-1:1 petrol-EtOAc as eluent gave N-Boc piperazine 
(S)-308 (13.4 g, 93%) as a pale yellow oil, RF (7:3 petrol-EtOAc) 0.2; [α]D –40.3 (c 1.0 
in CHCl3) (lit.,
183
 [α]D –32 (c 1.04 in CHCl3) for (S)-308 of >99:1 er); 
1
H NMR (400 
MHz, CDCl3) δ 7.33-7.20 (m, 5H, Ph), 3.39 (t, J = 5.0 Hz, 4H, NCH2), 3.37 (q, J = 6.5 
Hz, 1H, CHMe), 2.44-2.41 (m, 2H, NCH), 2.35-2.31 (m, 2H, NCH), 1.43 (s, 9H, 
CMe3), 1.36 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 (C=O), 
143.6 (ipso-Ph), 128.2 (Ph), 127.6 (Ph), 127.0 (Ph), 79.4 (CMe3) 64.7 (NCHPh), 50.2 
(NCH2); 44.0 (NCH2), 28.4 (CMe3), 19.6 (CHMe). Spectroscopic data consistent with 
those reported in the literature.
183
 
Lab Book Reference: JDF5_426 
 
(R)-tert-Butyl 4-(1-phenylethyl)piperazine-1-carboxylate (R)-308 
 
Using the above procedure, di-tert-butyl dicarbonate (1.9 g, 8.7 mmol, 1.1 eq.) and 
piperazine (R)-325 (1.5 g, 7.9 mmol, 1.0 eq.) in CH2Cl2 (30 mL) gave N-Boc piperazine 
(R)-308 (2.2 g, 96%) as a pale yellow oil, [α]D +43.5 (c 1.0 in CHCl3) (lit.,
183
 [α]D –32 
(c 1.04 in CHCl3) for (S)-308 of >99:1 er); Spectroscopic data consistent with those 
reported in the literature.
183
 
Lab Book Reference: JDF6_538 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 (TMEDA) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, TMEDA (151 mg, 195 µL, 1.3 mmol, 1.3 eq.) was 
added followed by a solution N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308 (290 mg, 
1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the 
stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 10 min. 
For N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308, a peak at 1702 cm-1 was observed 
and assigned to νC=O. After addition of s-BuLi, a new peak at 1680 cm
-1
 was observed 
which was assigned to νC=O in the pre-lithiation complex 326. A new peak at 1647 cm
-1
 
was observed which was assigned to νC=O in the lithiated intermediate 327. After a 
lithiation time of 7 min, complete lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 to give the lithiated intermediate 327 was observed. 
Lab Book Reference: JDF4_363 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 ((–)-sparteine) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) 
was added followed by a solution N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308 (290 
mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred for 5 min (to verify the 
stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred at –78 °C for 2 h. 
For N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308, a peak at 1702 cm-1 was observed 
and assigned to νC=O. After addition of s-BuLi, a new peak at 1679 cm
-1
 was observed 
which was assigned to νC=O in the pre-lithiation complex 326. A new peak at 1645 cm
-1
 
was observed which was assigned to νC=O in the lithiated intermediate 327. After a 
lithiation time of 2 h, incomplete lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 to give the lithiated intermediate 327 and N-Boc-N′-(S)-α-methylbenzyl 
piperazine (S)-308 was observed. 
Lab Book Reference: JDF4_365 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 ((+)-sparteine surrogate (+)-26) 
 
Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C a solution of diamine (+)-26 (252 mg, 1.3 mmol, 1.3 
eq.) in Et2O (2 mL) was added followed by a solution N-Boc-N′-(S)-α-methylbenzyl 
piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.) in Et2O (2 mL). The solution was stirred 
for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 mL of a 1.3 
M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The solution was stirred 
at –78 °C for 5 min. 
For N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308, a peak at 1701 cm-1 was observed 
and assigned to νC=O. After addition of s-BuLi, a new peak at 1681 cm
-1
 was observed 
which was assigned to νC=O in the pre-lithiation complex 326. A new peak at 1645 cm
-1
 
was observed which was assigned to νC=O in the lithiated intermediate 327. After a 
lithiation time of 2 min, complete lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 to give the lithiated intermediate 327 was observed. 
Lab Book Reference: JDF5_430 
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ReactIR
™
 monitoring of the lithiation of N-Boc-N′-(S)-α-methylbenzyl piperazine 
(S)-308 (THF) 
 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR
™
 probe at rt 
under Ar. After cooling to –78 °C, a solution of N-Boc-N′-(S)-α-methylbenzyl 
piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.) in THF (2 mL) was added. The solution 
was stirred for 5 min (to verify the stability of readout on ReactIR
™
). Then, s-BuLi (1.0 
mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added dropwise. The 
solution was stirred at –78 °C for 130 min. 
For N-Boc-N′-(S)-α-methylbenzyl piperazine (S)-308, a peak at 1697 cm-1 was observed 
and assigned to νC=O. After addition of s-BuLi, a new peak at 1644 cm
-1
 was observed 
which was assigned to νC=O in the lithiated intermediate 328. After a lithiation time of 
130 min, complete lithiation of N-Boc-N′-methyl piperazine (S)-308 to give the lithiated 
intermediate was observed 328. 
Lab Book Reference: JDF6_557 
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(S)-1,1-Diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-
one (S,S)-309 and (R)-1,1-diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-
oxazolo[3,4-a]pyrazin-3(5H)-one (S,S)-310 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) for 3 h 
and a solution of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in THF (1 mL), worked up 
with saturated NaHCO3(aq) (10 mL) gave the crude product which contained a 60:40 
mixture of (S,S)-309 and (R,S)-310 (by 
1
H NMR spectroscopy). Purification by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave N-Boc 
piperazine (S,S)-309 (207 mg, 52%) as a white solid, mp 139-140 °C; RF (7:3 petrol-
EtOAc) 0.2; [α]D –244.9 (c 1.0 in CHCl3) (lit.,
183
 [α]D +213 (c 0.108 in CHCl3) for 
(S,S)-309 of >99:1 er); 
1
H NMR (400 MHz, CDCl3) δ 7.54-7.51 (m, 2H, Ph), 7.40-7.22 
(m, 11H, Ph), 7.18-7.16 (m, 2H, Ph), 4.51 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.74 (ddd, J 
= 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.34 (q, J = 7.0 Hz, 1H, CHMe), 3.04 (ddd, J = 13.0, 
12.0, 3.5 Hz, 1H, NCH), 2.72-2.60 (m, 2H, NCH), 1.86 (td, J = 12.0, 3.5 Hz, 1H, NCH), 
1.46 (t, J = 11.0 Hz, 1H, NCH), 1.22 (d, J = 7.0 Hz, 3H, CHMe); 
13
C NMR (100.6 
MHz, CDCl3) δ 156.0 (C=O), 142.7 (ipso-Ph), 142.3 (ipso-Ph), 138.7 (ipso-Ph), 128.5 
(Ph), 128.4 (Ph), 128.3 (Ph), 128.2 (Ph), 127.8 (Ph), 127.3 (Ph), 127.2 (Ph), 126.0 (Ph), 
125.8 (Ph), 85.3 (Ph2CO), 64.3 (CH), 61.4 (CH), 52.5 (NCH2), 49.1 (NCH2), 41.9 
(NCH2), 19.2 (CHMe) and N-Boc piperazine (R,S)-310 (128 mg, 32%) as a white solid, 
mp 127-129 °C; RF (7:3 petrol-EtOAc) 0.1; [α]D +187.7 (c 1.0 in CHCl3) (lit.,
183
 [α]D –
132 (c 0.11 in CHCl3) for (R,S)-310 of >99:1 er); 
1
H NMR (400 MHz, CDCl3) δ 7.48-
7.45 (m, 2H, Ph), 7.38-7.20 (m, 11H, Ph), 7.18-7.14 (m, 2H, Ph), 4.43 (dd, J = 11.0, 3.5 
Hz, 1H, NCH), 3.81 (ddd, J = 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.48 (q, J = 7.0 Hz, 1H, 
CHMe), 3.10 (ddd, J = 13.0, 12.0, 3.5 Hz, 1H, NCH), 2.82-2.70 (m, 1H, NCH), 2.43 
(ddd, J = 12.0, 3.5, 1.0 Hz, 1H, NCH), 2.02 (td, J = 12.0, 3.5 Hz, 1H, NCH), 1.49 (t, J = 
11.0 Hz, 1H, NCH), 1.26 (d, J = 7.0 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 
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155.8 (C=O), 142.0 (ipso-Ph), 141.8 (ipso-Ph), 138.3 (ipso-Ph), 128.1 (Ph), 128.0 (Ph), 
127.9 (Ph), 127.8 (Ph), 127.4 (Ph), 127.1 (Ph), 126.8 (Ph), 125.6 (Ph), 125.4 (Ph), 84.9 
(Ph2CO), 63.3 (CH), 61.2 (CH), 52.8 (NCH2), 47.1 (NCH2), 41.6 (NCH2), 16.7 
(CHMe); Spectroscopic data for (S,S)-309 and (R,S)-310 consistent with those reported 
in the literature.
183
 
Lab Book Reference: JDF4_389 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.), TMEDA (148 mg, 195 
µL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone (364 mg, 
2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 mL) gave 
the crude product which contained a 70:30 mixture of (S,S)-309 and (R,S)-310 (by 
1
H 
NMR spectroscopy). Purification by flash column chromatography on silica with 7:3 
petrol-EtOAc as eluent gave N-Boc piperazine (S,S)-309 (231 mg, 58%) as a white solid 
and N-Boc piperazine (R,S)-310 (59 mg, 15%) as a white solid. 
Lab Book Reference: JDF4_388 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.), TMEDA (148 mg, 195 
µL, 1.3 mmol, 1.3 eq.) in MTBE (7 mL) for 1 h and a solution of benzophenone (364 
mg, 2.0 mmol, 2.0 eq.) in MTBE (1 mL), worked up with saturated NaHCO3(aq) (10 mL) 
gave the crude product which contained a 70:30 mixture of (S,S)-309 and (R,S)-310 (by 
1
H NMR spectroscopy). Purification by flash column chromatography on silica with 
7:3-1:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-309 (218 mg, 56%) as a 
white solid and N-Boc piperazine (R,S)-310 (80 mg, 20%) as a white solid. 
Lab Book Reference: JDF4_391 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (152 mg, 1.3 mmol, 1.3 eq.), N-Boc piperazine 
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(S)-308 (290 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of 
benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product which contained a 90:10 mixture of (S,S)-
309 and (R,S)-310 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 7:3-1:1 petrol-Et2O as eluent gave N-Boc piperazine 
(S,S)-309 (122 mg, 31%) as a white solid, and N-Boc piperazine (R,S)-310 (15 mg, 4%) 
as a white solid. 
Lab Book Reference: JDF4_399 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (S,S)-27 (404 mg, 1.3 mmol, 1.3 eq.), N-Boc piperazine (S)-308 (290 
mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone (364 mg, 
2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 mL) gave 
the crude product which contained a 91:9 mixture of (S,S)-309 and (R,S)-310 (by 
1
H 
NMR spectroscopy). Purification by flash column chromatography on silica with 7:3-
1:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-309 (126 mg, 32%) as a white 
solid, and N-Boc piperazine (R,S)-310 (9 mg, 2%) as a white solid. 
Lab Book Reference: JDF4_397 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), diamine (R,R)-27 (404 mg, 1.3 mmol, 1.3 eq.), N-Boc piperazine (S)-308 (290 
mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone (364 mg, 
2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 mL) gave 
the crude product which contained a 30:70 mixture of (S,S)-309 and (R,S)-310 (by 
1
H 
NMR spectroscopy). Purification by flash column chromatography on silica with 7:3-
1:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-309 (24 mg, 6%) as a white solid, 
and N-Boc piperazine (R,S)-310 (60 mg, 15%) as a white solid. 
Lab Book Reference: JDF4_395  
 
  
Chapter Six: Experimental 
 
370 
 
(S,S)-1,1-Diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-oxazolo[3,4-a]pyrazin-
3(5H)-one (S,S)-309, (R)-1,1-diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-
oxazolo[3,4-a]pyrazin-3(5H)-one (S,S)-310 and (S)-tert-butyl 4-(1-phenylethyl)-3,4-
dihydropyrazine-1(2H)-carboxylate (S)-329 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.), N-Boc piperazine (S)-308 
(290 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) for 1 h and a solution of benzophenone 
(364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 
mL) gave the crude product which contained a 40:60 mixture of (S,S)-309 and (R,S)-310 
(by 
1
H NMR spectroscopy). Purification by flash column chromatography on silica with 
8:2-1:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-309 (67 mg, 16%) as a white 
solid, N-Boc piperazine (R,S)-310 (113 mg, 29%) as a white solid and alkene (S)-329 as 
a clear oil (29 mg, 10%), RF (8:2 petrol-Et2O) 0.2; IR (CHCl3) 2971, 1664 (C=O), 1505, 
1471, 1430, 1371, 1347, 1203, 1189, 1147, 914, 774, 722, 691 cm
–1
;
 1
H NMR (400 
MHz, CDCl3) (70:30 mixture of rotamers) δ 7.41-7.21 (m, 5H, Ph), 6.00 (d, J = 6.5 Hz, 
0.3H, CH=CH), 5.85 (d, J = 6.5 Hz, 0.7H, CH=CH), 5.64 (d, J = 6.5 Hz, 0.3H, 
CH=CH), 5.50 (d, J = 6.5 Hz, 0.7H, CH=CH), 4.11-4.00 (m, 1H, CHMe), 3.69-3.58 (m, 
1H, NCH), 3.57-3.47 (m, 1H, NCH), 2.95 (t, J = 5.0 Hz, 1.4H, NCH), 2.91 (t, J = 5.0 
Hz, 0.6H, NCH), 1.48 (s, 2.7H, CMe3), 1.46 (s, 6.3H, CMe3), 1.44 (s, 3H, CHMe);
 13
C 
NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 151.7 (C=O), 143.8 (ipso-Ph), 142.2 
(ipso-Ph), 128.4 (Ph), 128.3 (Ph), 127.5 (Ph), 127.2 (Ph), 127.0 (Ph), 126.5 (Ph), 118.0 
(CH=CH), 117.1 (CH=CH), 102.9 (CH=CH), 102.7 (CH=CH), 80.1 (CMe3), 61.3 
(NCHPh), 44.1 (NCH2), 42.1 (NCH2), 40.8 (NCH2), 28.4 (CMe3), 18.3 (CHMe); MS 
(ESI) m/z 289 [(M + H)
+
, 100] 233 [(M – CMe3)
+
, 20]; HRMS m/z calcd for 
C17H24N2O2 (M + H)
+
 289.1906, found 289.1911 (+1.6 ppm error). 
Lab Book Reference: JDF4_394 
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(R)-1-tert-Butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate (R,S)-
331, (S)-1-tert-butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate 
(S,S)-330 and (S)-1-tert-butyl 2,2-dimethyl 4-(1-phenylethyl)piperazine-1,2,2-
tricarboxylate (S)-332 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.), TMEDA (148 mg, 195 
µL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl chloroformate (189 mg, 155 
µL, 2.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product which contained a 68:32 mixture of (R,S)-330 and (S,S)-331 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica with 4:1-1:1 
petrol-Et2O as eluent gave N-Boc piperazine (R,S)-331 (27 mg, 8%) as a colourless oil, 
RF (4:1 petrol-Et2O) 0.2; [α]D +23.4 (c 1.1 in CHCl3); IR (CHCl3) 1717 (C=O, CO2Me), 
1660 (C=O, Boc), 1498, 1453, 1398, 1346, 1199, 1101, 999, 913, 760 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) (55:45 mixture of rotamers) δ 7.34-7.16 (m, 5H, Ph), 4.73 (s, 0.55H, 
NCH), 4.56 (s, 0.45H, NCH), 3.74 (s, 1.65H, CO2Me), 3.72 (s, 1.35H, CO2Me), 3.82-
3.63 (m, 1H, CHMe), 3.52-3.36 (m, 2H, NCH), 3.18 (td, J = 12.5, 3.5 Hz, 0.55H, 
NCH), 3.07 (td, J = 12.5, 3.5 Hz, 0.45H, NCH), 2.69 (br d, J = 11.0 Hz, 0.45H, NCH), 
2.62 (br d, J = 11.0 Hz, 0.55H, NCH), 2.23 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 2.06-1.94 
(m, 1H, NCH), 1.45 (s, 5H, CMe3), 1.42 (s, 4H, CMe3), 1.31 (d, J = 6.5 Hz, 3H, 
CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.6 (CO2Me), 171.3 
(CO2Me), 155.9 (NC=O), 155.3 (NC=O), 143.6 (ipso-Ph), 143.4 (ipso-Ph), 128.5 (Ph), 
127.4 (Ph), 126.9 (Ph), 80.1 (CMe3), 63.5 (NCHPh), 63.3 (NCHPh), 55.7 (NCH), 54.6 
(NCH), 52.0 (CO2Me), 50.4 (NCH2), 50.2 (NCH2), 50.0 (NCH2), 42.3 (NCH2), 41.3 
(NCH2), 28.3 (CMe3), 18.7 (CHMe), 18.3 (CHMe); MS (ESI) m/z 349 (M + H)
+
; HRMS 
m/z calcd for C19H28N2O4 (M + H)
+
 349.2118, found 349.2118 (+0.6 ppm error), N-Boc 
piperazine (S,S)-330 (65 mg, 19%) as a colourless oil, RF (4:1 petrol-Et2O) 0.15; [α]D –
45.7 (c 1.5 in CHCl3); IR (CHCl3) 1717 (C=O, CO2Me), 1661 (C=O, Boc), 1431, 1346, 
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1282, 1197, 1145, 1102, 1051, 959, 743 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 
mixture of rotamers) δ 7.34-7.17 (m, 5H, Ph), 4.62 (s, 0.55H, NCH), 4.45 (s, 0.45H, 
NCH), 3.88 (br d, J = 12.5 Hz, 0.45H, NCH), 3.79 (br d, J = 12.5 Hz, 0.55H, NCH), 
3.71 (s, 1.35H, CO2Me), 3.69 (s, 1.65H, CO2Me), 3.41-3.14 (m, 3H, CHMe + NCH), 
3.00 (br d, J = 11.0 Hz, 0.45H, NCH), 2.94 (br d, J = 11.0 Hz, 0.55H, NCH), 2.10-1.98 
(m, 2H, NCH), 1.46 (s, 5H, CMe3), 1.40 (s, 4H, CMe3), 1.31 (d, J = 6.5 Hz, 3H, 
CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.2 (CO2Me), 171.0 
(CO2Me), 155.8 (NC=O), 155.3 (NC=O), 143.4 (ipso-Ph), 143.2 (ipso-Ph), 128.1 (Ph), 
127.4 (Ph), 127.1 (Ph), 80.2 (CMe3), 80.1 (CMe3), 64.1 (NCHPh), 55.6 (NCH), 54.4 
(NCH), 51.8 (CO2Me), 51.7 (NCH2), 51.5 (NCH2), 49.2 (NCH2), 42.2 (NCH2), 41.2 
(NCH2), 28.3 (CMe3), 28.2 (CMe3), 19.9 (CHMe), 19.7 (CHMe); MS (ESI) m/z 349 (M 
+ H)
+
; HRMS m/z calcd for C19H28N2O4 (M + H)
+
 349.2118, found 349.2116 (+1.2 ppm 
error) and N-Boc piperazine (S)-332 (99 mg, 24%) as a colourless oil, RF (4:1 petrol-
Et2O) 0.1; [α]D –16.3 (c 1.0 in CHCl3); IR (CHCl3) 1744 (C=O, CO2Me), 1662 (C=O, 
Boc), 1430, 1346, 1267, 1146, 1062, 973, 746 cm
–1
; 
1
H NMR (400 MHz, CHCl3) 
(55:45 mixture of rotamers) δ 7.34-7.28 (m, 4H, Ph), 7.26-7.21 (m, 1H, Ph), 4.01-3.87 
(m, 1H, CHMe), 3.85 (m, 3H, CO2Me), 3.65 (br s, 1.65H, CO2Me), 3.56 (s, 1.35H, 
CO2Me), 3.52–3.33 (m, 2H, NCH), 3.12-2.83 (m, 1.45H, NCH), 2.69 (br s, 0.55H, 
NCH), 2.53-1.93 (m, 2H, NCH), 1.42 (s, 9H, CMe3), 1.38 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.4 (CO2Me), 153.4 (NC=O), 
152.5 (NC=O), 147.3 (ipso-Ph), 143.3 (ipso-Ph), 128.4 (Ph), 127.8 (Ph), 127.2 (Ph), 
80.4 (CMe3), 64.3 (CHMe), 63.9 (CHMe), 58.9 (OMe), 55.7 (OMe), 50.2 (NCH2), 48.4 
(NCH2), 48.3 (NCH2), 43.9 (NCH2), 28.2 (CMe3), 20.1 (CHMe), 19.9 (CHMe); MS 
(ESI) m/z 407 (M + H)
+
; HRMS m/z calcd for C21H20N2O6 (M + H)
+
 407.2177, found 
407.2185 (–0.2 ppm error). 
Lab Book Reference: JDF5_404 
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(R)-1-tert-Butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate (R,S)-
331, (S)-1-tert-butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate 
(S,S)-330  
 
Using general procedure C, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (505 mg, 2.6 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (581 mg, 2.0 mmol, 1.0 eq.) in Et2O (10 mL) for 10 min and methyl 
chloroformate (378 mg, 309 µL, 4.0 mmol, 2.0 eq.), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product which contained a 95:5 mixture of (S,S)-
330 and (R,S)-331 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 8:2-7:3 petrol-Et2O as eluent gave N-Boc piperazine 
(R,S)-331 (31 mg, 4%) as a colourless oil and N-Boc piperazine (S,S)-330 (623 mg, 
90%, >99:1 er by CSP-HPLC) as a colourless oil, CSP-HPLC: Chiralcel AD-H (98:2 
hexane:i-PrOH, 1.0 mL min
–1
) (R,R)-330 7.3 min, (S,S)-330 10.8 min, 
Lab Book Reference: JDF8_708 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc piperazine (S)-308 
(145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 3 h and methyl chloroformate (95 mg, 
77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product which contained a 37:63 mixture of (S,S)-330 and (R,S)-331 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica with 8:2-7:3 
petrol-Et2O as eluent gave N-Boc piperazine (R,S)-331 (85 mg, 49%) as a colourless oil 
and N-Boc piperazine (S,S)-330 (47 mg, 27%) as a colourless oil. 
Lab Book Reference: JDF8_710 
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(R)-1-tert-Butyl 2-methyl 4-((R)-1-phenylethyl)piperazine-1,2-dicarboxylate (R,R)-
330 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc piperazine (S)-308 
(145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and methyl chloroformate (95 mg, 
77 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product which contained a >95:5 mixture of (R,R)-330 and (S,R)-331 (by 
1
H 
NMR spectroscopy). Purification by flash column chromatography on silica with 7:3 
petrol-Et2O as eluent gave N-Boc piperazine (R,R)-330 (158 mg, 91%) as a colourless 
oil. 
Lab Book Reference: JDF7_621 
 
(R)-tert-butyl 2-benzoyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (R,S)-334 
and (S)-tert-butyl 2-benzoyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (S,S)-
333 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (145 mg, 0.5 mmol, 1.0 eq.), TMEDA (74 mg, 97 
µL, 1.3 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and N-methoxy-N-methylbenzamide (107 
mg, 99 µL, 0.65 mmol, 1.3 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product which contained a 29:71 mixture of (R,S)-334 and (S,S)-333 (by 
1
H NMR 
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spectroscopy). Purification by flash column chromatography on silica with 99:1-97:3 
CH2Cl2-Et2O as eluent gave N-Boc piperazine (R,S)-334 (34 mg, 17%) as a white solid, 
mp 104-105 °C; RF (98:2 CH2Cl2-Et2O) 0.2; [α]D +1.9 (c 0.65 in CHCl3); IR (CHCl3) 
2967, 2933, 2772, 1674 (C=O, PhCO), 1661 (C=O, Boc), 1429, 1385, 1345, 1283, 
1234, 1144, 1102, 1051, 931, 848 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 mixture of 
rotamers) δ 7.83-7.69 (m, 2H, Ph), 7.56-7.46 (m, 1H, Ph), 7.46-7.37 (m, 2H, Ph), 7.22-
7.07 (m, 5H, Ph), 5.48 (br s, 0.55H, NCH), 5.31 (br s, 0.45H, NCH), 3.78 (br d, J = 11.0 
Hz, 0.45H, NCH), 3.69 (br d, J = 11.0 Hz, 0.55H, NCH), 3.50-3.23 (m, 3H, CHMe + 
NCH), 2.78-2.56 (m, 1H, NCH), 2.49-2.34 (m, 1H, NCH), 2.14-1.97 (m, 1H, NCH), 
1.45 (s, 4.95H, CMe3), 1.37 (s, 3.05H, CMe3), 1.02 (d, J = 6.5 Hz, 3H, CHMe); 
13
C 
NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 199.4 (COPh), 156.1 (NC=O), 
143.4 (ipso-Ph), 136.6 (ipso-Ph), 136.5 (ipso-Ph), 132.3 (Ph), 128.6 (Ph), 128.6 (Ph), 
128.5 (Ph), 128.5 (Ph), 127.8 (Ph), 127.7 (Ph), 127.5 (Ph), 127.2 (Ph), 126.8 (Ph), 80.1 
(CMe3), 64.5 (CHMe), 59.0 (NCH), 58.0 (NCH), 52.9 (NCH2), 50.4 (NCH2), 42.5 
(NCH2), 41.7 (NCH2), 28.3 (CMe3), 28.3 (CMe3), 18.4 (CHMe), 18.3 (CHMe); MS 
(ESI) m/z 395 (M + H)
+
; HRMS m/z calcd for C24H30N2O3 (M + H)
+
 395.2329, found 
395.2312 (+4.3 ppm error), and N-Boc piperazine (S,S)-333 (123 mg, 62%) as a white 
solid, mp 127-129 °C; RF (98:2 CH2Cl2-Et2O) 0.1; [α]D –2.6 (c 0.8 in CHCl3); IR 
(CHCl3) 2967, 2933, 2772, 1674 (C=O, PhCO), 1661 (C=O, Boc), 1430, 1385, 1346, 
1281, 1234, 1150, 1102, 1051, 931, 848 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 
mixture of rotamers) δ 7.75-7.59 (m, 2H, Ph), 7.55-7.43 (m, 1H, Ph), 7.41-7.31 (m, 2H, 
Ph), 7.06-6.78 (m, 5H, Ph), 5.39 (br s, 0.55H, NCH), 5.21 (br s, 0.45H, NCH), 3.91 (br 
d, J = 12.0 Hz, 0.45H, NCH), 3.82 (br d, J = 12.0 Hz, 0.55H, NCH), 3.62-3.43 (m, 1H, 
CHMe), 3.24-3.02 (m, 2.45H, NCH), 2.98 (br d, J = 10.0 Hz, 0.55H), 2.22 (dd, J = 12.0, 
4.5 Hz, 1H, NCH), 2.04 (br s, 1H, NCH), 1.47 (s, 4.95H, CMe3), 1.36 (s, 3.05H, CMe3), 
1.17 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
200.0 (COPh), 156.2 (NC=O), 155.6 (NC=O), 143.2 (ipso-Ph), 143.1 (ipso-Ph), 136.1 
(ipso-Ph), 136.1 (ipso-Ph), 132.6 (Ph), 128.6 (Ph), 128.5 (Ph), 128.0 (Ph), 127.7 (Ph), 
127.0 (Ph), 126.7 (Ph), 80.2 (CMe3), 64.5 (CHMe), 58.9 (NCH), 57.9 (NCH), 52.3 
(NCH2), 52.3 (NCH2), 49.7 (NCH2), 42.6 (NCH2), 41.8 (NCH2), 28.5 (CMe3), 28.3 
(CMe3), 20.2 (CHMe); 20.1 (CHMe); MS (ESI) m/z 395 (M + H)
+
; HRMS m/z calcd for 
C24H30N2O3 (M + H)
+
 395.2329, found 395.2311 (+4.3 ppm error). 
Lab Book Reference: JDF8_703 
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Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and N-methoxy-N-
methylbenzamide (107 mg, 99 µL, 0.65 mmol, 1.3 eq.), worked up with saturated 
NaHCO3(aq) (10 mL) gave the crude product which contained a 7:93 mixture of (R,S)-
334 and (S,S)-333 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 99:1-97:3 CH2Cl2-Et2O as eluent gave N-Boc piperazine 
(R,S)-334 (12 mg, 6%) as a white solid and N-Boc piperazine (S,S)-333 (170 mg, 86%) 
as a white solid. 
Lab Book Reference: JDF8_723 
 
(S)-tert-Butyl 4-((S)-1-phenylethyl)-2-(p-tolylthio)piperazine-1-carboxylate (S,S)-
336 and (R)-tert-butyl 4-((S)-1-phenylethyl)-2-(p-tolylthio)piperazine-1-carboxylate 
(R,S)-335 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (145 mg, 0.5 mmol, 1.0 eq.), TMEDA (74 mg, 97 
µL, 1.3 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and p-tolyl disulfide (246 mg, 1.0 mmol, 
2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude product which 
contained a 31:69 mixture of (S,S)-336 and (R,S)-335 (by 
1
H NMR spectroscopy). 
Purification by flash column chromatography on silica (prewashed with 99:1 CH2Cl2-
Et3N) with CH2Cl2 as eluent gave N-Boc piperazine (S,S)-336 (55 mg, 27%) as a pale 
yellow oil, RF (CH2Cl2) 0.2; [α]D –46.5 (c 0.4 in CHCl3); IR (CHCl3) 2931, 2881, 1661 
(C=O), 1469, 1429, 1387, 1347, 1283, 1283, 1253, 1146, 1101, 1001, 930, 846, 801 cm
–
1
; 
1
H NMR (400 MHz, CDCl3) (65:45 mixture of rotamers) δ 7.44-7.30 (m, 6H, Ar), 
7.29-7.23 (m, 1H, Ar), 7.08 (br d, J = 7.0 Hz, 2H, Ar), 5.76 (br s, 0.35H, NCH), 5.56 (br 
s, 0.65H, NCH), 3.86 (br d, J = 12.0 Hz, 0.65H, NCH), 3.69 (br s, 0.35H, NCH), 3.60-
Chapter Six: Experimental 
 
377 
 
3.38 (m, 2H, NCH + CHMe), 3.27 (br d, J = 10.5 Hz, 1H, NCH), 2.77 (br s, 1H, NCH), 
2.41 (br d, J = 9.5 Hz, 1H, NCH), 2.32 (s, 3H, ArMe), 2.00 (br s, 1H, NCH), 1.36 (d, J = 
6.5 Hz, 3H, CHMe), 1.29 (br s, 3.2H, CMe3), 1.10 (br s, 5.8H, CMe3); 
13
C NMR (100.6 
MHz, CDCl3) (mixture of rotamers) δ 153.4 (C=O), 143.4 (ipso-Ph), 138.0 (ipso-Ph), 
135.1 (Ph), 134.2 (Ph), 131.0 (ipso-Ph), 129.8 (Ph), 129.6 (Ph), 128.5 (Ph), 128.3 (Ph), 
127.6 (Ph), 127.0 (Ph), 79.9 (CMe3), 65.0 (NCH), 63.8 (CHMe), 54.8 (NCH2), 50.5 
(NCH2), 40.0 (NCH2), 38.5 (NCH2), 28.0 (CMe3), 27.7 (CMe3), 21.1 (ArMe), 19.0 
(CHMe); MS (ESI) m/z 413 (M + H)
+
; HRMS m/z calcd for C24H32N2O2S (M + H)
+
 
413.2257, found 413.2268 (–3.0 ppm error) and N-Boc piperazine (R,S)-335 (130 mg, 
67%) as a pale yellow oil, RF (CH2Cl2) 0.1; [α]D +37.9 (c 1.0 in CHCl3); IR (CHCl3) 
2934, 2776, 1662 (C=O), 1469, 1429, 1388, 1346, 1287, 1196, 1149, 1101, 1047, 998, 
921, 844, 764 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (65:45 mixture of rotamers) δ 7.34 (br 
d, J = 4.0 Hz, 6H, Ar), 7.29-7.22 (m, 1H, Ar), 7.06 (br d, J = 7.0 Hz, 2H, Ar), 5.67 (br s, 
0.35H, NCH), 5.46 (br s, 0.65H, NCH), 3.98 (br d, J = 11.5 Hz, 0.65H, NCH), 3.80 (br 
s, 0.35H, NCH), 3.62 (br t, J = 11.5 Hz, 1H, NCH), 3.43 (br s, 1H, CHMe), 3.15-2.95 
(m, 2H, NCH), 2.30 (s, 3H, ArMe), 2.32-2.22 (m, 1H, NCH), 2.08 (br t, J = 10.0 Hz, 
1H, NCH) 1.40 (br d, J = 6.5 Hz, 3H, CHMe), 1.29 (br s, 3.2H, CMe3), 1.08 (br s, 5.8H, 
CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 153.3 (C=O), 142.8 
(ipso-Ph), 137.9 (ipso-Ph), 137.7 (ipso-Ph), 135.1 (Ph), 134.3 (Ph), 130.7 (ipso-Ph), 
130.2 (ipso-Ph), 129.6 (Ph), 128.3 (Ph), 127.6 (Ph), 127.0 (Ph), 79.9 (CMe3), 64.6 
(NCH), 64.3 (CHMe), 55.4 (NCH2), 54.5 (NCH2), 50.0 (NCH2), 39.8 (NCH2), 38.4 
(NCH2), 28.1 (CMe3), 27.6 (CMe3), 21.0 (ArMe), 19.8 (CHMe); MS (ESI) m/z 413 (M 
+ H)
+
; HRMS m/z calcd for C24H32N2O2S (M + H)
+
 413.2257, found 413.2247 (+2.5 
ppm error). 
Lab Book Reference: JDF8_711 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and p-tolyl disulfide (246 
mg, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product which contained a 5:95 mixture of (S,S)-336 and (R,S)-335 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica (prewashed with 
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99:1 CH2Cl2-Et3N) with CH2Cl2 as eluent gave N-Boc piperazine (S,S)-336 (8 mg, 4%) 
as a pale yellow oil, and N-Boc piperazine (R,S)-335 (178 mg, 86%) as a pale yellow 
oil. 
Lab Book Reference: JDF8_723 
 
(S)-tert-Butyl 2-methyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (S,S)-338 
and (R)-tert-butyl 2-methyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (R,S)-
337 
 
Using general procedure B, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (290 mg, 1.0 mmol, 1.0 eq.), TMEDA (148 mg, 195 
µL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) for 1 h and methyl iodide (284 mg, 125 µL, 2.0 
mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude product 
which contained a 37:63 mixture of (S,S)-338 and (R,S)-337 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica with 17:3-7:3 
petrol-Et2O as eluent gave N-Boc piperazine (S,S)-338 (104 mg, 35%) as a colourless 
oil, RF (4:1 petrol-Et2O) 0.2; [α]D +24.2 (c 1.0 in CHCl3); IR (CHCl3) 2961, 2889, 2769, 
1654 (C=O), 1430, 1394, 1346, 1301, 1258, 1212, 1196, 1147, 1112, 1068, 1015, 744 
cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.34-7.28 (m, 4H, Ph), 7.25-7.21 (m, 1H, Ph), 4.20 
(br s, 1H, NCH), 3.70 (br d, J = 13.0 Hz, 1H, NCH), 3.34 (q, J = 6.5 Hz, 1H, CHMe), 
3.00 (td, J = 13.0, 3.5 Hz, 1H, NCH), 2.77 (dt, J = 11.0, 2.0 Hz, 1H, NCH), 2.64-2.60 
(m, 1H, NCH), 2.16 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 1.89 (ddd, J =  13.0, 12.0, 3.5 Hz, 
1H, NCH), 1.44 (s, 9H, CMe3), 1.31 (d, J = 6.5 Hz, 3H, CHMe), 1.26 (d, J = 6.5 Hz, 
3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 154.7 (C=O), 144.4 (ipso-Ph), 128.8 
(Ph), 127.5 (Ph), 126.8 (Ph), 79.2 (CMe3), 64.0 (NCHPh), 53.9 (NCH2), 51.1 (NCH2), 
47.2 (NCH), 39.3 (NCH2), 28.4 (CMe3), 19.2 (CHMe), 16.0 (CHMe); MS (ESI) m/z 305 
(M + H)
+
; HRMS m/z calcd for C18H28N2O2 (M + H)
+
 305.2224, found 305.2238 (–3.4 
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ppm error) and N-Boc piperazine (R,S)-337 (189 mg, 62%) as a colourless oil, RF (4:1 
petrol-Et2O) 0.1; [α]D –92.8 (c 1.0 in CHCl3); IR (CHCl3) 2933, 2770, 1645 (C=O), 
1430, 1394, 1346, 1297, 1268, 1196, 1149, 1114, 1067, 1014, 743 cm
–1
; 
1
H NMR (400 
MHz, CDCl3) δ 7.32-7.20 (m, 5H, Ph), 4.07 (br s, 1H, NCH), 3.83 (br d, J = 13.0 Hz, 
1H, NCH), 3.29 (q, J = 6.5 Hz, 1H, CHMe), 3.12 (td, J = 13.0, 3.5 Hz, 1H, NCH), 3.01-
2.96 (m, 1H, NCH), 2.50 (dt, J = 11.0, 2.0 Hz, 1H, NCH), 2.02-1.94 (m, 2H, NCH), 
1.43 (s, 9H, CMe3), 1.33 (d, J = 6.5 Hz, CHMe), 1.17 (d, J = 6.5 Hz, CHMe); 
13
C NMR 
(100.6 MHz, CDCl3) δ 154.7 (C=O), 144.4 (ipso-Ph), 128.2 (Ph), 127.3 (Ph), 126.8 
(Ph), 79.2 (CMe3), 64.5 (NCHPh), 55.6 (NCH2), 49.9 (NCH2), 47.1 (NCH), 39.4 
(NCH2), 28.4 (CMe3), 20.0 (CHMe), 15.6 (CHMe); MS (ESI) m/z 305 (M + H)
+
; HRMS 
m/z calcd for C18H28N2O2 (M + H)
+
 305.2224, found 305.2223 (+0.6 ppm error). 
Lab Book Reference: JDF5_413 
 
Using general procedure C, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (152 mg, 1.3 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (290 mg, 1.0 mmol, 1.0 eq.), in Et2O (7 mL) for 1 h and methyl iodide (284 mg, 
125 µL, 2.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product which contained a 24:76 mixture of (S,S)-338 and (R,S)-337 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica with 9:1-1:1 
petrol-Et2O as eluent gave N-Boc piperazine (S,S)-338 (46 mg, 15%) as a colourless oil, 
and N-Boc piperazine (R,S)-337 (161 mg, 53%) as a colourless oil 
Lab Book Reference: JDF5_420 
 
Using general procedure B, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (145 mg, 0.5 mmol, 1.0 eq.), TMEDA (74 mg, 97 
µL, 0.65 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h and methyl trifluoromethanesulfonate 
(164 mg, 113 µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) 
gave the crude product which contained a 28:72 mixture of (S,S)-338 and (R,S)-337 (by 
1
H NMR spectroscopy). Purification by flash column chromatography on silica with 
17:3-7:3 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-338 (33 mg, 23%) as a 
colourless oil, and N-Boc piperazine (R,S)-337 (104 mg, 72%) as a colourless oil. 
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Lab Book Reference: JDF10_976 
 
(S)-tert-Butyl 2-allyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (S,S)-340 and 
(R)-tert-butyl 2-allyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (R,S)-339 
 
Using general procedure E, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), N-Boc piperazine (S)-308 (145 mg, 0.5 mmol, 1.0 eq.), TMEDA (76 mg, 97 
µL, 0.65 mmol, 1.3 eq.) in Et2O (5 mL) for 1 h, CuCN.2LiCl (0.25 mmol, 0.5 eq.) in 
THF (1 mL) and allyl bromide (121 mg, 87 µL, 1.0 mmol, 2.0 eq.), worked up with 
saturated NaHCO3(aq) (10 mL) gave the crude product which contained a 32:68 mixture 
of (S,S)-340 and (R,S)-339 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-
340 (37 mg, 23%) as a colourless oil, RF (9:1 petrol-Et2O) 0.2; [α]D +7.6 (c 1.4 in 
CHCl3); IR (CHCl3) 2960, 2770, 2323, 2304, 1654 (C=O), 1430, 1397, 1346, 1304, 
1282, 1233, 1152, 1092, 1050, 929, 904, 746 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.34-
7.28 (m, 4H, Ph), 7.27-7.21 (m, 1H, Ph), 5.74 (td, J = 17.0, 7.5 Hz, 1H, CH=CH2), 5.09-
5.02 (m, 1H, CH=CHAHB), 5.02-4.98 (m, 1H, CH=CHAHB), 4.08 (s, 1H, NCH), 3.74 (s, 
1H, NCH), 3.34 (q, J = 6.5 Hz, 1H, CHMe), 3.04-2.85 (m, 2H, NCH), 2.70-2.40 (m, 
3H, NCH + CH2), 2.08 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 1.91 (td, J = 12.0, 3.5 Hz, 1H, 
NCH), 1.43 (s, 9H, CMe3), 1.29 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, 
CDCl3) δ 154.8 (C=O), 144.4 (ipso-Ph), 135.6 (CH=CH2), 128.2 (Ph), 127.4 (Ph), 126.8 
(Ph), 117.0 (CH=CH2), 79.3 (CMe3), 64.0 (CHMe), 51.0 (NCH2), 50.9 (NCH2), 39.7 
(br, NCH2), 34.3 (CH2), 28.3 (CMe3), 19.0 (CHMe); MS (ESI) m/z 331 (M + H)
+
; 
HRMS m/z calcd for C20H30N2O2 (M + H)
+
 331.2380, found 331.2371 (+2.5 ppm error), 
and (R,S)-339 (93 mg, 56%) as a colourless oil, RF (9:1 petrol-Et2O) 0.1; [α]D –47.3 (c 
1.0 in CHCl3); IR (CHCl3) 2931, 2323, 2304, 1653 (C=O), 1430, 1390, 1345, 1300, 
1282, 1233, 1148, 1092, 1050, 935, 904, 746 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.32-
7.27 (m, 4H, Ph), 7.26-7.20 (m, 1H, Ph), 5.63 (td, J = 17.0, 7.5 Hz, 1H, CH=CH2), 5.01 
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(dd, J = 17.0, 1.5 Hz, 1H, CH=CHAHB), 4.95-4.90 (m, 1H, CH=CHAHB), 3.90 (br s, 2H, 
NCH), 3.30 (q, J = 6.5 Hz, 1H, CHMe), 3.07 (br t, J = 12.5 Hz, 1H, NCH), 2.98 (br d, J 
= 8.0 Hz, 1H, NCH), 2.61 (d, J = 11.0 Hz, 1H, NCH), 2.53-2.31 (m, 2H, CH2), 1.99 (td, 
J = 11.5, 6.0 Hz, 1H, NCH), 1.93 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 1.43 (s, 9H, CMe3), 
1.33 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) δ 154.8 (C=O), 144.0 
(ipso-Ph), 135.5 (CH=CH2), 128.2 (Ph), 127.5 (Ph), 126.9 (Ph), 117.0 (CH=CH2), 79.3 
(CMe3), 64.5 (CHMe), 52.8 (NCH2), 49.8 (NCH2), 39.3 (br, NCH2), 34.4 (CH2), 28.4 
(CMe3), 19.8 (CHMe); MS (ESI) m/z 331 (M + H)
+
; HRMS m/z calcd for C20H30N2O2 
(M + H)
+
 331.2380, found 331.2372 (+2.5 ppm error). 
Lab Book Reference: JDF7_699 
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of (+)-sparteine surrogate (+)-26 (194 mg, 0.65 mmol, 1.3 eq.) in 
Et2O (4 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 15 
min. Then, a solution of N-Boc piperazine (S)-308 (145 mg, 0.5 mmol, 1.0 eq.), in Et2O 
(1 mL) was added dropwise. The resulting solution was stirred at –78 °C for 1 h. Then a 
solution of CuCN.2LiCl (0.25 mmol, 0.5 eq.) in THF (1 mL) was added dropwise. The 
resulting solution was stirred at –78 °C for 1 h. Then, allyl bromide (121 mg, 87 µL, 1.0 
mmol, 2.0 eq.) was added dropwise. The reaction mixture was allowed to warm to rt 
over 16 h. Then, saturated NH4Cl(aq) (10 mL) and saturated NaHCO3(aq) (10 mL) was 
added and the two layers were separated. The aqueous layer was extracted with Et2O (3 
× 10 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product which contained a 5:95 mixture of 
(S,S)-340 and (R,S)-339 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave N-Boc piperazine (S,S)-
340 (8 mg, 5%) as a colourless oil and (R,S)-339 (130 mg, 79%) as a colourless oil. 
Lab Book Reference: JDF8_706 
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(S)-tert-Butyl 4-((S)-1-phenylethyl)-2-(tributylstannyl)piperazine-1-carboxylate 
(S,S)-342 and (R)-tert-butyl 4-((S)-1-phenylethyl)-2-(tributylstannyl)piperazine-1-
carboxylate (R,S)-341 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and Bu3SnCl (325 mg, 271 
µL, 1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product which contained a 7:93 mixture of (S,S)-342 and (R,S)-341 (by derivatisation to 
(R,S)-331 and (S,S)-330). Purification by flash column chromatography on silica with 
19:1 petrol-EtOAc as eluent gave a mixture of diastereomeric N-Boc piperazine (S,S)-
342 and (R,S)-341 (272 mg, 94%) as a pale yellow oil, RF (19:1 petrol-EtOAc) 0.2; 
1
H 
NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.19-7.35 (m, 5H, Ph), 3.97-
4.16 (m, 1H, CHMe), 3.60 (br s, 0.5H, NCH), 3.45 (br s, 0.5H, NCH), 3.21-3.38 (m, 
1.5H, NCH), 2.94 (br d, J = 9.5 Hz, 0.5H, NCH), 2.65-2.77 (m, 0.5H, NCH), 2.56-2.68 
(m, 1H, NCH), 2.39-2.46 (m, 1H, NCH), 2.18-2.32 (m, 1H, NCH), 1.93-2.04 (m, 0.5H, 
NCH), 1.32-1.7 (m, 18H, CH2 + CHMe + CMe3), 1.21-1.34 (m, 6H, CH2), 0.79-0.97 (m, 
15H, CH2 + Me).  
Lab Book Reference: JDF8_725 
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(R)-1-tert-Butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate (R,S)-
331, (S)-1-tert-butyl 2-methyl 4-((S)-1-phenylethyl)piperazine-1,2-dicarboxylate 
(S,S)-330  
 
n-BuLi (51 µL of a 2.2 M solution in hexanes, 0.11 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of diastereomeric stannanes (S,S)-342 and (R,S)-341 (50 mg, 0.09 
mmol, 1.0 eq.) and TMEDA (13 mg, 17 µL, 0.11 mmol, 1.3 eq.) in Et2O (3 mL) at –78 
°C under Ar. The resulting solution was stirred at –78 °C for 10 min. Then, methyl 
chloroformate (16 mg, 13 µL, 0.17 mmol, 2.0 eq.) was added dropwise. The reaction 
mixture was stirred at –78 °C for 15 min and then allowed to warm to rt over 30 min. 
Then, saturated NH4Cl(aq) (5 mL) and saturated NaHCO3(aq) (5 mL) were added and the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 5 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure gave the crude product which contained a 7:93 mixture of (R,S)-331 and (S,S)-
330 (by 
1
H NMR spectroscopy). Purification by flash column chromatography on silica 
with 19:1 petrol-EtOAc as eluent gave a mixture of diastereomeric N-Boc piperazines 
(R,S)-331 and (S,S)-330 (19 mg, 64%). 
Lab Book Reference: JDF8_727 
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(R)-tert-Butyl 2-methyl-4-((R)-1-phenylethyl)piperazine-1-carboxylate (R,R)-338 
and (S)-tert-butyl 2-methyl-4-((R)-1-phenylethyl)piperazine-1-carboxylate (S,R)-
337 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.), N-Boc piperazine (R)-308 
(145 mg, 0.5 mmol, 1.0 eq.), in Et2O (5 mL) for 3 h and methyl iodide (142 mg, 62 µL, 
1.0 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the crude 
product which contained a 45:55 mixture of (R,R)-338 and (S,R)-337 (by 
1
H NMR 
spectroscopy). Purification by flash column chromatography on silica with 9:1-1:1 
petrol-Et2O as eluent gave N-Boc piperazine (R,R)-338 (41 mg, 27%) as a colourless 
oil, [α]D –7.8 (c 1.6 in CHCl3) and N-Boc piperazine (S,R)-337 (48 mg, 32%) as a 
colourless oil, [α]D +80.2 (c 1.0 in CHCl3). 
Lab Book Reference: JDF6_577 
 
s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of (–)-sparteine (152 mg, 149 µL, 0.65 mmol, 1.3 eq.) in Et2O (4 
mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 15 min. Then, 
a solution of N-Boc piperazine (R)-308 (145 mg, 0.5 mmol, 1.0 eq.) in Et2O (1 mL) was 
added dropwise. The resulting solution was stirred at –78 °C for 3 h. Then, TMEDA 
(240 mg, 375 µL, 2.5 mmol, 5.0 eq.) was added dropwise, and the resulting solution 
was stirred at –78 °C for 30 min. Then, methyl iodide (142 mg, 62 µL, 1.0 mmol, 2.0 
eq.) was added dropwise. The reaction mixture was allowed to warm to rt over 16 h. 
Then, saturated NH4Cl(aq) (10 mL) and saturated NaHCO3(aq) (10 mL) were added and 
the two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). 
The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude products in which contained a 10:90 mixture of 
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(R,R)-338 and (S,R)-337 (by 
1
H NMR spectroscopy). Purification by flash column 
chromatography on silica with 9:1-7:3 petrol-Et2O as eluent gave N-Boc piperazine 
(R,R)-338 (5 mg, 3%) as a colourless oil and N-Boc piperazine (S,R)-337 (106 mg, 
70%) as a colourless oil. 
Lab Book Reference: JDF6_578 
 
(R)-tert-butyl 2-methyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate (R,S)-337 
 
n-BuLi (51 µL of a 2.2 M solution in hexanes, 0.11 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of diastereomeric stannanes (S,S)-342 and (R,S)-341 (50 mg, 0.09 
mmol, 1.0 eq.) and TMEDA (13 mg, 17 µL, 0.11 mmol, 1.3 eq.) in Et2O (3 mL) at –78 
°C under Ar. The resulting solution was stirred at –78 °C for 10 min. Then, methyl 
iodide (25 mg, 11 µL, 0.17 mmol, 2.0 eq.) was added dropwise. The reaction mixture 
was stirred at –78 °C for 15 min and then allowed to warm to rt over 30 min. Then, 
saturated NH4Cl(aq) (5 mL) and saturated NaHCO3(aq) (5 mL) were added and the two 
layers were separated. The aqueous layer was extracted with Et2O (3 × 5 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure gave the crude product which contained a 7:93 mixture of (S,S)-338 and (R,S)-
337 (by 
1
H NMR spectroscopy). Purification by flash column chromatography on silica 
with 19:1 petrol-EtOAc as eluent gave N-Boc piperazine (R,S)-337 (18 mg, 69%). 
Lab Book Reference: JDF8_732 
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(S)-tert-Butyl (2-(methyl(1-phenylethyl)amino)ethyl)(vinyl)carbamate (S)-343 
 
Using general procedure C, s-BuLi (0.5 mL of a 1.3 M solution in hexanes, 0.65 mmol, 
1.3 eq.), (+)-sparteine surrogate (+)-26 (126 mg, 0.65 mmol, 1.3 eq.), N-Boc piperazine 
(S)-308 (145 mg, 0.5 mmol, 1.0 eq.) in Et2O (5 mL) for 1 h and methyl 
trifluoromethanesulfonate (164 mg, 113 µL, 1.0 mmol, 2.0 eq.), worked up with 
saturated NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica  with 4:1-1:1 petrol-Et2O as eluent gave alkene (S)-343 (71 
mg, 46%) as a colourless oil, RF (4:1 petrol-Et2O) 0.2; [α]D –21.0 (c 1.1 in CHCl3); IR 
(CHCl3) 2973, 2930, 2851, 2779, 1707 (C=O), 1623 (C=C), 1453, 1419, 1360, 1324, 
1247, 1205, 1150, 1060, 863, 832, 769 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.36-7.27 
(m, 4H, Ph), 7.25-7.18 (m, 1H, Ph), 7.08-6.82 (br m, 1H, CH=CH2), 4.17-3.92 (m, 2H, 
CH=CH2), 3.70-3.36 (m, 3H, NCH + CHMe), 2.59-2.53 (m, 1H, NCH), 2.46-2.32 (m, 
1H, NCH), 2.30 (br s, 3H, NMe), 1.45 (br s, 9H, CMe3), 1.35 (d, J = 6.5 Hz, 3H, 
CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 153.2 (C=O), 152.4 
(C=O), 143.9 (ipso-Ph), 132.7 (CH=CH2), 128.2 (Ph), 127.5 (Ph), 126.8 (Ph), 90.3 
(CH=CH2), 81.0 (CMe3), 63.9 (CHMe), 63.7 (CHMe), 50.4 (NCH2), 49.9 (NCH2), 41.5 
(NCH2), 41.0 (NCH2), 28.1 (CMe3), 18.6 (CHMe), 18.4 (CHMe); MS (ESI) m/z 305 (M 
+ H)
+
; HRMS m/z calcd for C18H28N2O2 (M + H)
+
 305.2224, found 305.2224 (+0.3 ppm 
error). 
Lab Book Reference: JDF10_977 
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(S)-1-(tert-Butoxycarbonyl)-4-((S)-1-phenylethyl)piperazine-2-carboxylic acid 
(S,S)-344 
 
Lithium hydroxide (4 mg, 0.17 mmol, 3.0 eq.) was added to a stirred solution of methyl 
ester (S,S)-330 (20 mg, 0.06 mmol, 1.0 eq.) in THF/MeOH/water (4:1:1, 3 mL) under 
air. The resulting solution was stirred at room temperature for 48 h. The volatiles were 
removed under reduced pressure. Then, water (5 mL) was added and the pH was 
adjusted to pH 4-5 with 1M HCl(aq). The aqueous was extracted with CH2Cl2 (3 × 5 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give N-Boc piperazine (S,S)-344 (18 mg, 94%) as a white solid, mp 
72-74 °C; [α]D –70.8 (c 0.75 in CHCl3); IR (CHCl3) 2934, 1666 (C=O), 1433, 1371, 
1346, 1280, 1148, 1102, 1048, 894 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (55:45 mixture 
of rotamers) δ 8.08 (br s, 1H, COOH), 7.29-7.40 (m, 5H, Ph), 4.75 (br s, 0.45H, NCH), 
4.60 (br s, 0.55H, NCH), 4.12 (q, J = 7.0 Hz, 1H, CHMe), 3.97 (br d, J = 14.0 Hz, 
0.55H, NCH), 3.85 (br d, J = 14.0 Hz, 0.45H, NCH), 3.76 (t, J = 11.0 Hz, 1H, NCH), 
3.41-3.64 (m, 1H, NCH), 3.29 (br d, J = 10.5 Hz, 0.55H, NCH), 3.21 (br d, J = 10.5 Hz, 
0.45H, NCH), 2.47 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 2.18-2.38 (m, 1H, NCH), 1.56-
1.69 (m, 3H, CHMe), 1.41 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) (mixture of 
rotamers) δ 172.7 (COOH), 155.1 (NC=O), 154.9 (NC=O), 136.9 (ipso-Ph), 128.8 (Ph), 
128.7 (Ph), 80.4 (CMe3), 64.8 (CHMe), 64.7 (CHMe), 54.7 (NCH), 53.5 (NCH), 49.3 
(NCH2), 40.5 (NCH2), 39.1 (NCH2), 28.3 (CMe3), 16.9 (CHMe), 16.8 (CHMe); MS 
(ESI) m/z 335 (M + H)
+
; HRMS m/z calcd for C18H26N2O4 (M + H)
+
 335.1965, found 
335.1961 (+0.9 ppm error). 
Lab Book Reference: JDF8_719 
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(S)-tert-Butyl 2-(tert-butylcarbamoyl)-4-((S)-1-phenylethyl)piperazine-1-
carboxylate (S,S)-345 
 
HATU (36 mg, 0.094 mmol, 1.5 eq.) was added in one portion to a stirred solution of 
acid (S,S)-344 (21 mg, 0.063 mmol, 1.0 eq.), tert-butylamine (7 mg, 10 µL, 0.094 
mmol, 1.5 eq.) and DIPEA (16 mg, 22 µL, 0.126 mmol, 2.0 eq.) in DMF (2 mL) at rt 
under Ar. The resulting solution was stirred at rt for 16 h. Saturated NaHCO3(aq) (5 mL) 
was added and the aqueous layer was extracted with Et2O (3 × 5 mL). The combined 
organic layers were washed with brine (3 × 5 mL), dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave N-Boc 
piperazine (S,S)-345 (24 mg, 98%) as a white solid, mp 91-93 °C; RF (7:3 petrol-EtOAc) 
0.3; [α]D –61.1 (c 0.8 in CHCl3); IR (CHCl3) 2974, 2932, 1653 (C=O), 1490, 1431, 
1394, 1346, 1194, 1148, 1101, 1015, 914, 769, 731, 658 cm
–1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.20-7.35 (m, 5H, Ph), 6.18 (br s, 1H, NH), 4.37 (br s, 1H, NCH), 3.94 (br s, 
1H, NCH), 3.45 (q, J = 6.5 Hz, 1H, CHMe), 3.20 (br d, J = 11.5 Hz, 1H, NCH), 3.09 (br 
s, 1H, NCH), 2.89 (br d, J = 9.5 Hz, 1H, NCH), 1.94-2.12 (m, 2H, NCH), 1.44 (s, 9H, 
CMe3), 1.36 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 168.9 (Me3CNC=O), 
155.0 (OC=O), 142.4 (ipso-Ph), 128.2 (Ph), 127.7 (Ph), 127.2 (Ph), 80.5 (OCMe3), 64.1 
(CHMe), 56.4 (NCH), 51.0 (NCMe3), 50.7 (NCH2), 49.2 (NCH2), 41.4 (NCH2), 28.7 
(CMe3), 28.3 (CMe3), 18.2 (CHMe); MS (ESI) m/z 390 (M + H)
+
; HRMS m/z calcd for 
C22H35N3O3 (M + H)
+
 390.2739, found 390.2751 (+3.5 ppm error). 
Lab Book Reference: JDF8_762 
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(S)-N-tert-Butylpiperazine-2-carboxamide dihydrochloride (S)-347 
 
1-Chloroethylchloroformate (27 mg, 20 µL, 0.189 mmol, 3.0 eq.) was added to a stirred 
solution of N-Boc piperazine (S,S)-345 (25 mg, 0.063 mmol, 1.0 eq.) in 1,2-
dichloroethane (3 mL) at rt under Ar. The resulting solution was stirred and heated at 
reflux for 3 h. After cooling to rt, the solvent was evaporated under reduced pressure. 
The intermediate bis-carbamate was purified by flash column chromatography on silica 
with 4:1 to 7:3 petrol-EtOAc as eluent, RF (7:3 petrol-EtOAc) 0.2. A solution of bis-
carbamate in MeOH (3 mL) was stirred and heated at reflux for 2 h. After cooling to rt, 
the solvent was evaporated under reduced pressure to give the N-Boc piperazine 
hydrochloride (S)-346 as a white gum (17 mg, 84%), 
1
H NMR (400 MHz, CDCl3) δ 
11.28 (br s, 1H, NH2
+
), 7.99 (br s, 1H, NH2
+
), 6.36 (br, s, 1H, CONH), 4.69 (br s, 1H, 
NCH), 4.07 (br s, 1H, NCH), 3.83 (br s, 1H, NCH), 3.60 (br d, J = 11.0 Hz, 1H, NCH), 
3.30 (t, J = 13.0 Hz, 1H, NCH), 3.10 (br s, 2H, NCH), 1.48 (s, 9H, CMe3), 1.31 (s, 9H, 
CMe3). The crude product was used in the next step without further purification (≥90% 
purity by 
1
H NMR spectroscopy). 
Lab Book Reference: JDF8_765 
 
HCl (2.0 M solution in Et2O, 1 mL) was added to a stirred solution of N-Boc piperazine 
hydrochloride (S)-346 (17 mg, 0.053 mmol, 1.0eq.) in Et2O (1 mL) at rt under air. The 
resulting suspension was stirred for 2 h. The resulting solids were removed by filtration 
and dried under reduced pressure to give piperazine dihydrochloride (S)-347 (10 mg, 
98%) as a white solid, mp 244-248 °C (decomp.); [α]D +4.5 (c 0.7 in MeOH); IR (ATR) 
3460, 3376, 3255, 2978, 2930, 2689, 1697 (C=O), 1681, 1646, 1449, 1366, 1296, 1290, 
1254, 1223, 1075, 1067, 1053, 960, 931 cm
–1
; 
1
H NMR (400 MHz, MeOD-d4) δ 4.37 
(dd, J = 12.0, 3.5 Hz, 1H, NCH), 3.90 (dd, J = 13.5, 3.0 Hz, 1H, NCH), 3.64-3.74 (m, 
2H, NCH), 3.55 (td, J =13.5, 3.0 Hz, 1H, NCH), 3.25-3.41 (m, 2H, NCH), 1.38 (s, 9H, 
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CMe3); 
13
C NMR (100.6 MHz, MeOD-d4) δ 164.0 (C=O), 55.2 (NCH), 53.2 (CMe3), 
44.3 (NCH2), 41.1 (NCH2), 40.7 (NCH2), 28.7 (CMe3); MS (ESI) m/z 186 (M + H)
+
; 
HRMS m/z calcd for C9H20N3O (M + H)
+
 186.0601, found 186.1610 (–4.4 ppm error). 
Lab Book Reference: JDF8_769 
 
(S)-tert-Butyl 2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazine-1-
carboxylate (S)-348 
 
3-(Chloromethyl)pyridine hydrochloride (13mg, 0.077 mmol, 2.5 eq.) was added to a 
stirred solution of N-Boc piperazine hydrochloride (S)-346 (10 mg, 0.031 mmol, 1.0 
eq.) and Et3N (16 mg, 22 µL, 0.155 mmol, 5.0 eq.) in CH2Cl2 (2 mL) at rt under Ar. The 
resulting solution was stirred at rt for 16 h. Then, 20% NaOH(aq) (3 mL) was added and 
the layers were separated. The aqueous was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 19:1 CH2Cl2:MeOH as eluent gave N-Boc piperazine (S)-348 (8 mg, 69%) as 
a pale yellow oil, [α]D –35.5 (c 0.3 in CHCl3); IR (CHCl3) 2924, 2883, 1652 (C=O), 
1487, 1432, 1372, 1346, 1283, 1145, 1102, 961 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 
8.51 (s, 1H, Ar), 7.70 (br s, 1H, Ar), 7.25-7.32 (m, 2H, Ar), 5.91 (br s, 1H, NH), 4.49 
(br s, 1H, NCH), 3.98 (br s, 1H, NCH), 3.57 (d, J = 13.5 Hz, 1H, CHAHBAr), 3.49 (d, J 
= 13.5 Hz, 1H, CHAHBAr), 3.41 (dt, J = 11.5, 1.5 Hz, 1H, NCH), 3.05 (s, 1H, NCH), 
2.71 (d, J = 10.5 Hz, 1H, NCH), 2.12-2.21 (m, 1H, NCH), 2.07 (td, J = 11.5, 2.5 Hz, 
1H, NCH), 1.47 (s, 9H, CMe3), 1.36 (s, 9H, CMe3); MS (ESI) m/z 377 (M + H)
+
; 
HRMS m/z calcd for C20H32N4O3 (M + H)
+
 377.2547, found 377.2535 (+2.6 ppm error). 
Lab Book Reference: JDF8_776 
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 (5R,8aS)-5-Methyl-1,1-diphenyl-7-((S)-1-phenylethyl)tetrahydro-1H-oxazolo[3,4-
a]pyrazin-3(5H)-one (R,S,S)-349 
 
Using general procedure B, s-BuLi (0.16 mL of a 1.3 M solution in hexanes, 0.21 
mmol, 1.3 eq.), N-Boc piperazine (R,S)-337 (50 mg, 0.16 mmol, 1.0 eq.), TMEDA (25 
mg, 32 µL, 0.21 mmol, 1.3 eq.) in Et2O (3 mL), with a solution of benzophenone (60 
mg, 0.33 mmol, 2.0 eq.) in Et2O (0.5 mL), worked up with saturated NaHCO3(aq) (10 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 8:2 petrol-Et2O as eluent gave oxazolidinone (R,S,S)-349 (33 mg, 49%) as a white 
solid, mp 116-119 °C; RF (8:2 petrol-Et2O) 0.2; [α]D –177.1 (c 1.6 in CHCl3); IR 
(CHCl3) 2983, 2963, 1718 (C=O), 1469, 1428, 1397, 1298, 1216, 1184, 1054, 1017, 
986, 691, 654 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.53-7.46 (m, 2H, Ph), 7.42-7.17 (m, 
13H, Ph), 4.67 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 4.06-3.98 (m, 1H, NCH), 3.28 (q, J = 
6.5 Hz, 1H, CHMe), 2.70 (ddd, J = 11.0, 3.5, 1.5 Hz, 1H, NCH), 2.51 (br d, J = 11.5 
Hz, 1H, NCH), 1.99 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 1.42 (t, J = 11.0 Hz, 1H, NCH), 
1.31 (d, J = 6.5 Hz, 3H, CHMe), 1.20 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 
MHz, CDCl3) δ 155.6 (C=O), 143.3 (ipso-Ph), 142.3 (ipso-Ph), 138.9 (ipso-Ph), 128.5 
(Ph), 128.4 (Ph), 128.3 (Ph), 128.2 (Ph), 127.8 (Ph), 127.2 (Ph), 127.0 (Ph), 126.1 (Ph), 
125.9 (Ph), 85.3 (CMe3), 64.1 (CHMe), 58.0 (NCH), 54.3 (NCH2), 52.8 (NCH2), 46.4 
(NCH), 19.5 (CHMe), 16.3 (CHMe); MS (ESI) m/z 413 (M + H)
+
; HRMS m/z calcd for 
C27H28N2O2 (M + H)
+
 413.2224, found 413.2216 (+1.7 ppm error). 
Lab Book Reference: JDF8_740 
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(2S,6R)-1-tert-Butyl 2-methyl 6-methyl-4-((S)-1-phenylethyl)piperazine-1,2-
dicarboxylate (S,R,S)-351 
 
Using general procedure B, s-BuLi (0.16 mL of a 1.3 M solution in hexanes, 0.21 
mmol, 1.3 eq.), N-Boc piperazine (R,S)-337 (50 mg, 0.16 mmol, 1.0 eq.), TMEDA (25 
mg, 32 µL, 0.21 mmol, 1.3 eq.) in Et2O (3 mL) for 1 h and a methyl chloroformate (31 
mg, 25 µL 0.33 mmol, 2.0 eq.), worked up with saturated NaHCO3(aq) (10 mL) gave the 
crude product. Purification by flash column chromatography on silica with 19:1-7:3 
petrol-Et2O as eluent gave N-Boc piperazine (R,R,S)-351 (46 mg, 77%) as pale yellow 
oil, RF (8:2 petrol-Et2O) 0.2; [α]D –45.2 (c 1.1 in CHCl3); IR (CHCl3) 2932, 2777, 1716 
(C=O, ester), 1665 (C=O, Boc), 1468, 1431, 1347, 1298, 1235, 1151, 1068, 1011, 895, 
847 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.36-7.20 (m, 5H, Ph), 4.20 (dd, J = 7.5, 4.0 
Hz, 1H, NCH), 3.99-3.88 (m, 1H, NCH), 3.72 (s, 3H, CO2Me), 3.32 (q, J = 6.5 Hz, 1H, 
CHMe), 2.86 (br s, 1H, NCH), 2.45 (br s, 2H, NCH), 2.31 (br s, 1H, NCH), 1.42 (s, 9H, 
CMe3), 1.32 (d, J = 6.5 Hz, 3H, CHMe), 1.26-1.20 (m, 3H, CHMe); 
13
C NMR (100.6 
MHz, CDCl3) δ 172.1 (CO2Me), 155.6 (NC=O), 143.5 (ipso-Ph), 128.2 (Ph), 127.4 
(Ph), 127.0 (Ph), 80.6 (CMe3), 64.1 (CHMe), 56.1 (br, NCH2), 52.2 (NCH2), 52.0 
(CO2Me), 49.0 (NCH), 28.1 (CMe3), 19.7 (CHMe), 17.9 (CHMe) (NCH not resolved); 
MS (ESI) m/z 363 (M + H)
+
; HRMS m/z calcd for C20H30N2O4 (M + H)
+
 363.2278, 
found 363.2272 (+1.2 ppm error). 
Lab Book Reference: JDF8_749 
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(2R,6R)-tert-Butyl 2,6-diallyl-4-((S)-1-phenylethyl)piperazine-1-carboxylate 
(R,R,S)-353 
 
Using general procedure E, s-BuLi (0.15 mL of a 1.3 M solution in hexanes, 0.20 mmol, 
1.3 eq.), N-Boc piperazine (R,S)-339 (50 mg, 0.15 mmol, 1.0 eq.), TMEDA (23 mg, 29 
µL, 0.20 mmol, 1.3 eq.) in Et2O (3 mL) for 1 h, CuCN.2LiCl (0.076 mmol, 0.5 eq.) in 
THF (0.5 mL) and allyl bromide (37 mg, 26 µL, 0.3 mmol, 2.0 eq.), worked up with 
saturated NaHCO3(aq) (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 19:1 petrol-Et2O as eluent gave N-Boc piperazine 
(R,R,S)-353 (32 mg, 57%) as a colourless oil, RF (9:1 petrol-Et2O) 0.2; [α]D –35.9 (c 1.5 
in CHCl3); IR (CHCl3) 2972, 2932, 2886, 2774, 1665 (C=O), 1430, 1370, 1346, 1301, 
1196, 1151, 980, 906, 840, 747, 692, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 7.33-
7.27 (m, 4H, Ph), 7.25-7.20 (m, 1H, Ph), 5.75-5.62 (m, 2H, CH=CH2), 5.05-4.94 (m, 
4H, CH=CH2), 3.74-3.68 (m, 2H, NCH), 3.34 (q, J = 6.5 Hz, 1H, CHMe), 2.66-2.42 (m, 
6H, CH2 + NCH), 2.36 (br d, J = 6.0 Hz, 1H, CH2 or NCH), 2.33 (br d, J = 6.0 Hz, 1H, 
CH2 or NCH), 1.44 (s, 9H, CMe3), 1.34 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR (100.6 
MHz, CDCl3) δ 156.0 (C=O), 144.0 (ipso-Ph), 135.6 (CH=CH2), 128.2 (Ph), 127.5 (Ph), 
126.9 (Ph), 116.9 (CH=CH2), 79.6 (CMe3), 64.4 (CHMe), 53.1 (NCH), 52.5 (NCH2), 
36.7 (CH2), 28.4 (CMe3), 19.9 (CHMe); MS (ESI) m/z 371 (M + H)
+
; HRMS m/z calcd 
for C23H34N2O2 (M + H)
+
 371.2693, found 371.2689 (+0.7 ppm error). 
Lab Book Reference: JDF8_743 
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(2R,6R)-tert-Butyl 2,6-diallylpiperazine-1-carboxylate hydrochloride (R,R)-354 
 
1-Chloroethylchloroformate (36 mg, 27 µL, 0.25 mmol, 3.0 eq.) was added to a stirred 
solution of N-Boc piperazine (R,R,S)-353 (31 mg, 0.08 mmol, 1.0 eq.) in 1,2-
dichloroethane (3 mL) at rt under Ar. The resulting solution was stirred and heated at 
reflux for 3 h. After cooling to rt, the solvent was evaporated under reduced pressure. 
The intermediate bis-carbamate was purified by flash column chromatography on silica 
with 9:1 petrol-EtOAc as eluent, RF (9:1 petrol-EtOAc) 0.2. A solution of bis-carbamate 
in MeOH (3 mL) was stirred and heated at reflux for 2 h. After cooling to rt, the solvent 
was evaporated under reduced pressure to give the N-Boc piperazine hydrochloride 
(R,R)-354 as a hydroscopic solid (14 mg, 55%), [α]D –34.9 (c 0.7 in CHCl3); IR 
(CHCl3) 2933, 2666 (NH2
+
), 1664 (C=O), 1564, 1438, 1366, 1347, 1313, 1240, 1196, 
1150, 1103, 1047, 894, 741 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 10.17 (s, 2H, NH2
+
), 
5.84-5.72 (m, 2H, CH=CH2), 5.41 (d, J = 17.0 Hz, 2H, CH=CHACHB), 5.17 (d, J = 10.0 
Hz, 2H, CH=CHACHB), 4.01-3.90 (m, 2H, NCH), 3.45-3.23 (m, 4H, NCH), 2.59-2.48 
(m, 2H, CH2), 2.48-2.38 (m, 2H, CH2), 1.47 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, 
CDCl3) δ 153.8 (C=O), 133.0 (CH=CH2), 120.0 (CH=CH2), 81.1 (CMe3), 48.9 (NCH), 
40.7 (NCH2), 37.8 (CH2), 28.3 (CMe3); MS (ESI) m/z 267 (M + H)
+
; HRMS m/z calcd 
for C15H26N2O2 (M + H)
+
 267.2067, found 267.2055 (+4.3 ppm error). 
Lab Book Reference: JDF8_777 
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(R)-tert-Butyl 3,4-dimethylpiperazine-1-carboxylate (R)-356 
 
A solution of N-Boc piperazine (R,S)-337 (244 mg, 0.80 mmol, 1.0 eq.) in THF (5 mL) 
was added dropwise to a stirred suspension of lithium aluminium hydride (122 mg, 3.2 
mmol, 4.0 eq.) in THF (5 mL) at 0 °C under Ar. The resulting mixture was allowed to 
warm to rt and then stirred at reflux for 16 h. After cooling to 0
 
°C, the mixture was 
diluted with Et2O (10 mL). Water (122 µL), 20% NaOH(aq) (244 µL) and water (122 
µL) were sequentially added dropwise and the mixture stirred for 15 min. Then, 
anhydrous MgSO4 was added and the mixture stirred for 30 min. The solids were 
removed by filtration through Celite
®
 and washed with Et2O (10 mL). The filtrate was 
concentrated under reduced pressure to give the crude amine (R,S)-355 (153 mg, 88%) 
as a pale yellow oil, 
1
H NMR (400 MHz, CDCl3) δ 7.27-7.33 (m, 4H, Ph), 7.19-7.25 (m, 
1H, Ph), 3.33 (q, J = 6.5 Hz, 1H, CHMe), 2.92 (br d, J = 11.0 Hz, 1H, NCH), 2.67-2.77 
(m, 1H, NCH), 2.58-2.67 (m, 1H, NCH), 2.28 (s, 3H, NMe), 2.09-2.28 (m, 3H, NCH), 
1.91 (m, 1H, NCH), 1.36 (d, J = 6.5 Hz, 3H, CHMe), 1.08 (d, J = 6.5 Hz, 3H, CHMe). 
The crude product was used in the next step without further purification (≥90% purity 
by 
1
H NMR spectroscopy). 
Lab Book Reference: JDF9_810 
 
10% Pd/C (20 mg) was added to a stirred solution of N-Boc-N′-cumyl piperazine (R,S)-
355 (153 mg, 0.70 mmol, 1.0 eq.) in MeOH (10 mL) and conc. HCl (5 drops). Then, the 
reaction flask evacuated under reduced pressure and back filled with Ar three times. 
After a final evacuation, a balloon of H2 was attached and the reaction mixture was 
stirred vigorously at rt under H2 for 16 h. The mixture was filtered through Celite
®
 and 
washed with MeOH (20 mL). The filtrate was evaporated under reduced pressure to 
give crude secondary amine hydrochloride. A solution of di-tert-butyl dicarbonate (183 
mg, 0.84 mmol, 1.2 eq.) in CH2Cl2 (20mL) was added dropwise a stirred solution of 
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secondary amine hydrochloride (max. 0.7 mmol, 1.0 eq.) in CH2Cl2 (3 mL) and Et3N 
(354 g, 488 mL, 3.5 mmol, 5.0 eq.) at 0 °C under Ar. The resulting solution was 
allowed to warm to rt and stirred at rt for 16 h. Then, 20% NaOH(aq) (10 mL) was added 
and the two layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 5 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 19:1 CH2Cl2-MeOH as eluent gave N-Boc piperazine 
(R)-356 (130 mg, 87%) as a pale yellow oil, RF (19:1 CH2Cl2-MeOH) 0.1; [α]D –0.3 (c 
0.9 in CHCl3); IR (CHCl3) 2934, 2889, 2809, 2755, 1659 (C=O), 1435, 1406, 1370, 
1345, 1319, 1270, 1252, 1227, 1135, 1093, 1070, 1049, 1024, 964, 868 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) δ 3.66-3.97 (m, 2H, NCH), 3.00 (br t, J = 11.0, 1H, NCH), 2.71 (br 
d, J = 11.5 Hz, 1H, NCH), 2.59 (br s, 1H, NCH), 2.27 (s, 3H, NMe), 2.15 (td, J = 11.5, 
3.0 Hz, 1H, NCH), 1.96-2.07 (m, 1H, NCH), 1.42 (s, 9H, CMe3), 1.04 (d, J = 6.0 Hz, 
3H, CHMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 154.5 (C=O), 79.6 
(CMe3), 57.5 (NCH), 54.9 (NCH2), 50.2 (NCH2), 49.2 (NCH2), 44.0 (NCH2), 43.2 
(NCH2), 42.4 (NMe), 28.2 (CMe3), 16.3 (CHMe); MS (ESI) m/z 215 [(M + H)
+
, 100], 
159 [(M – CMe3)
+
, 20]; HRMS  m/z calcd for C11H22N2O2 (M + H)
+
 215.1754, found 
215.1746 (+3.9 ppm error).  
Lab Book Reference: JDF9_812 
 
(6R,8R)-6,7-Dimethyl-1,1-diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 
(R,R)-347 
 
Using general procedure B, s-BuLi (0.14 mL of a 1.3 M solution in hexanes, 0.18 
mmol, 1.3 eq.), N-Boc piperazine (R)-356 (30 mg, 0.14 mmol, 1.0 eq.), TMEDA (21 
mg, 27 µL, 0.18 mmol, 1.3 eq.) in Et2O (3 mL) for 1 h and a solution of benzophenone 
(51 mg, 0.28 mmol, 2.0 eq.) in Et2O (1 mL), worked up with saturated NaHCO3(aq) (10 
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mL) gave the crude product. Purification by flash column chromatography on silica 
with EtOAc as eluent gave oxazolidinone (R,R)-357 (24 mg, 53%) as white solid, mp 
184-187 °C; RF (EtOAc) 0.2; [α]D +151.4 (c 1.2 in CHCl3); IR (CHCl3) 2972, 2885, 
2813, 1724 (C=O), 1471, 1427, 1322, 1196, 1069, 996, 949, 915, 746 cm
–1
; 
1
H NMR 
(400 MHz, CDCl3) δ 7.47-7.55 (m, 2H, Ph), 7.26-7.42 (m, 8H, Ph), 4.63 (dd, J = 11.0, 
3.0 Hz, 1H, NCH), 3.76 (dd, J = 13.0 Hz, 3.5, 1H, NCH), 2.79 (dd, J = 13.0, 11.5 Hz, 
1H, NCH), 2.46 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 2.21 (s, 3H, NMe) 1.99-2.11 (m, 1H, 
NCH), 1.70 (t, J = 11.5 Hz, 1H, NCH), 1.08 (d, J = 6.5 Hz, 3H, CHMe); 
13
C NMR 
(100.6 MHz, CDCl3) δ 155.9 (C=O), 142.2 (ipso-Ph), 138.5 (ipso-Ph), 128.6 (Ph), 128.5 
(Ph), 128.4 (Ph), 127.9 (Ph), 125.9 (Ph), 125.7 (Ph), 85.2 (Ph2CO), 60.8 (NCH), 57.6 
(NCH2), 56.9 (NCH), 47.8 (NCH2), 42.7 (NMe), 16.5 (CHMe); MS (ESI) m/z 323 (M + 
H)
+
; HRMS m/z calcd for C20H23N2O2 (M + H)
+
 323.1754, found 323.1741 (+3.7 ppm 
error). 
Lab Book Reference: JDF9_817 
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6.6 Experimental for Chapter Five 
 
Ethyl 2-(pyridin-2-yl)acetate 364 
 
n-BuLi (2.5 M solution in hexanes, 84.0 mL, 0.21 mol, 2.05 eq.) was added dropwise to 
a stirred solution of diisopropylamine (22.3 g, 30.8 mL, 0.22 mol, 2.10 eq.) in THF (100 
mL) at –78 °C under Ar. The resulting solution was warmed to 0 °C and stirred at 0 °C 
for 1 h. Then, the solution was transferred via cannula to a stirred solution of 2-picoline 
402 (9.3 g, 9.9 mL, 0.10 mol, 1.0 eq.) and diethyl carbonate (35.4 g, 36.3 mL, 0.30 mol, 
3.0 eq.) in THF (100 mL) at –78 °C under Ar. The resulting solution was stirred at –78 
°C for 1 h. Then, the solution was allowed to warm to rt and stirred at rt for 30 min. 
Saturated NH4Cl(aq) (50 mL) and water (200 mL) were added. The two layers were 
separated and the aqueous layer was extracted with Et2O (3 × 100 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by Kugelrohr distillation gave ester 364 (14.7 g, 
89%) as a bright yellow oil, bp 110-120 °C/2.3 mmHg (lit.,
274
 bp 110 °C/3 mmHg); 
1
H 
NMR (400 MHz, CDCl3) δ 8.54 (m, 1H, o-Ar), 7.64 (td, J = 7.5, 2.0 Hz, 1H, p-Ar), 7.28 
(d, J = 7.5 Hz, 1H, m-Ar), 7.17 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, m-Ar), 4.16 (q, J = 7.0 
Hz, 2H, CH2Me), 3.82 (s, 2H, ArCH2), 1.24 (t, J = 7.0 Hz, 3H, CH2Me); 
13
C NMR 
(100.6 MHz, CDCl3) δ 170.6 (C=O), 154.4 (ipso-Ar), 149.4 (Ar), 136.6 (Ar), 123.8 
(Ar), 122.0 (Ar), 61.0 (CH2Me), 43.9 (ArCH2), 14.1 (CH2Me). Spectroscopic data 
consistent with those reported in the literature.
275
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Ethyl 2-(piperidin-2-yl)acetate 365 
 
PtO2·H2O (223 mg, 0.91 mmol, 0.006 eq.) was added to a stirred solution of pyridine 
364 (25.0 g, 151 mmol, 1.0 eq.) in EtOH (250 mL) and 6M HCl(aq) (45 mL). The 
reaction flask evacuated under reduced pressure and back filled with N2 three times. 
After a final evacuation, H2 was charged at 2 atm and the reaction mixture was stirred 
vigorously at rt for 24 h. The mixture was filtered through Celite
®
 and washed with 
EtOH (300 mL) and the filtrate was evaporated under reduced pressure. Then, the 
residue was dissolved in 2M NH4OH(aq) (200 mL) and the aqueous layer was extracted 
with CH2Cl2 (5 × 100 mL). The combined organic layers were dried (MgSO4), filtered 
and evaporated under reduced pressure to give the piperidine 365 (23.2 g, 90%) as a 
clear oil, 
1
H NMR (400 MHz, CDCl3) δ 4.10 (q, J = 7.0 Hz, 2H, CH2Me), 2.96-3.05 (m, 
1H, NCH), 2.87 (dddd, J = 10.5, 7.5, 5.5, 2.5 Hz, 1H, NCH), 2.58-2.68 (m, 1H, NCH), 
2.33-2.37 (m, 1H, CHAHBCO2Et), 2.27-2.32 (m, 1H, CHAHBCO2Et), 2.04 (br s, 1H, 
NH), 1.68-1.78 (m, 1H, CH2), 1.49-1.62 (m, 2H, CH2), 1.26-1.44 (m, 2H, CH2), 1.22 (t, 
J = 7.0 Hz, 3H, CH2Me), 1.05-1.18 (m, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 
172.4 (C=O), 60.3 (CH2Me), 53.3 (NCH), 46.8 (NCH2), 41.7 (CH2), 32.6 (CH2), 26.0 
(CH2), 24.6 (CH2), 14.2 (CH2Me). Spectroscopic data consistent with those reported in 
the literature.
276 
Lab Book Reference: JDF10_927 
 
Ethyl 3-(2-(2-ethoxy-2-oxoethyl)piperidin-1-yl)propanoate 366 
 
Ethyl acrylate (36.8 g, 40.1 mL, 0.37 mol, 3.0 eq.) was added dropwise to a stirred 
solution of piperidine 365 (21.0 g, 123 mmol, 1.0 eq.) and Et3N (74.5 g, 103 mL, 0.74 
mol, 6.0 eq.) in EtOH (400 mL) at rt under Ar. The resulting solution was stirred at rt 
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for 4 d. The mixture was concentrated under reduced pressure to give the crude product. 
Purification by Kugelrohr distillation gave di-ester 366 (31.3 g, 94%) as a clear oil, bp 
155-165 °C/1.0 mmHg (lit.,
213
 bp 175-180 °C/1.0 mmHg); 
1
H NMR (400 MHz, CDCl3) 
δ 4.12 (q, J = 7.0 Hz, 2H, CH2Me), 4.11 (q, J = 7.0 Hz, 2H, CH2Me), 2.96–2.82 (m, 2H, 
NCH), 2.77–2.59 (m, 3H, NCH), 2.45 (t, J = 7.5 Hz, 2H, CH2CO2Et), 2.39–2.23 (m, 
2H, CH2CO2Et), 1.73–1.30 (m, 6H, CH2), 1.24 (t, J = 7.0 Hz, 3H, CH2Me), 1.24 (t, J = 
7.0 Hz, 3H, CH2Me); 
13
C NMR (100.6 MHz, CDCl3) δ 172.6 (C=O), 60.4 (CH2Me), 
60.3 (CH2Me), 56.3 (NCH), 50.2 (NCH2), 49.4 (NCH2), 35.7 (CH2), 31.9 (CH2), 30.7 
(CH2), 25.2 (CH2), 22.0 (CH2), 14.2 (Me), 14.2 (Me). Spectroscopic data consistent 
with those reported in the literature.
213
 
Lab Book Reference: JDF10_902 
 
Hexahydro-1H-quinolizin-2(6H)-one 361 
 
LHMDS (118 mL of a 1 M solution in THF, 118 mmol, 2.0 eq.) was added dropwise to 
a stirred solution of di-ester 366 (16.0 g, 58.9 mmol, 1.0 eq.) in THF (60 mL) at –78 °C 
under N2. After stirring for 2 h at –78 °C, water (40 mL) was added and the solution 
was warmed to room temperature. 12 M HCl(aq) (30 mL) was added and the mixture was 
extracted with MTBE (3 × 100 mL). Then, saturated K2CO3(aq) was added to the 
aqueous layer until pH 10 was obtained. The aqueous layer was extracted with MTBE 
(3 × 100 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude β-keto ester as a yellow oil. Then, 6 
M HCl (300 mL) was added and the resulting solution was stirred and heated at reflux 
for 16 h. After cooling to room temperature, the solution was carefully neutralised with 
solid potassium carbonate until gas evolution stopped and the solution was saturated. 
The solid was removed by filtration and washed with MTBE (100 mL). Then, the layers 
were separated and the aqueous was extracted with MTBE (3 × 100 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude amino ketone 361 (7.15 g, 79%) as a pale yellow oil which was 
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sufficiently pure by 
1
H NMR spectroscopy,
 1
H NMR (400 MHz, CDCl3) δ 3.11–3.03 
(m, 1H, NCH), 3.00–2.92 (m, 1H, NCH), 2.73–2.60 (m, 1H, NCH), 2.39–2.22 (m, 4H, 
NCH + CH2CO), 2.12–1.98 (m, 2H, CH2CO), 1.80–1.56 (m, 4H, CH2), 1.41-1.15 (m, 
2H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 208.4 (C=O), 61.8 (NCH), 55.4 (NCH2), 
55.3 (NCH2), 48.1 (CH2CO), 41.3 (CH2CO), 33.6 (CH2), 25.5 (CH2), 23.2 (CH2). 
Spectroscopic data consistent with those reported in the literature.
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3-Methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-12-one 362 
 
Methylamine (8.8 mL of a 8.0 M solution in EtOH, 46.6 mmol, 1.5 eq.) was added to a 
stirred solution of amino ketone 361 (7.10 g, 46.6 mmol, 1.0 eq.), paraformaldehyde 
(4.20 g, 140 mmol, 3.0 eq.) and acetic acid (2.80 g, 2.67 mL, 46.6 mmol, 1.0 eq.) in 
MeOH (100 mL) at room temperature under N2. The resulting solution was stirred and 
heated at reflux for 24 h. After cooling to room temperature, the solvent was evaporated 
under reduced pressure and 50% KOH(aq) (50 mL) was added to the residue. The 
aqueous mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by Kugelrohr distillation gave diazatricyclic ketone 362 (3.27 g, 
34%) as a colourless oil, bp 160-170 °C/1.0 mmHg (lit.,
213
 bp 140-150 °C/0.8 mmHg); 
1
H NMR (400 MHz, CDCl3) δ 3.21 (dd, J = 11.0, 3.0 Hz, 1H, NCH or CHCO), 3.09–
2.95 (m, 3H, NCH or CHCO), 2.94–2.86 (m, 1H, NCH or CHCO), 2.79 (ddd, J = 11.0, 
8.5, 1.5 Hz, 1H, NCH or CHCO), 2.59–2.52 (m, 1H, NCH or CHCO), 2.40 (dd, J = 
11.5, 3.0 Hz, 1H, NCH or CHCO), 2.36–2.29 (m, 1H, NCH or CHCO), 2.25 (s, 3H, 
NMe), 2.12 (dt, J = 11.0, 2.0 Hz, 1H, NCH or CHCO), 1.97–1.86 (m, 1H, NCH or 
CHCO), 1.81–1.70 (m, 1H, CH2), 1.69–1.52 (m, 3H, CH2), 1.41–1.32 (m, 1H, CH2), 
1.29–1.12 (m, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 214.7 (C=O), 66.8 (NCH), 
62.5 (NCH2), 60.5 (NCH2), 56.4 (NCH2), 55.0 (NCH2), 52.2 (NMe), 47.5 (CH), 45.4 
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(CH), 29.9 (CH2), 25.5 (CH2), 23.4 (CH2). Spectroscopic data consistent with those 
reported in the literature.
213
 
Lab Book Reference: JDF9_896 
 
Methylamine (6.5 mL of a 8.0 M solution in EtOH, 52.2 mmol, 1.0 eq.) was added to a 
stirred solution of amino ketone 361 (7.95 g, 52.2 mmol, 1.0 eq.), paraformaldehyde 
(3.14 g, 105 mmol, 2.0 eq.) and acetic acid (3.13 g, 2.99 mL, 52.2 mmol, 1.0 eq.) in 
MeOH (80 mL) at room temperature under N2. The resulting solution was stirred and 
heated at reflux for 24 h. After cooling to room temperature, the solvent was evaporated 
under reduced pressure and 50% KOH(aq) (50 mL) was added to the residue. The 
aqueous mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by Kugelrohr distillation gave diazatricyclic ketone 362 (4.07 g, 
37%) as a colourless oil. 
Lab Book Reference: JDF10_931 
 
 
 
Methylamine (188 µL of a 8.0 M solution in EtOH, 1.5 mmol, 1.5 eq.) was added to a 
stirred solution of amino ketone 361 (152 mg, 1.0 mmol, 1.0 eq.), paraformaldehyde (90 
mg, 3.0 mmol, 3.0 eq.) and acetic acid (90 mg, 86 µL, 1.5 mmol, 1.5 eq.) in MeOH (30 
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mL) at room temperature under N2. The reaction mixture was quickly transferred to a 
pre-heated aluminium heating block and stirred and heated to reflux. After 10 min (from 
the beginning heating) a small sample (100 µL) was removed, diluted with MeOH (1 
mL) and analysed by GC to determine the conversion of bicyclic ketone 361 to 
bispidone 362. Samples were periodically taken over 24 h and analysed by GC.   
Lab Book Reference: JDF10_923 
 
 
 
Methylamine (152 µL of a 8.0 M solution in EtOH, 1.0 mmol, 1.0 eq.) was added to a 
stirred solution of amino ketone 361 (152 mg, 1.0 mmol, 1.0 eq.), paraformaldehyde (60 
mg, 2.0 mmol, 2.0 eq.) and acetic acid (60 mg, 57 µL, 1.0 mmol, 1.0 eq.) in MeOH (30 
mL) at room temperature under N2. The reaction mixture was quickly transferred to a 
pre-heated aluminium heating block and stirred and heated to reflux. After 10 min (from 
the beginning heating) a small sample (100 µL) was removed, diluted with MeOH (1 
mL) and analysed by GC to determine the conversion of bicyclic ketone 361 to 
bispidone 362. Samples were periodically taken over 24 h and analysed by GC.   
Lab Book Reference: JDF10_922 
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Attempted synthesis of 3-Phenyldecahydro-1H-1,5-methanopyrido[1,2-
a][1,5]diazocin-12-one 404 
 
dl-Proline (6 mg, 0.05 mmol, 0.1 eq.) was added to a stirred solution of bicyclic ketone 
361 (77 mg, 0.5 mmol, 1.0 eq.), aniline (70 mg, 68 µL, 1.5 eq.) and paraformaldehyde 
(45 mg, 1.5 mmol, 3.0 eq.) in DMSO (2 mL) and water (100 µL) at rt under air. The 
resulting mixture was stirred at rt for 48 h. Then, 20% NaOH(aq.) (5 mL) and Et2O (5 
mL) were added. The two layers were separated and the aqueous layer was extracted 
with Et2O (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 
mL), dried (MgSO4), filtered and evaporated under reduced pressure to give a crude 
mixture which contained a complex mixture of products (by 
1
H NMR spectroscopy and 
mass spectrometry).  
Lab Book Reference: JDF10_932 
 
3-Methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 26 
 
Hydrazine monohydrate (4.89 g, 4.74 mL, 97.7 mmol, 5.0 eq.) was added to a stirred 
solution of diazatricyclic ketone 362 (4.07 g, 19.5 mmol, 1.0 eq.) and KOH (11.0 g, 195 
mmol, 10 eq.) in diethylene glycol (60 mL) at rt under N2. The resulting solution was 
stirred and heated at 160 °C for 16 h. After cooling to 60 °C, H2O (50 mL) and 1M 
HCl(aq) (50 mL) were added. The aqueous layer was extracted with MTBE (3 × 50 mL). 
Then, the pH of the aqueous layer was adjusted to pH 12 with 50% KOH(aq). The 
aqueous was extracted with MTBE (3 × 50 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by Kugelrohr distillation gave diamine 26 (2.56 g, 68%) as a 
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colourless oil, bp 170-180 °C/2.0 mmHg (lit.,
213
 bp 150-160 °C/0.8 mmHg); 
1
H NMR 
(400 MHz, CDCl3) δ 3.00-2.95 (m, 2H, NCH), 2.89 (m, 2H, NCH), 2.22 (ddd, J = 11.0, 
3.5, 1.5 Hz, 1H, NCH), 2.14-2.11 (m, 1H, NCH), 2.13 (s, 3H, NMe), 1.94 (dd, J = 11.5, 
3.0 Hz, 1H, NCH), 1.87 (br d, J = 11.0 Hz, 1H, NCH), 1.77-1.46 (m, 9H, NCH + CH), 
1.32-1.20 (m, 2H, CH); 
13
C NMR (100.6 MHz, CDCl3) δ 66.4 (NCH), 60.4 (NCH2), 
60.3 (NCH2), 57.6 (NCH2), 56.3 (NCH2), 47.2 (NMe), 35.0 (CH), 33.8 (CH2), 30.4 
(CH), 25.5 (CH2), 24.9 (CH2). Spectroscopic data consistent with those reported in the 
literature.
213
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Resolution of 3-methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 26 
 
Using general procedure F, the results shown in Tables 5.2 and 5.3 were obtained 
Entry Resolving agent Solvent Yield / % er [(–)/(+)]a 
1 (+)-367 MeCN – – 
2 (+)-367 Acetone – – 
3 (+)-367 IPA – – 
4 (+)-367 MTBE 43 50:50 
5 (–)-368 MeCN – – 
6 (–)-368 Acetone 20 27:73 
7 (–)-368 IPA – – 
8 (–)-368 MTBE 26 36:64 
9 (–)-369 MeCN 12 98:2 
10 (–)-369 Acetone 32 72:28 
11 (–)-369 IPA – – 
12 (–)-369 MTBE 49 55:45 
13 (S)-370 MeCN – – 
14 (S)-370 Acetone – – 
15 (S)-370 IPA – – 
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16 (S)-370 MTBE – – 
17 (–)-369 MeOAc 33 77:23 
18 (–)-369 EtOAc 40 80:20 
19 (–)-369 nPrOAc 35 77:23 
20 (–)-369 iPrOAc 33 69:31 
21 (–)-369 BuOAc 38 66:34 
22 (–)-369 MEK – – 
23 (–)-369 MIBK – – 
24 (–)-369 Et2O 25 63:27 
25 (–)-369 THF 31 81:19 
26 (–)-369 2-Me THF 25 67:33 
27 (–)-369 CPME 28 74:26 
28 (–)-369 Toluene 40 57:42 
29 (–)-369 Cyclohexane – – 
30 (–)-369 BuCN – – 
31 (–)-369 PhCN – – 
32 (–)-369 8:2 MeCN / 
acetone 
23 97:3 
33 (–)-369 1:1 MeCN / 
acetone 
23 90:10 
34 (–)-369 19:1 MeCN / H2O – – 
35 (–)-369 9:1 MeCN / H2O – – 
36 (–)-369 8:2 MeCN / H2O – – 
a
 Enantiomeric ratio of the free base determined by CSP-GC 
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(1S,5R,11aR)-3-Methyldodecahydro-1,5-methanopyrido[1,2-a][1,5]diazocine-3,7-
diium (2R,3R)-2,3-bis((4-methylbenzoyl)oxy)succinate (–)-26.(–)-369 
 
A solution of (−)-O,O′-di-p-toluoyl-L-tartaric acid (–)-369 (193 mg, 0.5 mmol, 0.5 eq.) 
in 4:1 MeCN/acetone (0.3 mL) was added to a stirred solution of 26 (194 mg, 1.0 mmol, 
1.0 eq.) in 4:1 MeCN/acetone (0.3 mL) at rt. The resulting mixture was stirred at rt for 
16 h. The solid was collected by filtration, washed with cold 4:1 MeCN-acetone (2 mL) 
and dried under reduced pressure to give salt (–)-26.(–)-369 (154 mg, 27%) as a white 
solid, mp 155-156 °C (decomposition); 
1H NMR (400 MHz, MeOD) δ 8.02 (d, J = 8.0 
Hz, 4H, Ar), 7.29 (d, J = 8.0 Hz, 4H, Ar), 5.87 (s, 2H, CHCO2H), 3.39 (br d, J = 12.0 
Hz, 1H, NCH), 3.29-3.21 (m, 2H, NCH), 3.20-3.12 (m, 1H, NCH), 2.95-2.82 (m, 2H, 
NCH), 2.69 (dt, J = 11.5, 2.5 Hz, 1H, NCH), 2.62-2.55 (m, 1H, NCH), 2.46 (s, 3H, 
NMe), 2.49-2.38 (m, 1H, NCH), 2.41 (s, 6H, ArMe), 2.17-2.10 (m, 1H, CH), 1.91-1.83 
(m, 4H, CH + CH2), 1.84- 1.64 (m, 4H, CH2), 1.58-1.44 (m, 1H, CH2); 
13
C NMR (100.6 
MHz, MeOD) δ 171.9 (C=O), 169.5 (C=O), 145.3 (ipso-Ar), 131.1 (Ar), 130.0 (Ar), 
128.6 (ipso-Ar), 75.2 (CHCO2H), 67.7 (NCH), 61.1 (NCH2), 61.0 (NCH2), 57.2 
(NCH2), 56.9 (NCH2), 45.5 (NMe), 34.2 (CH), 32.2 (CH2), 30.2 (CH2), 29.9 (CH), 25.5 
(CH2), 24.2 (CH2), 21.7 (ArMe). Then, a portion of salt (–)-26.(–)-369 (20 mg, 0.034 
mmol) was dissolved in 20% KOH(aq) (2 mL) and MTBE (2 mL). The layers were 
separated and the aqueous layer was extracted with MTBE (2 × 2 mL). The combined 
organics were dried (MgSO4), and evaporated under reduced pressure to give the 
resolved surrogate (–)-26 (95:5 er by CSP-GC), CSP-GC: Cyclodex-B column (110-140 
°C, 1 °C/min), (+)-26 23.1 min, (–)-26 23.2 min. 
Lab Book Reference: JDF10_937 
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A solution of (−)-O,O′-di-p-toluoyl-L-tartaric acid (–)-369  (1.93 g, 5.0 mmol, 0.5 eq.) 
in 4:1 MeCN/acetone (2 mL) was added to a stirred solution of 26 (1.94 g, 10 mmol, 1.0 
eq.) in 4:1 MeCN/acetone (4 mL) at rt. The resulting mixture was stirred at rt for 16 h. 
The solid was collected by filtration, washed with cold 4:1 MeCN-acetone (5 mL) and 
dried under reduced pressure to give salt (–)-26.(–)-369 (1.92 g, 33%) as a white solid. 
Then, a portion of the salt (20 mg, 0.034 mmol) was dissolved in 20% KOH(aq) (2 mL) 
and MTBE (2 mL). The layers were separated and the aqueous layer was extracted with 
MTBE (2 × 2 mL). The combined organics were dried (MgSO4), and evaporated under 
reduced pressure to give the resolved surrogate (–)-26 (93:7 er by CSP-GC), CSP-GC: 
Cyclodex-B column (110-140 °C, 1 °C/min), (+)-26 23.0 min, (–)-26 23.3 min. 
Lab Book Reference: JDF10_938 
 
(R)-2-(4-Methylphenylsulfonamido)pentanedioic acid (R)-407 
 
p-Toluenesulfonyl chloride (22.9 g, 120 mmol, 1.2 eq.) was added portionwise over 30 
min to a stirred solution of D-glutamic acid (14.7 g, 100 mmol, 1.0 eq.) in 2M NaOH(aq) 
(200 mL) at 70 °C under air. The resulting solution was heated at 70 °C for 1 h. 2M 
NaOH(aq) was added dropwise to keep the pH > 9. Upon cooling to 0 °C the pH was 
adjusted to pH 1 with 12M HCl(aq). The aqueous mixture was extracted with EtOAc (3 × 
100 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give N-tosyl glutamic acid (R)-407 as a white solid (13.9 g, 
46%) which was sufficiently pure by 
1
H NMR spectroscopy, mp 114-116 °C (lit.,
249
 
122-125°C); [α]D –20.3 (c 1.0 in EtOAc) (lit.,
278
 [α]D +22 (c 1.0 in EtOAc) for (S)-407); 
1
H NMR (400 MHz, DMSO-d6) δ 12.42 (br s, 2H, COOH), 8.07 (d, J = 9.0 Hz, 1H, 
NH), 7.64 (d, J = 9.0 Hz, 2H, Ar), 7.34 (d, J = 8.0 Hz, 2H, Ar), 3.74 (td, J = 9.0, 5.0 Hz, 
1H, NCH), 2.36 (s, 3H, ArMe), 2.19 (t, J = 7.5 Hz, 2H, CH2COOH), 1.77-1.88 (m, 1H, 
CH2), 1.58-1.7 (m, 1H, CH2); 
13
C NMR (100.6 MHz, DMSO-d6) δ 173.5 (NC=O), 
172.6 (C=O), 142.5 (ipso-Ar), 138.3 (ipso-Ar), 129.4 (Ar), 126.5 (Ar), 54.7 (NCH), 
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29.5 (CH2), 27.4 (CH2), 21.0 (ArMe); Spectroscopic data consistent with those reported 
in the literature.
249
 
Lab Book Reference: JDF9_816 
 
 (R)-5-Oxo-1-tosylpyrrolidine-2-carboxylic acid (R)-406 
 
N,N′-Dicyclohexylcarbodiimide (3.41 g, 16.5 mmol, 1.25 eq.) was added to a solution 
of N-tosyl glutamic acid (R)-407 (3.98 g, 13.2 mmol, 1.0 eq.) in MeCN (100 mL) at 0 
°C under Ar. The resulting solution was heated to 60 °C and stirred at 60 °C for 16 h. 
Upon cooling to 0 °C the mixture was filtered through Celite
®
 and washed with cold 
MeCN (20 mL). Then, the filtrate was concentrated under reduced pressure. The residue 
was taken up in EtOAc (30 mL) and washed with saturated NaHCO3(aq) (2 × 30 mL). 
The combined aqueous layers were acidified with 12M HCl(aq) and extracted with Et2O 
(3 × 50 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude N-tosyl pyrrolidinone (R)-406 as a white solid 
(3.22 g, 86%) which was sufficiently pure by 
1
H NMR spectroscopy, mp 126-127 °C 
(lit.,
279
 128-129°C); [α]D +25.4 (c 1.1 in EtOAc) (lit.,
279
 [α]D –27.5 (c 1.5 in EtOAc) for 
(S)-406);
 1
H NMR (400 MHz, CDCl3) δ 8.25 (br s, 1H, COOH), 7.97 (d, J = 8.5 Hz, 2H, 
Ar), 7.34 (d, J = 8.5 Hz, 2H, Ar), 4.91 (dd, J = 9.0, 2.5 Hz, 1H, NCH), 2.64–2.40 (m, 
3H, CH2), 2.44 (s, 3H, ArMe), 2.28–2.12 (m, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) 
δ 175.5 (NC=O), 172.9 (COOH), 145.6 (ipso-Ar), 134.5 (ipso-Ar), 129.4 (Ar), 129.0 
(Ar), 59.1 (NCH), 30.3 (CH2), 23.1 (CH2), 21.7 (Me). Spectroscopic data consistent 
with those reported in the literature.
279
 
Lab Book Reference: JDF9_881 
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(R)-2-(2-Ethoxy-2-oxoethyl)piperidin-1-ium (R)-5-oxo-1-tosylpyrrolidine-2-
carboxylate (R)-365.(R)-406 
 
N-tosyl pyrrolidinone (R)-406 (1.0 g, 3.5 mmol, 0.5 eq.) was added to a stirred solution 
of piperidine 365 (1.21 g, 7.0 mmol, 1.0 eq.) in IPA (52 mL) at rt. The resulting solution 
was stirred at rt for 30 min. Then, the mixture was cooled in a fridge for 3 h. The white 
solid was collected by filtration, washed with cold IPA (10 mL) and dried under 
reduced pressure to give salt (R)-365.(R)-406 as a crystalline white solid (1.64 g, 36%, 
93:7 er by CSP-HPLC of a derivative (R)-374). Salt (R)-365.(R)-406 (1.1 g, 2.42 mmol) 
was added to IPA (88 mL) and the resulting suspension was heated to 80 °C. The 
resulting solution was stirred at 80 °C for 30 min. Upon cooling to rt white crystals 
formed. Then, the mixture was cooled in a fridge for 3 h. The salt was collected by 
filtration and washed with cold IPA (10 mL) and dried under reduced pressure to give 
the salt (R)-365.(R)-406 as a crystalline white solid (890 mg, 81% (29% from 365), 
>99:1 er by CSP-HPLC of a derivative (R)-374).  
 
Lab Book Reference: JDF9_888 
 
(R)-tert-Butyl 2-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (R)-374 
 
A solution of di-tert-butyl dicarbonate (423 mg, 1.93 mmol, 1.2 eq.) in CH2Cl2 (5 mL) 
was added dropwise a stirred solution of salt (R)-365.(R)-406 (712 mg, 1.61 mmol, 1.0 
eq.) and Et3N (489 mg, 674 µL, 3.0 eq.) in CH2Cl2 (5 mL) at 0 °C under Ar. The 
resulting solution was allowed to warm to rt and stirred at rt for 16 h. Then, 1M HCl(aq) 
(20 mL) was added and the two layers were separated. The aqueous layer was extracted 
with CH2Cl2 (3 × 5 mL). The combined organic layers were dried (MgSO4), filtered and 
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evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 9:1-4:1 petrol-EtOAc as eluent gave N-Boc 
piperidine (R)-374 (363 g, 85%, >99:1 er) as a colourless oil, RF (9:1 petrol-EtOAc) 0.3;
 
[α]D +7.5 (c 1.0 in CHCl3) (lit.,
225
 [α]D +7.4 (c 1.0 in CHCl3); 
1
H NMR (400 MHz, 
CDCl3) δ 4.67 (s, 1H, NCH), 4.10 (q, J = 7.0 Hz, 2H, CH2Me), 3.97 (br d, J = 12.0 Hz, 
1H, NCH), 2.76 (br t, J = 12.0 Hz, 1H, NCH), 2.51-2.6 (m, 1H, CHAHBCO2Et), 2.45-
2.55 (m, 1H, CHAHBCO2Et), 1.3-1.7 (m, 6H, CH2), 1.43 (s, 9H, CMe3), 1.23 (t, J = 7.0 
Hz, 3H, CH2Me); 
13
C NMR (100.6 MHz, CDCl3) δ 171.4 (CO2Et), 154.7 (NC=O), 79.4 
(CMe3), 60.4 (CH2Me), 47.8 (NCH), 39.2 (NCH2), 35.3 (CH2), 28.4 (CMe3), 28.1 
(CH2), 25.2 (CH2), 18.8 (CH2), 14.1 (CH2Me); CSP-HPLC: Chiralcel OD-H (99:1 
hexane:i-PrOH, 0.5 mL min
–1
) (R)-374 16.7 min, (S)-374 18.1 min. Spectroscopic data 
consistent with those reported in the literature.
276
 
Lab Book Reference: JDF9_877 
 
Methyl 2-(pyridin-2-yl)acetate 410 
 
n-BuLi (2.5 M solution in hexanes, 20.0 mL, 50 mmol, 2.0 eq.) was added dropwise to a 
stirred solution of diisopropylamine (5.57 g, 7.71 mL, 55 mmol, 2.2 eq.) in THF (20 
mL) at –78 °C under Ar. The resulting solution was warmed to 0 °C and stirred at 0 °C 
for 30 min. Then, the solution was transferred via cannula to a stirred solution of 2-
picoline 402 (2.33 g, 2.47 mL, 25 mmol, 1.0 eq.) and dimethylcarbonate (6.76 g, 6.32 
mL, 75 mmol, 3.0 eq.) in THF (20 mL) at –78 °C under Ar. The resulting solution was 
stirred at –78 °C for 1 h. The solution was allowed to warm to rt and stirred at rt for 30 
min. Saturated NH4Cl(aq) (10 mL) and water (20 mL) were added. The two layers were 
separated and the aqueous layer was extracted with Et2O (3 × 30 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by Kugelrohr distillation gave ester 410 (2.86 g, 
76%) as a bright yellow oil, bp 90-95 °C/1.2 mmHg (lit.,
280
 bp 74-78 °C/2 mmHg); 
1
H 
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NMR (400 MHz, CDCl3) δ 8.56-8.54 (m, 1H, Ar), 7.65 (tt, J = 7.5, 2.0 Hz, 1H, Ar), 
7.28 (d, J = 7.5 Hz, 1H, Ar), 7.21-7.16 (m, 1H, Ar), 3.86 (s, 2H, CH2CO2Me), 3.73 (s, 
3H, CO2Me); 
13
C NMR (100.6 MHz, CDCl3) δ 171.0 (C=O), 154.3 (ipso-Ar), 149.5 
(Ar), 136.6 (Ar), 123.8 (Ar), 122.1 (Ar), 52.1 (CH2CO2Me), 43.7 (CO2Me). 
Spectroscopic data consistent with those reported in the literature.
281
 
Lab Book Reference: JDF9_826 
 
Methyl 2-(piperidin-2-yl)acetate 405 
 
PtO2.H2O (49 mg, 0.20 mmol, 0.006 eq.) was added to a stirred solution of pyridine 410 
(5.00 g, 33.1 mmol, 1.0 eq.) in MeOH (50 mL) and 6M HCl(aq) (9 mL). Then, the 
reaction flask evacuated under reduced pressure and back filled with N2 three times. 
After a final evacuation, H2 was charged at 2 atm and the reaction mixture was stirred 
vigorously at rt for 24 h. The mixture was filtered through Celite
®
 and washed with 
MeOH (50 mL). The filtrate was evaporated under reduced pressure. Then, the residue 
was dissolved in 2M NH4OH(aq) (50 mL) and the aqueous layer was extracted with 
CH2Cl2 (5 × 50 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the piperidine 405 (4.30 g, 83%) as a clear 
oil, bp 90-94 °C/5.0 mmHg (lit.,
282
 bp 101-102 °C/5 mmHg); 
1
H NMR (400 MHz, 
CDCl3) δ 3.64 (s, 3H, CO2Me), 3.04–2.97 (m, 1H, NCH), 2.87 (dddd, J = 10.5, 7.5, 5.0, 
2.5 Hz, 1H, NCH), 2.62 (td, J = 11.5, 2.5 Hz, 1H, NCH), 2.36 (dd, J = 14.5, 3.5 Hz, 1H, 
CHAHBCO2Me), 2.31 (dd, J = 14.5, 6.5 Hz, 1H, CHAHBCO2Me), 1.98 (br s, 1H, NH), 
1.78–1.68 (m, 1H, CH2), 1.62–1.50 (m, 2H, CH2), 1.44–1.26 (m, 2H, CH2), 1.20–1.05 
(m, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 172.8 (C=O), 53.2 (NCH), 51.5 
(CO2Me), 46.8 (CH2CO2Me), 41.4 (NCH2), 32.6 (CH2), 26.0 (CH2), 24.5 (CH2). 
Spectroscopic data consistent with those reported in the literature.
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Lab Book Reference: JDF9_897 
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tert-Butyl 2-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate 408 
 
A solution of di-tert-butyl dicarbonate (7.16 g, 32.8 mmol, 1.2 eq.) in CH2Cl2 (20 mL) 
was added dropwise a stirred solution of piperidine 405 (4.3 g, 27.4 mmol, 1.0 eq.) in 
CH2Cl2 (80 mL) at 0 °C under Ar. The resulting solution was allowed to warm to rt and 
stirred at rt for 16 h. Then, 1 M HCl(aq) (100 mL) was added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 9:1-
4:1 petrol-EtOAc as eluent gave N-Boc piperidine 408 (6.9 g, 97%) as a colourless oil, 
RF (9:1 petrol-EtOAc) 0.2;
 1
H NMR (400 MHz, CDCl3) δ 4.76–4.58 (m, 1H, NCH), 
3.98 (br d, J = 12.5 Hz, 1H, NCH), 3.63 (s, 3H, CO2Me), 2.77 (br t, J = 12.5 Hz, 1H, 
NCH), 2.59 (dd, J = 14.0, 7.5 Hz, 1H CHAHBCO2Et), 2.51 (dd, J = 14.0, 8.0 Hz, 1H, 
CHAHBCO2Et), 1.70–1.55 (m, 4H, CH2), 1.52–1.33 (m, 2H, CH2), 1.44 (s, 9H, CMe3); 
13
C NMR (100.6 MHz, CDCl3) δ 171.8 (CO2Me), 154.6 (NC=O), 79.4 (CMe3), 51.6 
(CO2Me), 47.8 (NCH), 39.1 (NCH2), 35.0 (CH2), 28.3 (CMe3), 28.2 (CH2), 25.2 (CH2), 
18.8 (CH2). Spectroscopic data consistent with those reported in the literature.
223
 
Lab Book Reference: JDF9_900 
 
tert-Butyl 2-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 374 
 
A solution of di-tert-butyl dicarbonate (13.4 g, 61.3 mmol, 1.2 eq.) in CH2Cl2 (50 mL) 
was added dropwise a stirred solution of piperidine 365 (10.0 g, 58.4 mmol, 1.0 eq.) in 
CH2Cl2 (150 mL) at 0 °C under Ar. The resulting solution was allowed to warm to rt 
and stirred at rt for 16 h. Then, 1M HCl(aq) (200 mL) was added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
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organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 9:1-
4:1 petrol-EtOAc as eluent gave N-Boc piperidine 374 (15.1 g, 95%) as a colourless oil. 
Lab Book Reference: JDF10_928 
 
A solution of di-tert-butyl dicarbonate (11.1 g, 50.7 mmol, 1.0 eq.) in CH2Cl2 (50 mL) 
was added dropwise a stirred solution of piperidine 365 (8.69 g, 50.7 mmol, 1.0 eq.) in 
CH2Cl2 (150 mL) at 0 °C under Ar. The resulting solution was allowed to warm to rt 
and stirred at rt for 16 h. Then, 1M HCl(aq) (200 mL) was added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give N-Boc piperidine 374 (13.7 g, 99%) as a colourless oil, which was sufficiently pure 
by 
1
H NMR spectroscopy. 
Lab Book Reference: JDF12_1103 
 
(R)-tert-Butyl 2-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate (R)-408 and (S)-2-
(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid (S)-409 
 
Using general procedure G, methyl ester 408 (257 mg, 1.0 mmol), lipase (250 mg), 0.1 
M phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at rt for 48 h, extracted 
with Et2O (3 × 10 mL) gave ester (R)-408 (104 mg, 41%, 88:12 er by CSP-HPLC) as a 
clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-408 
17.1 min, (S)-408 19.3 min, and acid (S)-409 (103 mg, 42%, 87:13 er by CSP-HPLC of 
a derivative (S)-408) as a white solid, mp 93-95 °C (lit.,
254
 95 °C); 
1
H NMR (400 MHz, 
CDCl3) δ 4.69 (dd, J = 11.5, 7.0 Hz, 1H, NCH), 3.99 (d, J = 13.0 Hz, 1H, NCH), 2.79 (t, 
J = 13.0 Hz, 1H, NCH), 2.66 (dd, J = 14.5, 7.0 Hz, 1H, CHACHBCO2H), 2.57 (dd, J = 
14.5, 7.0 Hz, 1H, CHACHBCO2H), 1.74–1.38 (m, 6H, CH2), 1.45 (s, 9H, CMe3); NMR 
(100.6 MHz, CDCl3) δ 176.4 (COOH), 154.9 (NC=O), 79.9 (CMe3), 47.5 (NCH), 39.2 
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(NCH2 or CH2COOH), 35.3 (NCH2 or CH2COOH), 28.3 (CMe3), 25.1 (CH2), 18.8 
(CH2). Spectroscopic data consistent with those reported in the literature.
254
 
Lab Book Reference: JDF10_909 
 
Using general procedure G, methyl ester 408 (257 mg, 1.0 mmol), lipase (250 mg), 0.1 
M phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at 35 °C for 48 h, 
extracted with Et2O (3 × 10 mL) gave ester (R)-408 (120 mg, 47%, 97:3 er by CSP-
HPLC) as a clear oil, [α]D +9.0 (c 1.0 in CHCl3) (lit.,
284
 [α]D +8.1 (c 2.0 in CHCl3 for 
>99:1 er); CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-408 
15.5 min, (S)-408 17.5 min, and acid (S)-409 (98 mg, 40%, >99:1 er by CSP-HPLC of a 
derivative (S)-408) as a white solid, [α]D –11.8 (c 0.9 in MeOH) (lit.,
254
 [α]D –8 (c 1.53 
in MeOH). 
Lab Book Reference: JDF10_907 
 
Using general procedure G, methyl ester 408 (257 mg, 1.0 mmol), lipase (250 mg), 0.1 
M phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at 50 °C for 28 h, 
extracted with Et2O (3 × 10 mL) gave ester (R)-408 (116 mg, 45%, 90:10 er by CSP-
HPLC) as a clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) 
(R)-408 16.6 min, (S)-408 18.9 min, and acid (S)-409 (94 mg, 39%, 96:4 er by CSP-
HPLC of a derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_910 
 
(S)-tert-Butyl 2-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate (S)-408 
 
(Trimethylsilyl)diazomethane (113 µL of a 2.0 M solution in Et2O, 0.216 mmol, 1.03 
eq.) was added to a stirred solution of carboxylic acid (S)-409 (50 mg, 0.210 mmol, 1.0 
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eq.) in THF (3 mL) and MeOH (1 mL) at at 0 °C under Ar. The resulting solution was 
stirred at 0 °C for 30 min. Then, the solvent was removed under reduced pressure. The 
residue was partitioned between water (5 mL) and Et2O (5 ml). The layers were 
separated and the aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the methyl ester (S)-408 (50 mg, 93%, >99:1 er by CSP-HPLC) as a pale yellow 
oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
-1
) (R)-408 18.1 min, 
(S)-408 20.2 min. 
Lab Book Reference: JDF4_317 
 
(R)-tert-Butyl 2-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (R)-374 and (S)-2-
(1-(tert-butoxycarbonyl)piperidin-2-yl)acetic acid (S)-409 
 
Using general procedure G, ethyl ester 374 (271 mg, 1.0 mmol), lipase (250 mg), 0.1 M 
phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at rt for 24 h, extracted with 
Et2O (3 × 10 mL) gave ester (R)-374 (127 mg, 47%, 97:3 er by CSP-HPLC) as a clear 
oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-374 15.5 
min, (S)-374 16.6 min, and acid (S)-409 (104 mg, 44%, 98:2 er by CSP-HPLC of a 
derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_915 
 
Using general procedure G, ethyl ester 374 (271 mg, 1.0 mmol), lipase (250 mg), 0.1 M 
phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at rt for 48 h, extracted with 
Et2O (3 × 10 mL) gave ester (R)-374 (113 mg, 42%, >99:1 er by CSP-HPLC) as a clear 
oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-374 14.7 
min, (S)-374 not observed, and acid (S)-409 (112 mg, 46%, 92:8 er by CSP-HPLC of a 
derivative (S)-408) as a white solid. 
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Lab Book Reference: JDF10_920 
 
Using general procedure G, ethyl ester 374 (271 mg, 1.0 mmol), lipase (250 mg), 0.1 M 
phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at 35 °C for 24 h, extracted 
with Et2O (3 × 10 mL) gave ester (R)-374 (112 mg, 42%, >99:1 er by CSP-HPLC) as a 
clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-374 
15.3 min, (S)-374 16.2 min, and acid (S)-409 (103 mg, 42%, 96:4 er by CSP-HPLC of a 
derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_921 
 
Using general procedure G, ethyl ester 374 (271 mg, 1.0 mmol), lipase (125 mg), 0.1 M 
phosphate buffer(aq) (8 mL), H2O (8 mL), and THF (2 mL), at 35 °C for 72 h, extracted 
with Et2O (3 × 10 mL) gave ester (R)-374 (112 mg, 42%, >99:1 er by CSP-HPLC) as a 
clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) (R)-374 
16.0 min, (S)-374 not observed, and acid (S)-409 (107 mg, 44%, 95:5 er by CSP-HPLC 
of a derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_929 
 
Using general procedure G, ethyl ester 374 (2.71 g, 10.0 mmol), lipase (2.50 g), 0.1 M 
phosphate buffer(aq) (40 mL), H2O (40 mL), and THF (10 mL), at 35 °C for 48 h, 
extracted with Et2O (3 × 50 mL) gave ester (R)-374 (1.23 g, 45%, >99:1 er by CSP-
HPLC) as a clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) 
(R)-374 17.4 min, (S)-374 not observed, and acid (S)-409 (1.18 g, 45%, 96:4 er by CSP-
HPLC of a derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_934 
 
Using general procedure G, ethyl ester 374 (13.6 g, 50.0 mmol), lipase (12.5 g), 0.1 M 
phosphate buffer(aq) (200 mL), H2O (200 mL), and THF (50 mL), at 35 °C for 64 h, 
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extracted with Et2O (3 × 100 mL) gave ester (R)-374 (6.23 g, 46%, >99:1 er by CSP-
HPLC) as a clear oil, CSP-HPLC: Chiralcel OD-H (99:1 hexane:i-PrOH, 0.5 mL min
–1
) 
(R)-374 15.2 min, (S)-374 not observed, and acid (S)-409 (5.33 g, 44%, 96:4 er by CSP-
HPLC of a derivative (S)-408) as a white solid. 
Lab Book Reference: JDF10_960 
 
Ethyl 2-(bromomethyl)acrylate 375 
 
A solution of K2CO3 (14.8 g, 107 mmol, 1.2 eq.) in H2O (15 mL) was added dropwise 
to a stirred solution of triethyl phosphonoacetate 411 (20.0 g, 17.7 mL, 89.2 mmol, 1.0 
eq.) and formaldehyde (37% aqueous solution, 29.2 mL, 360 mmol, 4.0 eq.) at rt under 
air. The resulting mixture was stirred at rt for 15 min. Then, Et2O (75 mL) and brine (75 
mL) were added and the layers separated. The aqueous layer was extracted with Et2O (3 
× 30 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude alcohol 412. PBr3 (14.5 g, 5.0 mL, 53.5 mmol, 
0.6 eq.) was added dropwise to a stirred solution of crude alcohol 412 in Et2O (100 mL) 
at 0 °C under Ar. The resulting solution was warmed to rt and stirred at rt for 16 h. 
Then, sat NaHCO3(aq) (200 mL) was added slowly with stirring and the layers separated. 
The aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by Kugelrohr distillation gave acrylate 375 (10.8 g, 63%) as a 
clear oil, bp 75-80 °C/3.5 mmHg (lit.,
285
 bp 55-61 °C/2 mmHg); 
1
H NMR (400 MHz, 
CDCl3) δ 6.32 (d, J = 1.0 Hz, 1H, C=CHAHB), 5.94 (d, J = 1.0 Hz, 1H, C=CHAHB), 4.26 
(q, J = 7.0 Hz, 2H, CH2Me), 4.17 (s, 2H, CH2Br), 1.32 (t, J = 7.0 Hz, 3H, CH2Me); 
13
C 
NMR (100.6 MHz, CDCl3) δ 174.8 (C=O), 137.5 (C=CH2), 138.9 (C=CH2), 61.2 
(CH2Me), 29.4 (CH2Br), 14.1 (CH2Me). Spectroscopic data consistent with those 
reported in the literature.
285
 
Lab Book Reference: JDF10_957 
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(R)-Diethyl 2-((R)-1-(tert-butoxycarbonyl)piperidin-2-yl)-4-
methylenepentanedioate (R,R)-376 
 
LHMDS (5.83 mL of a 1.0 M solution in THF, 5.83 mmol, 1.4 eq.) was added dropwise 
to a stirred solution of N-Boc ester (R)-374 (1.13 g, 4.16 mmol, 1.0 eq.) in THF (30 mL) 
at –78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, acrylate 
375 (1.13 g, 805 µL, 5.83 mmol, 1.4 eq.) was added dropwise and the resulting solution 
was stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. Water (50 mL) and 
Et2O (20 mL) were added and the two layers were separated. The aqueous layer was 
extracted with Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification 
by flash column chromatography on silica with 4:1 petrol-EtOAc as eluent gave N-Boc 
ester (R,R)-376 (1.55 g, 97%, >99:1 er by CSP-HPLC) as a colourless oil, RF (4:1 
petrol-EtOAc) 0.3; [α]D +49.5 (c 1.2 in CHCl3); IR (CHCl3) 2972, 2936, 2894, 1697 
(C=O, CO2Et), 1654 (C=O, Boc), 1606 (C=CH2), 1453, 1425, 1396, 1370, 1346, 1316, 
1283, 1257, 1231, 1196, 1136, 1071, 1011, 971, 941, 911, 825, 743 cm
–1
; 
1
H NMR (400 
MHz, CDCl3) δ 6.15 (d, J = 1.0 Hz, 1H, C=CHAHB), 5.60 (d, J = 1.0 Hz, 1H, 
C=CHAHB), 4.56-4.28 (m, 1H, NCH), 4.28-4.12 (m, 2H, CH2Me), 4.12-3.79 (m, 3H, 
CH2Me and NCH), 3.21 (td, J = 11.0, 3.5 Hz, 1H, CHCO2Et), 2.93 (br s, 1H, NCH), 
2.64-2.37 (m, 2H, CH2C=CH2), 1.83 (d, J = 11.5 Hz, 1H, CH2), 1.68–1.48 (m, 5H, 
CH2), 1.41 (s, 9H, CMe3), 1.30 (t, J = 7.0 Hz, 3H, CH2Me), 1.17 (t, J = 7.0 Hz, 3H, 
CH2Me); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 172.9 (CO2Et), 172.8 
(CO2Et), 166.5 (CO2Et), 154.3 (NC=O), 137.6 (C=CH2), 127.2 (C=CH2), 79.3 (CMe3), 
60.8 (CH2Me), 60.2 (CH2Me), 53.2 (NCH), 52.0 (NCH), 44.9 (CHCO2Et), 44.4 
(CHCO2Et), 40.1 (NCH2), 38.9 (NCH2), 32.6 (CH2C=CH2), 28.3 (CMe3), 26.0 (CH2), 
25.2 (CH2), 19.0 (CH2), 14.1 (CH2Me); MS (ESI) m/z 406 [(M + Na)
+
, 100], 384 [(M + 
H)
+
, 60]; HRMS  m/z calcd for C20H33NO6 (M + H)
+
 384.2381, found 384.2376 (+1.0 
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ppm error); CSP-HPLC: Chiralcel AD-H (98:2 hexane:i-PrOH, 0.5 mL min
–1
) (S,S)-376 
13.2 min, (R,R)-376 14.8 min. 
Lab Book Reference: JDF10_950 
 
Diethyl 2-(1-(tert-butoxycarbonyl)piperidin-2-yl)-4-methylenepentanedioate 376 
 
LHMDS (1.4 mL of a 1.0 M solution in THF, 1.4 mmol, 1.4 eq.) was added dropwise to 
a stirred solution of N-Boc ester 374 (271 mg, 1.0 mmol, 1.0 eq.) in THF (8 mL) at –78 
°C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, acrylate 375 
(270 g, 193 µL, 1.4 mmol, 1.4 eq.) was added dropwise and the resulting solution was 
stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. Water (20 mL) and Et2O 
(10 mL) were added and the two layers were separated. The aqueous layer was 
extracted with Et2O (3 × 20 mL). The combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification 
by flash column chromatography on silica with 4:1 petrol-EtOAc as eluent gave N-Boc 
ester 376 (358 mg, 94%) as a colourless oil.  
Lab Book Reference: JDF9_868 
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(1R,3S,9aR)-Diethyl octahydro-1H-quinolizine-1,3-dicarboxylate (R,S,R)-379 
 
Trifluoroacetic acid (1.5 mL, 19.6 mmol) was added to a stirred solution of N-Boc ester 
(R,R)-376 (1.49 g, 3.89 mmol, 1.0 eq.) in CH2Cl2 (30 mL) at rt under Ar. The resulting 
solution was stirred at rt for 16 h. Then, the volatiles were removed under reduced 
pressure and EtOH (30 mL) and K2CO3 (5.37 g, 38.9 mmol, 10 eq.) were added. The 
resulting mixture was stirred at rt under Ar for 16 h. Then, the solvent was removed 
under reduced pressure. Water (50 mL) and CH2Cl2 (30 mL) were added and the two 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 30 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 97:3 CH2Cl2-MeOH as eluent gave di-ester (R,S,R)-379 (890 mg, 81%) as a 
colourless oil, RF (97:3 CH2Cl2-MeOH) 0.2; [α]D +3.8 (c 1.0 in CHCl3); IR (CHCl3) 
2974, 2938, 2892, 2816, 1698 (C=O), 1424, 1348, 1331, 1244, 1196, 1135, 1067, 1041, 
1015, 738, 658 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 4.14 (q, J = 7.0 Hz, 2H, CH2Me), 
4.13 (q, J = 7.0 Hz, 2H, CH2Me), 3.30 (ddd, J = 12.5, 4.5, 2.5 Hz, 1H, NCH, H
1
), 3.06 
(t, J = 11.5 Hz, 1H, NCH, H
4
), 3.02-2.92 (m, 2H, NCH), 2.76 (dt, J = 13.0, 4.5 Hz, 1H, 
NCH, H
2
), 2.70 (dd, J = 11.5, 4.0 Hz, 1H, NCH, H
5
), 2.56 (tt, J = 11.5, 4.0 Hz, 1H, H
3
), 
2.07 (dt, J = 13.5, 3.5 Hz, 1H, CH2), 1.91-1.80 (m, 1H, CH2), 1.80-1.63 (m, 3H, CH2), 
1.47 (qt, J = 13.0, 4.0 Hz, 1H, CH2), 1.26 (t, J = 7.0 Hz, 3H, CH2Me), 1.25 (t, J = 7.0 
Hz, 3H, CH2Me), 1.22-1.14 (m, 1H, CH2), 1.01-0.93 (m, 1H, CH2); 
13
C NMR (100.6 
MHz, CDCl3) δ 173.7 (C=O), 172.7 (C=O), 60.5 (CH2Me), 60.5 (CH2Me), 57.2 (NCH), 
54.9 (NCH2), 46.5 (NCH2), 45.2 (CH), 41.8 (CH), 25.2 (CH2), 23.7 (CH2), 18.6 (CH2), 
18.2 (CH2), 14.2 (CH2Me), 14.2 (CH2Me); MS (ESI) m/z 284 (M + H)
+
; HRMS m/z 
calcd for C15H25NO4 (M + H)
+
 284.1856, found 284.1850 (+2.6 ppm error). 
Lab Book Reference: JDF10_956 
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(1R,3S,9aR)-Diethyl octahydro-1H-quinolizine-1,3-dicarboxylate (R,S,R)-379 
 
LHMDS (13.3 mL of a 1.0 M solution in THF, 13.3 mmol, 1.2 eq.) was added dropwise 
to a stirred solution of N-Boc ester (R)-374 (3.0 g, 11.1 mmol, 1.0 eq.) in THF (70 mL) 
at –78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, acrylate 
375 (2.56 g, 1.89 mL, 5.83 mmol, 1.2 eq.) was added dropwise and the resulting 
solution was stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. Water (100 
mL) and Et2O (30 mL) were added and the two layers were separated. The aqueous 
layer was extracted with Et2O (3 × 50 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude N-Boc ester 
(R,R)-376 which was used in the next step without further purification (≥90% purity by 
1
H NMR spectroscopy). Trifluoroacetic acid (5.0 mL, 65.3 mmol) was added to a stirred 
solution of N-Boc ester (R,R)-376 (max. 11.1 mmol, 1.0 eq.) in CH2Cl2 (100 mL) at rt 
under Ar. The resulting solution was stirred at rt for 16 h. Then, the volatiles were 
removed under reduced pressure and EtOH (100 mL) and K2CO3 (15.3 g, 111 mmol, 10 
eq.) were added. The resulting mixture was stirred at rt under Ar for 16 h. Then, the 
solvent was removed under reduced pressure. Water (100 mL) and CH2Cl2 (50 mL) 
were added and the two layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 × 50 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 97:3 CH2Cl2-MeOH as eluent gave di-ester 
(R,S,R)-379 (2.51g, 80%) as a colourless oil.   
Lab Book Reference: JDF12_1112 and 1114 
 
  
Chapter Six: Experimental 
 
423 
 
3-Methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 26 and 
Decahydro-1,5-methanopyrido[2,1-d][1,5]oxazocine 413 
 
A solution of di-ester 379 (1.41 g, 5.0 mmol, 1.0 eq.) in THF (10 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (755 mg, 20.0 mmol, 4.0 
eq.) in THF (20 mL) at 0 °C under Ar. The resulting mixture was allowed to warm to rt 
and then stirred at rt for 1 h. After cooling to 0
 
°C the mixture was diluted with Et2O (30 
mL), water (755 µL), 20% NaOH(aq) (1.51 mL) and water (755 µL) were sequentially 
added dropwise and the mixture stirred for 30 min. Then, anhydrous MgSO4 was added 
and the mixture stirred for 30 min. The solids were removed by filtration through 
Celite
®
 and washed with EtOAc (100 mL). The filter cake was suspended in EtOAc (50 
mL) and stirred for 30 min. The solids were removed by filtration through Celite
®
 and 
washed with EtOAc (100 mL). The combined filtrate was concentrated under reduced 
pressure to give the crude diol 381. MsCl (1.15 g, 790 µL, 10.0 mmol, 2.0 eq.) was 
added dropwise to a stirred solution of the crude diol 381 and Et3N (1.52 g, 2.09 mL, 
15.0 mmol, 3.0 eq.) in CH2Cl2 (30 mL) at 0 °C under Ar. The resulting mixture was 
allowed to warm to rt and then stirred at rt for 16 h. Water (20 mL) was added and the 
layers separated. The aqueous was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude di-mesylate 382. Crude di-mesylate 382 was dissolved in methyl amine 
(20 mL of a 8 M solution in EtOH) under Ar. The resulting solution was stirred and 
heated at reflux for 16 h. After cooling to rt, the solvent was evaporated under reduced 
pressure. 20% NaOH(aq) (20 mL) and Et2O (20 mL) were added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 20 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product containing a 5:1 mixture of sparteine surrogate 26 and 
tetrahydropyran 413 (by 
1
H NMR spectroscopy). Purification by Kugelrohr distillation 
gave diamine a 5:1 mixture of diamine 26 and tetrahydropyran 413 (765 mg) as a 
colourless oil. 
Chapter Six: Experimental 
 
424 
 
Lab Book Reference: JDF10_952 
 
di-mesylate 382 (278 mg, 0.78 mmol, 1.0 eq.) was dissolved in methyl amine (10 mL of 
a 8 M solution in EtOH) under Ar. The resulting solution was stirred and heated at 
reflux for 16 h. After cooling to rt, the solvent was evaporated under reduced pressure. 
20% NaOH(aq) (20 mL) and Et2O (20 mL) were added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 20 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product containing a 9:1 mixture of sparteine surrogate 26 and 
tetrahydropyran 413 (by 
1
H NMR spectroscopy) (120 mg). 
Lab Book Reference: JDF10_978 
 
 Decahydro-1,5-methanopyrido[2,1-d][1,5]oxazocine 413 
 
A solution of di-mesylate 413 (174 mg, 0.49 mmol, 1.0 eq.) in 20% KOH(aq) (10 mL) 
was heated and stirred at reflux for 16 h. Upon cooling to rt, Et2O (10 mL) was added 
and the two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1 CH2Cl2-MeOH then 89:10:1 CH2Cl2-MeOH-35% 
NH4OH(aq) as eluent gave tetrahydropyran 413 (22 mg, 25%) as a pale yellow oil, RF 
(89:10:1 CH2Cl2-MeOH-35% NH4OH(aq)) 0.2; IR (ATR) 2927, 2853, 1462, 1442, 1287, 
1272, 1203, 1149, 1136, 1118, 1099, 1072, 1045, 1033, 885, 854, 823, 806, 741 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 4.08 (br d, J = 11.5 Hz, 1H, OCH), 4.00 (br d, J = 11.5 
Hz, 1H, OCH), 3.73 (dt, J = 11.0, 2.5 Hz, 1H, OCH), 3.58 (dd, J = 11.5, 2.5 Hz, 1H, 
OCH), 3.00 (d, J = 11.0 Hz, 1H, NCH), 2.94–2.83 (m, 1H, NCH), 2.34 (dt, J = 11.0, 2.5 
Hz, 1H, NCH), 2.03 (d, J = 11.0 Hz, 1H, NCH), 1.94–1.50 (m, 8H, NCH + 2CH, + 
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5CH2), 1.44–1.20 (m, 3H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 71.4 (OCH2), 67.3 
(OCH2), 66.1 (NCH), 60.6 (NCH2), 57.7 (NCH2), 35.5 (CH), 33.3 (CH2), 30.8 (CH), 
30.6 (CH2), 25.5 (CH2), 24.9 (CH2); MS (ESI) m/z 182 (M + H)
+
; HRMS m/z calcd for 
C11H19NO (M + H)
+
 182.1539, found 182.1545 (–3.2 ppm error). 
Lab Book Reference: JDF10_998 
 
Octahydro-1H-quinolizine-1,3-diyl)bis(methylene) dimethanesulfonate 382 
 
A solution of di-ester 379 (490 mg, 1.73 mmol, 1.0 eq.) in THF (2 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (262 mg, 6.91 mmol, 4.0 
eq.) in THF (3 mL) at 0 °C under Ar. The resulting mixture was allowed to warm to rt 
and then stirred at rt for 1 h. After cooling to 0
 
°C the mixture was diluted with Et2O (10 
mL), water (262 µL), 20% NaOH(aq) (524 µL) and water (262 µL) were sequentially 
added dropwise and the mixture stirred for 30 min. Then, anhydrous MgSO4 was added 
and the mixture stirred for 30 min. The solids were removed by filtration through 
Celite
®
 and washed with EtOAc (50 mL). The filter cake was suspended in EtOAc (20 
mL) and stirred for 30 min. The solids were removed by filtration through Celite
®
 and 
washed with EtOAc (50 mL).The combined filtrate was concentrated under reduced 
pressure to give the crude diol 381. MsCl (418 mg, 288 µL, 3.65 mmol, 2.1 eq.) was 
added dropwise to a stirred solution of the crude diol 381 and Et3N (699 mg, 936 µL, 
6.91 mmol, 4.0 eq.) in CH2Cl2 (5 mL) at 0 °C under Ar. The resulting mixture was 
allowed to warm to rt and then stirred at rt for 16 h. Water (5 mL) was added and the 
layers separated. The aqueous was extracted with CH2Cl2 (2 x 5 mL). The combined 
organic layers were dried (MgSO4), filtered and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 9:1 
CH2Cl2-MeOH as eluent gave di-ester 382 (522 mg, 85%) as a pale yellow oil, RF (9:1 
CH2Cl2-MeOH) 0.2; IR (ATR) 2932, 1347, 1332, 1243, 1168, 946, 827, 733 cm
–1
; 
1
H 
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NMR (400 MHz, CDCl3) δ 4.20-4.12 (m, 3H, CH2OMs and CHAHBOMs), 4.06 (dd, J = 
10.0, 7.0 Hz, 1H, CHAHBOMs), 3.03 (s, 3H, OMs), 3.03 (s, 3H, OMs), 2.97-2.74 (m, 
4H, NCH), 2.54 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 2.32-2.09 (m, 2H, CH), 1.87 (d, J = 
11.5 Hz, 1H, CH), 1.73-1.36 (m, 4H, CH), 1.35-1.14 (m, 3H, CH); 
13
C NMR (100.6 
MHz, CDCl3) δ 72.1 (CH2OMs), 70.8 (CH2OMs), 58.3 (NCH), 55.4 (NCH2), 49.8 
(NCH2), 38.6 (CH or Me), 37.4 (CH or Me), 37.4 (CH or Me), 35.9 (CH or Me), 25.2 
(CH2), 25.1 (CH2), 20.3 (CH2), 19.8 (CH2); MS (ESI) m/z 356 (M + H)
+
; HRMS m/z 
calcd for C13H26N2O6S2 (M + H)
+
 356.1196, found 356.1182 (+3.5 ppm error). 
Lab Book Reference: JDF11_1052 
 
3-((2-Nitrophenyl)sulfonyl)decahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 
417 and Decahydro-1,5-methanopyrido[2,1-d][1,5]oxazocine 413 
 
DIAD (146 mg, 142 µL, 0.71 mmol, 2.0 eq.) was added dropwise to a stirred solution of 
diol 381 (70 mg, 0.35 mmol, 1.0 eq.), 2-nitrobenzenesulfonamide (142 mg, 0.71 mmol, 
2.0 eq.) and PPh3 (185 mg, 0.71 mmol, 2.0 eq.) in THF at 0 °C under Ar. The resulting 
solution was warmed to rt and stirred at rt for 16 h. Then, the mixture was concentrated 
under reduced pressure and Et2O (10 mL) was added. The resulting white precipitate 
was removed by filtration and washed with Et2O (30 mL).  The filtrate was concentrated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 19:1-9:1 CH2Cl2-MeOH then 89:10:1 CH2Cl2-MeOH:-
35% NH4OH(aq) as eluent gave bispidine 417 (13 mg, 10%) as a pale yellow oil, RF 
(19:1 CH2Cl2-MeOH) 0.1; IR (ATR) 2928, 1739, 1542, 1375, 1346, 1175, 1149, 1122, 
1104, 1008, 946, 760, 746, 728 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 8.36-8.12 (m, 1H, 
Ar), 7.71-7.50 (m, 3H, Ar), 3.99 (d, J = 12.5 Hz, 1H, NCH), 3.76 (d, J = 12.5 Hz, 1H, 
NCH), 3.18 (ddd, J = 12.0, 3.5, 2.0 Hz, 1H, NCH), 3.03 (dd, J = 12.5, 3.5 Hz, 1H, 
NCH), 2.89 (br d, J = 10.0 Hz, 1H, NCH), 2.71 (br d, J = 10.0 Hz, 1H, NCH), 2.30 (br 
s, 1H, NCH), 2.13-1.13 (m, 12H, NCH + CH + CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 
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148.5 (ipso-Ar), 134.3 (ipso-Ar), 134.1 (Ar), 132.8 (Ar), 131.3 (Ar), 123.9 (Ar), 65.0 
(NCH), 60.3 (NCH2), 56.9 (NCH2), 50.0 (NCH2), 45.5 (NCH2), 33.7 (CH), 32.2 (CH2), 
30.0 (CH2), 28.9 (CH), 25.4 (CH2), 24.6 (CH2); MS (ESI) m/z 366 (M + H)
+
; HRMS 
m/z calcd for C17H23N3O4S (M + H)
+
 366.1482, found 366.1492 (–2.8 ppm error), and 
tetrahydropyran 413 (40 mg, 63%) as a pale yellow oil. 
 Lab Book Reference: JDF11_1010 
 
(1S,5S,11aR)-Methyl octahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine-3(2H)-
carboxylate (S,S,R)-419 
 
A solution of di-ester (R,S,R)-379 (2.35 g, 8.29 mmol, 1.0 eq.) in THF (20 mL) was 
added dropwise to a stirred suspension of lithium aluminium hydride (1.26 g, 33.2 
mmol, 4.0 eq.) in THF (30 mL) at 0 °C under Ar. The resulting mixture was allowed to 
warm to rt and then stirred at rt for 1 h. After cooling to 0
 
°C, the mixture was diluted 
with Et2O (50 mL). Water (1.26 mL), 20% NaOH(aq) (2.52 mL) and water (1.26 mL) 
were sequentially added dropwise and the mixture stirred for 30 min. Then, anhydrous 
MgSO4 was added and the mixture stirred for 30 min. The solids were removed by 
filtration through Celite
®
 and washed with EtOAc (100 mL). The filter cake was 
suspended in EtOAc (50 mL) and stirred for 30 min. The solids were removed by 
filtration through Celite
®
 and washed with EtOAc (100 mL). The combined filtrate was 
concentrated under reduced pressure to give the crude diol (R,S,R)-381. MsCl (1.99 g, 
1.38 mL, 17.4 mmol, 2.1 eq.) was added dropwise to a stirred solution of the crude diol 
(R,S,R)-381 and Et3N (3.36 g, 4.62 mL, 33.2 mmol, 4.0 eq.) in CH2Cl2 (20 mL) at 0 °C 
under Ar. The resulting mixture was allowed to warm to rt and then stirred at rt for 16 h. 
Water (50 mL) was added and the layers separated. The aqueous was extracted with 
CH2Cl2 (2 x 50 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude di-mesylate (R,S,R)-382. Freshly 
distilled allylamine (10 mL) was added to di-mesylate (R,S,R)-382 at rt under Ar. The 
Chapter Six: Experimental 
 
428 
 
resulting solution was stirred and heated at reflux for 16 h. After cooling to rt, the 
solvent was evaporated under reduced pressure. Then, 20% NaOH(aq) (20 mL) and 
CHCl3 (20 mL) were added and the layers were separated. The aqueous layer was 
extracted with CHCl3 (3 × 20 mL). The combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude allyl bispidine (S,R,R)-
418. Methyl chloroformate (2.35 g, 1.92 mL, 24.9 mmol, 3.0 eq.) was added to a stirred 
solution of crude allyl bispidine (S,R,R)-418 in CHCl3 (30 mL) at rt under Ar. The 
resulting solution was stirred and heated at reflux for 16 h. After cooling to rt, 1M 
HCl(aq) (20 mL) was added and the two layers separated. The organic layer was 
extracted with 1M HCl(aq) (3 × 20 mL). Then, the pH of the aqueous layer was adjusted 
to pH 12 with 20% NaOH(aq). The aqueous was extracted with Et2O (5 × 30 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1 CH2Cl2-MeOH as eluent gave methyl carbamate (S,S,R)-419 (1.21 g, 
61%) as a pale yellow oil, RF (9:1 CH2Cl2-MeOH) 0.1; [α]D –25.6 (c 1.0 in CHCl3); IR 
(ATR) 2917, 1697 (C=O), 1473, 1441, 1412, 1374, 1330, 1309, 1288, 1262, 1231, 
1188, 1131, 1120, 1121, 1101, 1071, 1042 cm
-1
; 
1
H NMR (400 MHz, CDCl3) (55:45 
mixture of rotamers) δ 4.43 (dd, J = 13.5, 1.5 Hz, 0.45H, NCH), 4.34-4.20 (m, 1H, 
NCH), 4.08 (dd, J = 13.5, 1.5 Hz, 0.55H, NCH), 3.69 (s, 1.65H, CO2Me), 3.64 (s, 
1.35H, CO2Me), 3.05 (dt, J = 13.0, 3.0 Hz, 0.45H, NCH), 2.97 (dt, J = 13.0, 3.0 Hz, 
0.55H, NCH), 2.92-2.76 (m, 2H, NCH), 2.66 (br d, J = 11.0 Hz, 0.55H, NCH), 2.61 (br 
d, J = 11.0 Hz, 0.45H, NCH), 2.28-2.12 (m, 1H, NCH), 1.93 (br s, 0.45H, NCH), 1.91 
(br s, 0.55H, NCH), 1.86-1.55 (m, 6H, NCH, CH and CH2), 1.53- 1.11 (m, 5H, CH2); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 156.4 (CO2Me), 65.5 (CO2Me), 
65.5 (CO2Me), 61.1 (NCH), 60.8 (NCH2), 57.2 (NCH2), 57.0 (NCH2), 52.2 (NCH), 52.1 
(NCH), 48.9 (NCH2), 48.8 (NCH2), 44.9 (NCH2), 44.6 (NCH2), 34.5 (CH), 34.1 (CH2), 
34.0 (CH2), 30.5 (CH2), 30.4 (CH2), 29.6 (CH), 29.5 (CH), 26.0 (CH2), 25.7 (CH2), 24.9 
(CH2), 24.9 (CH2); MS (ESI) m/z 237 (M + H)
+
; HRMS m/z calcd for C13H21N2O2 (M + 
H)
+
 237.1598, found 237.1593 (+2.3 ppm error). 
Lab Book Reference: JDF12_1118 and 1121 
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(1S,5R,11aR)-3-Methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine (–)-
26 
 
A solution of methyl carbamate (S,R,R)-419 (1.12 g, 4.70 mmol, 1.0 eq.) in THF (10 
mL) was added dropwise to a stirred suspension of lithium aluminium hydride (535 mg, 
14.1 mmol, 3.0 eq.) in THF (20 mL) at 0 °C under Ar. The resulting mixture was 
allowed to warm to rt and then stirred at reflux for 16 h. After cooling to 0
 
°C, the 
mixture was diluted with Et2O (30 mL). Water (535 µL), 20% NaOH(aq) (1.07 mL) and 
water (535 µL) were sequentially added dropwise and the mixture stirred for 30 min. 
Then, anhydrous MgSO4 was added and the mixture stirred for 30 min. The solids were 
removed by filtration through Celite
®
 and washed with Et2O (100 mL). The filtrate was 
concentrated under reduced pressure to give the (–)-sparteine surrogate (–)-26 (880 mg, 
97%, 99:1 by CSP-GC) as a colourless oil, [α]D –28.4 (c 1.0 in EtOH) (lit.,
213
 [α]D +26.5 
(c 1.0 in EtOH for (+)-26); IR (ATR) 2928, 2854, 2755, 2734, 2722, 2693, 1463, 1440, 
1374, 1321, 1280, 1267, 1223, 1158, 1147, 1125, 1112, 1082, 1066, 1046, 1029, 992, 
882, 838, 780 cm
–1
; 
1
H NMR (400 MHz, CDCl3) δ 3.05-2.95 (m, 2H, NCH), 2.94-2.81 
(m, 2H, NCH), 2.24 (ddd, J = 11.0, 3.5, 1.5 Hz, 1H, NCH), 2.19-2.12 (m, 1H, NCH), 
2.15 (s, 3H, NMe), 1.97 (dd, J = 11.5, 3.0 Hz, 1H, NCH), 1.90 (br d, J = 11.0 Hz, 1H, 
NCH), 1.83 (dd, J = 5.5, 3.0 Hz, 1H, NCH), 1.81-1.45 (m, 8H, CH), 1.37-1.22 (m, 2H, 
CH); 
13
C NMR (100.6 MHz, CDCl3) δ 66.5 (NCH), 60.5 (NCH2), 60.5 (NCH2), 57.7 
(NCH2), 56.3 (NCH2), 47.5 (NMe), 35.3 (CH), 34.0 (CH2), 30.9 (CH2), 30.7 (CH), 25.8 
(CH2), 25.2 (CH2); MS (ESI) m/z 195 (M + H)
+
; HRMS m/z calcd for C12H22N2 (M + 
H)
+
 195.1856, found 195.1860 (–1.8 ppm error); CSP-GC: Cyclodex-B column (110-
140 °C, 1 °C/min), (+)-26 22.8 min, (–)-26 23.1 min. Spectroscopic data consistent with 
those reported in the literature.
213
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tert-Butyl 2-(2-(benzyl(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate 423 
 
Lithium hydroxide (706 mg, 29.5 mmol, 4.0 eq.) was added to a stirred solution of N-
Boc ester 374 (2.0 g, 7.37 mmol, 1.0 eq.) in 4:1:1 THF-MeOH-water (60 mL) under air. 
The resulting solution was stirred at room temperature for 1 h. The volatiles were 
removed under reduced pressure. Then, water (30 mL) was added and the pH was 
adjusted to pH 4-5 with 1M HCl(aq). The aqueous was extracted with CH2Cl2 (3 × 20 
mL). The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give crude carboxylic acid as a white solid. Methyl chloroformate 
(696 mg, 570 µL, 7.37 mmol, 1.0 eq.) was added to a stirred solution of crude 
carboxylic acid and Et3N (745 mg, 1.03 mL, 7.37 mmol, 1.0 eq.) in THF at 0 °C under 
Ar. The resulting solution was stirred at 0 °C for 30 min. Then, N-methylbenzylamine 
(982 mg, 1.05 ml, 8.11 mmol, 1.1 eq.) was added dropwise and the resulting solution 
stirred at 0 °C for 1.5 h. Then, saturated NaHCO3(aq) (20 mL) and Et2O (20 mL) were 
added and the layers separated. The aqueous layer was extracted with Et2O (3 × 20 mL). 
The combined organic layers were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 petrol-EtOAc as eluent gave N-Boc amide 423 (2.12 
g, 83%) as a colourless oil, RF (1:1 petrol-EtOAc) 0.4; IR (ATR) 2984, 2942, 2863, 
1707, 1682 (C=O, Boc), 1641 (C=O, Amide), 1476, 1451, 1400, 1363, 1267, 1252, 
1160, 1139, 1098, 1072, 1042, 953, 874, 734, 699 cm
–1
; 
1
H NMR (400 MHz, CDCl3) 
(55:45 mixture of rotamers) δ 7.39-7.20 (m, 4H, Ph), 7.15 (br d, J = 7.5 Hz, 1H, Ph), 
4.75-4.57 (m, 2H, CH2Ph), 4.57-4.37 (m, 1H, NCH), 3.96 (br s, 1H, NCH), 2.99 (s, 
1.65H, NMe), 2.91 (s, 1.35H, NMe), 2.89-2.65 (m, 2H, NCH + CHAHBCO), 2.63-2.43 
(m, 1H, CHAHBCO), 1.78-1.69 (m, 1H, CH2), 1.68-1.54 (m, 4H, CH2), 1.50-1.33 (m, 
1H, CH2), 1.44 (s, 4.95H, CMe3), 1.41 (s, 4.05H, CMe3); 
13
C NMR (100.6 MHz, 
CDCl3) (mixture of rotamers) δ 171.0 (CH2C=O), 170.6 (CH2C=O), 154.8 (C=O), 154.8 
(C=O), 137.3 (ipso-Ph), 136.7 (ipso-Ph), 128.8 (Ph), 128.5 (Ph), 128.0 (Ph), 127.5 (Ph), 
127.2 (Ph), 126.2 (Ph), 79.4 (CMe3), 79.4 (CMe3), 53.4 (CH2Ph), 50.6 (CH2Ph), 47.9 
(NCH), 47.6 (NCH), 39.5 (NCH2), 35.0 (NMe), 34.4 (CH2CO), 34.1 (CH2CO), 33.8 
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(NMe), 28.4 (CMe3), 28.3 (CMe3), 27.6 (CH2), 27.5 (CH2), 25.2 (CH2), 25.1 (CH2), 18.8 
(CH2), 18.7 (CH2); MS (ESI) m/z 369 [(M + Na)
+
, 100], 347 [(M + H)
+
, 20]; HRMS  
m/z calcd for C20H31N2O3 (M + H)
+
 347.2329, found 347.2329 (–0.3 ppm error).  
Lab Book Reference: JDF10_997 
 
tert-Butyl-2-(1-(benzyl(methyl)amino)-4-(ethoxycarbonyl)-1-oxopent-4-en-2-
yl)piperidine-1-carboxylate 422 
 
LHMDS (2.81 mL of a 1.0 M solution in THF, 2.81 mmol, 1.2 eq.) was added dropwise 
to a stirred solution of N-Boc amide 423 (809 mg, 2.34 mmol, 1.0 eq.) in THF (20 mL) 
at –78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, acrylate 
375 (542 mg, 387 µg, 2.81 mmol, 1.2 eq.) was added dropwise and the resulting 
solution was stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. Water (20 
mL) and Et2O (10 mL) were added and the two layers were separated. The aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 7:3 petrol-EtOAc as eluent 
gave a mixture of diastereomeric N-Boc esters 422 (786 mg, 69%) as a colourless oil, 
RF (7:3 petrol-EtOAc) 0.2; 
1
H NMR (400 MHz, CDCl3) (mixture of rotamers) δ 7.36-
7.01 (m, 5H, Ph), 6.23-6.07 (m, 1H, C=CHAHB), 5.81-5.57 (m, 1H, C=CHAHB), 4.84-
3.90 (m, 6H), 3.81-3.58 (m, 1H), 2.88-2.72 (m, 3H, NMe), 2.65-2.45 (m, 2H), 1.89 (br 
d, J = 11.0 Hz, 1H), 1.73-1.52 (m, 5H), 1.51-1.40 (m, 10H, CMe3 + CH), 1.27 (t, J = 7.0 
Hz, 2.2H, CH2Me), 1.21 (t, J = 7.0 Hz, 0.8H, CH2Me); MS (ESI) m/z 481 (M + Na)
+
; 
HRMS m/z calcd for C26H38N2NaO5 (M + H)
+
 481.2673, found 481.2655 (+3.8 ppm 
error). 
Lab Book Reference: JDF10_1000 
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Ethyl 1-(benzyl(methyl)carbamoyl)octahydro-1H-quinolizine-3-carboxylate 424 
and Ethyl 1-(benzyl(methyl)carbamoyl)octahydro-1H-quinolizine-3-carboxylate 
421 
 
Trifluoroacetic acid (3 mL, 39.2 mmol) was added to a stirred solution of 
diastereomeric N-Boc esters 422 (786 mg, 1.71 mmol, 1.0 eq.) in CH2Cl2 (10 mL) at rt 
under Ar. The resulting solution was stirred at rt for 16 h. Then, the volatiles were 
removed under reduced pressure and EtOH (20 mL) and K2CO3 (2.37 g, 17.1 mmol, 10 
eq.) were added. The resulting mixture was stirred at rt under Ar for 16 h. Then, the 
solvent was removed under reduced pressure. Water (50 mL) and CH2Cl2 (50 mL) were 
added and the two layers were separated. The aqueous layer was extracted with CH2Cl2 
(3 × 20 mL). The combined organic layers were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product which contained a 1:4 mixture of 424 
and 421 (by 
1
H NMR spectroscopy). Purification by flash column chromatography on 
silica with 19:1 to 9:1 CH2Cl2-MeOH as eluent gave bicyclic amide 424 (125 mg, 20%) 
as a colourless oil, RF (9:1 CH2Cl2-MeOH) 0.4; IR (ATR) 2932, 1725 (C=O, Ester), 
1638 (C=O, Amide), 1451, 1411, 1368, 1315, 1298, 1252, 1179, 1149, 1139, 1107, 
1073, 1047, 1028, 729, 699 cm
-1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of 
rotamers) δ 7.39-7.19 (m, 5H, Ph), 4.92 (d, J = 14.5 Hz, 0.4H, CHAHBPh), 4.62 (d, J = 
14.5 Hz, 0.6H, CHAHBPh), 4.57 (d, J = 14.5 Hz, 0.6H, CHAHBPh), 4.48 (d, J = 14.5 Hz, 
0.4H, CHAHBPh), 4.23-4.06 (m, 2H, CH2Me), 3.18 (br t, J = 10.5 Hz, 1H, NCH), 3.05 
(s, 1.8H, NMe), 2.91 (s, 1.2H, NMe), 2.99-2.82 (m, 1H, NCH), 2.73 (br t, J = 11.0 Hz, 
1H, NCH), 2.69-2.60 (m, 1H, NCH), 2.38-2.28 (m, 1H, NCH), 2.28-2.15 (m, 2H, 
CHCO), 2.03 (td, J = 11.0, 4.0 Hz, 0.5H, CH2), 1.98 (td, J = 11.0, 4.0 Hz, 0.5H, CH2), 
1.82-1.39 (m, 5H, CH2), 1.34-1.20 (m, 1H, CH2), 1.25 (t, J = 7.0 Hz, 1.8H, CH2Me), 
1.15 (t, J = 7.0 Hz, 1.2H, CH2Me), 1.11-0.84 (m, 1H, CH2); 
13
C NMR (100.6 MHz, 
CDCl3) (mixture of rotamers) δ 174.8 (C=O), 174.6 (C=O), 174.0 (C=O), 173.8 (C=O), 
137.5 (ipso-Ph), 137.0 (ipso-Ph), 128.7 (Ph), 128.5 (Ph), 127.8 (Ph), 127.4 (Ph), 127.2 
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(Ph), 126.6 (Ph), 63.8 (NCH), 60.4 (CH2Me), 57.1 (NCH2 or CH2Ph), 57.0 (NCH2 or 
CH2Ph), 56.4 (NCH2 or CH2Ph), 56.4 (NCH2 or CH2Ph), 52.9 (NCH2), 50.6 (NCH2), 
42.0 (CHCO or NMe), 39.0 (CHCO or NMe), 34.8 (CHCO or NMe), 33.6 (CHCO or 
NMe), 30.4 (CH2), 30.4 (CH2), 29.1 (CH2), 28.5 (CH2), 25.6 (CH2), 25.5 (CH2), 24.2 
(CH2), 24.2 (CH2), 14.1 (CH2Me), 14.1 (CH2Me); MS (ESI) m/z 359 (M + H)
+
; HRMS 
m/z calcd for C21H30N2O3 (M + H)
+
 359.2329, found 359.2328 (+0.1 ppm error), and 
bicyclic amide 421 (442 mg, 72%) as a colourless oil, RF (9:1 CH2Cl2-MeOH) 0.2; IR 
(ATR) 2927, 1726 (C=O, Ester), 1639 (C=O, Amide), 1495, 1450, 1410, 1367, 1319, 
1255, 1188, 1153, 1093, 1080, 1056, 1030, 733, 700 cm
-1
;  
1
H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 7.40-7.24 (m, 3H, Ph), 7.24-7.19 (m, 1H, Ph), 7.12 (br d, 
J = 7.0 Hz, 1H, Ph), 4.77 (d, J = 14.5 Hz, 0.4H, CH2Ph), 4.62-4.52 (m, 1.6H, CH2Ph), 
4.20-4.09 (m, 2H, CH2Me), 3.22-2.98 (m, 6H, NCH + CHCO), 3.03 (s, 1.8H, NMe), 
2.91 (s, 1.2H, NMe), 2.82-2.53 (m, 2H, CHCO + CH2), 2.19-1.63 (m, 5H, CH2), 1.50-
1.29 (m, 1H, CH2), 1.26 (t, J = 7.0 Hz, 1.8H, CH2Me), 1.25 (t, J = 7.0 Hz, 1.2H, 
CH2Me), 1.20-1.05 (m, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) 
δ 173.0 (C=O), 172.9 (C=O), 172.1 (C=O), 171.4 (C=O), 137.1 (ipso-Ph), 136.8 (ipso-
Ph), 129.0 (Ph), 128.6 (Ph), 128.0 (Ph), 127.6 (Ph), 126.1 (Ph), 126.6 (Ph), 60.8 
(CH2Me), 60.8 (CH2Ph), 56.9 (NCH), 56.5 (NCH), 54.5 (CH2Ph), 53.2 (CH2Ph), 51.0 
(NCH2), 45.8 (NCH2), 42.2 (CHCO or NMe), 40.9 (CHCO or NMe), 34.9 (CHCO or 
NMe), 34.3 (CHCO or NMe), 29.7 (CH2), 24.7 (CH2), 24.6 (CH2), 24.4 (CH2), 18.6 
(CH2), 18.3 (CH2), 14.1 (CH2Me); HRMS m/z calcd for C21H30N2O3 (M + H)
+
 
359.2329, found 359.2330 (–0.3 ppm error), 
Lab Book Reference: JDF11_1030 
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3-methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 26 
 
A solution of bicyclic ester 421 (442 mg, 1.23 mmol, 1.0 eq.) in THF (4 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (233 mg, 6.15 mmol, 5.0 
eq.) in THF (6 mL) at 0 °C under Ar. The resulting mixture was allowed to warm to rt 
and then stirred at rt for 2 h. After cooling to 0
 
°C, the mixture was diluted with Et2O 
(20 mL). Water (233 µL), 20% NaOH(aq) (466 µL) and water (233 µL) were 
sequentially added dropwise and the mixture stirred for 15 min. Then, anhydrous 
MgSO4 was added and the mixture stirred for 30 min. The solids were removed by 
filtration through Celite
®
 and washed with Et2O (50 mL). The filtrate was concentrated 
under reduced pressure to give the amino alcohol 425 (342 mg, 92%) as a white solid, 
mp 101-103 °C, 
1
H NMR (400 MHz, CDCl3) δ 7.33-7.28 (m, 4H, Ph), 7.28-7.23 (m, 
1H, Ph), 3.78-3.66 (m, 1H, CH2Ph or OCH2), 3.66-3.54 (m, 2H, CH2Ph or OCH2), 3.28 
(br d, J = 12.5 Hz, 1H, CH2Ph or OCH2), 2.82 (br d, J = 11.5 Hz, 1H, NCH), 2.75 (br s, 
1H, OH), 2.60 (dd, J = 11.5, 4.0 Hz, 1H, NCH), 2.35-2.11 (m, 3H, NCH), 2.09 (s, 3H, 
NMe), 1.97 (br s, 3H, NCH + CH), 1.76 (br d, J = 12.0 Hz, 1H, CH), 1.71-1.17 (m, 8H, 
CH). The crude product was used in the next step without further purification (≥90% 
purity by 
1
H NMR spectroscopy). 
Lab Book Reference: JDF11_1036 
 
20% Pd(OH)2/C (50 mg) was added to a stirred solution of crude amino alcohol 425 
(430 mg, 1.42 mmol, 1.0 eq.) and ammonium formate (447 mg, 7.1 mmol, 5.0 eq.) in 
EtOH (20 mL) at rt under Ar. The resulting solution was stirred and heated at reflux for 
2 h. After cooling to rt, the mixture was filtered through Celite
®
 and washed with EtOH 
(50 mL). The filtrate was evaporated under reduced pressure to give crude secondary 
alcohol 420 (246 mg, 81%) as a colourless oil, 
1
H NMR (400 MHz, CDCl3) δ 3.72-3.63 
(m, 1H, OCHAHB), 3.54 (dd, J = 11.5, 7.0 Hz, 1H, OCHAHB), 2.80 (br d, J = 12.0 Hz, 
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1H, NCH), 2.76-2.54 (m, 3H, NCH), 2.41 (s, 3H, NMe), 2.35-2.14 (m, 3H, NCH), 1.96-
1.69 (m, 4H, CH or OH or NH), 1.64-1.19 (m, 8H, CH or OH or NH). The crude 
product was used in the next step without further purification (≥90% purity by 1H NMR 
spectroscopy). 
Lab Book Reference: JDF11_1038 
 
Carbon tetrabromide (576 mg, 1.74 mmol, 1.5 eq.) was added a solution of secondary 
alcohol 420 (246 mg, 1.15 mmol, 1.0 eq.), PPh3 (456 mg, 1.74 mmol, 1.5 eq.) and Et3N 
(351 mg, 484 µL, 3.47 mmol, 3.0 eq.) in CHCl3 (5 mL) at rt under Ar. The resulting 
solution was stirred at rt for 16. Then, 1M HCl(aq) (10 mL) was added and the layer 
separated. The aqueous layer was extracted with CHCl3 (2 × 10 mL). Then, the pH of 
the aqueous layer was adjusted to pH 12 with 20% NaOH(aq). The aqueous was 
extracted with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification 
by Kugelrohr distillation gave diamine 26 (171 mg, 76%) as a colourless oil. 
Lab Book Reference: JDF11_1039 
 
N-Benzyl-N-methylacrylamide 431 
 
Acryloyl chloride 430 (4.53 g, 4.06 mL, 50 mmol, 1.0 eq.) was added dropwise to a 
stirred solution of N-methylbenzylamine (6.06 g, 6.45 ml, 50 mmol, 1.0 eq.) and Et3N 
(5.06 g, 6.97 ml, 50 mmol, 1.0 eq.) in THF (100 mL) at 0 °C under Ar. The resulting 
solution was stirred at 0 °C for 2.5 h then warmed to rt. Then, water (100 mL) and Et2O 
(50 mL) were added and the layers were separated. The aqueous layer was extracted 
with Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 1:1 petrol-EtOAc as eluent gave acrylamide 431 
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(5.46 g, 62%) as a colourless oil, RF (1:1 petrol-EtOAc) 0.2; IR (ATR) 2933, 1645 
(C=O), 1611 (CH=CH2), 1494, 1477, 1450, 1414, 1402, 1379, 1356, 1258, 1220, 1186, 
1116, 1098, 1077, 1056, 978, 792, 731, 697 cm
–1
; 
1
H NMR (400 MHz, CDCl3) (50:50 
mixture of rotamers) δ 7.40-7.23 (m, 4H, Ph), 7.21-7.14 (m, 1H, Ph), 6.64 (dd, 0.5H, J = 
16.5, 10.5 Hz, CH=CH2), 6.58 (dd, 0.5H, J = 16.5, 10.5 Hz, CH=CH2), 6.40 (dd, J = 
16.5, 1.5 Hz, 0.5H, CH=CHAHB), 6.40 (dd, J = 16.5, 1.5 Hz, 0.5H, CH=CHAHB), 5.74 
(dd, J = 10.5, 1.5 Hz, 0.5H, CH=CHAHB), 5.68 (dd, J = 10.5, 1.5 Hz, 0.5H, 
CH=CHAHB), 4.66 (s, 1H, CH2Ph), 4.60 (s, 1H, CH2Ph), 3.01 (s, 1.5H, NMe), 2.99 (s, 
1.5H, NMe); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 167.2 (C=O), 
166.6 (C=O), 137.2 (ipso-Ph), 136.9 (ipso-Ph), 129.0 (CH=CH2 or Ph), 128.7 (CH=CH2 
or Ph), 128.4 (CH=CH2), 128.4 (CH=CH2), 128.2 (CH=CH2 or Ph), 127.8 (CH=CH2 or 
Ph), 127.7 (CH=CH2 or Ph), 127.5 (CH=CH2 or Ph), 126.5 (CH=CH2 or Ph),  53.5 
(CH2Ph), 51.2 (CH2Ph), 35.0 (NMe), 34.2 (NMe); MS (ESI) m/z 198 [(M + Na)
+
, 100], 
176 [(M + H)
+
, 60]; HRMS  m/z calcd for C11H13NO (M + H)
+
 176.1070, found 
176.1068 (+1.2 ppm error). Spectroscopic data consistent with those reported in the 
literature.
286
 
Lab Book Reference: JDF11_1079 
 
N-Benzyl-2-(bromomethyl)-N-methylacrylamide 429 
 
Acrylamide 431 (5.46 g, 31.2 mmol, 1.0 eq.) was added to a stirred solution of 
paraformaldehyde (4.68 g, 156 mmol, 5.0 eq.), DABCO (3.50 g, 31.2 mmol, 1.0 eq.) 
and phenol (734 mg, 7.8 mmol, 0.25 eq.) in 7:3 H2O-
t
BuOH (4 mL) at rt under Ar. The 
resulting mixture was stirred and heated at 80 °C for 16 h. After cooling to rt, the 
solvent was evaporated under reduced pressure. Then, CH2Cl2 (100 mL) was added and 
mixture was filtered through Celite
®
 and washed with CH2Cl2 (100 mL). The filtrate 
was evaporated under reduced pressure. Filtration through a plug of silica eluting with 
9:1 CH2Cl2-MeOH gave crude alcohol 432 (6.7 g). PBr3 (5.06 g, 1.76 mL, 18.7 mmol, 
0.6 eq.) was added dropwise to a stirred solution of crude alcohol 432 in Et2O (50 mL) 
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at 0 °C under Ar. The resulting solution was stirred at rt for 16 h. Then, saturated 
NaHCO3(aq) (100 mL) was added slowly with stirring and the layers separated. The 
aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 1:1 petrol-EtOAc 
as eluent gave acrylamide 429 (3.35 g, 40%) as a colourless oil that solidified upon 
standing, mp 51-53 °C; RF (1:1 petrol-EtOAc) 0.3; IR (ATR) 1641 (C=O), 1612 
(C=CH2), 1491, 1455, 1429, 1410, 1391, 1361, 1321, 1301, 1258, 1211, 1129, 1094, 
959, 933, 895, 782, 739, 713, 699, 583 cm
-1
; 
1
H NMR (400 MHz, CDCl3) (60:40 
mixture of rotamers) δ 7.42-7.20 (m, 5H, Ph), 5.57 (br s, 0.6H, C=CHAHB), 5.46 (br s, 
0.4H, C=CHAHB), 5.23 (br s, 1H, C=CHAHB), 4.72 (br s, 0.8H, CH2Ph), 4.68 (br s, 
1.2H, CH2Ph), 4.28 (s, 2H, CH2Br), 3.03 (s, 1.8H, NMe), 2.95 (s, 1.2H, NMe); 
13
C 
NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 169.8 (C=O), 169.3 (C=O), 140.0 
(C=CH2), 139.9 (C=CH2), 136.5 (ipso-Ph), 128.8 (Ph), 128.6 (Ph), 127.9 (Ph), 127.5 
(Ph), 127.4 (Ph), 126.6 (Ph), 118.0 (C=CH2), 118.0 (C=CH2), 54.6 (CH2Ph), 50.4 
(CH2Ph), 36.3 (NMe), 33.4 (CH2Br), 32.9 (CH2Br); MS (ESI) m/z 290 [(M + Na)
+
, 
100], 268 [(M + H)
+
, 60]; HRMS  m/z calcd for C12H14BrNO (M + H)
+
 268.0332, found 
268.0336 (–1.7 ppm error). 
  Lab Book Reference: JDF11_1085 
 
tert-Butyl 2-(4-(benzyl(methyl)carbamoyl)-1-ethoxy-1-oxopent-4-en-2-
yl)piperidine-1-carboxylate 428 
 
LHMDS (1.20 mL of a 1.0 M solution in THF, 1.20 mmol, 1.2 eq.) was added dropwise 
to a stirred solution of N-Boc ester 374 (271 mg, 1.0 mmol, 1.0 eq.) in THF (5 mL) at –
78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of 
acrylamide 429 (321 mg, 1.20 mmol, 1.2 eq.) in THF (1 mL) was added dropwise and 
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the resulting solution was stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. 
Water (20 mL) and Et2O (10 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 6:4 petrol-EtOAc 
as eluent gave N-Boc ester 428 (426 mg, 93%) as a colourless oil, RF (1:1 petrol-EtOAc) 
0.3; IR (ATR) 2932, 1731 (C=O, Ester), 1687 (C=O, Boc), 1645 (C=O, Amide), 1618 
(C=CH2), 1476, 1450, 1413, 1364, 1306, 1274, 1249, 1158, 1096, 1028, 920, 867, 729, 
699 cm
-1
; 
1
H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 7.39-7.14 (m, 5H, 
Ph), 5.33 (br s, 0.6H, C=CHAHB), 5.21 (br s, 0.4H, C=CHAHB), 5.14 (br s, 1H, 
C=CHAHB), 4.78-4.22 (m, 3H, NCH + CH2Ph),  4.15-3.91 (m, 3H, CH2Me + NCH), 
3.13 (br s, 1H, NCH), 2.96 (br s, 1H, CHCO2Et), 2.92 (s, 3H, NMe), 2.75-2.44 (m, 2H, 
CH2C=CH2), 1.85-1.71 (m, 2H, CH2), 1.66-1.48 (m, 4H, CH2), 1.42 (s, 9H, CMe3), 1.16 
(br t, J = 6.0 Hz, 3H, CH2Me); 
13
C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 
173.1 (C=O), 173.0 (C=O), 154.3 (C=O, Boc), 141.7 (C=CH2), 136.9 (ipso-Ph), 128.6 
(Ph), 128.0 (Ph), 127.4 (Ph), 116.7 (C=CH2), 79.4 (CMe3), 60.4 (CH2Me), 54.5 (NCH), 
50.4 (CH2Ph), 43.4 (CHCO2Et), 40.0 (NCH2), 36.4 (NMe), 34.3 (CH2C=CH2), 28.3 
(CMe3), 25.9 (CH2), 25.2 (CH2), 19.0 (CH2), 14.1 (CH2Me); MS (ESI) m/z 481 [(M + 
Na)
+
, 100], 459 [(M + H)
+
, 30]; HRMS  m/z calcd for C26H38N2O5 (M + H)
+
 459.2853, 
found 459.2860 (–1.4 ppm error). 
Lab Book Reference: JDF11_1087 
 
Ethyl 3-(benzyl(methyl)carbamoyl)octahydro-1H-quinolizine-1-carboxylate 427 
and Ethyl 3-(benzyl(methyl)carbamoyl)octahydro-1H-quinolizine-1-carboxylate 
433 
 
Trifluoroacetic acid (1 mL, 13.1 mmol) was added to a stirred solution of N-Boc ester 
428 (329 mg, 0.72 mmol, 1.0 eq.) in CH2Cl2 (5 mL) at rt under Ar. The resulting 
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solution was stirred at rt under Ar for 16 h. Then, the volatiles were removed under 
reduced pressure and EtOH (10 mL) and K2CO3 (991 mg, 7.17 mmol, 10 eq.) were 
added. The resulting mixture was stirred at rt for 16 h. Then, the solvent was removed 
under reduced pressure. Water (20 mL) and CH2Cl2 (20 mL) were added and the two 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product which contained a 1:4 mixture of 427 and 433 (by 
1
H 
NMR spectroscopy). Purification by flash column chromatography on silica with 99:1 
to 19:1 CH2Cl2-MeOH as eluent gave bicyclic amide 427 (52 mg, 20%) as a colourless 
oil, RF (97:3 CH2Cl2-MeOH) 0.2; IR (ATR) 2933, 2857, 1727 (C=O, Ester), 1635 (C=O, 
Amide), 1495, 1450, 1414, 1352, 1261, 1194, 1169, 1144, 1094, 1079, 1027, 732, 700 
cm
-1
; 
1
H NMR (400 MHz, CDCl3) (65:35 mixture of rotamers) δ 7.39-7.26 (m, 3H, Ph), 
7.22-7.13 (m, 2H, Ph), 4.61 (d, J = 14.5 Hz, 1H, CHAHBPh), 4.52 (d, J = 14.5 Hz, 1H, 
CHAHBPh), 4.15 (q, J = 7.0 Hz, 1.3H, CH2Me), 4.11 (q, J = 7.0 Hz, 0.7H, CH2Me), 3.61 
(br d, J = 11.5 Hz, 0.65H, NCH), 3.54-3.42 (m, 1H, NCH), 3.39 (d, J = 11.5 Hz, 0.35H, 
NCH), 3.30-2.99 (m, 4H, NCH + CHCO), 2.98 (s, 1.95H, NMe), 2.95 (s, 1.05H, NMe), 
2.83-2.62 (m, 1H, NCH or CHCO), 2.07-1.73 (m, 6H, CH2), 1.65-1.41 (m, 2H, CH2), 
1.25 (t, J = 7.0 Hz, 1.95H, CH2Me), 1.22 (t, J = 7.0 Hz, 1.05H, CH2Me); 
13
C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 172.2 (C=O), 171.1 (C=O), 136.9 (ipso-
Ph), 136.3 (ipso-Ph), 129.0 (Ph), 128.7 (Ph), 127.9 (Ph), 127.7 (Ph), 127.5 (Ph), 126.4 
(Ph), 61.0 (CH2Me), 60.7 (CH2Me), 57.4 (NCH), 57.3 (NCH), 54.4 (NCH2 or CH2Ph), 
54.3 (NCH2 or CH2Ph), 53.2 (NCH2 or CH2Ph), 47.0 (NCH2 or CH2Ph), 46.6 (NCH2 or 
CH2Ph), 44.3 (CHCO), 44.0 (CHCO), 38.3 (CHCO), 37.9 (CHCO), 34.8 (NMe), 34.3 
(NMe), 24.2 (CH2), 23.9 (CH2), 23.8 (CH2), 23.2 (CH2), 18.3 (CH2Me), 18.2 (CH2Me); 
MS (ESI) m/z 359 (M + H)
+
; HRMS m/z calcd for C21H30N2O3 (M + H)
+
 359.2329, 
found 359.2319 (+2.5 ppm error), and secondary amine 433 (165 mg, 64%) as a 
colourless oil, RF (9:1 CH2Cl2-MeOH) 0.2; IR (ATR) 2982, 2937, 1725 (C=O, Ester), 
1648 (C=O, Amide), 1618 (C=CH2), 1494, 1450, 1396, 1254, 1159, 1122, 1094, 1029, 
919, 856, 729, 696 cm
-1
; 
1
H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 
7.39-7.11 (m, 5H, Ph), 5.32 (br s, 0.5H, C=CHAHB), 5.22 (br s, 0.5H, C=CHAHB), 5.14 
(br s, 1H, C=CHAHB), 4.61 (br s, 2H, CH2Ph), 4.10-3.92 (m, 2H, CH2Me), 3.09 (br d, J 
= 9.5 Hz, 1H, NCH), 2.92 (br s, 3H, NMe), 2.83-2.45 (m, 6H, NCH2 + COCH + 
CH2C=CH2 + NH), 1.87-1.77 (m, 1H, CH2), 1.73 (br d, J = 12.5 Hz, 1H, CH2), 1.62-
1.49 (m, 1H, CH2), 1.40–1.30 (m, 2H, CH2), 1.28-1.09 (m, 4H, CH2 + CH2Me); 
13
C 
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NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 173.9 (C=O), 172.2 (C=O), 171.4 
(C=O), 141.9 (C=CH2), 136.8 (ipso-Ph), 136.6 (ipso-Ph), 128.7 (Ph), 128.6 (Ph), 128.0 
(Ph), 127.4 (Ph), 126.5 (Ph), 117.0 (C=CH2), 116.4 (C=CH2), 60.5 (CH2Me), 58.2 
(NCH), 50.3 (CHCO), 46.9 (NCH2), 36.2 (NMe), 33.1 (CH2), 32.7 (CH2), 30.0 (CH2), 
26.2 (CH2), 24.5 (CH2), 14.2 (CH2Me); MS (ESI) m/z 359 (M + H)
+
; HRMS m/z calcd 
for C21H30N2O3 (M + H)
+
 359.2329, found 359.2311 (+3.8 ppm error). 
Lab Book Reference: JDF11_1090 
 
2-(Bromomethyl)acrylonitrile 436 
 
A solution of K2CO3 (7.8 g, 56.4 mmol, 2.0 eq.) in H2O (8 mL) was added dropwise to 
a stirred solution of diethyl cyanomethylphosphonate 434 (5.0 g, 4.6 mL, 28.2 mmol, 
1.0 eq.) and formaldehyde (37% aqueous solution, 9.2 mL, 113 mmol, 4.0 eq.) at rt 
under air. The resulting mixture was stirred at rt for 1 h. Then, Et2O (75 mL) and brine 
(75 mL) were added and the layers separated. The aqueous layer was extracted with 
Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude alcohol 435. PBr3 (4.6 g, 1.59 mL, 
16.9 mmol, 0.6 eq.) was added dropwise to a stirred solution of crude alcohol 435 in 
Et2O (40 mL) at 0 °C under Ar. The resulting solution was stirred at rt for 16 h. Then, 
saturated NaHCO3(aq) (100 mL) was added slowly with stirring and the layers separated. 
The aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic layers 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification flash column chromatography on silica with 7:3 petrol-EtOAc as 
eluent gave acrylonitrile 436 (1.20 g, 29%) as a clear oil, RF (7:3 petrol-EtOAc) 0.4; 
1
H 
NMR (400 MHz, CDCl3) δ 6.05 (s, 1H, C=CHAHB), 6.02 (s, 1H, C=CHAHB), 4.00 (s, 
2H, CH2Br); 
13
C NMR (100.6 MHz, CDCl3) δ 133.3 (C=CH2), 120.2 (C=CH2 + CN), 
29.4 (CH2Br). Spectroscopic data consistent with those reported in the literature.
287
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tert-Butyl 2-(4-cyano-1-ethoxy-1-oxopent-4-en-2-yl)piperidine-1-carboxylate 437 
 
LHMDS (1.20 mL of a 1.0 M solution in THF, 1.20 mmol, 1.2 eq.) was added dropwise 
to a stirred solution of N-Boc ester 374 (271 mg, 1.0 mmol, 1.0 eq.) in THF (5 mL) at –
78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of 
acrylonitrile 436 (175 mg, 1.20 mmol, 1.2 eq.) in THF (1 mL) was added dropwise and 
the resulting solution was stirred at –78 °C for 4 h and allowed to warm to rt over 16 h. 
Water (20 mL) and Et2O (10 mL) were added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 9:1 to 7:3 
petrol:Et2O as eluent gave N-Boc ester 437 (243 mg, 72%) as a colourless oil, RF (8:2 
petrol:Et2O) 0.1; 
1
H NMR (400 MHz, CDCl3) δ 5.87 (br s, 1H, C=CHAHB), 5.79 (br s, 
1H, C=CHAHB), 4.40 (br s, 1H, NCH), 4.18-3.86 (m, 3H, CH2Me + NCH), 3.20 (td, J = 
11.5, 2.5 Hz, 1H, NCH), 2.96 (br t, J = 13.5 Hz, 1H, CHCO2Et or CH2C=CH2), 2.72-
2.54 (br t, J = 13.5 Hz, 1H, CHCO2Et or CH2C=CH2), 2.33 (br d, J = 14.0 Hz, 1H, 
CHCO2Et or CH2C=CH2), 1.77-1.44 (m, 6H, CH2), 1.41 (s, 9H, CMe3), 1.21 (t, J = 7.0 
Hz, 3H, CH2Me);  
Lab Book Reference: JDF12_1113 
 
Ethyl 3-cyanooctahydro-1H-quinolizine-1-carboxylate 438 
 
Trifluoroacetic acid (1.0 mL, 13.1 mmol) was added to a stirred solution of N-Boc ester 
437 (217 mg, 0.65 mmol, 1.0 eq.) in CH2Cl2 (5 mL) at rt under Ar. The resulting 
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solution was stirred at rt for 16 h. Then, the volatiles were removed under reduced 
pressure and EtOH (10 mL) and K2CO3 (898 mg, 6.5 mmol, 10 eq.) were added. The 
resulting mixture was stirred at rt under Ar for 16 h. Then, the solvent was removed 
under reduced pressure. Water (20 mL) and CH2Cl2 (10 mL) were added and the two 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 98:2 CH2Cl2-MeOH as eluent gave bicyclic ester 438 (108 mg, 70%) as a 
white solid, mp 57-58 °C; RF (98:2 CH2Cl2-MeOH) 0.1; IR (ATR) 2938, 2860, 2251 
(CN), 1729 (C=O), 1447, 1378, 1351, 1320, 1264, 1197, 1171, 1143, 1080, 1027, 1012, 
860 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 4.14 (q, J = 7.0 Hz, 2H, CH2Me), 3.26-3.16 
(m, 1H, NCH), 3.12 (t, J = 12.0 Hz, 1H, NCH), 3.01-2.82 (m, 2H, NCH), 2.77-2.62 (m, 
3H, NCH + CH), 2.15-2.07 (m, 1H, CH2), 1.94-1.81 (m, 2H, CH2), 1.79-1.59 (m, 2H, 
CH2), 1.54-1.39 (m, 1H, CH2), 1.25 (t, J = 7.0 Hz, 3H, CH2Me), 1.24-1.17 (m, 1H, 
CH2), 1.01 (br dd, J = 13.5, 2.5 Hz, 1H, CH2); 
13
C NMR (100.6 MHz, CDCl3) δ 171.6 
(C=O), 120.5 (CN), 60.7 (CH2Me), 57.1 (NCH), 55.0 (NCH2), 47.6 (NCH2), 44.5 
(CHCO2Et), 27.5 (CHCN), 25.0 (CH2), 24.7 (CH2), 19.0 (CH2), 18.5 (CH2), 14.1 
(CH2Me); MS (ESI) m/z 237 (M + H)
+
; HRMS m/z calcd for C13H20N2O2 (M + H)
+
 
237.1598, found 237.1593 (+2.3 ppm error), 
Lab Book Reference: JDF12_1115 
 
Attempted Synthesis of 3-(aminomethyl)octahydro-1H-quinolizin-1-yl)methanol 
439 
 
A solution of nitrile 438 (103 mg, 0.43 mmol, 1.0 eq.) in THF (2 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (66 mg, 1.74 mmol, 4.0 
eq.) in THF (3 mL) at 0 °C under Ar. The resulting mixture was allowed to warm to rt 
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and then stirred at rt for 1 h. After cooling to 0
 
°C, the mixture was diluted with Et2O 
(50 mL). Water (66 µL), 20% NaOH(aq) (122 µL) and water (66 µL) were sequentially 
added dropwise and the mixture stirred for 30 min. Then, anhydrous MgSO4 was added 
and the mixture stirred for 30 min. The solids were removed by filtration through 
Celite
®
 and washed with Et2O (20 mL).The filtrate was concentrated under reduced 
pressure to give the crude product which contained a complex mixture of decomposition 
products. 
Lab Book Reference: JDF12_1120 
  
Chapter Six: Experimental 
 
444 
 
Abbreviations 
9-BBN 9-borabicyclo[3.3.1]nonane 
Ac acetyl 
aq.  aqueous 
Ar aryl 
atm atmospheres 
BINAP (1,1′-binaphthalene-2,2′-diyl)bis(diphenylphosphine) 
Bn benzyl 
Boc t-butoxycarbonyl 
bp boiling point 
br broad 
Bu butyl 
Cbz carboxybenzyl 
CIPE complex induced proximity effect 
cm
-1
 wavenumber 
COD 1,5-cyclooctadiene 
CSP-GC chiral stationary phase gas chromatography 
CSP-HPLC chiral stationary phase high performance liquid chromatography 
Cy cyclohexyl 
d doublet 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DavePhos 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl 
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dba dibenzylideneacetone 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC N,N′-dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
DIAD diisopropyl azodicarboxylate 
DIBAL-H diisobutylaluminum hydride 
DIPEA N,N-diisopropylethylamine 
DKR dynamic kinetic resolution 
DMF dimethylformamide 
DMP Dess–Martin periodinane 
DMSO dimethylsulfoxide 
DPEPhos (oxydi-2,1-phenylene)bis(diphenylphosphine) 
dppe ethylenebis(diphenylphosphine) 
dppf 1,1′-bis(diphenylphosphino)ferrocene 
dppp 1,3-bis(diphenylphosphino)propane 
dr diastereomeric ratio 
DTR dynamic thermodynamic resolution 
E
+
 electrophile 
eq. equivalent(S) 
er enantiomeric ratio 
ESI electrospray ionisation 
Et ethyl 
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FDA Food and Drug Administration 
Fmoc 9-fluorenylmethyloxycarbonyl  
g gram(S) 
GC gas chromatography 
glyme dimethoxyethane 
h hour(S) 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HFIP hexafluoro-2-propanol 
HIV human immunodeficiency virus 
HMPA hexamethylphosphoramide 
HRMS high resolution mass spectrometry 
Hz Hertz 
IPA isopropyl alcohol 
IR infra-red 
J coupling constant in Hz 
JohnPhos (2-biphenyl)di-tert-butylphosphine 
LDA lithium diisopropylamide 
LHMDS lithium bis(trimethylsilyl)amide 
LiDMAE lithiated dimethylethanolamine 
m multiplet 
M molar 
m/z mass to charge ratio 
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M
+
 molecular ion 
Me methyl 
mg milligrams 
min minutes 
mL millilitre 
mmol millimole 
mp melting point 
MS mass spectrometry 
MS molecular sieves 
Ms mesyl 
MTBE methyl tert-butyl ether 
NMR nuclear magnetic resonance 
Ns 2-nitrobenzenesulfonyl 
PEPPSI-i-Pr 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-
chloropyridyl)palladium(II) dichloride 
Petrol petroleum ether (fraction which boils at 40-60
 o
C) 
Ph phenyl 
PhFl 9-phenylfluoren-9-yl 
Pin pinacol 
PMP para-methoxyphenyl 
ppm parts per million 
Pr propyl 
p-Tol p-tolyl 
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q quartet 
QPhos 1,2,3,4,5-pentaphenyl-1′-(di-tert-butylphosphino)ferrocene 
R alkyl group 
RF retention factor 
rt room temperature 
RuPhos 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl 
s singlet 
SET single electron transfer 
SnAP tin amine protocol 
(+)-sp (+)-sparteine 
SPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl 
t triplet 
Tf trifluoromethylsulfonyl 
TFA trifluoroacetic acid 
TFAA trifluoroacetic anhydride 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TMCDA N,N,N′,N′-tetramethyl-1,2-diaminocyclohexane 
TMEDA N,N,N′,N′-tetramethylethylenediamine 
Tr trityl 
Trisyl 2,4,6-triisopropylbenzenesulfonyl 
Ts tosyl 
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UV ultraviolet 
Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
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